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“To the patients whom we treat, allowing us to slowly convert the “art of medicine” into the 
“science of medicine”.   
Most interventional physicians believe that Andrea Gruentzig, who performed the 
first successful coronary angioplasty in 1977 in Zurich, Switzerland, began the era of 
less invasive intervention performed via the transcatheter route.  At that time, in his 
first case, utilizing a kitchen-built catheter, he successfully performed dilation of an 80% 
lesion of a 3 mm section of the left anterior descending artery.  He presented his first 
four coronary angioplasty cases at the “1977 American Heart Association” meeting 
and the rest, they say, was history.  Fascinatingly, at the 10-year anniversary of the 
initial patient, the patient underwent elective repeat angiography which noted that the 
LAD narrowing remained almost perfectly expanded.  Sadly, the German cardiologist, 
along with his wife, tragically died in a plane crash on October 27, 1985 at the young 
age of 46.  If he was alive today, he would be amazed at the progress being made in 
the angioplasty arena for the treatment of congenital and acquired vessel stenosis.  Dr. 
Gruentzig’s initial foray into the coronary world served as the “launch pad” for the 
development of ideas and technology in the treatment of peripheral vascular lesions. 
For quite some time the treatment of coronary artery pathology has lead the way 
towards the development and treatment of other vascular lesions.. 
The past three decades has seen an explosion in interventional techniques to treat both 
congenital and acquired lesions in the vascular system.  When I was first asked to edit 
this book on angioplasty, it came to my surprise that a similar book dealing with the 
techniques and issues of these congenital and acquired lesions had not been 
previously undertaken.  Certainly individual chapters and reports have been written 
in these areas, though no formal book discussing the technical as well as current 
ongoing challenges in these areas have compiled in one setting. 
In particular, the past decade has seen a significant advancement in balloon, wire, and 
catheter technology in the treatment of complicated congenital and acquired vascular 
lesions. This decade has born witness to the development of angioplasty procedures 
that many interventionalists had never imagined being able to treat via the 
transcatheter route, especially in the peripheral arena.  The improvement of stent 
technology, especially regarding tracking capabilities of the newer generation stents, 
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have played a significant role in the treatment of tortuous vascular lesions that 
otherwise were exclusively relegated to be treated in the surgical operating theater.   
At first look, in reviewing the topics covered in this book, one’s initial impression may 
be that this is a compilation of multiple different types of lesions and the treatment of 
these lesions.  The common thread linking these procedures together relates to both 
the technology shared between disciplines, and the common techniques used to treat 
various lesions throughout the vascular system.  A perfect example of this relates to 
chronic total obstructive lesions in the peripheral vascular system and the technique 
used to overcome technical challenges of a completely occluded coronary vessel.  
One should not consider this textbook is a compendium of obscure interventional 
procedures. I believe that this textbook represents the greatest growth potential area in 
much of interventional cardiovascular medicine.  For example, as techniques continue 
to improve regarding re-vascularization if distal extremities, especially in patients 
with peripheral vasculopathy secondary to diabetes, tens of thousands of patients will 
benefit from not having to undergo amputation procedures, or at least forestalling the 
amputation procedure until a much later time.  The treatments, whether it be related 
to carotid stenosis, mesenteric ischemia, neural vascular spasm, or congenital vascular 
lesions, have the potential of reaching millions of patients every year. 
This book also bridges issues related to complications or other challenges related to 
performing aggressive angioplasty procedures.  Whether it be hyperperfusion 
syndrome following aggressive angioplasty or oxygen stress and altered function of 
platelets in patients with peripheral arterial vascular disease, not only do 
interventionalists need to be knowledgeable in the technique in performing an 
intervention, they also must have a strong understanding of what the potential 
ramifications are both on an anatomic and molecular level. 
To end, this first edition on Angioplasty will hopefully inspire interventionalists to 
“cross-link” their experience with other interventionalists regarding the techniques 
used to treat complicated lesions.  I personally feel that communication is the most 
important ally to overcoming challenges in both acquired and congenital vascular 
lesions.  Hopefully this book will inspire this to occur between interventional 
radiologists, cardiologists, neurologists, and neurosurgeons.  I would not be surprised, 
with the continued explosion of a technology in this area, that revision of this book 
will be required within the next 7-10 years.  Finally, one would be remiss in not giving 
credit to Warner Forsmann for his insight in the catheterization procedure and, as 
previously mentioned, Andre Gruentzig in launching us into an interventional era for 
the treatment of vascular stenosis.  On the shoulders of these two giants (and many 
others) we are able to proceed onto an exciting and changing world of interventional 
cardiology. 
I would like to greatly acknowledge the authors of this book for their time in writing 
the chapters.  Without their dedication to sharing their interventional expertise, this 
        Preface XI 
 
book would never come to fruition.  I also would like to thank my lovely wife Marie 
who, without her dedication to raising nine children (myself included), I would never 
have had the remote possibility for being able to find the time to undertake this 
endeavor.    
 
Dr. Thomas Forbes 
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1. Introduction 
Mesenteric ischaemia due to impaired arterial supply is an important cause of abdominal 
pain, especially in older patients with risk factors for vascular disease. Until recently, 
surgical revascularisation procedures such as endarterectomy and aorto-coeliac or aorto-
mesenteric bypass grafting were the only available treatment options for patients with 
mesenteric ischaemia. However, reported rates of peri-operative major complications and 
mortality are high, influenced by a high prevalence of significant patient co-morbidities. 
Percutaneous angioplasty and stenting have been shown to be effective and safe alternatives 
to surgical revascularisation in high-risk patients with mesenteric ischaemia. Indeed, in 
high-surgical risk patients and in those with suitable lesions, such endovascular 
revascularisation has emerged as the primary treatment modality.  
Here, we review current concepts in the diagnosis, treatment selection and outcomes for 
percutaneous angioplasty and stenting for patients with either chronic or acute mesenteric 
ischemia. 
2. Chronic mesenteric ischaemia 
Chronic mesenteric ischaemia (CMI) most commonly arises from atherosclerotic diseases of 
the mesenteric arteries. Other causes of CMI include aortic dissection, fibromuscular 
dysplasia, vasculitides and median arcuate ligament syndrome.  
Atherosclerotic disease of the mesenteric arteries is estimated to occur in 17% of patients 
over the age 65 years (Hansen et al., 2004). Despite its prevalence, the majority of these 
patients are asymptomatic as a result of the extensive collateral circulation between the 
celiac trunk, superior mesenteric artery (SMA) and inferior mesenteric artery (IMA). 
Whether or not ischaemia ensues depends on the site of the stenosis or occlusion and the 
development or otherwise of collateral vessels (Loffroy et al., 2009). CMI typically occurs in 
patients who have SMA lesions in conjunction with lesions in either the celiac trunk or IMA. 
However, mesenteric ischaemia can also develop in patients with a single vessel lesion. 
Distal lesions are more likely to be symptomatic compared with more proximal arterial 
pathology due to the absence of an effective collateral circulation.  
1 
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3. Clinical presentation 
CMI commonly affects people over the age of 60 years, with women three times more likely 
to be affected than men (Hansen et al., 2004). Most patients have multiple cardiovascular 
risk factors and atherosclerotic complications in other vascular territories.  
Classic symptoms of CMI include postprandial abdominal pain, fear of eating and 
significant weight loss. Patients may also present with persistent nausea and diarrhoea. 
These symptoms are non-specific and extensive investigations are generally undertaken to 
exclude other pathologies such as gastrointestinal or pancreatic malignancy.  
4. Diagnosis  
Duplex ultrasound is a useful, non-invasive screening test for mesenteric ischaemia (Moneta 
et al., 1993) (Table 1). Its accuracy is affected by operator experience and patient factors such 
as fasting status, body habitus and presence of bowel gas. CT-angiography and MR-
angiography are of value in cases where duplex ultrasound is inconclusive (Cademartiri et 
al., 2008; Horton et al., 2007; Laissy et al., 2002). CT-angiography also provides excellent 3-D 
anatomical reconstruction to facilitate planning for endovascular revascularisation. 
Nevertheless, digital subtraction angiography remains the gold standard in evaluating the 
degree of stenosis in mesenteric vessels.  
 
Vessel Duplex criteria Sensitivity Specificity Accuracy 
SMA PSV > 275cm/s 92% 96% 96% 
Coeliac trunk PSV > 200cm/s 87% 82% 82% 
PSV: peak systolic velocity 
Table 1. Duplex ultrasound criteria for detecting >70% stenosis in mesenteric vessels (from 
Moneta et al., 1993).  
5. Treatment options 
Treatment of symptomatic CMI is aimed at relieving symptoms and preventing progression to 
acute mesenteric ischaemia (AMI) and intestinal infarction. Prophylactic treatment of 
asymptomatic patients is controversial. The risk of progressing to AMI is greatest in patients 
with three-vessel disease with an estimated one third of these patients progressing to intestinal 
infarction if left untreated (Kolkman et al., 2004). The prognosis is relatively benign in those 
with single-vessel disease. In participants of the Cardiovascular Health Study who were found 
to have isolated coeliac trunk or mesenteric artery disease on duplex ultrasound, there was no 
increased risk of mortality, intestinal infarction or development of symptoms consistent with 
CMI over a median follow up period of 6.5years (Wilson et al., 2006).  
The gold standard of treatment has traditionally been surgical revascularisation in the form 
of bypass, endarterectomy or embolectomy. Given that patients affected by CMI are 
generally malnourished, of advanced age and have multiple cardiovascular co-morbidities, 
there is considerable peri-operative mortality (0-17%) and morbidity (15-33%) associated 
with surgical revascularisation (Kougias et al., 2009).  
Endovascular revascularisation is increasingly being offered to patients affected by CMI. In 
a large US registry study comprising of 5583 patients treated for CMI during the years 1988 
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to 2006 (Schermerhorn et al., 2009), the number of endovascular procedures steadily 
increased, surpassing all surgery for CMI in 2002. Endovascular revascularisation is 
associated with a lower in-hospital mortality and morbidity rate as well as shorter length of 
stay. Significantly lower rates of bowel resection, as well as fewer renal, cardiac and 
respiratory complications have been reported in patients who received endovascular 
revascularisation compared to surgically-treated counterparts (Table 2). A later analysis of 
published data concerning procedures performed between 2000 and 2009 similarly 
demonstrated a significantly reduced peri-operative complication rate in patients managed 








Mortality 3.7% 15.4% <0.001 
Overall morbidity 20% 38% <0.05 
Bowel resection 3% 8% <0.001 
Cardiac events 0.7% 5.9% <0.001 
Respiratory events 0.3% 5.7% <0.001 
Acute renal failure 6.0% 10.5% <0.05 
LOS                               
median (range), days 
5 (0-94) 11 (1-135) <0.001 
Table 2. Mortality, morbidity, peri-operative complications and length of stay (LOS): 
endovascular revascularisation vs. surgical revascularisation. (adapted from Schermerhorn 
et al., 2009)  
A serious potential complication of endovascular treatment is the precipitation of acute 
intestinal ischemia by plaque embolization or dissection of the artery. Standard catheter 
based salvage techniques such as stent deployment, embolectomy or thrombolysis are 
usually successful in treating these complications. Emergency laparotomy with mesenteric 
bypass and bowel resection is also used as salvage treatment. We recently reported the 
occurrence of splenic infarction complicating otherwise successful celiac artery stenting, 
presumably as a consequence of distal embolization of disrupted calcific plaque, with this 
complication representing a novel cause of abdominal pain post-procedure (Almeida & 
Riordan, 2008). 
The most common procedural complication of endovascular therapy relates to the puncture 
site, manifesting as either haemorrhage or thrombosis. Haemorrhage is generally controlled 
with local pressure and/or injection of thrombin. Insertion of interventional sheaths in small 
arteries is associated with an increased risk of thrombosis. Rapid heparinization after sheath 
insertion is usually an adequate preventative measure. 
Another important issue is the longer-term arterial patency rate in patients treated by 
endovascular means compared to those managed surgically. In a recent review of 328 
patients undergoing endovascular treatment for chronic mesenteric ischaemia, the overall 
technical success rate was 91% and immediate symptomatic relief was achieved in 82% of 
patients (Kougias et al., 2007). Despite the initial success rate, approximately one third of 
patients (84/292) available for follow up developed restenosis over a mean follow up period 
of 26 months. The 30-day mortality rate was 3-5%. Clinical series comparing endovascular 
and surgical revascularisation have shown that long term patency rates and freedom from 
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stay. Significantly lower rates of bowel resection, as well as fewer renal, cardiac and 
respiratory complications have been reported in patients who received endovascular 
revascularisation compared to surgically-treated counterparts (Table 2). A later analysis of 
published data concerning procedures performed between 2000 and 2009 similarly 
demonstrated a significantly reduced peri-operative complication rate in patients managed 








Mortality 3.7% 15.4% <0.001 
Overall morbidity 20% 38% <0.05 
Bowel resection 3% 8% <0.001 
Cardiac events 0.7% 5.9% <0.001 
Respiratory events 0.3% 5.7% <0.001 
Acute renal failure 6.0% 10.5% <0.05 
LOS                               
median (range), days 
5 (0-94) 11 (1-135) <0.001 
Table 2. Mortality, morbidity, peri-operative complications and length of stay (LOS): 
endovascular revascularisation vs. surgical revascularisation. (adapted from Schermerhorn 
et al., 2009)  
A serious potential complication of endovascular treatment is the precipitation of acute 
intestinal ischemia by plaque embolization or dissection of the artery. Standard catheter 
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usually successful in treating these complications. Emergency laparotomy with mesenteric 
bypass and bowel resection is also used as salvage treatment. We recently reported the 
occurrence of splenic infarction complicating otherwise successful celiac artery stenting, 
presumably as a consequence of distal embolization of disrupted calcific plaque, with this 
complication representing a novel cause of abdominal pain post-procedure (Almeida & 
Riordan, 2008). 
The most common procedural complication of endovascular therapy relates to the puncture 
site, manifesting as either haemorrhage or thrombosis. Haemorrhage is generally controlled 
with local pressure and/or injection of thrombin. Insertion of interventional sheaths in small 
arteries is associated with an increased risk of thrombosis. Rapid heparinization after sheath 
insertion is usually an adequate preventative measure. 
Another important issue is the longer-term arterial patency rate in patients treated by 
endovascular means compared to those managed surgically. In a recent review of 328 
patients undergoing endovascular treatment for chronic mesenteric ischaemia, the overall 
technical success rate was 91% and immediate symptomatic relief was achieved in 82% of 
patients (Kougias et al., 2007). Despite the initial success rate, approximately one third of 
patients (84/292) available for follow up developed restenosis over a mean follow up period 
of 26 months. The 30-day mortality rate was 3-5%. Clinical series comparing endovascular 
and surgical revascularisation have shown that long term patency rates and freedom from 
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symptoms may be inferior in patients who have had endovascular revascularisation 
(Kougias et al., 2009; Atkins et al., 2007; Kasiragjan et al., 2001). Indeed, an analysis of all 
published literature comparing surgical and endovascular treatment options for CMI 
performed between 2000 and 2009 concluded that 5-year primary patency rates were 3.8 
times greater in the surgical group (P<0.001), while freedom from symptoms at 5 years was 
4.4 times greater in patients managed surgically compared to those treated with 
endovascular techniques (p<0.001) (Gupta et al., 2010). 
6. Angioplasty vs stenting 
There is general agreement that stenting is indicated for residual stenosis following primary 
angioplasty (defined as residual stenosis of 30% or more, or pressure gradient higher than 
15mmHg), for ostial or eccentric lesions, or as a salvage procedure for acute dissection after 
angioplasty (Kougias et al., 2007).  Balloon-expandable stents are preferred because of their 
accuracy and ability to generate considerable radial force. More distal or long lesions may be 
better suited to self-expandable stents given their flexibility (Loffroy et al., 2009).  
Kougias et al (2007) reported that technical success was significantly higher with stenting 
compared with angioplasty alone (95% vs 83%, p=0.007), although the rate of restenosis was 
also higher in the stented subgroup, a finding that may have been biased by the inclusion of 
earlier studies where more primitive stents were used and peri-procedural anticoagulant 
and antiplatelet treatment regimens were not standardized. A recent case series 
demonstrated that long-term patency rate was higher in patients managed with primary 
stenting compared to angioplasty alone (Daliri et al., 2010). 
7. Which vessel to treat 
Literature from the surgical revascularisation setting has shown that complete 
revascularisation of the coeliac trunk and SMA is associated with improved long-term 
outcomes (Mateo et al., 1999; McAfee et al., 1992; Foley et al., 2000). The simultaneous 
treatment of two vessels prevents symptom recurrence in the event of restenosis in either 
artery. Improved graft patency and survival with complete reconstruction (McAfee et al., 
1992), and a higher incidence of symptoms and graft failure with single vessel therapy 
(Foley et al., 2000) have each been demonstrated.  
There is a tendency to treat fewer vessels when choosing endovascular revascularisation 
compared with surgical revascularisation (Kougias et al., 2009). The conventional approach 
to endovascular intervention is to treat SMA lesions in preference to celiac trunk or IMA 
lesions. There is conflicting evidence as to whether treatment of both SMA and celiac 
arteries will produce better long-term patency. A recent series by Peck et al indicated that 
two-vessel treatment resulted in lower symptomatic recurrences, improved patency and 
fewer re-interventions (Peck et al., 2010). On the other hand, Sarac et al. (2008) did not report 
any difference in 1 year patency between single-vessel and two-vessel treatment, while 
Malgor et al. (2010) similarly found in a study of longer follow-up of 3 years that two-vessel 
celiac  artery and SMA stenting did not result in improved outcomes when compared with 
single-vessel SMA stent placement for CMI. 
Traditionally, there has been a preference for treating stenotic rather than occlusive lesions 
by endovascular means. Although the presence of an occluded vessel is not an absolute 
contraindication to endovascular intervention, the practice in many centres is to convert 
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from endovascular to open surgical revascularisation when an occlusion is found 
(Kasiragjan et al., 2001).  Endovascular passage of guide wires and stents through totally 
occluded lesions is a technically challenging procedure and not without significant risks of 
vessel perforation or dissection. Although not statistically validated, the degree of difficulty 
is likely to increase with the length of occlusion. A theoretical concern also exists for plaque 
fragmentation and distal embolization, which also increases with the length of occlusion.   
Although the efficacy of endovascular intervention in treating occluded mesenteric vessels 
is not well established, evolving endovascular technology with low-profile systems has now 
made recanalization of occluded vessels feasible. Landis et al. (2005) reported technical 
success and 1-year patency rates of 100% in 9 patients with mesenteric occlusion. A case 
series by Peck et al also indicated that patients with occluded SMA who underwent 
revascularisation had lower 3-year symptom recurrence rates, with three year patency rates 
of 90% for treated SMA occlusions versus 40% for untreated SMA occlusions (Peck et al., 
2010). This difference however was not statistically significant, possibly due to the small 
numbers of patients studied.  
8. Surveillance of vessel patency 
There is a lack of uniformity in the follow up of patients who have received endovascular 
therapy for CMI. Although recurrence of symptoms is correlated with restenosis, this alone 
is not a reliable predictor of vessel patency, with sensitivity as low as 33% for detection of 
restenosis (McMillan et al., 1995). Failure to diagnose progressive disease in asymptomatic 
patients may result in the subsequent development of acute mesenteric thrombosis. This is a 
potentially fatal vascular emergency with overall mortality rate ranging from 32% to 65% 
(Park et al., 2002).  
Abdominal duplex ultrasonography is the most commonly used method of surveillance due 
to its non-invasive nature. Although duplex ultrasonography has been validated in the 
diagnosis of mesenteric arterial stenosis (Zwolak et al., 1998), there is no current consensus 
on which velocity criteria should be used to define high-grade recurrent disease (Kasirajan 
et al., 2001; Armstrong et al., 2007; Fenwick et al., 2007). CT-angiography and MR-
angiography are alternative modalities of imaging, although digital substraction 
angiography is generally considered the gold standard. There is a potential role for 
functional studies such as gastrointestinal tonometry to detect mesenteric ischemia and 
guide treatment (Otte et al., 2008).   
9. Acute mesenteric ischemia 
Acute mesenteric ischemia is associated with a daunting mortality rate of greater than 50% 
(Schermerhorn et al., 2009). Prompt diagnosis and institution of revascularisation therapy 
are crucial for a successful outcome.  
Endovascular treatment for AMI was traditionally reserved for selected patients who have 
prohibitive operative risk, no clinical signs of peritoneal inflammation, or those with a 
contaminated peritoneal cavity and no autogenous vessel available for grafting (Loffroy et 
al., 2009). With evolving expertise and technological advancements in endovascular therapy, 
there has been an increase in the use of endovascular revascularisation for treatment of AMI. 
In the US registry study of 5237 patients treated for AMI, the outcomes of patients who were 
treated with endovascular intervention were compared to those who were treated with 
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surgery (Schermerhorn et al., 2009). Patients who were treated with endovascular measures 
tended to have higher rates of cardiovascular comorbidities than those undergoing open 
surgical repair, including hypertension, peripheral vascular disease, coronary artery disease 
and chronic renal failure. Despite these unfavourable patient characteristics, mortality was 
significantly lower in the endovascular group compared with the surgical group (16% vs 
39%, p<0.001).  
In a recent retrospective, single centre case series of 70 patients with AMI, the largest such 
case series to date, Arthurs et al. (2011) demonstrated that the use of endovascular therapy 
as primary treatment for AMI produced lower complication rates and better outcomes 
(Arthurs et al., 2011). During a 9-year study period, endovascular therapy was initiated in 56 
patients while surgical therapy was used in 24 patients. Overall, technical success for 
endovascular therapy was 87%. Failures in endovascular therapy were treated with 
embolectomy in 78% and revascularisation in 22%. Successful endovascular treatment 
resulted in a mortality rate of 36%, which was significantly lower compared with a rate of 
50% in those treated surgically (p<0.05). Patients who failed endovascular treatment had a 
mortality rate of 50%, an outcome which was equivalent to that of traditional surgical 
therapy. Block et al. (2010) have also recently reported improved 30 day and long-term 
survival with endovascular revascularisation of the SMA compared to surgery in patients 
identified through the Swedish Vascular Registry from 1999 to 2006, although the need for 
prospective randomised data to confirm group differences was highlighted. 
The general view that laparotomy is crucial for all patients with AMI to assess intestinal 
viability and perform resection as required has also recently been questioned. Arthurs et al. 
(2011) challenged this philosophy by performing laparotomy only on patients who had 
signs of peritoneal inflammation or deteriorated clinically following initial revascularisation. 
Over 30% of patients in the endovascular therapy group did not ultimately require 
laparotomy, thereby avoiding further physiologic insult to patients who are already 
critically ill.   
Another important issue is to what extent ischaemia-reperfusion injury of the intestine, 
leading to microvascular injury and cellular necrosis and apoptosis, contributes to morbidity 
and mortality in patients in whom arterial revascularisation is attained and whether various 
recent advances in preventing or limiting this phenomenon described in the experimental 
situation can be translated clinically (Santora et al., 2011; Petrat & de Groot, 2011; Flessas et 
al., 2011).  
10. Conclusions 
There has been a recent paradigm shift in the treatment of mesenteric ischaemia. Whereas 
endovascular therapy was once reserved for the few patients who had prohibitive operative 
risks, it is now increasingly used for revascularisation of both chronic and acute mesenteric 
ischemia. Endovascular therapy is less invasive than open surgery, and is associated with 
lower peri-procedural morbidity and mortality. There is growing evidence that stenting 
may achieve better technical success and patency rates compared with angioplasty alone. 
The timing and choice of imaging modality for surveillance of vessel patency remains an 
important question for clinicians. Effective approaches to improving longer-term vessel 
patency rates following endovascular therapy are required, along with strategies to prevent 
ischaemia-reperfusion injury in those patients with acute mesenteric ischaemia in whom 
revascularisation is achieved. 
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1. Introduction 
Cerebral hyperperfusion syndrome (CHS) was first described by Sundt et al. (1981) as a 
clinical syndrome following carotid endarterectomy (CEA) characterized by headache, 
neurological deficit, and epileptic seizures that is not caused by cerebral ischemia.   
This chapter deals with this uncommon but not exceptional complication of endovascular 
treatment of the arteries that supply the brain. We use the term carotid artery stenting (CAS) 
to refer to stenting of the internal carotid artery (ICA) because most publications are 
centered on this artery. Moreover, we include angioplasty without stent placement in the 
term CAS to facilitate reading comprehension because the relation between endovascular 
treatment and CHS is related to revascularization itself rather than to stent placement per se.  
Given the high rate of ischemic brain disease in relation to carotid stenosis and the high 
prevalence of asymptomatic carotid stenosis, numerous publications discuss CHS in relation 
to CEA: the incidence in these series ranges from 0.3% to 2.2%. However, CAS has 
continually evolved in recent years to the point where, after more than 40 years’ experience, 
it is considered an alternative to CEA. Furthermore, the development of new materials for 
stents, filters for distal protection, dual antiplatelet treatment, and the learning curve are 
minimizing the short- and long-term adverse effects of CAS.  
Documented complications of CAS include cerebral embolism, hemodynamic compromise, 
vessel dissection, and early restenosis and occlusion, as well as the hyperperfusion 
syndrome we deal with in this chapter. Moreover, the spectacular increase in endovascular 
treatment has revealed that hyperperfusion syndrome can also occur after revascularization 
of other arteries, such as the vertebral arteries, the subclavian arteries, or even those located 
within the brain, mainly the middle cerebral artery (MCA).  
In this chapter we will begin by discussing the pathophysiology, clinical presentation, and 
incidence of CHS in the different published series. We will then discuss the risk factors, 
diagnostic methods, and strategies for prevention and treatment. We will also discuss a 
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condition that shares the same pathophysiology as CHS, contrast-induced encephalopathy, 
in which contrast agents crossing the blood-brain barrier have a toxic effect on the brain 
parenchyma, resulting in signs and symptoms similar to those of CHS. Given the larger 
number of publications about hyperperfusion after CEA and the obvious similarities in 
aspects like the pathophysiology and risk factors, we refer to CEA on numerous occasions in 
this chapter.  
2. Pathophysiology  
First, we must differentiate between the concept of hyperperfusion and CHS. In general, 
hyperperfusion is considered to occur when cerebral blood flow (CBF) in the revascularized 
territory increases by 100% or more with respect to the baseline values. In series by 
Ogasawara (2007) and Fukuda (2007), 16.7% to 28.6% of the patients with an increase in CBF 
100% developed CHS. Moreover, a few cases of CHS in which CBF had increased less than 
100% have been reported (Karapanayiotides et al, 2005; Henderson et al, 2001). Thus, other 
factors must be involved in CHS (Hosoda et al, 2003; Kaku et al, 2004; Ogasawara et al 2003; 
Suga et al, 2007; Yoshimoto et al, 1997).  
All authors agree that it is very likely that there has to be damage to cerebral autoregulation, 
in other words, impaired cerebral vasoreactivity (CVR), for CHS to occur (Keunen et al, 
2001). 
Cerebral hemodynamics and CVR are individualized in each patient. This could be 
explained by the different extent of collateral circulation available and by the autoregulatory 
mechanisms of the cerebral circulation. The presence of sufficient collateral circulation has a 
key role in the preservation of CVR, and thus protects against CHS.   
Similarly, other risk factors for CHS are low pulsatility index, severe ipsilateral and 
contralateral carotid disease, and an incomplete circle of Willis (Jansen et al, 1994; Reigel et 
al, 1987; Sbarigia et al 1993). 
CVR makes it possible to keep blood pressure (BP) between acceptable limits (60 mmHg - 160 
mmHg) through arteriolar vasodilatation or vasoconstriction in response to changes in carbon 
dioxide. This response is most pronounced in smaller arteries (diameter 0·5–1·0 mm), whereas 
arteries with a diameter of 2·5 mm or more like the ICA show no substantial change.  
Regulation involves a myogenic and a neurogenic component. In myogenic autoregulation, 
increased intravascular pressure results in vasoconstriction of small arterioles at high 
systemic BP, but when BP exceeds the limit of myogenic autoregulation, the remaining 
autoregulation in small arteries is dependent on sympathetic autonomic innervation. As a 
result of sparse sympathetic innervation, the vertebrobasilar system is less protected than 
other regions of the brain, which explains why this system is more affected in entities like 
hypertensive encephalopathy. Impaired CVR results in failure of the arterial system to 
respond to a sudden increase in CBF and is usually due to severe vascular stenosis together 
with insufficient collateral blood flow. When these two factors coexist, cerebral perfusion is 
maintained by the maximum dilation of the arterioles. This prolonged vasodilation makes 
the vessels unable to respond with vasoconstriction when blood flow is increased, and 
especially when it is increased suddenly (Ascher et al, 2003; Jansen et al, 1994; Reigel et al, 
1987; Tang et al, 2008 Sbarigia et al, 1993).  
At the end of the 1990s, some surgical reports already suggested that patients with 
preoperative hemodynamic failure were at definite risk for CHS (Baker et al, 1998; Cikrit et 
al 1997; Yoshimoto et al, 1997) and that the presence of a critical stenosis in the ICA 
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increased the risk of intracranial hemorrhage (ICH) (Jansen et al, 1994; Macfarlane et al, 
1991; Ouriel et al, 1999; Sbarigia et al, 1993). Preoperative significant reduction in flow 
velocity compared with baseline values is indicative of hypoperfusion and is associated with 
postoperative hyperperfusion (Keunen et al, 2001). 
Sudden revascularization brought about by angioplasty leads to dysfunction of the blood-
brain barrier after the failure of arteriolar vasoconstriction. This results in transudation of 
fluid into the pericapillary astrocytes and interstitium, giving rise to vasogenic edema. This 
hydrostatic edema predominantly affects the vertebrobasilar circulation territory in both 
CHS and hypertensive encephalopathy, possibly as a result of regional variation in cerebral 
sympathetic innervation. 
The most extreme form of this syndrome is bleeding, either ICH, which results in high 
morbidity and mortality, or subarachnoid hemorrhage (SAH), which has a better prognosis.  
The pathophysiology of the hemorrhage that results from revascularization might be 
different from that of CHS described by Sundt, et al (1981). Some authors (Karapanayiotides 
et al, 2005) prefer to call this entity “reperfusion syndrome” to emphasize the damage to 
tissues caused by simple reperfusion. Several investigators have analyzed the characteristics 
of this ICH when it appears in the first few hours and without prodromes, attributing it to 
the rupture of deep penetrating arteries as a result of the sudden normalization of the 
pressure of cerebral perfusion after angioplasty, similar to what occurs in hemorrhage due 
to hypertension (Buhk et al, 2006; Coutts et al, 2003).  
Many cases of SAH after CAS have been reported (Abou-Chebl et al, 2004;  Coutts et al, 
2003; Hartmann et al, 2004; Ho et al, 2000; McCabe et al, 1999; Meyers et al, 2000; Morrish et 
al, 2000; Nikolsky et al, 2002; Pilz et al, 2006; Qureshi et al, 2002); these have a better 
prognosis than ICH.  
It is logical to assume that CBF increases substantially after CAS in a severely stenosed 
carotid artery. However, studies show that the increase in CBF is actually related to 
impaired CVR. In a study by Hosoda et al (1998) CBF significantly increased on the first 
postoperative day in subjects with reduced preoperative CVR but not in those with normal 
preoperative CVR. Similarly, in a study of 23 patients, Ko et al (2005) were unable to 
demonstrate a relation between the degree of stenosis and the increase in CBF. In short, the 
degree of stenosis cannot be considered a key risk factor for CHS, although some series have 
taken it into account.  
Ascher et al (2003) studied 455 patients undergoing CEA and found no relation between 
CHS and the severity of ipsilateral or contralateral carotid stenosis, arterial hypertension, or 
perioperative perfusion pressure. However, mean ICA volume flow and peak systolic 
velocity measured at the onset of symptoms in the 9 CHS cases were higher than in the 
remaining 446 cases. 
In most cases of symptomatic carotid stenoses due to a hemodynamic mechanism CVR is 
also deficient, so it is logical to think that they will be more susceptible to developing CHS 
after revascularization (Brantley et al, 2009). However, in a study of 333 patients undergoing 
CAS, Karkos et al (2010) found no significant differences between symptomatic and 
asymptomatic patients.  
Fukuda et al (2007) carried out an interesting study of CBF and cerebral blood volume 
(CBV) in 15 patients without contralateral carotid stenosis undergoing CEA.  They observed 
a correlation between increased CBV and increased CBF after CEA on single-photon 
emission computed tomography (SPECT) and magnetic resonance imaging (MRI), with 
signs of hyperperfusion in seven patients (47%). Two of these seven patients developed 
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CHS, whereas none of the eight patients with normal CBV developed CHS. In this study, 
elevated preoperative CBV was the only significant independent predictor of post-CEA 
hyperperfusion.   
The endothelial damage caused mainly by chronic hypertension in the small arteries may 
also be related to cerebral autoregulation (Skydell et al, 1987). In fact, some authors relate a 
history of stroke with a greater risk of CHS (Chamorro et al, 2000; McCabe et al, 1999).  
Another important but not essential factor associated with CHS is high blood pressure. High 
blood pressure is the only factor we can treat, so it has become the principal target for 
prevention and treatment. Indeed, the pathophysiology of CHS is similar to that of 
hypertensive encephalopathy in which the blood-brain barrier ruptures as a consequence of 
severe hypertension. Furthermore, histologic changes like fibrinoid necrosis and petechial 
hemorrhage also occur in both hypertensive encephalopathy and CHS (Bernstein et al, 1984; 
Mansoor et al, 1996; Schwartz 2002; Vaughan & Delanty, 2000).  
The mechanisms by which BP increases after carotid revascularization are poorly 
understood. The baroreceptor reflex might break down after receptor denervation after CEA 
or CAS, and hypertension accompanying this feature might increase cerebral perfusion 
which is more evident after bilateral carotid surgery (Ahn et al, 1989; Bove et al, 1979; 
Timmers et al, 2004) and is reported in 19% to 64% after CEA.  
The stimulation of these baroreceptors in the carotid bifurcation during angioplasty can 
cause transient bradycardia and hypotension  that can be followed by rebound 
hypertension. Other phenomena proposed to explain the high blood pressure include 
increased norepinephrine levels probably related to cerebral edema and increased 
intracranial pressure, the release of vasoactive neuropeptides, the use of anesthetic drugs, 
and perioperative stress (Bajardi et al, 1989; Benzel & Hoppens, 1991; Macfarlane et al, 1991; 
Towne JB & Bernhard, 1980; Skydell et al, 1987; Skudlarick & Mooring, 1982;). 
Another possible mediator of impaired autoregulation in CHS is nitric oxide, which causes 
vasodilatation and can increase the permeability of cerebral vessels. Increased nitric oxide 
levels during clamping of the ICA and increased oxygen-derived free radicals produced 
during the restoration of cerebral perfusion are involved in endothelial dysfunction and 
deterioration of autoregulatory mechanisms after CEA (Suga et al, 2007). Several authors 
(Ogasawara et al, 2004; Saito et al, 2007) have reported that the degree of reactive oxygen 
species production after ischemia and reperfusion during CEA depends on the intensity of 
cerebral ischemia during ICA clamping.  
Reactive oxygen species can play a role in the pathogenesis of post-CEA hyperperfusion, 
leading to widespread endothelial damage in the ipsilateral cerebral arteries and thereby 
increasing the risk of ICH in the early postoperative period. Furthermore, administering a 
free-radical scavenger can prevent CHS, providing additional support for this mechanism 
(Ogasawara et al, 2004). 
Finally, an axon-like trigeminovascular reflex has been implicated in the pathophysiology of 
CHS (Macfarlane et al, 1991). The release of vasoactive neuropeptides from perivascular 
sensory nerves via axon reflex-like mechanisms has a significant bearing upon a number of 
hyperperfusion syndromes. 
3. Clinical presentation  
The typical clinical presentation of CHS combines symptoms due to ICH and those due to 
brain damage caused by vasogenic edema. The most common symptoms caused by ICH are 
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headache, confusion, altered levels of consciousness, and sometimes vomiting. On the other 
hand, the edema usually manifests as a neurological deficit on the side of the untreated 
carotid artery, often associated with epileptic activity (seizures, usually starting as partial 
seizures). Arterial hypertension is the norm in patients that develop symptoms of CHS; 
however, it is important to remember that bradycardia and hypotension often occur initially 
after angioplasty due to stimulation of the baroreceptor reflex.  
When a patient has symptoms of neurological deficit after angioplasty, the first diagnosis 
considered is embolic stroke from carotid plaque broken off during the procedure. Thus, 
CHS can mimic a stroke or transient ischemic attack (TIA), so it is important to take into 
account symptoms like headache, seizures, and altered mental status that can suggest CHS. 
Nevertheless, acute neurological deficit accompanied by headache or even seizures is 
obviously compatible with ICH, which can be ruled out only by neuroimaging.  
Neurological deficit due to vasogenic edema is usually transitory, given the absence of 
ischemic infarction (Bernstein et al, 1984; Piepgras et al 1988; Reigel et al, 1987; Sundt et al, 
1981; Solomon et al, 1986). Although the neurological symptoms can vary, the most common 
are visual or motor deficits and aphasia. Other, rarer, symptoms include psychotic 
alterations or mild cognitive deficit (Ogasawara et al, 2005). 
Seizures are generally partial at first and sometimes become generalized later, although 
generalized seizures can also occur initially (Ho et al, 2000); in fact, even status epilepticus 
has been reported up to two weeks after the procedure (Kaku et al, 2004). One third of 
patients with CHS after CEA have seizures without hemiparesis, another third have 
hemiparesis without seizures, and another third have both (Bouri et al, 2011).  
Curiously, the onset of symptoms after CEA and CAS differs. Symptoms usually do not 
appear until three to six days after CEA. In contrast, symptoms usually appear within a few 
hours of CAS. Ogasawara et al (2007) report that the incidence of CHS peaks six days after 
CEA and 12 hours after CAS. After reviewing 36 studies, Bouri et al (2011) concluded CHS 
peaks five days after CEA and the latest case occurred after 28 days.  
The same is true of ICH, which appears 10.7 ± 9.9 days after CEA and 1.7 ± 2.1 days after 
CAS, peaking in the first 12 hours. Tan et al (2004) studied the appearance and onset of 
complications after CAS in 201 patients; they report 10 cases with  TIA (4.9%), 5 of which 
occurred more than 48 hours after the procedure, and 8 strokes (3.9%), 5 of which occurred 
between 2 and 19 days after the procedure. Curiously, however, these authors found no 
cases of CHS. 
The headache in CHS is usually moderate to severe and throbbing, similar to a migraine 
headache (Coutts et al, 2003), and it usually affects the same side as the artery treated.  
Headache may be the only manifestation of CHS (Connolly 2000; Ouriel et al, 1999; Sbarigia 
et al, 1993), so occasionally it has been considered a diagnostic criterion. After CEA, 
headaches are reported in 20% of patients without CHS, in 59% of those with CHS, and in 
84% of those with ICH (Bouri et al, 2011). 
Postprocedural hypertension is a critical, though not essential, finding associated with CHS 
(Solomon et al, 1986; Schroeder et al, 1987; Ouriel et al 1999). Bouri et al review (2011) found 
that the mean systolic BP of CHS cases was 189 mmHg at presentation, and the proportion 
of patients with severe hypertension was significantly higher in patients who developed 
CHS after CEA than in those who did not.  
Hypotension occurs immediately after CAS in 19% to 51% of patients. It is usually transient 
and rarely symptomatic, although it lasts longer than 24 hours in nearly 5% of patients. 
Bradycardia is also common, with an incidence of 3% to 37% in patients administered 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
12
CHS, whereas none of the eight patients with normal CBV developed CHS. In this study, 
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species production after ischemia and reperfusion during CEA depends on the intensity of 
cerebral ischemia during ICA clamping.  
Reactive oxygen species can play a role in the pathogenesis of post-CEA hyperperfusion, 
leading to widespread endothelial damage in the ipsilateral cerebral arteries and thereby 
increasing the risk of ICH in the early postoperative period. Furthermore, administering a 
free-radical scavenger can prevent CHS, providing additional support for this mechanism 
(Ogasawara et al, 2004). 
Finally, an axon-like trigeminovascular reflex has been implicated in the pathophysiology of 
CHS (Macfarlane et al, 1991). The release of vasoactive neuropeptides from perivascular 
sensory nerves via axon reflex-like mechanisms has a significant bearing upon a number of 
hyperperfusion syndromes. 
3. Clinical presentation  
The typical clinical presentation of CHS combines symptoms due to ICH and those due to 
brain damage caused by vasogenic edema. The most common symptoms caused by ICH are 
 
Cerebral Hyperperfusion Syndrome After Angioplasty 
 
13 
headache, confusion, altered levels of consciousness, and sometimes vomiting. On the other 
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prophylactic atropine and of 20% to 60% in series with no use of prophylactic atropine. 
Increased age, symptomatic lesions, presence of ulceration and calcification, and carotid 
bulb lesions are significant predictors of bradycardia during CAS (Cayne et al, 2005; Lin et 
al, 2007; Pappada et al, 2006 & Taha et al, 2008). 
Another complication with more dramatic consequences is ICH, which affects less than 1% of 
patients after CEA and between 0.36% and 4.5% after CAS. Generally, ICH has a poor 
prognosis, with a 37% to 80% mortality rate and a 20% to 30% risk of poor recovery in 
survivors after CEA (Piepgras et al,1988; Connolly 2000) and similar consequences after CAS.   
4. Diagnosis 
The diagnosis of CHS is based on the initial suspicion arising from the characteristic triad of 
headache, focal neurological deficit, and seizure after arterial revascularization. The 
differential diagnosis should include stroke and TIA. Seizures and altered consciousness 
favor the diagnosis of CHS. After the initial clinical suspicion, neuroimaging plays a crucial 
role because in addition to ruling out ischemic and hemorrhagic lesions it can reveal 
characteristic signs of hyperperfusion.  
Given the widespread availability of CT, any acute neurological event after 
revascularization is usually studied with this technique. CT is most useful for ruling out 
hemorrhagic processes. Given that the initial symptoms of CHS can mimic stroke or TIA, CT 
can give us clues that argue against an ischemic stroke, because CT findings are usually 
normal after a TIA and are often normal within hours after a stroke. Diffusion MRI is the 
technique of choice to rule out acute ischemic stroke; MRI has shown that there are a greater 
number of embolic lesions up to 48 hours after CAS, although nearly all are asymptomatic 
(Rapp et al, 2007).  
We will comment on two important aspects of neuroimaging studies. First, we will discuss 
their usefulness in the diagnosis of CHS, as apart from demonstrating typical findings like 
vasogenic edema (Case 1) they also enable CBF to be quantified (increases in CBF > 100% 
with respect to baseline values have been related to greater risk of developing CHS). Second, 
we will discuss the usefulness of these techniques in the evaluation of CVR, the key 
pathophysiological factor in CHS.   
4.1 Diagnosing cerebral hyperperfusion 
The imaging techniques that can demonstrate hyperperfusion are single-photon emission 
computed tomography (SPECT), positron emission tomography (PET), transcranial Doppler 
(TCD), CT and MRI. According to Penn et al (1995), xenon-enhanced CT is the best method 
for demonstrating hyperperfusion. Nevertheless, SPECT and TCD are the most common 
methods in the literature, followed by CT and MRI.  
CT in CHS typically reveals ipsilateral sulcal effacement and cerebral edema immediately 
following the onset of symptoms; these findings are considered indirect signs of 
hyperperfusion. CT findings early after the onset of symptoms can be completely normal, 
even when SPECT shows hyperperfusion.  
Without doubt, T2-weighted and FLAIR MRI sequences are more precise in demonstrating 
areas of cerebral edema, and diffusion-weighted MRI makes it possible to rule out 
hyperacute ischemic lesions.  
However, normal findings on MRI do not exclude the presence of CHS. Both MRI and CT 
enable angiographic maps to be constructed to rule out arterial occlusions and perfusion 
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maps can show local hyperemia. Karapanayiotides et al (2005) reported no abnormalities on 
diffusion-weighted MRI in patients with CHS after CEA, ruling out acute ischemia; 
however, perfusion sequences revealed differences in CBF between the hemispheres.  
Hypoperfusion before revascularization and especially hyperperfusion (increase in CBF > 
100% with respect to baseline values) after revascularization are conditions that are closely 
related with CHS. TCD is the method most often used to detect these conditions because it 
enables variations in CBF to be calculated in real time. TCD has many advantages and 
multiple indications in cerebral vascular disease (Alexandrov et al, 2010). TCD monitoring 
can provide direct and real-time information on MCA flow indicative of preoperative 
cerebral hypoperfusion, CVR, postoperative hyperperfusion, and emboli after CEA and 
CAS. Moreover, TCD is widely available, noninvasive, and reproducible. It is important to 
do a baseline study to enable flow velocities before and after revascularization to be 
compared (Dalman et al, 1999; Jansen et al, 1994).  
Asher et al (2003) studied 455 patients undergoing CEA and reported a significant increase 
in mean ICA flow volume in all patients with CHS during the symptomatic period; 
moreover, after flow velocities return to normal, the symptoms of hyperperfusion 
disappear.  
Diverse publications about patients undergoing CAS emphasize the role of TCD in detecting 
hemodynamic changes that make it possible to select patients with greater risk of 
developing CHS. For example, in one interesting study published recently, Kablak et al 
(2010) monitored both MCAs before and after CAS, finding a relation between ICH in 3 
patients and an increase in peak systolic velocities in both MCAs after CAS. Fujimoto et al 
(2004) examined the changes in the MCA mean flow velocity measured by TCD before and 4 
days after CEA. They reported a significant correlation between changes in mean flow 
velocity and changes in regional CBF; mean flow velocity increased more than 50% in all 
cases of CHS.  
Some studies have used both TCD and SPECT to assess patients before and after 
revascularization. Recently, Iwata et al (2011) used these two techniques to study 64 patients 
and found 9 patients who fulfilled the clinical criteria for CHS. These authors relate CHS 
with decreased CVR and changes in MCA flow velocity after angioplasty.  
Perfusion CT has also contributed to our understanding of CHS. Tseng at al (2009) used CT 
to study 55 patients with symptomatic stenoses >70% of the ICA, analyzing absolute values 
of CBV, mean transit time (MTT), and CBF. Three (5%) of 55 patients had CHS after CAS. 
The only significant factor related to the occurrence of CHS was MTT. An MTT cutoff of 3 
seconds distinguished between the occurrence and absence of CHS. MTT prolongation is 
proportional to the degree of stenosis and decrease in blood flow (Maeda et al, 1999; 
Lythgoe et al, 2000; Soinne et al, 2003). Findings of decreased CBF together with MTT 
prolongation and a slight increase in CBV indicate that blood vessels are dilated, thus 
confirming that the autoregulation mechanism is impaired.  
Several authors have examined the role of CT and MRI in demonstrating hyperperfusion 
(Adhiyaman & Alexander 2007; Imai et al 2005; Sundt et al, 1981). Multislice dynamic 
susceptibility contrast MRI or perfusion-weighted MRI can also be used in the preoperative 
assessment of CBF (Fukuda et al, 2007; Wiart et al 2000). Perfusion sequences, however, are 
not quantitative and can only help in the absence of contralateral ICA stenosis.  
PET has also provided valuable information about CHS. Matsubara et al (2009) used PET to 
study patients before and after angioplasty. They found that the vascular reserve tended to 
improve gradually after CAS, while CBF, cerebral perfusion pressure, and cerebral 
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metabolic rate of oxygen increased rapidly and peaked soon after CAS. These results 
suggest that a large discrepancy between rapidly increased CBF, perfusion pressure, and a 
small increase in vascular reserve in the acute stage after CAS could cause CHS. 
Cerebral oxygen saturation can serve as an indirect measure of CBF. Clinically, regional 
cerebral oxygen saturation can be monitored using transcranial near-infrared spectroscopy, 
which enables noninvasive continuous real-time detection of changes in the ratio of 
oxyhemoglobin to deoxyhemoglobin in the frontal cortex, an indirect measure of cerebral 
oxygenation. Recently, a strong linear correlation was reported between increased 
transcranial regional cerebral oxygen saturation and increased CBF after CEA (Ogasawara et 
al, 2003). When compared with SPECT, the sensitivity and specificity of transcranial regional 
cerebral oxygen saturation for the detection of hyperperfusion were 100%. Transcranial 
near-infrared spectroscopy can demonstrate decreased cerebral oxygenation resulting from 
ICA clamping (Beese et al, 1998; Duncan et al, 1995; Kirkpatrick et al, 1995; Samra et al, 1996) 
and can predict post-CEA CHS. Matsumoto et al (2009) used transcranial near-infrared 
spectroscopy to study 64 patients undergoing CAS, two of whom developed CHS 
(diagnosed by increased CBF at SPECT the day after treatment). An increase in regional 
oxygen saturation > 24% three minutes after revascularization was associated with the 
development of CHS (with impaired CVR). In contrast, in patients without CHS, the normal 
upper limit of the change in regional oxygen saturation three minutes after revascularization 
was 10 %.  
Oxygen saturation should be monitored for a prudential time because bradycardia and 
hypotension often occur with CAS and can occasionally lead to low initial values. As occurs 
in many studies, the small number of patients with CHS in this study does not allow clear 
conclusions to be drawn; nevertheless, given that transcranial near-infrared spectroscopy  
is noninvasive and easy to perform, it should be considered for monitoring patients at risk 
for CHS.  
Alternative methods have been applied to identify risk factors for postoperative 
hyperperfusion, but their utility is not yet clearly established. Electroencephalography is 
used for neurological monitoring during CEA, but it is of low predictive value for CHS 
(Reigel et al, 1987). Nicholas et al (1993) reported that a postoperative increase in ocular 
blood flow greater than 204% measured by ocular pneumoplethysmography is associated 
with a high risk for CHS.  
4.2 Diagnosing hemodynamic reserve 
One strategy that is key to preventing CHS is the study of CVR, which is usually done by 
TCD and SPECT.  
SPECT is sensitive for recognizing CHS, differentiating between ischemia and 
hyperperfusion, and identifying patients at risk for hyperperfusion after CEA (Hosoda et al, 
2001; Naylor et al, 2003; Sfyroeras et al, 2006). Several studies using SPECT have 
demonstrated that decreased CVR using acetazolamide is a significant predictor of post-
CEA hyperperfusion (Ogasawara et al, 2003; Yoshimoto et al, 1997).  
Fewer studies have focused on patients undergoing CAS. Kaku et al (2004) published one of 
the first studies about predicting CHS with nuclear medicine techniques in patients 
undergoing CAS.  
They measured resting CBF and CVR to acetazolamide to evaluate CVR, using split-dose [123I] 
iodoamphetamine SPECT before and 7 days after CAS in 30 patients with critical carotid 
stenosis. The 3 patients with hyperperfusion all had impaired CVR and asymmetrical carotid  
 





A 71-year–old man with symptomatic pseudo-occlusion of the right ICA had a seizure  
with Todd´s paralysis six days after CEA. Neuroimaging showed vasogenic edema  
(1- CT, 2- Axial T2-weighted MRi, 3-Coronal FLAIR MRi, 4- Axial diffusion-weighted MRi, 
5- CT angiography) 
CBF.  These authors determined that pretreatment resting CBF value, degree of carotid 
stenosis, and interval from the onset of ischemic symptoms were not significant risk factors.  
However, the high cost and limited availability of SPECT preclude its clinical use.  
TCD has numerous advantages in diagnosing hemodynamic reserve: it is noninvasive, 
relatively simple, cheap, and reproducible, and it is risk free when the breath-hold and 
hyperventilation method is used. TCD enables CVR to be calculated using stimuli like 
hypocapnia (induced by breath holding or by inhalation of CO2) or acetazolamide.  
The response to these stimuli reflects the cerebral autoregulation capacity and thus makes it 
possible to determine which patients have a high risk of developing CHS (Sfyroeras 2006, 
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hypocapnia (induced by breath holding or by inhalation of CO2) or acetazolamide.  
The response to these stimuli reflects the cerebral autoregulation capacity and thus makes it 
possible to determine which patients have a high risk of developing CHS (Sfyroeras 2006, 
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2009). However, TCD has some drawbacks. The absence of a cranial window makes TCD 
impossible in 15% of patients, mainly elderly women. Moreover, TCD is operator-
dependent and the results also depend on anatomic variants, the degree of collateralization, 
and contralateral ICA occlusion or stenosis.  
Table 1 shows the formulas to calculate the CVR using breath-holding and CO2 inhalation 
or acetazolamide. In the breath-hold method, patients are asked to hold their breath for at 
least 30 seconds during continuous MCA flow velocity monitoring; normal values are 1.2 
+/- 0.6% / sec. In the hyperventilation/ breath-holding method, patients are asked to 
hyperventilate for 40 seconds followed by a breath-holding phase of at least 30 seconds. 
Flow velocity values under maximal hyperventilation and hypoventilation are compared; a 
relative difference greater than 15% argues against relevant impairment of CVR. 
 
 
                       Breath-holding index (BHI) 
 
                             V apnea  - V baseline 
               BHI =     -------------------------  x 100 
                             V baseline x T apnea 
---------------------------------------------------------------------------- 
                   CO2 inhalation test/acetazolamide test 
 
                           CO2/acetazolamide – V baseline 
             CVR =     --------------------------------------    x 100%) 
                                         Vbaseline 
 
Table 1. 
Chang et al (2009) used functional MRI to assess baseline CVR and changes in CBF after 
CAS. Although this small series of 14 patients had no cases of CHS, this study revealed that 
after CAS early CBF changes on the lesion side are more prominent in patients with 
impaired CVR. Therefore, baseline CVR might predict early CBF increase after CAS. New 
MRI techniques like dynamic susceptibility contrast MRI or perfusion-weighted MRI can 
determine CVR (Wiart et al, 2000).  
5. Incidence and risk factors  
This section reviews the incidence of CHS after CAS in the most relevant series included in 
PubMed from 2003 to April 2011. We focus on three aspects of CHS: extracranial CAS, 
angioplasty of intracranial arteries (including the ICA) with or without stenting, and 
cerebral hemorrhage, the most-feared complication of this treatment.  
5.1 Extracranial carotid angioplasty 
Most articles about CHS refer to CAS or CEA of the ICA because occlusive disease is more 
prevalent in these arteries than elsewhere. Bouri et al (2011) reviewed 36 studies of patients 
undergoing CEA and found 1% incidence of CHS and a 0.5% incidence of ICH.  
In many CAS series, patients referred for endovascular treatment comprise a high-risk 
cohort of suboptimal candidates for conventional surgical management. This might partially 
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explain the greater number of complications, including CHS, in patients treated with CAS. 
Furthermore, the endovascular procedure is performed with stricter antithrombotic 
management, with anticoagulation and dual antiplatelet treatment that might lead to a 
higher rate of hemorrhagic events, although not all authors agree with this hypothesis 
(Abou-Chebl et al, 2004; Meyers et al, 2000). Table 2 lists risk factors for CHS, broken down 
into modifiable and non-modifiable factors.  
Although procedural and midterm complication rates of CAS in elderly patients are 
acceptable, high age seems to be a possible risk factor for CHS (Kadkhodayan et al, 2007). 
Other risk factors often mentioned in the literature are severe (>90%) ipsilateral stenosis, 
impaired collateral flow secondary to advanced occlusive disease in other extracranial 
cerebral vessels or an incomplete circle of Willis, perioperative and postoperative 
hypertension, and the use of antiplatelet agents or other anticoagulants (Chamorro et al, 
2000; Reigel et al, 1987; Sfyroeras et al 2008; Zahn et al, 2007). 
Abou et al (2004) report a series of 450 patients undergoing CAS where 5 (1.1%) developed 
CHS, 3 of them developed ICH (0.67%), and 2 of them (0.44%) died. All the patients that 
developed CHS had stenoses >90%, contralateral stenoses >80%, and longstanding 
preprocedural hypertension. The authors calculate that in patients with these three 
conditions, the risk of developing CHS was 16%. Only 5.8% of the patients that did not 
develop CHS met these three criteria. The low incidence of CHS in this series might be due 
to the fact that CHS was not diagnosed in cases with headache and vomiting. Two of the 
cases of ICH appeared a few days after CAS and only one occurred immediately after the 
procedure.  
Ogasawara et al (2007) published a series of 4494 patients revascularized with CEA or CAS. 
Of the 1596 patients treated with CEA, 30 (1.9%) developed CHS and 6 of these developed 
ICH (0.4% of the total). Of the 2898 patients treated with CAS, 31 (1.1%) developed CHS and 
21 (0.7% of the total) of these developed ICH. In the group of patients treated with CEA but 
not in those treated with CAS, poor BP control after revascularization correlated with CHS. 
CHS and ICH ocurred significantly earlier after CAS than after CEA. The difference between 
the two procedures in terms of the timing of CHS onset may be explained as follows. First, 
the higher incidence of embolisms after CAS (Roh et al, 2005) might explain how a 
hemorrhagic transformation could occur after the resolution of the embolism in the tissue 
that was damaged; from a pathophysiological point of view, however, this would represent 
hemorrhagic infarction due to reperfusion rather than CHS. Second, the higher incidence of 
bradycardia and hypotension after the stimulation of the carotid baroreceptors during CAS 
(Mendelsohn et al, 1998; McKevitt et al, 2003; Qureshi et al, 1999) can favor cerebral ischemia 
and CHS after severe rebound hypertension (Abou-Chebl et al, 2007). In an earlier 
publication (Ogasawara et al, 2003), these authors suggested that SPECT findings of 
hyperperfusion continuing at least three days after revascularization predisposes to CHS.  
In an excellent review of 9 studies of CAS comprising a total of 4446 patients, Moulakakis et 
al (2009) found the incidences of CHS and ICH were 1.16% (range, 0.44% - 11.7%) and 0.74% 
(range, 0.36% -4.5%), respectively. Table 3 shows the incidence of CHS and of ICH in the 
largest series published before 2010, including series of patients undergoing angioplasty of 
intracranial arteries.   
In order to document the incidence of CHS after CAS and to determine possible 
predisposing factors, Sfyroeras et al (2009) studied 29 patients with CT, MRI, TCD including 
assessment of CVR, and SPECT before and after the procedure. A total of 5 patients 
developed adverse neurological events. Two of them developed CHS (6.9%); both had 
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2009). However, TCD has some drawbacks. The absence of a cranial window makes TCD 
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explain the greater number of complications, including CHS, in patients treated with CAS. 
Furthermore, the endovascular procedure is performed with stricter antithrombotic 
management, with anticoagulation and dual antiplatelet treatment that might lead to a 
higher rate of hemorrhagic events, although not all authors agree with this hypothesis 
(Abou-Chebl et al, 2004; Meyers et al, 2000). Table 2 lists risk factors for CHS, broken down 
into modifiable and non-modifiable factors.  
Although procedural and midterm complication rates of CAS in elderly patients are 
acceptable, high age seems to be a possible risk factor for CHS (Kadkhodayan et al, 2007). 
Other risk factors often mentioned in the literature are severe (>90%) ipsilateral stenosis, 
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cerebral vessels or an incomplete circle of Willis, perioperative and postoperative 
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CHS, 3 of them developed ICH (0.67%), and 2 of them (0.44%) died. All the patients that 
developed CHS had stenoses >90%, contralateral stenoses >80%, and longstanding 
preprocedural hypertension. The authors calculate that in patients with these three 
conditions, the risk of developing CHS was 16%. Only 5.8% of the patients that did not 
develop CHS met these three criteria. The low incidence of CHS in this series might be due 
to the fact that CHS was not diagnosed in cases with headache and vomiting. Two of the 
cases of ICH appeared a few days after CAS and only one occurred immediately after the 
procedure.  
Ogasawara et al (2007) published a series of 4494 patients revascularized with CEA or CAS. 
Of the 1596 patients treated with CEA, 30 (1.9%) developed CHS and 6 of these developed 
ICH (0.4% of the total). Of the 2898 patients treated with CAS, 31 (1.1%) developed CHS and 
21 (0.7% of the total) of these developed ICH. In the group of patients treated with CEA but 
not in those treated with CAS, poor BP control after revascularization correlated with CHS. 
CHS and ICH ocurred significantly earlier after CAS than after CEA. The difference between 
the two procedures in terms of the timing of CHS onset may be explained as follows. First, 
the higher incidence of embolisms after CAS (Roh et al, 2005) might explain how a 
hemorrhagic transformation could occur after the resolution of the embolism in the tissue 
that was damaged; from a pathophysiological point of view, however, this would represent 
hemorrhagic infarction due to reperfusion rather than CHS. Second, the higher incidence of 
bradycardia and hypotension after the stimulation of the carotid baroreceptors during CAS 
(Mendelsohn et al, 1998; McKevitt et al, 2003; Qureshi et al, 1999) can favor cerebral ischemia 
and CHS after severe rebound hypertension (Abou-Chebl et al, 2007). In an earlier 
publication (Ogasawara et al, 2003), these authors suggested that SPECT findings of 
hyperperfusion continuing at least three days after revascularization predisposes to CHS.  
In an excellent review of 9 studies of CAS comprising a total of 4446 patients, Moulakakis et 
al (2009) found the incidences of CHS and ICH were 1.16% (range, 0.44% - 11.7%) and 0.74% 
(range, 0.36% -4.5%), respectively. Table 3 shows the incidence of CHS and of ICH in the 
largest series published before 2010, including series of patients undergoing angioplasty of 
intracranial arteries.   
In order to document the incidence of CHS after CAS and to determine possible 
predisposing factors, Sfyroeras et al (2009) studied 29 patients with CT, MRI, TCD including 
assessment of CVR, and SPECT before and after the procedure. A total of 5 patients 
developed adverse neurological events. Two of them developed CHS (6.9%); both had 
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exhausted CVR in the preoperative TCD examination. All studies that investigate CVR 
before treatment have found a relation between impaired CVR and the risk of CHS. 
Brantley et al (2009) studied 482 patients, 7 (1.45%) of whom developed CHS after CAS. 
None had an ICH and all recovered within 6 to 24 hours. All had been classified as high risk 
for CEA, and CHS was more common in those with a previous TIA. The absence of ICH was 
probably related to the fact that 64% of the patients had asymptomatic stenoses. These 
authors found no significant relation between CHS and risk factors reported in other series 
like hypertension, high-grade ICA stenosis, and contralateral disease. The postprocedural 
BP in the CHS cohort tended to be higher than in the other patients, but this difference did 
not reach statistical significance. 
 
Potential risk factors for CHS 
Modifiable                                                    Not modifiable 
 
High blood pressure                                    Diminished CVR   
Excessive administration of antithrombotic drugs         Hypertensive microangiopathy 
Simultaneous revascularization of multiple vessels       Recent minor stroke 
Use of high doses of volatile halogenated                  Age >70 years 
hydrocarbon anesthetics 
 
Recent (<3 months) contralateral CEA                      High grade carotid artery stenosis 
                                                                                                   Incomplete circle of Willis  
                                                                                                   Contralateral carotid occlusion 
                                                                                                   Poor collateral flow 
                                                                                                          Increase in regional cerebral  
                                       oxygen saturation  >24% 
                                                                                                          Diabetes mellitus, Hypertension 
                                                                                                   Increase in perfusion >100% 
                                                                                                   Preoperative hypoperfusion 
Table 2. 
Grunwald et al (2009) report a series of 417 patients treated with CAS in whom BP was 
meticulously controlled during the first 24 hours; furthermore, MRI was performed before 
and after the procedure in 269 cases. The mean degree of carotid stenosis was 87%, and 65% 
of the patients were symptomatic. Of the 10 (2.4%) patients who developed CHS, seven had 
excessive small vessel disease with old territorial infarcts or freshly demarked lesions. Small 
vessel disease is considered a risk factor for CHS because it impairs the capacity of these 
arteries to contract. Curiously, none of these patients had severe hypertension. In three 
cases, ICH occurred within a few hours of CAS, and all of these had extensive microvascular 
changes and impaired collateral blood flow due to high-grade stenosis (>80%) of the 
contralateral ICA. However, 23% of the patients that did not develop CHS also had high-
grade stenosis of the contralateral ICA. On MRI, all had increased signal intensity in the 
subarachnoid space on the same side as the stented ICA, which resolved within 3–5 days.  
Curiously, this study was unable to demonstrate a relation between CHS and factors like 
postprocedural hypertension, advanced age, degree of ipsilateral stenosis, or contralateral 
disease.  
Regarding prior stroke as a risk factor for CHS, many authors have found that diseases like 
diabetes mellitus or longstanding pre-existing hypertension in which microangiopathy 
affects the endothelium of small vessels predispose to hyperperfusion and CHS (Chamorro 
et al, 2000; McCabe et al, 1999; Naylor et al, 2003; van Mook et al, 2005). 
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Tietke et al (2010) analyzed the outcomes of 358 patients treated with CAS using small 
closed-cell stents without distal protection. The peri-interventional and 30-day 
mortality/stroke rate was 4.19% (15/358). These events included 3 deaths, 5 CHS 
(comprising one death by a secondary fatal ICH), one SAH and 7 ischaemic strokes. All but 
one of the patients with CHS had an initial stenosis of >90%; the remaining patient had an 
initial stenosis of 50% to 70% and was the only one with CHS without ICH. The patient who 
died was the only woman with CHS and she also had an occluded contralateral ICA. Most 
complications occurred in initial symptomatic patients (5.36%).  
The risk of CHS related to the type of protection (proximal or distal) has not been 
thoroughly studied. Pieniazek et al. (2004) compared the complications in 135 patients 
undergoing CAS, 42 with proximal protection and 93 with distal protection, but only one 
case of CHS developed.   
Bilateral carotid stenoses are generally treated in two separate stenting procedures to 
minimize hemodynamic impairment from stimulation of the carotid sinus baroreceptor 
reflex (severe bradycardia, hypotension) and the risk of CHS. As we explained in section 2 
(pathophysiology), the baroreceptor reflex might break down after receptor denervation 
after CEA or CAS; this is more common after bilateral carotid surgery, and accompanying 
hypertension might increase the risk of CHS.  
 
 
Author / Year Patients CHS (%) ICH (%) 
Meyers / 2000 140 7 (5%) 1 (0.7%) 
Coutts / 2003 44 3 (6.8%) 2 (4.5%) 
Abou / 2004 450 2 (0.44%) 3 (0.67%) 
Kaku / 2004 30 1 (3.33%) 0% 
Imai / 2005  17 2 (11.7%) 2 (11.7%) 
du Mesnil de Rochemontn / 2006 50 1 (2%) 0% 
Kablak-Ziembicka / 2006 92 2 (2.2%) 2 (2.2%) 
Abou / 2007  836 8 (0.96%) 3 (0.36%) 
Ogasawara / 2007  2989 31 (1.1%) 21 (0.7%) 
Sfyroeras / 2008  29 2 (7%) 0% 
Brantley / 2009 482 7 (1.5%) 0% 
Grunwald / 2009 417 7 (1.7%) 3 (0.7%) 
Tietke et al (2010) 358 4 (1.1%) 1 (0.27%) 
Karkos et al (2010).  316 10 (3%) 0% 
 
Table 3. Incidence of hyperperfusion syndrome, and intracranial hemorrhage after CAS in 
the reviewed series from 2003 to 2010 
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excessive small vessel disease with old territorial infarcts or freshly demarked lesions. Small 
vessel disease is considered a risk factor for CHS because it impairs the capacity of these 
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contralateral ICA. However, 23% of the patients that did not develop CHS also had high-
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Curiously, this study was unable to demonstrate a relation between CHS and factors like 
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Regarding prior stroke as a risk factor for CHS, many authors have found that diseases like 
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Few studies have addressed the subject of simultaneous bilateral CAS. Henry et al. (2005) 
reported a series of 17 patients who underwent simultaneous bilateral CAS and 40 patients 
who underwent bilateral CAS in a staged manner (among these 40 patients 10 underwent 
the second procedure 24 hours after the first, while the other 30 underwent the second 
procedure from 2 days to 2 months after the first). Two cases of CHS occurred, one each 
group, although the patient in the simultaneous treatment group who developed CHS died. 
Lee et al. (2006) found no CHS in a series of 27 patients who underwent bilateral CAS. 
Diehm et al. (2008) studied patients treated with bilateral CAS with at least one month 
between procedures and reported no significant differences in complications compared to 
patients treated with unilateral CAS.   
An interesting study that deals with pseudo-occlusive carotids was published by Choi  
et al (2010). These authors analyze the outcome after CAS in 48 patients with nearly 
occlusive stenosis of the ICA. The procedural success rate was 98% and a good outcome  
at six months (modified Rankin scale 2) was achieved in 44 patients (92%). Four (8%) 
patients developed CHS.  
Another interesting article was published by Karkos et al (2010). They studied the 
complications in the first 30 days in 333 angioplasties in 316 patients, 35% of whom had 
symptomatic carotid disease. Perioperative neurological events included stroke in 6 patients 
(1.8%), TIA in 15 (4.5%), and CHS in 10 (3.0%). The incidence of CHS did not differ between 
the group of patients with symptoms and those without. Bradycardia was noted in 48 
patients (14%) and hypotension in 45 (13%), and two of these patients (0.6%) required 
admission to the intensive care unit for hemodynamic instability. Curiously, the only factors 
related to increased morbimortality were hyperlipidemia and current or previous smoking. 
5.2 Angioplasty in intracranial arteries  
As is to be expected, fewer studies have addressed CHS in relation to intracranial 
angioplasty because this procedure is newer than angioplasty in extracranial arteries. In this 
section, we will discuss the most interesting series and cases of patients treated with this 
technique. In 2000, Meyers et al reported the first SAH due to stenosis of the intracranial 
vertebral artery. In their series of 140 patients treated with CAS (including 10 intracranial 
carotids, 14 intracranial vertebral arteries, 4 basilar arteries, and 1 MCA), the incidence of 
CHS was 5% (7 of 140 patients, 5 carotids and 2 vertebral arteries), one with ICH and 
another with SAH. Importantly, six patients (85%) were symptomatic with crescendo TIAs 
before treatment, and these symptoms were probably related to impaired CVR. The first 
case of CHS with ICH after intracranial MCA angioplasty was reported by Liu et al in 2001. 
One of the first series of patients undergoing intracranial CAS was published by Terada et al 
(2006). These authors reported 106 procedures in 99 patients (57 patients had intracranial 
ICA stenosis, 23 had MCA stenosis, and 19 had vertebrobasilar stenosis). The ICA stenosis 
involved the petrous or cavernous in 47 cases (24 patients were treated with angioplasty and 
23 with stenting). Four hemorrhagic complications occurred in 106 procedures. One patient 
had SAH and the other 3 cases had the following characteristics: severe stenosis with poor 
collateral flow, low perfusion with CVR damage on SPECT, appearance of ICH between 30 
minutes and 16 hours after the procedure, and patient age greater than 70 years. The rate of 
ICH directly related to CAS was 3%. In two of three cases, CHS was strongly suspected from 
the SPECT findings. In the nonhemorrhagic group, hemodynamic compromise was found in 
27 of 47 (57%) patients. 
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It is important to remember that hemorrhage caused by vessel injury is also a possible 
mechanism of hemorrhagic complications. For instance, in the patient with SAH in Terada 
et al (2006) studies, wall dissection, perforation of the vessel wall by the guidewire, or 
rupture of a tiny aneurysm located at the distal part of ICA were not completely ruled out. 
Rezende et al (2006) reported a case of CHS after stenting for intracranial vertebral stenosis. 
They point out the significant hemodynamic component due to the absence of the 
contralateral vertebral artery and collateral supply from the carotid territory.  
More recent articles about intracranial angioplasty show more promising results. Guo et al 
(2010) implanted 53 self-expanding stents with a technical success rate of 98%.  
Complications included SAH (1.9%) and occlusion (3.8%), but there were no cases of CHS.  
Zhang et al (2008) reported the first case of ICH after CAS in both vertebral arteries with 
stenosis >90%. The flow velocity of both vertebral arteries measured by TCD increased more 
than 100% and high BP coincided with the abrupt onset of ICH three hours after the 
procedure.  
In conclusion, the factors involved in the development of CHS after intracranial procedures 
seem similar to those involved in extracranial procedures, and the results of intracranial 
angioplasty are very promising.  
5.3 Intracranial hemorrhage after angioplasty 
ICH is the severest form of CHS and it has the worst prognosis (Case 2). The low incidence 
of ICH and the small number of patients in the various series reported precludes clear 
conclusions about the risk factors involved, although presumably they are the same as those 
involved in CHS. The first question is whether ICH is an extreme consequence of CHS or 
whether it has a distinct pathophysiology. Numerous mechanisms are possible: CHS, 
hemorrhagic diathesis caused by antiplatelet and anticoagulation therapy after stenting, 
hemorrhage around or in a recent infarction or other associated lesion (including 
hypertensive ICH), or rupture of an intracranial aneurysm. 
In an interesting article published in 2003, Coutts et al try to narrow the definition of CHS. 
After studying 129 patients treated with CEA and 44 treated by CAS, these authors 
postulate that three different syndromes can occur in relation to hyperperfusion: acute focal 
edema, acute hemorrhage, and delayed classic presentation described for Sundt et al (1981). 
One of their patients had ICH three hours after CAS in the absence of high BP or symptoms 
suggestive of hyperperfusion. Other authors like Buhk et al (2006) argue for the existence of 
two distinct syndromes: first, classic CHS, in which symptoms of ipsilateral, frontotemporal, 
or retro-orbital headache, neurological deficit, and sometimes seizures typically begin 
between the fifth and seventh days after revascularization, and second, a more dramatic 
clinical presentation with ICH considered as damage due to reperfusion (Imparato et al, 
1984; Takolander & Bergqvist 1983). In many of the cases published, ICH occurred within a 
few hours of the procedure and predominantly affected the basal ganglia; furthermore, all 
the patients in these cases presented with a high-grade stenosis. Therefore, the 
pathophysiology of this type of ICH might differ from that of CHS, being closer to that of 
hypertensive ICH, in this case due to rupture of small perforating arteries in the basal 
ganglia after acute exposure to suddenly normalized perfusion pressure after angioplasty of 
a high grade stenosis.  
Brantley et al (2009) reported a patient with a nearly occlusive ICA stenosis who developed 
a fatal ipsilateral ICH immediately after the intervention; ICH was due to hemorrhagic 
conversion of a prior stroke.   
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Few studies have addressed the subject of simultaneous bilateral CAS. Henry et al. (2005) 
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It is important to remember that hemorrhage caused by vessel injury is also a possible 
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The incidence of ICH after CEA in the series published ranges between 0.2% and 0.7% 
(Piepgras et al, 1988; Pomposelli et al, 1988; Solomon et al, 1986; Wilson & Ammar, 2005), 
whereas the incidence of ICH after CAS is higher (Timaran et al, 2009), reaching 5% in some 
series.   
Schoser et al (1997) reported the first case of ICH after CAS, a 59-year-old woman with 
severe stenosis of the left ICA who developed putaminal hemorrhage on the third day after 
the procedure. CT showed an ipsilateral border zone infartion.  
McCabe et al (1999) reported the first fatal case of ICH after CAS, a man with severe stenosis 
who developed ICH within hours of CAS without any prodromes. Mori et al (1999) reported 
a similar case in which ICH affected the basal zones with ventricular and subarachnoid 
extension. Both cases had signs of microangiopathy, which is associated with increased risk 




1- Angiogram showing 95% stenosis of the left ICA in a patient with 
 occlusion of the right ICA.  
2- Angiogram after left CAS.  
3- No lesions were discernible on the pre-treatment CT .   
4- CT 24 hours later shows extensive hematoma in the left frontal lobe  
(Courtesy of Dr. Carlos Castaño).  
Tan and Phatouros (2009) reviewed 170 patients treated with CAS, 4 (2.3%) of whom 
developed CHS, one of these with cerebral edema, one with petechial hemorrhage, and two 
with ICH, which was fatal in one case. All developed CHS within six hours of the procedure 
and all had stenoses of the internal carotid >95%. Both patients who developed ICH had 
been treated within three weeks after an ischemic event.  
Morrish et al (2000) observed a 4.4% incidence of ICH after 104 CAS in 90 patients; the mean 
ICA stenosis was 95% in those who developed ICH. In two of the patients, who died, ICH 
involved the basal ganglia. In this series, the incidence of ICH may have been increased due 
to a high dose of heparin and the absence of distal protection, given that recent ischemia is a 
risk factor for ICH.  
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Matsuo et al (2000) reported two cases of ICH, one of which affected the basal ganglia the 
day after CAS. The fatal ICH reported by Abou et al (2004) appeared at the level of the basal 
ganglia one hour after CAS. Finally, the series of 161 patients reported by Koch et al (2002) 
included a single case of fatal ICH after CAS in a severely stenosed ICA. Kablak et al (2010) 
reported 3 (1.4%) cases ICH among 210 patients, one of whom had SAH. In their study, 
increased systolic velocity in both MCAs was a clear risk factor, and one of the three patients 
had occlusion or severe stenosis of the contralateral carotid.  
In addition to impaired CVR, the most widely accepted risk factors are insufficient 
intracranial collateralization and signs of cerebral microangiopathy. We know that 
hypertensive encephalopathy does not consist only of periventricular demyelination but 
possibly also includes small areas of perivascular hemorrhage that can be associated with 
higher risk of developing ICH. It also seems that the severity of the stenosis plays an 
important role, as most patients in the literature have severe stenosis.  
6. Contrast-induced encephalopathy  
Neurotoxicity from contrast agents is a rare but well-known complication of diagnostic and 
therapeutic procedures that employ these agents.  
Leptomeningeal enhancement is often reported after CAS due to the abrupt increase in 
blood flow even when this does not cause symptoms (Wilkinson et al, 2000). Nevertheless, 
some authors purport that this phenomenon represents the extravasation of contrast 
material toward the subarachnoid space; Bretschneider and Strotzer (2000) reported 11 
cases, some of which were related to hypoxic brain damage. Ekel et al (1998) reported a case 
of contrast enhancement mimicking SAH, and Mamourian et al (2000) used an animal 
model to demonstrate that contrast material can cross into the cerebrospinal spinal fluid in 
sufficient concentration to alter the appearance of the subarachnoid space on MRI. Dangas et 
al (2001) reported a case of contrast-induced encephalopathy after CAS in an 82-year-old 
man with a TIA and 90% stenosis in the right carotid. Immediately after CAS, this patient 
presented confusion and left hemiparesis in the territory of the right carotid. CT showed 
marked cortical enhancement and edema of the right cerebral hemisphere. The patient 
improved rapidly and by day 2 was completely recovered; MRI found no cortical edema 
and normal sulci.  
Canovas et al (2007) published a case of extravasation of contrast material immediately after 
the rupture of the balloon in a woman with a very calcified plaque (Case 3) in whom the 
pressure of the balloon reached 8 atmospheres. The pressure of the balloon  probably 
magnified the hemodynamic effect, making the extravasation of the contrast material very 
aggressive and giving rise to a clinical picture identical to an embolic stroke of the MCA. As 
in other cases reported in the literature, this patient’s condition improved and the imaging 
findings were normal after 48 h.  
Contrast-induced encephalopathy should be differentiated from the classical CHS described 
Sundt et al (1981), although it probably has a similar pathophysiology. A high dose of 
contrast agent may result in acute breakdown of the blood-brain barrier, allowing the 
contrast material to enter the brain and resulting in the acute development of a dramatic 
clinical presentation. The higher osmolality of ioxaglate compared with blood may in turn 
produce fluid extravasation and cerebral edema. The prognosis is usually excellent, as is 
evidenced by other recently published cases occurring after endovascular procedures 
(Guimaraens et al, 2010, Fang et al, 2009; Paúl et al, 2009).  
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1- Angiogram before left CAS showing 70% stenosis of the left ICA 
2- Angiogram after left CAS  
3- Axial diffusion-weighted MRi showing ipsilateral silent ischemic lesions  
4- CT with extravasation of the contrast 
5- Axial FLAIR MRi  
6- Axial T1-weighted MRi  
7. Prevention and treatment 
It is crucial to identify patients with risk factors for developing hyperperfusion so that 
preventive measure can be taken during and after revascularization. In the previous section, 
we discussed the factors most commonly considered to increase this risk, and in this section 
we discuss the most interesting preventive strategies.  
There is a consensus that the most important risk factors are severely impaired CVR and 
deficient collaterality (severe ipsilateral stenosis, impaired collateral flow, occlusive disease 
in other extracranial cerebral vessels, and incomplete circle of Willis). Other proposed 
factors include advanced age, perioperative and postoperative hypertension, and the use of 
antiplatelet agents or other anticoagulants. Thus, we should concentrate our efforts on the 
factors in which we can intervene. Regarding preventive measures before the procedure, we 
will discuss the assessment of CVR as the primary measure and we will also examine the 
usefulness of assessing the supra-aortic trunks and the circle of Willis.  Regarding 
preventive measures during and after the procedure, we will focus on detecting cerebral 
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hyperperfusion and thus on the importance of strict, prolonged BP control and appropriate 
antithrombotic management.  
As we discussed in the Diagnosis section, various options are available for assessing CVR. 
Probably the most widely available option is TCD, which has many advantages and enables 
us to measure cerebral flow at rest and under certain stimuli (breath-holding, inhalation of 
CO2, intravenous acetazolamide administration). The simplest and most noninvasive TCD 
test is breath-holding with or without hyperventilation (see the Diagnosis section). 
Therefore, the first preventive measure that is recommended before revascularization is 
CVR assessment using TCD (Sfyroeras 2006, 2009).   
It would also be advisable to do a thorough MRI study of the supra-aortic trunks and of the 
circle of Willis as well as a study of the cerebral parenchyma using FLAIR, T2-weighted, and 
diffusion sequences to detect hyperacute lesions and small-vessel disease, which are also 
related to increased risk of CHS. As mentioned in the Diagnosis section, CVR can also be 
assessed by SPECT, CT, and MRI, although these approaches are more expensive and less 
widely available.  
Again, TCD is very useful for monitoring cerebral flow during revascularization 
procedures. In patients undergoing CEA, TCD can detect increases in MCA flow velocity 
greater than 100% during the intervention, thus alerting to a situation of risk. Likewise, TCD 
monitoring during CAS and probably in the hours after the procedure can help select high 
risk patients (Dalman et al, 1999; Fujimoto et al, 2004; Kablak et al, 2010; Jansen et al, 1994; 
Iwata et al, 2011; Sfyroeras et al, 2009).  
Strict control of hypertension is one of the preventive measures that has received the most 
attention. Most Investigators recommend strict control of BP in the postoperative period to 
prevent ICH after CEA (Ahn et al, 1989; Bernstein et al, 1984; Bove et al, 1979; Buhk et al, 
2006; Hosoda et al, 2001; Ko et al, 2005; Roh et al, 2005; Safian et al, 2006; Tang et al, 2008) 
and after CAS, as we will see below.  
It has been suggested that even BP in the normal range may be deleterious in patients at 
high risk for CHS (Piepgras et al, 1988; Ouriel et al, 1999; Jorgensen & Schroeder, 1993).  
Regarding strict control of BP, Abou-Chebl et al (2007) published an interesting study that 
analyzed the presence of CHS and ICH in 836 patients treated with CAS. These authors 
maintained BP < 140/90 mmHg in patients with lower risk and BP < 120/80 mm Hg in 
patients with a treated stenosis  90%, contralateral stenosis   80%, and hypertension (i.e., 
risk factors for CHS). They conclude that comprehensive management of arterial 
hypertension can lower the incidence of ICH and CHS in high-risk patients following CAS, 
without additional complications or prolonged hospitalization. The strict control of BP must 
be maintained until CVR is restored, and this interval varies among patients. Thus, the use 
of TCD to assess the recovery of CVR can probably help guide antihypertensive therapy 
(Buhk 2006). 
Bando et al (2001) reported a stroke patient with a 90% stenosis of the intracranial left 
vertebral artery treated with CAS. Immediately after the procedure, hyperperfusion was 
detected by SPECT and TCD. The patient recovered from CHS quickly after a week’s 
antihypertensive therapy. 
Brus-Ramer et al (2010) published an interesting case of a patient treated with CAS who 
developed signs of hyperperfusion detected by TCD and depicted on angiography as 
hyperintense punctate foci potentially representing small dilations in the vascular territory 
of stented arteries. Lowering BP by 40% probably prevented CHS; thus, in high risk patients, 
aggressive BP management during and after CAS can prevent potentially serious sequelae. 
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Another aspect that remains to be determined is the most appropriate type of drugs for 
these patients. In this context, it seems logical that drugs that have no direct effects on CBF 
and those that give some degree of cerebral vasoconstriction could be beneficial. Drugs like 
nitroprusside and calcium antagonists that increase CBF should be avoided. The ß 1-
adrenergic antagonists (beta-blockers) reduce BP with little effect on intracranial pressure 
within the autoregulatory range, although they can exacerbate the bradycardia that can 
occur after CAS.  
The mixed alpha-adrenergic antagonist and ß -adrenergic antagonist labetalol, which has no 
direct effects on CBF and decreases the cerebral perfusion pressure and mean arterial 
pressure by about 30% compared with baseline, has successfully been used in CHS after 
CEA (Halliday et al, 2004). The alpha 2-adrenergic agonist clonidine, which is commonly 
used after CEA (associated with raised cranial and plasma catecholamine concentrations), 
has the advantage of decreasing CBF.  
General anesthesia is often unnecessary for CAS.  However, when general anesthesia is 
required, it is important to use anesthetics that do not increase CBF. Studies of CBF during 
surgery have shown that high doses of volatile halogenated hydrocarbon anesthetics may 
lead to the development of CHS (Skydell et al, 1987). Isoflurane is the volatile anesthetic of 
choice in neurosurgery because it results in less pronounced vasodilation than other 
halogenated anesthetics at equipotent doses. The effects of isoflurane on cerebral metabolic 
rate and autoregulation are dose dependent, with impairment of CVR at high doses. 
Propofol has been used in patients with CHS, it normalizes CBF, probably because of its 
effects on cerebral metabolism (Kaisti et al, 2003). 
Safety concerns have been raised about the effects of anticoagulants and antiplatelet agents 
and the risk of ICH following CEA, but no causal link has been found (Ouriel et al, 1999; 
Penn et al, 1995). Likewise, no association between these drugs and ICH has been found in 
patients undergoing CAS (Abou et al, 2003), although some studies have reported higher 
incidences of ICH, probably related to higher than usual doses of anticoagulants (Meyers et 
al, 2000 ; Morrish et al, 2000). 
Levy et al (2002) propose an interesting preventive strategy consisting of performing 
angioplasty in two phases, with posterior stent collocation. These authors published a series 
of 8 cases of intracranial vertebral stenosis with good outcomes despite one case of arterial 
dissection that required stenting. Yoshimura et al (2009) also used two-step endovascular 
treatment in high risk patients with impaired CVR. These authors first performed 
angioplasty with a small balloon (3 mm), and once hyperperfusion improved on SPECT 
about one month later they performed a second, definitive angioplasty with stent 
placement. None of the 9 patients treated with the two-step approach had problems related 
with hyperperfusion (one required stenting for a dissected artery), whereas 5 of the  
9 patients in the control group had hyperperfusion and one had status epilepticus related  
to CHS.  
Additional efforts to reduce the risk of ICH may include limiting the duration of balloon 
inflation and employing emboli-prevention devices, as these practices have been related to 
ischemia with posterior development of ICH  (Jansen et al, 1994; Sakaki et al, 1992; Sundt et 
al 1981). 
An important, somewhat controversial factor is the optimal interval between stroke and 
revascularization. We know that an extensive ischemic lesion represents a greater risk of 
damage due to reperfusion. Furthermore, classically a six-week interval was recommended 
to avoid treatment complications. However, studies like the NASCET show that the benefits 
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of carotid revascularization are greatest in the first two weeks after the event, and the 
subgroup of patients with less risk for early revascularization are those with small ischemic 
lesions and mild neurologic impairment (Keldahl et al, 2010). A recent (<3 months) 
contralateral CEA is an additional potential risk factor for CHS and should also be 
considered in the timing of surgery (Ascher et al, 2003). Very few studies have addressed 
the use of CAS in hyperacute strokes, but those that have report good safety outcome 
(Miyamoto et al, 2008; Setacci et al 2010).  
Some authors (Henry et al, 2005; Lee et al, 2006) claim that treatment of both carotid arteries 
is feasible in carefully selected patients, either in the same procedure or in two procedures 
separated by an interval of one day; these authors report safety and complication rates 
comparable to those of large published series in high-risk patients. Nevertheless, careful 
monitoring of the patient, blood pressure, and heart rate is mandatory to avoid 
complications related to CHS.  
Owing to the presence of free radicals during reperfusion and their relation to post-ischemic 
hyperperfusion, substances like edaravone have been investigated. Edaravone inhibits lipid 
peroxidation and vascular endothelial cell injury, improving edema cerebral and tissue 
injury.  Pretreatment with edaravone decreased the incidence of hyperperfusion after CEA 
as measured by SPECT (Ogasawara et al, 2004).  
Once CHS occurs, aggressive measures to lower BP are imperative. As there are no data 
from randomized trials comparing the optimal perioperative management protocol for 
patients with CHS due to the rarity of this complication, we must focus on controlling BP, 
reducing cerebral edema, and, according to some authors, temporarily withdraw 
antithrombotic therapy. Treatments for cerebral edema include adequate sedation, 
hyperventilation, and administration of mannitol or hypertonic saline. Evidently, there are 
no data to support these treatments in CHS. Corticosteroids and barbiturates have also been 
used in CHS.   
There are no available data recommending prophylactic use of anticonvulsant therapy in 
patients undergoing carotid revascularization; however, in the presence of seizures, 
treatment with anticonvulsants is indicated. 
In conclusion, assessing CVR before treatment and monitoring CBF velocities during and 
after the procedure can help select the patients who need strict control of BP to prevent 
CHS. The optimal BP remains to be determined, but BP should be lowered to below the 
baseline after luminal gain with stenting to prevent secondary injury. Despite the lack of a 
precise BP target, lowering systolic BP to at least 20% to 30% below baseline values seems 
critical, particularly in patients with critical stenosis and above all in patients with impaired 
CVR. Labetalol and clonidine seem to be the most appropriate drugs for BP control in this 
context.  
To determine when discharge is safe after CAS, patients should be divided into two 
groups. One group includes asymptomatic, hemodynamically stable patients with low 
comorbidity who could be discharged after 6 h of observation, according to some authors. 
These patients should be treated using a hemostatic closure device for the arterial 
puncture. The other group includes older patients with associated comorbidity, mainly 
those with altered renal function, those that require anticoagulation, and those with 
altered BP or bradycardia. Finally, it is recommendable to warn the family about 
symptoms that call for re-evaluation, especially seizures, neurological deficit, and 
headaches associated with hypertension. 
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Another aspect that remains to be determined is the most appropriate type of drugs for 
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has the advantage of decreasing CBF.  
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required, it is important to use anesthetics that do not increase CBF. Studies of CBF during 
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lead to the development of CHS (Skydell et al, 1987). Isoflurane is the volatile anesthetic of 
choice in neurosurgery because it results in less pronounced vasodilation than other 
halogenated anesthetics at equipotent doses. The effects of isoflurane on cerebral metabolic 
rate and autoregulation are dose dependent, with impairment of CVR at high doses. 
Propofol has been used in patients with CHS, it normalizes CBF, probably because of its 
effects on cerebral metabolism (Kaisti et al, 2003). 
Safety concerns have been raised about the effects of anticoagulants and antiplatelet agents 
and the risk of ICH following CEA, but no causal link has been found (Ouriel et al, 1999; 
Penn et al, 1995). Likewise, no association between these drugs and ICH has been found in 
patients undergoing CAS (Abou et al, 2003), although some studies have reported higher 
incidences of ICH, probably related to higher than usual doses of anticoagulants (Meyers et 
al, 2000 ; Morrish et al, 2000). 
Levy et al (2002) propose an interesting preventive strategy consisting of performing 
angioplasty in two phases, with posterior stent collocation. These authors published a series 
of 8 cases of intracranial vertebral stenosis with good outcomes despite one case of arterial 
dissection that required stenting. Yoshimura et al (2009) also used two-step endovascular 
treatment in high risk patients with impaired CVR. These authors first performed 
angioplasty with a small balloon (3 mm), and once hyperperfusion improved on SPECT 
about one month later they performed a second, definitive angioplasty with stent 
placement. None of the 9 patients treated with the two-step approach had problems related 
with hyperperfusion (one required stenting for a dissected artery), whereas 5 of the  
9 patients in the control group had hyperperfusion and one had status epilepticus related  
to CHS.  
Additional efforts to reduce the risk of ICH may include limiting the duration of balloon 
inflation and employing emboli-prevention devices, as these practices have been related to 
ischemia with posterior development of ICH  (Jansen et al, 1994; Sakaki et al, 1992; Sundt et 
al 1981). 
An important, somewhat controversial factor is the optimal interval between stroke and 
revascularization. We know that an extensive ischemic lesion represents a greater risk of 
damage due to reperfusion. Furthermore, classically a six-week interval was recommended 
to avoid treatment complications. However, studies like the NASCET show that the benefits 
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of carotid revascularization are greatest in the first two weeks after the event, and the 
subgroup of patients with less risk for early revascularization are those with small ischemic 
lesions and mild neurologic impairment (Keldahl et al, 2010). A recent (<3 months) 
contralateral CEA is an additional potential risk factor for CHS and should also be 
considered in the timing of surgery (Ascher et al, 2003). Very few studies have addressed 
the use of CAS in hyperacute strokes, but those that have report good safety outcome 
(Miyamoto et al, 2008; Setacci et al 2010).  
Some authors (Henry et al, 2005; Lee et al, 2006) claim that treatment of both carotid arteries 
is feasible in carefully selected patients, either in the same procedure or in two procedures 
separated by an interval of one day; these authors report safety and complication rates 
comparable to those of large published series in high-risk patients. Nevertheless, careful 
monitoring of the patient, blood pressure, and heart rate is mandatory to avoid 
complications related to CHS.  
Owing to the presence of free radicals during reperfusion and their relation to post-ischemic 
hyperperfusion, substances like edaravone have been investigated. Edaravone inhibits lipid 
peroxidation and vascular endothelial cell injury, improving edema cerebral and tissue 
injury.  Pretreatment with edaravone decreased the incidence of hyperperfusion after CEA 
as measured by SPECT (Ogasawara et al, 2004).  
Once CHS occurs, aggressive measures to lower BP are imperative. As there are no data 
from randomized trials comparing the optimal perioperative management protocol for 
patients with CHS due to the rarity of this complication, we must focus on controlling BP, 
reducing cerebral edema, and, according to some authors, temporarily withdraw 
antithrombotic therapy. Treatments for cerebral edema include adequate sedation, 
hyperventilation, and administration of mannitol or hypertonic saline. Evidently, there are 
no data to support these treatments in CHS. Corticosteroids and barbiturates have also been 
used in CHS.   
There are no available data recommending prophylactic use of anticonvulsant therapy in 
patients undergoing carotid revascularization; however, in the presence of seizures, 
treatment with anticonvulsants is indicated. 
In conclusion, assessing CVR before treatment and monitoring CBF velocities during and 
after the procedure can help select the patients who need strict control of BP to prevent 
CHS. The optimal BP remains to be determined, but BP should be lowered to below the 
baseline after luminal gain with stenting to prevent secondary injury. Despite the lack of a 
precise BP target, lowering systolic BP to at least 20% to 30% below baseline values seems 
critical, particularly in patients with critical stenosis and above all in patients with impaired 
CVR. Labetalol and clonidine seem to be the most appropriate drugs for BP control in this 
context.  
To determine when discharge is safe after CAS, patients should be divided into two 
groups. One group includes asymptomatic, hemodynamically stable patients with low 
comorbidity who could be discharged after 6 h of observation, according to some authors. 
These patients should be treated using a hemostatic closure device for the arterial 
puncture. The other group includes older patients with associated comorbidity, mainly 
those with altered renal function, those that require anticoagulation, and those with 
altered BP or bradycardia. Finally, it is recommendable to warn the family about 
symptoms that call for re-evaluation, especially seizures, neurological deficit, and 
headaches associated with hypertension. 
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1. Introduction  
Critical Limb Ischemia (CLI) is defined as the presence of ischemic rest pain for more than 
two weeks or ischemic tissue loss associated with an absolute ankle pressure less than 50 
mmHg or great toe pressure less than 30 mmHg (Norgren et al., 2007). Patients with CLI 
experience high amputation rates, significant morbidity and cardiovascular events 
exceeding those in patients with symptomatic coronary heart disease (Varu et al., 2010). In 
spite of recent developments in revascularization techniques and wound care centers, 
amputations continue to be performed, partly because patients with CLI are referred late to 
vascular surgeons (Varu et al., 2010). However, revascularization when compared with 
amputation have an overall lower perioperative mortality and enhanced long-term survival 
(Brosi et al., 2007; Varu et al., 2010). However, CLI is associated with multisegmental 
complex arterial lesions and consequently with high rates of revascularization failure (Allie 
et al., 2009). Specific features of the tibial vessels, such as the small caliber, the remote 
location, the slow flow of the distal bed, and the need of preserving runoff capacity, make 
this vascular territory particularly challenging for endovascular treatment (Blevins and 
Schneider, 2010). Meanwhile, continued technical improvements and very encouraging 
results have changed the paradigm of CLI therapy, until recently based on vein graft bypass. 
As so, the endovascular approach is, nowadays, the first-line modality for limb-threatening 
ischemia for a majority of authors (Allie et al., 2009; DeRubertis et al., 2007). 
2. Epidemiology 
CLI is a global epidemic, with high clinical, social and economic costs (Adam et al., 2005; 
Allie et al., 2009; Brosi et al., 2007). Its incidence in the United States (US) is estimated to be 
50-100 per 10 000 every year (Adam et al., 2005). It affects 1% of the population aged 50 and 
older and the incidence roughly doubles in the over 70 age group (Allie et al., 2009). The 
prevalence of CLI is also higher in diabetic patients and its prognosis is even worst in this 
population: one of every four diabetics will face CLI within his/her lifetime, and a diabetic 
is at 7 to 40 times greater risk of an amputation than a non-diabetic (Allie et al., 2009). As so, 
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it is expected that the incidence of CLI would rise significantly with the current aging 
population and the expected increase in inactivity, obesity and consequently in diabetes 
(Allie et al., 2009; van Dieren et al., 2010).  As a result and despite advances in medical 
therapies, the number of patients needing lower limb revascularization for severe limb 
ischemia will probably increase in the near future (Adam et al., 2005). Moreover, the 
diagnosis of CLI remains a predictor of poor survival and outcomes (Varu et al., 2010): the 
overall mortality in these patients approaches 50% at 5 years and 70% at 10 years (Varu et 
al., 2010). Within one year of being diagnosed with CLI, 20% to 25% will die and 40% to 50% 
of the diabetics will experience an amputation (Allie et al., 2009; Kroger et al., 2006). The 
economic impact of CLI is considerable. It has been assessed that the total cost of treating 
CLI in the US is $10 to $20 billion per year (Allie et al., 2009). The cost of follow-up, long-
term care, and treatment for an amputee who remains at home has been estimated at $49,000 
per year compared to only $600 to $800 per year after limb salvage (Allie et al., 2009). It is 
estimated that just a 25% reduction in amputations could save $2.9 to $3.0 billion yearly in 
US healthcare costs (Allie et al., 2009). Despite the facts noted above, CLI is still poorly 
understood, infrequently reported and inconsistently treated (Allie et al., 2009).  
3. The arterial lesions in patients with critical limb ischemia 
CLI is highly predictive for failure of both primary and secondary patency, as a result of the 
increased prevalence of advanced lesion severity and treatment complexity (DeRubertis et 
al., 2007). There is several indicators of lesion severity in these patients: (1) increasing TASC 
grade (mostly C and D lesions); (2) multilevel intervention; (3) general involvement of tibial 
arteries in diabetic patients; (4) diffusely diseased tibial arteries (combination of long 
stenoses and occlusions; (5) reduced outflow bed (DeRubertis et al., 2007; Graziani et al., 
2007; Ihnat and Mills, 2010). 
4. Revascularization in CLI patients 
4.1 Bypass surgery approach 
Historically, infrainguinal autogenous saphenous vein bypass surgery has been considered 
the gold-standard therapy for CLI, with long-term anatomical patency, clinical durability 
and high limb salvage rates (Adam et al., 2005; Allie et al., 2009; Varu et al., 2010). The 
Pomposelli’s classic report of more than 1000 pedal bypasses over a decade documented a 
10-year primary patency rate of 37.7% and limb salvage rates of 57.8% (Pomposelli et al., 
2003). Regrettably, most of these single center series were reported in optimal surgical 
candidates with favorable anatomy and adequate autogenous vein conduits (Allie et al., 
2009). Furthermore, the durability of the vein graft may rely on routine ultrasonography 
surveillance, frequently leading to repeated prophylactic re-interventions and relevant 
resource utilization (Adam et al., 2005; Varu et al., 2010). Unfortunately an adequate vein is 
often unavailable and the long-term results of bypasses constructed with prosthetic graft are 
clearly much less satisfactory (Adam et al., 2005). The good results of infrainguinal surgery 
are not applicable to contemporary CLI patients who seldom have favorable anatomy and 
recurrently have poor autogenous conduits (Allie et al., 2009). Additionally, the real world 
CLI patients are frequently very elderly and have numerous medical issues, significantly 
increasing the mortality and morbidity associated with infrainguinal bypass (Allie et al., 
2009; Brosi et al., 2007). Consequently the open surgery option could come at the cost of high 
morbidity and mortality, as well as substantial resource use (Adam et al., 2005). 
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Abou-Zamzam et al. analyzed the functional outcomes after surgery in CLI patients (Abou-
Zamzam et al., 1997). This report aimed at identifying the ideal post-infrainguinal bypass 
results from CLI patient’s functional perspective (Abou-Zamzam et al., 1997). The patient 
who survived the intervention, had his wounds healed at 6 months, was living 
independently and completely mobile, was defined as the ideal functioning patient  
(Abou-Zamzam et al., 1997). Disappointingly, despite excellent graft patency and limb 
salvage rates, only 14.3% of their infrainguinal bypass patients achieved the ideal result at 6 
months (Allie et al., 2009). Avoidance of incisional wound creation and subsequent common 
healing problems have been strongly considered an advantage in favor of endovascular 
intervention versus infrainguinal bypass in our practice (Allie et al., 2009; Chung et  
al., 2006).  
Meanwhile, in patients expected to live more than two years and who were fit, the apparent 
improved durability and reduced re-intervention rate of surgery might outweigh the short-
term considerations of increased morbidity and cost (Adam et al., 2005).  
4.2 Endovascular approach 
The endoluminal therapy for lower extremity occlusive disease has extraordinary evolved in 
the last decade and the armamentarium now available for the vascular interventionist is 
quite considerable (DeRubertis et al., 2007). This has allowed an impressive expansion of the 
endovascular approach in complex, formerly considered unachievable, infra-inguinal 
lesions (Allie et al., 2009). As a result, the endoluminal intervention is now considered the 
first-line treatment in CLI patients for a majority of authors. 
In addition, the understanding of CLI patients had improved considerably (Allie et al., 
2009). The so called limb salvage-graft patency gap has been consistently identified in all 
infrainguinal bypass surgery reports regardless of conduits (Allie et al., 2009). Even after an 
occlusion of an infrainguinal bypass graft following limb salvage, the limb will oftentimes 
remain viable and not regress back to CLI since the blood flow and metabolic needs to 
achieve wound healing in CLI are much greater than to keep viability (Allie et al., 2009). 
This paradigm shift has opened the door to a potential change of the goals in the post 
procedural follow-up of the CLI patients from vessel patency to limb salvage. This has 
become the cornerstone in treating CLI patients, allowing an impressive expansion of 
endovascular therapy indications (Allie et al., 2009). 
In fact, scrutinizing the data of endovascular approach for CLI treatment from the last 
decade shows very encouraging results in regard to limb salvage.  
Dorros et al. used percutaneous transluminal angioplasty (PTA) as the first treatment in 235 
CLI patients with a 91% 5-year limb salvage rate and a small number of complications 
(Dorros et al., 2001).  
Faglia et al. reported tibial PTA as primary treatment in 993 CLI diabetic patients. During a 
26±15 months follow-up, only 1.7% underwent major amputation. Limb salvage was 
achieved in more than 98% of patients and an 88% 5-year primary clinical patency rate was 
described (Faglia et al., 2005). 
Kudo et al. also published a 10-year PTA experience in 111 CLI patients. A 0.9% procedural 
mortality and a 96.4% technical success rate were described. The 5-year limb salvage rate 
was 89.1% (Kudo et al., 2005). The same authors published their 12-year experience of tibial 
PTA versus bypass surgery in 192 CLI patients. They further concluded that PTA was safe 
and effective, pointing it as the primary treatment for CLI (Kudo et al., 2006). 
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A meta-analysis of 30 articles from Romiti et al. looked at immediate technical success, 
primary and secondary patency, limb salvage, and survival after infrapopliteal PTA in CLI 
patients. The results were compared with a meta-analysis of popliteal-to-distal vein bypass 
graft that the authors had previously published (Albers et al., 2006). Even if there was a 
significant difference in favor of vein bypass concerning durability, the limb salvage rates 
were equivalent between both techniques (Albers et al., 2006; Romiti et al., 2008). 
From the data presented, it results that endovascular approach is currently considered as the 
first-line treatment for CLI patients with below-the-knee arteries involvement. 
5. Below-the-knee intervention – Technical issues 
5.1 Access 
The access for below the knee (BTK) vessels can be granted either by antegrade ipsilateral 
approach or by retrograde contralateral approach. 
5.1.1 Antegrade ipsilateral approach  
As it allows a nearer distance to the tibial arteries, the antegrade technique permits the 
utilization of shorter devices, which leads to an improvement of the guidewires and 
catheters’ characteristics like pushability, torqueability, crossability or trackability. As a 
result, it may become easier to treat complex lesions as long occlusions, distal lesions as in 
foot vessels or use complex techniques like the pedal-plantar loop technique. However,  
the antegrade puncture implies that the iliac arteries and the proximal superficial femoral 
artery are free of significant disease. Even if the pattern of arterial involvement in diabetic, 
CLI patients is mostly at BTK level, the presence of palpable femoral and popliteal pulses 
should not be considered as synonym of absence of an upstream significant lesion. As so, an 
arterial ultrasound of the iliac and femoral arteries should be previously performed to 
insure that an adequate inflow is available. Moreover, the antegrade approach can be 
difficult in obese patients. In those patients, some tricks can help in turning the puncture 
easier: (1) wrap the abdominal pannus with tape in cranial and contralateral directions; (2) 
put a folded sheet under the ipsilateral hip; (3) place the patient in Trendelenburg position; 
(4) consider longer needles; (5) consider reinforced sheaths (e.g. SuperArrow® Flex).  
The antegrade technique is also more prone to local complications and should be performed 
using a single wall needle to avoid a double puncture and its consequent additional 
potential problems. It should also be completed under fluoroscopy to localize the femoral 
head and puncture the common femoral artery (Dotter et al., 1978; Grier and Hartnell,  
1990). In hostile heavily scarred groins or in very obese patients, ultrasound guided 
puncture of either the common femoral or the superficial femoral arteries may reduce 
radiation doses, screen times and complications (Biondi-Zoccai et al., 2006; Marcus et al., 
2007; Yeow et al., 2002).  
5.1.2 Retrograde contralateral approach 
Contralateral puncture is technically easier to achieve and safer in regard to local 
complications (Nice et al., 2003). It permits performing a strategic arteriography and the 
correction of proximal iliac and femoral lesions. It allows a more secure utilization of closure 
devices and maintains the puncture site remote from the treated segment. The utilization of 
long sheaths especially designed for BTK intervention (e.g. Cook® Shuttle Tibial) may 
provide additional external support, allowing intervention in more demanding cases, but 
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potentially increasing total costs. Meanwhile, distal lesions are still difficult to reach and 
unfavorable aortic bifurcations or aortic grafts may preclude its utilization.  
Table 1 summarizes the advantages and disadvantages of each approach. 
 
 Antegrade access Contralateral access 
More complex and distal lesion   
Iliac and proximal SFA lesions   
More technically demanding   
More frequent local complications   
Remote access from treated 
segment   
Safer closure devices utilization   
Table 1. Antegrade and contralateral retrograde access 
5.2 Tibial vessel selection for intervention – The key step 
Perhaps the most critical decision in revascularizing CLI patients with predominant BTK 
arteries involvement is to decide which vessel(s) should be approached to achieve successful 
limb salvage. In spite of arbitrarily recanalize a tibial artery only based on arteriography, 
one should consider some basic and prevailing principles. 
5.2.1 Angiosome model  
The angiosome concept was initially described in plastic and reconstructive surgery papers 
and was intended to provide the basis for a logical planning of incisions and flaps (Taylor 
and Palmer, 1987; Taylor and Pan, 1998). These anatomical studies delineated three-
dimensional anatomic units of tissue (from skin to bone) fed by a given source artery, 
defined as angiosomes. In foot it has been described six angiosomes, arising from the 
posterior tibial artery (n=3), the anterior tibial artery (n=1), and the peroneal artery (n=2) 
(figure 1). The posterior tibial artery gives rise to a calcaneal branch that supplies the medial 
ankle and plantar heel, a medial plantar artery that feeds the medial plantar instep and a 
lateral plantar artery that supplies the lateral forefoot, plantar midfoot and entire plantar 
forefoot. The anterior tibial artery continues as the dorsalis pedis artery feeding the dorsum of 
the foot. The peroneal artery supplies the lateral ankle and plantar heel via the calcaneal 
branch and the lateral anterior upper ankle via an anterior perforating branch. Alexandrescu 
et al. applied more recently this angiosome model to guide endovascular procedures in 
diabetic CLI patients with remarkable results (Alexandrescu et al., 2008). This rational 
approach for the revascularization of the foot was followed by several authors who 
confirmed its relevance for ulcer healing and consequent limb salvage (Alexandrescu et al., 
2011; Iida et al., 2010; Neville et al., 2009). In fact, Iida et al. analyzed 203 limbs in 177 
patients and separated them into direct and indirect groups depending on whether feeding 
artery flow to the site of ulceration was successfully acquired or not based on the angiosome 
concept. They found that limb salvage rate was significantly higher in the direct group 
(86%) than in the indirect group (69%) for up to 4 years after the procedure (Iida et al., 2010). 
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potentially increasing total costs. Meanwhile, distal lesions are still difficult to reach and 
unfavorable aortic bifurcations or aortic grafts may preclude its utilization.  
Table 1 summarizes the advantages and disadvantages of each approach. 
 
 Antegrade access Contralateral access 
More complex and distal lesion   
Iliac and proximal SFA lesions   
More technically demanding   
More frequent local complications   
Remote access from treated 
segment   
Safer closure devices utilization   
Table 1. Antegrade and contralateral retrograde access 
5.2 Tibial vessel selection for intervention – The key step 
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and was intended to provide the basis for a logical planning of incisions and flaps (Taylor 
and Palmer, 1987; Taylor and Pan, 1998). These anatomical studies delineated three-
dimensional anatomic units of tissue (from skin to bone) fed by a given source artery, 
defined as angiosomes. In foot it has been described six angiosomes, arising from the 
posterior tibial artery (n=3), the anterior tibial artery (n=1), and the peroneal artery (n=2) 
(figure 1). The posterior tibial artery gives rise to a calcaneal branch that supplies the medial 
ankle and plantar heel, a medial plantar artery that feeds the medial plantar instep and a 
lateral plantar artery that supplies the lateral forefoot, plantar midfoot and entire plantar 
forefoot. The anterior tibial artery continues as the dorsalis pedis artery feeding the dorsum of 
the foot. The peroneal artery supplies the lateral ankle and plantar heel via the calcaneal 
branch and the lateral anterior upper ankle via an anterior perforating branch. Alexandrescu 
et al. applied more recently this angiosome model to guide endovascular procedures in 
diabetic CLI patients with remarkable results (Alexandrescu et al., 2008). This rational 
approach for the revascularization of the foot was followed by several authors who 
confirmed its relevance for ulcer healing and consequent limb salvage (Alexandrescu et al., 
2011; Iida et al., 2010; Neville et al., 2009). In fact, Iida et al. analyzed 203 limbs in 177 
patients and separated them into direct and indirect groups depending on whether feeding 
artery flow to the site of ulceration was successfully acquired or not based on the angiosome 
concept. They found that limb salvage rate was significantly higher in the direct group 
(86%) than in the indirect group (69%) for up to 4 years after the procedure (Iida et al., 2010). 
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Lately, Alexandrescu et al. compared 213 CLI limbs revascularized prior (n=89) and after 
(n=134) the introduction of the angiosome model. They also concluded that angiosome-
targeted revascularization was associated with significantly higher limb preservation (89% 
vs. 79% at 36 months) (Alexandrescu et al., 2011). To simply allow pulsatile flow to the 
correct portion of the foot is the contemporary paramount for ulcer healing. 
 
 
Fig. 1. Angiosome model. A – Calcaneal branch of the posterior tibial artery. B - Calcaneal 
branch of the peroneal artery. C – Anterior perforating branch of the peroneal artery. 
5.2.2 Additional concepts 
Adjacent angiosomes are bordered by reduced caliber (choke) or artery-similar caliber (true) 
anastomoses, which link neighboring angiosomes to one another and demarcate the border 
of each angiosome (Attinger et al., 2006; Taylor and Pan, 1998). In addition, these vessels are 
important safety conduits that allow a given angiosome to provide blood flow to an adjacent 
angiosome if the latter’s source artery is damaged. 
This concept should be taken into account in CLI limb revascularization. In fact, after having 
revascularized the key artery according to the angiosome concept, one may consider 
revascularizing other tibial vessels. The rationale to do so can be based on: (1) limited 
permeability rates with current angioplasty techniques may compromise the feeding artery 
before complete lesion healing; (2) trophic lesion may include more than one angiosome. 
Nevertheless, this attempt should never place the recanalized feeding artery at risk. 
Meanwhile, some technical issues, as the lack of visible run-off, the presence of heavy 
calcification precluding transluminal or subintimal occlusion crossing, an occlusion at an 
arterial bifurcation (like the anterior tibial artery origin) or the presence of an important 
collateral at the beginning of an occlusion may restrict or prevent revascularization 
 
Below the Knee Techniques: Now and Then 
 
47 
according to the angiosome model. In those circumstances, approaching an alternative tibial 
vessel considering the anastomoses between angiosomes may be the only option available in 
trying to preserve a CLI limb.   
5.3 BTK Recanalization  
In the past, the BTK interventional techniques were performed with large caliber, non-
specific instruments, which resulted in poor results and skepticism upon its applicability in 
this specific sector. The relative similarity between BTK and coronary vessels led vascular 
interventionists to employ low profiling coronary devices, which improved outcomes. 
Additional developments brought specifically designed devices, achieving results that 
changed the paradigm of CLI patients treatment approach. 
5.3.1 Imaging  
Fluoroscopy is supposed to have high resolution (less than 0.3 mm), should allow 
roadmapping and overlay techniques and must permit a high range of angulation. In fact, 
the last point is highly relevant since some significant lesions can be occulted or 
underestimated by standard posterior-anterior view. Moreover, oblique incidences allow 
clear observation of tibial vessels avoiding superposed bone and potentially revealing useful 
calcifications that can be used as natural roadmapping. 
5.3.2 Guidewires 
One may start with a 0.035” regular angled glidewire™ to cross simple stenoses. However, 
more complex lesions must be addressed with specific guidewires.  
Vascular specialists began BTK treatment with some scarcity of options in regard  
to guidewires, but currently there has been an increasing choice in this particular matter 
(Table 2).  
Tip load, tip stiffness, hydrophilic/hydrophobic coating of the tip and body, guidewire 
flexibility, ability to shape, shaping memory, shaft support, torque transmission, 
trackability, and pushability are all critical components for a BTK intervention guidewire, 
especially for chronic total occlusions (CTOs) (Godino et al., 2009) (see tables 2 & 3). 
The selection should consider some specificities of the lesion: (1) the localization (some 
authors prefer 0.018” guidewires for tibial arteries, leaving 0.014” guidewires for pedal 
arteries); (2) CTO or stenosis (occlusions may require specifically designed tip); (3) length 
(long lesions, especially CTOs, usually demand additional support to allow the passage of 
other interventional devices).    
Non-hydrophilic guidewires allow a better tactile feel and a more controlled torque 
response when compared with hydrophilic wires. They are less likely to cause dissection of 
a vessel but have a higher resistance within the lesion, which may decrease the chances of 
successful crossing, particularly in CTOs. To counterweigh this, some uncoated, spring-coil 
wires have a specifically designed tapered-tip which confers more penetrating power to the 
tip. On the other hand, some guidewires may have, rather than increased sharpness, greater 
tip stiffness due to weights addition, which increases their penetration ability. 
Hydrophilic wires typically advance with minimal resistance, providing good 
maneuverability in tortuous and long vessels but at a cost of reduced tactile feel. They are 
also more prone in penetrating beneath plaque inducing a dissection of the vessel. 
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the last point is highly relevant since some significant lesions can be occulted or 
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clear observation of tibial vessels avoiding superposed bone and potentially revealing useful 
calcifications that can be used as natural roadmapping. 
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One may start with a 0.035” regular angled glidewire™ to cross simple stenoses. However, 
more complex lesions must be addressed with specific guidewires.  
Vascular specialists began BTK treatment with some scarcity of options in regard  
to guidewires, but currently there has been an increasing choice in this particular matter 
(Table 2).  
Tip load, tip stiffness, hydrophilic/hydrophobic coating of the tip and body, guidewire 
flexibility, ability to shape, shaping memory, shaft support, torque transmission, 
trackability, and pushability are all critical components for a BTK intervention guidewire, 
especially for chronic total occlusions (CTOs) (Godino et al., 2009) (see tables 2 & 3). 
The selection should consider some specificities of the lesion: (1) the localization (some 
authors prefer 0.018” guidewires for tibial arteries, leaving 0.014” guidewires for pedal 
arteries); (2) CTO or stenosis (occlusions may require specifically designed tip); (3) length 
(long lesions, especially CTOs, usually demand additional support to allow the passage of 
other interventional devices).    
Non-hydrophilic guidewires allow a better tactile feel and a more controlled torque 
response when compared with hydrophilic wires. They are less likely to cause dissection of 
a vessel but have a higher resistance within the lesion, which may decrease the chances of 
successful crossing, particularly in CTOs. To counterweigh this, some uncoated, spring-coil 
wires have a specifically designed tapered-tip which confers more penetrating power to the 
tip. On the other hand, some guidewires may have, rather than increased sharpness, greater 
tip stiffness due to weights addition, which increases their penetration ability. 
Hydrophilic wires typically advance with minimal resistance, providing good 
maneuverability in tortuous and long vessels but at a cost of reduced tactile feel. They are 
also more prone in penetrating beneath plaque inducing a dissection of the vessel. 
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0.014” Guidewires Hydrophilic Tapered tip Tip stiffness (g) Remarks tip body 
Abbott HT Winn™ 40, 80, 200 Y HF Y (0.012-0.009”) 4.8, 9.7, 13 BTK GW 
Abbott Pilot™ 50, 150, 200 Y Y N 2,4,6 Coronary GW 
Abbott Wisper LS, MS, ES Y N N 1 Coronary GW 
Asahi Confianza™ N N Y (0.009”) 9 Coronary GW 
Asahi Intecc Miracle ™ N N N 3, 4.5, 6, 9, 12 Coronary GW 
Biotronik Cruiser® Hydro  
MS, ES Y N N 0.27 Coronary GW
Biotronik Cruiser® MS, ES HF N N 0.27 Coronary GW
Biotronik XT-14 Y N N NA BTK GW 
BS PT Graphix™; 
Grafix P2™ LS, MS Y Y N 3-4 Coronary GW 
Cook  Approach® Hydro ST Y N N NA BTK GW 
Cook  Approach® CTO N N N 6, 12, 18, 25 BTK GW 
Cordis Shinobi™ Y N N 2 Coronary GW 
Medtronic Provia™ N Y/N Y (0.009”)*1 3, 6, 9, 12, 15 BTK GW 
Table 2. Possible 0.014” guidewires for BTK purposes. BS – Boston Scientific. LS, MS, ES 
(light, medium, and extra support). Y/N – Both versions are available. *1 – Only in the 9, 12 
and 15 g tips. GW – Guidewire; HF hydrophobic; NA – Not Available. 
 
0.018” Guidewires Hydrophilic Tapered tip Tip stiffness (g) Remarks tip body 
Abbott SteelCore 18 LT N N N NA  
Biotronik Cruiser® 18 Y N N NA Increased body stiffness 
BS V-18™ Control Wire® Y N N 3-4 Increased body stiffness 
Cook Roadrunner® ES N N N NA Increased body stiffness 
Table 3. Possible 0.018” guidewires for BTK purposes. BS – Boston Scientific; NA – Not 
Available. 
5.3.3 Chronic Total Occlusions (CTOs) 
CTOs are generally defined as occluded arteries of three months duration or longer (Stone et 
al., 2005). CTOs are characterized by proximal and distal fibrous caps, a mix of luminal soft and 
hard plaque, thrombin, fibrin, inflammatory cells (in the intima, media, and adventitia), and 
neovascularization. The plaque is composed of a collagen rich extracellular matrix, intra, and 
extracellular lipids, smooth muscle cells, and calcium (Katsuragawa et al., 1993; Srivatsa et al., 
1997). The proximal and distal caps have higher concentrations of collagen and calcium 
(fibrocalcific), even if the distal cap is frequently softer than the proximal cap (Fefer et al., 
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2010). This may explain, at least partially, the relative ease in crossing tibial CTOs by 
retrograde pedal approach. The composition of the core correlates with CTO age. Older CTOs 
have higher concentrations of fibrocalcific material (“hard plaque”), while CTOs present for less 
than one year have more cholesterol clefts and foam cells among less fibrous material (“soft 
plaque”). This may, in part, explain the greater simplicity in crossing these younger CTOs.  
Neovascularization starts early, as part of the organization of the CTO, and increases with 
time. As it has been demonstrated in coronary arteries, many CTOs are not completely 
occluded when examined under the microscope (Srivatsa et al., 1997). In fact, the new 
sprouting vessels, in contrast with vasa vasorum that run in radial directions, proceed within 
and parallel to the occluded parent vessel (Strauss et al., 2005). As a result they may 
originate microchannels throughout the CTO which diameter can vary between 100 and 500 
m (Srivatsa et al., 1997; Stone et al., 2005). Those can be used to engage the tip of the 
guidewire, which can further help in crossing CTOs. In this particular matter, tapered tips 
increase the ability to insert the guidewire in those microchannels, while hydrophilic tips are 
more prone to progress inside them.  
5.3.3.1 Crossing CTOs  
According to the lesion and the guidewire, different techniques to penetrate CTOs fibrous 
caps may be applied. 
5.3.3.1.1 Antegrade techniques 
In the drilling technique, the tip is bended in a short extension and clockwise and counter-
clockwise rotations of the guidewire are performed while the tip is pushed modestly against 
the CTO lesion (figure 2). The important issue in this technique is that one does not push the 
guidewire very hard. If the tip of the guidewire does not advance any more with gentle 
pushing, it is by far better to exchange for a stiffer wire, rather than continue pushing. If one 
pushes the wire hard, it will easily go into the subintimal space. Yet, when a stiff guidewire 
is used, it may be difficult to perceive whether the tip has been engaged in the true or in a 
false lumen inside the CTO. The movement of the tip may help in distinguishing one from 
the other. Typically, when the guidewire is in the subadventitial space, the tip budges 
markedly. Additionally, the extension of the tip curve may look exaggerated, especially 
when using floppy tip guidewires. Tactile feel from the guidewire during pullback can also 
aid as true lumen usually offers higher resistance. This technique has an increased risk of 
perforation, especially when using stiff tips guidewires and is not usually recommended for 
complex lesions (Godino et al., 2009; Kim, 2010). 
 
 
Fig. 2. Drilling technique. 
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Fig. 2. Drilling technique. 
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In the penetration technique, the tip shape is usually straighter than in the drilling technique 
and a less rotational tip motion and a more direct forward probing is used (figure 3). Some 
heavily calcified CTO caps may require the use of very aggressive guidewires to achieve 
passage using the described technique (tapered stiff tips and increased body support 
guidewires, like the Abbott HT Winn 200™). Additionally, the target has to be clearly 
identified and careful monitoring of the progressive guidewire advancement should be 
done. Only experienced interventionists should make use of this technique in difficult 
CTOs, due to the particularly augmented risk of complications. 
 
 
Fig. 3. Penetration technique. 
The sliding technique utilizes hydrophilic guidewires. Reduced surface friction enhances 
passage through the CTO core. It is recommended that the tip is initially shaped with a 
single, long shallow bend and movement consists of simultaneous smooth tip rotation and 
gentle probing. The guidewire typically advances with minimal resistance and tactile feel, 
resulting frequently in inadvertent entry to the subintimal space.  
This technique is particularly indicated for engaging softer CTOs with microchannels, 
subtotal occlusions or angulated lesions (Godino et al., 2009). 
The subintimal dissection technique is usually performed when transluminal crossing has been 
unsuccessful. A hydrophilic guidewire with a floppy tip and an intermediate or stiff body is 
generally preferred. The loop is made with the floppy tip of the guidewire and should be 
relatively small to reduce the risk of perforation (figure 4). 
 
 
Fig. 4. A – Loop of the guidewire tip for subintimal dissection technique (BS V-18™ Control 
Wire®); B, C – Case of a long anterior tibial artery (ATA) occlusion (arrow pointing to distal 
ATA); D – Guidewire advanced subintimally all the way through ATA. E, F – Final result.  
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Highly calcified lesions may add some resistance to the guidewire progression, making pre-
dilatation necessary, and can, in addition, make difficult or impede re-entry in true lumen. 
Recoil is more common and care should be especially taken to avoid damaging collaterals. As 
subintimal space is larger than true lumen, the balloon should be slightly oversized (0.5 mm). 
In the parallel wire technique, when the initial wire passes into a dissection plane, it is left 
there using it as a reference point to assist in passing a second wire through the true lumen 
(figure 5. This technique has two main purposes: re-directing a wire inside the CTO and 
puncturing distal CTO fibrous cap.  
 
 
Fig. 5. Parallel wire technique. 
5.3.3.1.2 Subintimal Arterial Flossing with Antegrade–Retrograde Intervention (SAFARI) 
During antegrade recanalization, reentry into the distal true lumen can be difficult or 
impossible for several reasons. In those circumstances retrograde puncture has to be 
considered. This technique should also be envisaged when the proximal occlusion stump 
cannot be determined, which occurs most frequently with the anterior tibial artery (figure 6, 
case 1). It can be performed in all three leg arteries at the calf, ankle or foot levels. The 
puncture is performed under fluoroscopic guidance. Vessel calcification can be very useful. 
At the ankle or foot level, a 21 G, 4 cm long, needle can be used (the same needle used in a 
radial artery line placement). Crural level puncture implies a longer needle (21 G, 7 cm long, 
from a micropuncture kit). When the needle is in the artery lumen, a weak back-bleeding of 
arterial blood is observed. At that point, a 300 cm, 0.014”, hydrophilic, intermediate or stiff 
shaft guidewire is engaged in the true lumen of the target vessel, subsequently assisted by a 
low profile support catheter or balloon catheter, without sheath placement. Subsequently, 
retrograde subintimal recanalization is carried out and continued until entry in the proximal 
true lumen or in the subintimal space from the antegrade approach is achieved. Sometimes, 
neither are obtained after several attempts. At that moment, the rendez-vous technique should 
be performed to break the membrane that separates the retrograde and antegrade 
subintimal spaces and, consequently, get continuity between them (figures 6-F and 7). At 
that time, the guidewire is typically snared or directed into the antegrade catheter or sheath 
to create a flossing-type guidewire which provides reliable access and adequate support (as 
it is fixed at both ends) for antegrade balloon angioplasty or stent placement (Figure 6) 
(Spinosa et al., 2003). When adequate flow has been reestablished into the target vessel, a 
catheter (diagnostic catheter, low profile support catheter or balloon catheter) is advanced 
distally to the lesion. The guidewire is then retrieved proximally, inverted and re-inserted (if 
not damaged). Hemostasis of the retrograde puncture site in foot and ankle is achieved by 
gentle local compression. At the calf level, hemostasis is performed by inflating a short 
balloon in the artery at the puncture site, usually for two minutes and at low pressure.  
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(figure 5. This technique has two main purposes: re-directing a wire inside the CTO and 
puncturing distal CTO fibrous cap.  
 
 
Fig. 5. Parallel wire technique. 
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Fig. 6. SAFARI interventions. Case 1. A – Initial arteriography; occlusion of popliteal and all 
three tibial arteries (black arrow: patent dorsalis pedis artery). B – Snaring of the retrograde 
guidewire. C – Final result. / Case 2.  D – Initial arteriography; patent peroneal artery, but 
ending in unsatisfactory collaterals (black arrow head: proximal anterior tibial artery).  
E – X-Ray showing percutaneous retrograde guidewire. F – Rendez-vous technique. G – 
Retrograde guidewire introduced inside 4F Bernstein catheter (the catheter should be turned 
to the arterial wall; the angled tip of the guidewire have to be engaged inside catheter lumen 
through simultaneous smooth tip rotation and gentle probing). H – Final result (guidewire 
can still be seen in the foot in a percutaneous position). 
 
 
Fig. 7. Rendez-vous technique. A – Antegrade and retrograde guidewires in their respective 
subintimal space. B – A balloon catheter is advanced over each guidewire. C – The tip of the 
balloons are placed at the same level and guidewires tips are retrieved inside the balloon 
catheter. D – Balloons are inflated and the separating membrane broken. E – Retrograde 
guidewire is thoroughly advanced to proximal true lumen. 
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Meanwhile, there are several limitations to this technique. As so, an occluded or severely 
diseased artery may impede the puncture. Additionally, one should be extremely careful 
when the working artery is the only one patent in the leg, as a dissection, perforation or 
rupture may preclude a possible rescue surgery bypass. 
5.3.3.1.3 Pedal-plantar loop technique 
This technique consists in creating a loop with the guidewire from the anterior tibial artery 
to the posterior tibial artery, or the inverse, through the foot vessels (Fusaro et al., 2007; 
Manzi et al., 2009). The most common pathway is through dorsalis pedis artery, deep plantar 
artery, deep plantar arterial arch, lateral plantar artery and posterior tibial artery. 
Indications for this technique are similar to the SAFARI technique. However, unlike the 
SAFARI technique, it can be performed when no distal vessel is available for puncture, 
being also less invasive. Moreover, this technique can provide a better outflow for tibial 
arteries.  
On the other hand, complications related to foot vessels manipulations can precipitate a 
serious worsening of the ischemic condition. 
Additional information in regard to this technique is provided in the chapter from the 
present book written by Manzi et al. 
5.3.3.1.4 Revascularization through peroneal artery collaterals 
If neither the anterior nor the posterior tibial artery can be treated despite several 
intraluminal and subintimal crossing attempts, the alternative treatment may consist of 
providing direct flow along the peroneal artery. The distal peroneal artery has several 
collateral branches that connect with foot arteries. In particular, the communicating branch 
connects the peroneal with the posterior tibial artery, whereas the perforating branch goes 
through the interosseous membrane and links the peroneal to the dorsalis pedis artery. This 
technique aims at creating an effective pathway from the peroneal to tibial vessels by means 
of guidewire tracking through the referred collaterals (figure 8).  
The transcollateral technique may be of value specifically when a proximal occlusion stump 
is not evident, when a dissection flap or a perforation in the proximal tract of the target 
vessel impairs guidewire advancement, or when distal disease makes retrograde 
percutaneous puncture impossible. 
The major limitation of this technique is the absence of collaterals suitable for wiring (Fusaro 
et al., 2008; Graziani et al., 2008). 
In all the above described techniques, a low-profile supportive catheter (Cook CXI™, 
Spectranetics® Quickcross®, Medtronic/Invatec Diver) or a low-profile balloon catheter can 
be used to provide additional support to the advancement of the guidewire. They also allow 
wire exchange without sacrificing the progress made through the lesion. Additionally, their 
lumen can be used to inject contrast and verify position and distal outflow. In this 
circumstances, diluted contrast, with diminished viscosity, may be preferable as the very 
low profile of catheter lumen is associated with high flow resistance. 
5.3.4 Balloons 
Specific low-profile balloons (less than 4F) have been recently designed for BTK purposes. 
They are made to work on a 0.014” or a 0.018” platform. The catheters of those balloons 
should provide increased shaft strength to allow adequate pushability, particularly in 
complex CTOs. In those circumstances, the over-the-wire technique should be preferred as it 
Angioplasty, Various Techniques and Challenges in  




Fig. 6. SAFARI interventions. Case 1. A – Initial arteriography; occlusion of popliteal and all 
three tibial arteries (black arrow: patent dorsalis pedis artery). B – Snaring of the retrograde 
guidewire. C – Final result. / Case 2.  D – Initial arteriography; patent peroneal artery, but 
ending in unsatisfactory collaterals (black arrow head: proximal anterior tibial artery).  
E – X-Ray showing percutaneous retrograde guidewire. F – Rendez-vous technique. G – 
Retrograde guidewire introduced inside 4F Bernstein catheter (the catheter should be turned 
to the arterial wall; the angled tip of the guidewire have to be engaged inside catheter lumen 
through simultaneous smooth tip rotation and gentle probing). H – Final result (guidewire 
can still be seen in the foot in a percutaneous position). 
 
 
Fig. 7. Rendez-vous technique. A – Antegrade and retrograde guidewires in their respective 
subintimal space. B – A balloon catheter is advanced over each guidewire. C – The tip of the 
balloons are placed at the same level and guidewires tips are retrieved inside the balloon 
catheter. D – Balloons are inflated and the separating membrane broken. E – Retrograde 
guidewire is thoroughly advanced to proximal true lumen. 
C A B D E 
 
Below the Knee Techniques: Now and Then 
 
53 
Meanwhile, there are several limitations to this technique. As so, an occluded or severely 
diseased artery may impede the puncture. Additionally, one should be extremely careful 
when the working artery is the only one patent in the leg, as a dissection, perforation or 
rupture may preclude a possible rescue surgery bypass. 
5.3.3.1.3 Pedal-plantar loop technique 
This technique consists in creating a loop with the guidewire from the anterior tibial artery 
to the posterior tibial artery, or the inverse, through the foot vessels (Fusaro et al., 2007; 
Manzi et al., 2009). The most common pathway is through dorsalis pedis artery, deep plantar 
artery, deep plantar arterial arch, lateral plantar artery and posterior tibial artery. 
Indications for this technique are similar to the SAFARI technique. However, unlike the 
SAFARI technique, it can be performed when no distal vessel is available for puncture, 
being also less invasive. Moreover, this technique can provide a better outflow for tibial 
arteries.  
On the other hand, complications related to foot vessels manipulations can precipitate a 
serious worsening of the ischemic condition. 
Additional information in regard to this technique is provided in the chapter from the 
present book written by Manzi et al. 
5.3.3.1.4 Revascularization through peroneal artery collaterals 
If neither the anterior nor the posterior tibial artery can be treated despite several 
intraluminal and subintimal crossing attempts, the alternative treatment may consist of 
providing direct flow along the peroneal artery. The distal peroneal artery has several 
collateral branches that connect with foot arteries. In particular, the communicating branch 
connects the peroneal with the posterior tibial artery, whereas the perforating branch goes 
through the interosseous membrane and links the peroneal to the dorsalis pedis artery. This 
technique aims at creating an effective pathway from the peroneal to tibial vessels by means 
of guidewire tracking through the referred collaterals (figure 8).  
The transcollateral technique may be of value specifically when a proximal occlusion stump 
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Fig. 8. Transcollateral technique. A – Black arrow head: peroneal artery; white arrow head: 
occlusion of the distal anterior tibial artery; white arrow head: occlusion of the distal 
anterior tibial artery; white arrow: communicating branch of peroneal artery anastomosing 
with posterior tibial artery; black arrow: perforating branch anastomosing with dorsalis pedis 
artery. B – Inflated balloon throughout distal peroneal artery, perforating branch and dorsalis 
pedis artery. Notice the posterior to anterior transition. C - Final result.  
promotes better support when compared to the rapid-exchange monorail technique. The 
transition between the guidewire and the tip of the catheter should be as smooth as possible 
to avoid the catheter getting stuck in the lesion, optimizing its crossability. Hydrophilic 
coating of the catheter is particularly relevant in long complex lesions. Long catheters 
should be considered when the contralateral approach is performed.   
In regard to the balloon itself, its compliance should be kept at minimum, as diameter 
accuracy is crucial for BTK interventions. In this particular matter, even conical balloons 
have been recently released. Long sizes are now available allowing angioplasty of an almost 
entire tibial vessel. The shoulders should be reduced to keep precision on the extension of 
the vessel to be treated. Segmental pre-dilatation with smaller diameter balloons may be 
required to allow the passage of the definitive balloon.  
Although there is no consensus on insufflation time, most of the authors recommend a 
period longer than 3 minutes.  
5.3.5 Bare-metal stents 
The tibial arteries are small diameter vessels and have a limited flow. As so, they are 
particularly prone to neointimal hyperplasia and re-stenosis after balloon-expandable bare-
metal stent (BMS) placement (Siablis et al., 2005). In fact, reocclusion occurs in up to 50% of the 
cases by one year (Scheinert et al., 2006; Siablis et al., 2007; Siablis et al., 2005). Additionally, 
balloon-expandable stents are available in only small lengths as they are originally coronary 
stents. There is only one long balloon-expandable stent device (up to 8 cm) dedicated to the 
infrapopliteal segment (Medtronic Invatec Chromis Deep). However, data regarding its 
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behavior is lacking (Karnabatidis et al., 2009a). Meanwhile, balloon expandable stents in tibial 
vessels seem to be surprisingly less vulnerable to compressions and fracture than in the 
femoro-popliteal sector, except if placed distally (Karnabatidis et al., 2009b).  
Long, thin-strut, low-profile, self-expanding nitinol stents designed and engineered 
specifically for the infrapopliteal arteries are now commercially accessible. Yet, data 
concerning their efficacy is still scarce. More concrete and solid evidence will arise when the 
results from the Expand-Trial (Astron Pulsar Stent versus PTA in patients with symptomatic 
critical limb ischemia or Severe intermittent claudication) and the XXS-Trial (Balloon 
Angioplasty Versus Xpert Stent in CLI Patients) will become available. 
Though, considering the existing data, bare metal stents should be reserved to bailout 
situations after balloon angioplasty. As so, they should be inserted in the following 
situations: flow-limiting dissection resistant to prolonged balloon angioplasty, significant 
elastic recoil, and relevant residual stenosis (higher than 30%). Still, they have also been 
advocated to correct challenging lesions in bifurcations using the crush technique originally 
described in coronary arteries (Colombo et al., 2003; Schwarzmaier-D'Assie et al., 2007).  
5.4 Complications 
Systemic and access complications are common to all endovascular procedures. Additional 
considerations should be made in regard to some direct local complications.   
A perforation or an arteriovenous fistula that occurs while attempting to cross a tibial CTO 
is rarely of any clinical significance as it will almost constantly closes within few minutes 
when only a guidewire or a low-profile catheter has passed extraluminally (Lyden, 2009) 
(figure 9). Thus, one should be sure to be inside the vessel before inflating a balloon. 
Removing the devices to above the proximal extremity of the CTO and reattempting to cross 
the lesion from the top, may allow successful passage and aid in solving the perforation or 
the arteriovenous fistula. When those complications do not auto-resolve, external 
compression guided by angiography or temporary vessel occlusion with a balloon can be 
attempted. In very rare situations, coiling must be envisaged.  
 
 
Fig. 9. A – Perforation; extraluminal contrast is easily noticed. B – Peroneal  
arteriovenous fistula.  
A B 
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5.5 Adjunctive medication  
All patients should be placed on intravenous heparin when the sheath is introduced. The 
dose should be adjusted to keep an activated clotting time between 250 and 300. Other 
anticoagulants, such as bivalirudin, have been shown to be equally effective (Patel et al., 
2010).  
All patients should already be on a chronic aspirin regimen. Clopidogrel should be started 5 
days before the procedure. Alternatively, a 300 mg load can be administrated peri-
procedure. Although adequate evidence is lacking, aspirin plus clopidogrel should be kept 
for six months.  
Tibial arteries are particularly prone to vasospasm. As so, arterial vasodilators should be 
available at all times. There are mostly four that can be used in: nitroglycerin, papaverine, 
tansolusine and verapamil, although nitroglycerin is most commonly used (Cronenwett et 
al., 2005). Besides their use in treating catheterization-associated vasospasm, they may be 
administrated prophylactically before balloon insufflation or guidewire manipulation of 
tortuous vessels, especially foot vessels.  
Thrombolytics should also be accessible, as dissection, spasm or elastic recoil may 
precipitate an acute thrombosis.   
5.6 Emergent techniques and alternatives 
5.6.1 Drug-eluting stents 
Driven by the encouraging results of the trials on drug-eluting stents in coronary arteries, 
some vascular interventionists have applied them in the infrapopliteal arteries to overcome 
restenosis and prolong amputation- and reintervention-free survival of CLI patients (Schofer 
et al., 2003). Several single-center series have demonstrated that drug-eluting stents 
effectively seem to be associated with a higher primary patency and a reduced need for 
reintervention in comparison to bare metal stents (Scheinert et al., 2006; Siablis et al., 2009).  
Meanwhile, considering that bare metal stents have currently restricted indications, most of 
CLI patients have long complex infrapopliteal lesions, only short coronary drug-eluting 
balloon-expandable stents are currently available, and taking into account the so called limb 
salvage-graft patency gap, one could consider that the potential role for drug-eluting stents in 
BTK vessels is still to be determined. 
5.6.2 Drug-coated balloons 
The concept of delivering a local antiproliferative drug to the vessel surface utilizing drug-
coated balloons to prevent restenosis without placing a permanent foreign material seems 
very appealing. Moreover, in opposition to current drug-eluting stents, drug-coated 
balloons can treat long lesions.  
Nevertheless, more solid evidence is required to clarify the utility of drug-coated balloons in 
infrapopliteal arteries. The PICOLLO and PADI ongoing trials may provide the needed 
additional data (Hawkins and Hennebry, 2011). 
5.6.3 Atherectomy devices 
The OASIS trial proved that orbital atherectomy in infrapopliteal vessels may provide 
predictable and safe lumen enlargement. Short-term data demonstrated substantial 
symptomatic improvement and infrequent need for further revascularization or amputation 
(Korabathina et al., 2010). Specific directional atherectomy devices are also available for 
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tibial vessels. Nevertheless, more consistent data is needed to determinate the precise role of 
these tools in BTK intervention.  
5.6.4 Additional technology 
There are additional devices, some already available, other still in the pipeline of 
manufacturers, which may become relevant in near future. Bioabsorbable stents (drug-
eluting or not), cryoplasty, and laser atherectomy are among them.  
6. Conclusions 
Endoluminal therapy for BTK arteries is now a key part of the vascular specialist 
armamentarium. Tibial arteries endovascular approach has demonstrated to lead to high 
limb salvage rates with low morbidity and mortality. As a result, the paradigm for treatment 
of CLI patients has changed. One should now consider endovascular intervention as the first 
line treatment in the majority of CLI patients, especially in those with significant medical 
comorbidities. To do so, the vascular specialist should have a consistent knowledge of the 
BTK endovascular techniques and devices. The first step decision in tibial endovascular 
therapy is the access. In this context, antegrade ipsilateral approach is generally preferred. 
The next critical decision is the choice of the vessel(s) to be approached in order to reach 
successful limb salvage. Allowing pulsatile flow to the correct portion of the foot is the 
contemporary paramount for ulcer healing. As so, an adequate understanding of the current 
angiosome model should enhance clinical results. However, this concept does not preclude 
the recanalization of the other tibial vessels as trophic lesion may include more than one 
angiosome and the limited long-term permeability rate of angioplasty may compromise the 
feeding artery before complete lesion healing. The selection of the devices should be 
judicious. The choice of the guidewire is extremely relevant and should be based on the 
characteristics of the lesion (location, length, and stenosis/occlusion) as well as on the 
characteristics of the guidewire itself (tip load, stiffness, hydrophilic/hydrophobic coating, 
flexibility, torque transmission, trackability, and pushability). Going through chronic total 
occlusions may be quite challenging. Therefore, the vascular interventionist should master 
the techniques that have been recently described: antegrade techniques, including the 
drilling technique, the penetrating technique, the subintimal technique and the parallel 
technique; subintimal arterial flossing with antegrade-retrograde intervention (SAFARI); 
pedal-plantar loop technique and revascularization through peroneal artery collaterals. The 
specifically designed, low-profile, increased shaft strength, balloons catheters were 
conceived for a 0.0.014” or a 0.018” platform. The balloons should have minimal compliance 
and be available in long sizes.  Bare metal stents should be available, even though their use 
is presently reserved for bailout situations.  
Meanwhile, the continuous arising of new technologies will possibly convulse the currently 
accepted BTK endovascular techniques. In fact, drug-eluting stents, drug-coated balloons, 
atherectomy devices, bioabsorbable stents among others may play a relevant role in BTK 
intervention in the near future.  
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line treatment in the majority of CLI patients, especially in those with significant medical 
comorbidities. To do so, the vascular specialist should have a consistent knowledge of the 
BTK endovascular techniques and devices. The first step decision in tibial endovascular 
therapy is the access. In this context, antegrade ipsilateral approach is generally preferred. 
The next critical decision is the choice of the vessel(s) to be approached in order to reach 
successful limb salvage. Allowing pulsatile flow to the correct portion of the foot is the 
contemporary paramount for ulcer healing. As so, an adequate understanding of the current 
angiosome model should enhance clinical results. However, this concept does not preclude 
the recanalization of the other tibial vessels as trophic lesion may include more than one 
angiosome and the limited long-term permeability rate of angioplasty may compromise the 
feeding artery before complete lesion healing. The selection of the devices should be 
judicious. The choice of the guidewire is extremely relevant and should be based on the 
characteristics of the lesion (location, length, and stenosis/occlusion) as well as on the 
characteristics of the guidewire itself (tip load, stiffness, hydrophilic/hydrophobic coating, 
flexibility, torque transmission, trackability, and pushability). Going through chronic total 
occlusions may be quite challenging. Therefore, the vascular interventionist should master 
the techniques that have been recently described: antegrade techniques, including the 
drilling technique, the penetrating technique, the subintimal technique and the parallel 
technique; subintimal arterial flossing with antegrade-retrograde intervention (SAFARI); 
pedal-plantar loop technique and revascularization through peroneal artery collaterals. The 
specifically designed, low-profile, increased shaft strength, balloons catheters were 
conceived for a 0.0.014” or a 0.018” platform. The balloons should have minimal compliance 
and be available in long sizes.  Bare metal stents should be available, even though their use 
is presently reserved for bailout situations.  
Meanwhile, the continuous arising of new technologies will possibly convulse the currently 
accepted BTK endovascular techniques. In fact, drug-eluting stents, drug-coated balloons, 
atherectomy devices, bioabsorbable stents among others may play a relevant role in BTK 
intervention in the near future.  
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Altered Function of Platelets and Neutrophils,  
in the Patients with Peripheral Arterial Disease 
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1. Introduction 
Ischemia reperfusion injury (I/R) is a relevant problem in case of myocardial infarction 
(Moens AL, Claeys MJ et al. 2005.), stroke, (Kato H and Kogure K 1999), coronary bypass 
surgery, (Bakkaloglu C, and Soyagir B, 2006), under thrombolysis, (Krumholz HM and 
Goldberger 2006), revascularization surgery of lower limb (Arato et al 2006., Laird IR 2003), 
balloon angioplasty (Weissand A.G. and Zahger AT 1999) and in every cases, when the 
physiological blood flow in the occluded vessels are restored (Falkensammer J and 
Oldenburg WA 2006), (Ferencz A et al 2004). Vessel closure and hypoxia can be caused by 
embolism (thrombus, tumour, fat, foreign body) stenotic arteriopathy, arterial spasm, 
compression, arterial thrombus, trauma, etc. During the exclusion of a segment of the 
vessels from the circulation, ischemia and acidosis appeared in the surrounding tissues. In 
case of the heart, when oxygen supply is inadequate, the respiration shift from aerobic fatty 
acid consumption and metabolism to anaerobic glycolysis, resulting in a reduced ATP 
production. The results of hypoxia in the metabolically active tissues (cardiac, skeletal 
muscle and neuronal tissues) are more profound than in other cell types. The cells are 
exposed to hypoxia try to adapt to the absence of oxygen, by switching their metabolism 
from aerobic to anaerobic. Finally this strategy leads to tissue damages and loss of cells too, 
as it can be seen in acute or chronic occlusive diseases, as well. The measures of the tissue 
injuries depend on the duration of hypoxia, the mass of tissues are involved, the ATP 
requirement of the cell types and the blood pressure of the patients. Under hypoxic 
condition the generations of reactive oxygen species (ROS), such as O2.-, H2O2, are increased.  
During normoxyc, physiological condition mitochondria generate low level of ROS by the 
respiratory chain. These are managed by natural antioxidants, such as manganese superoxid 
dismutase (SOD) in the mitochondria, or copper-zinc SOD in the inter-membrane space in 
the mitochondria, and in the cytosol, making the dismutation of superoxide anion 
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generation to H2O2, which transformed further by catalase, glutathion plus glutathion 
peroxydase. Under hypoxic condition several sources of free radicals activated, e.g. the 
NADPH oxydase, xanthin oxidase, and others. ROS generated by hypoxia disrupts 
respiratory chain, causing a vicious cycle, manifested in modification in permeability 
transmission, loss of membrane potential, altering the function of mitochondrial complex I, 
III, and generating ubisemiquinon radical, which donates its electron to oxygen resulting in 
superoxyde anion. In reduced oxygen tension complex II switches its activity from succinate 
dehydrogenase to fumarate reductase (Henrich M et al, 2004.), Kolamunne RT et al 2011). 
Chronic sever hypoxia induces ATP depletion, and cell death. In the course of hypoxia, ATP 
generation decrees, exhausting the ATP sources, which responsible for the overflow of 
hypoxanthine, an ATP metabolite. Hypoxanthine in normoxyc condition metabolized 
further by xanthine dehydrogenase to xanthine (by means of nicotinamide adenine 
dinucleotide (NAD) as cofactor), but during hypoxia xanthin dehydrogenase converted to 
xanthin oxidase, which is unable to catalyse this conversion, but in the presence of high 
oxygen level in reoxygenation phase it continuously generates toxic ROS, because it uses 
oxygen as cofactor. ROS are effective oxidizing and reducing agents that directly damage 
cellular membranes, leading to impairment of membrane ion channels, disturbing cellular 
ionic balance resulting in cell swelling. ROS can activate leucocytes as well, and induce 
chemotaxis, cytokine release, leukocyte infiltration into the injured tissues, and due to 
endothelium dysfunction, a systemic reperfusion inflammatory response occurs. The most 
serious consequences of IR are the development of remote organ injuries in non-ischemic 
organs and can induce systemic inflammatory response injury (SIRS) or multiorgan failure 
syndrome (MOFS) which are responsible for of 20-40% of death in intensive care units (Levy 
JH, and Tanaka KA 2003). Tough reconstruction of the flow in the occluded vessels is not 
without risk, because of the generated volume, pressure and metabolic load, accompanied 
by further tissue damages resulting in the so-called reperfusion injury.  
The main components of the molecular pathophysiological cascades are the activated 
circulating cells, first of all the white blood cells (WBC), mainly the neutrophils, due to their 
intensive free radical production, but, thrombocytes (PLT), red blood cells (RBC), and the 
cells of the vessel wall (endothelial cells and smooth muscle cells) also participate in the free 
radical production and the tissue damage (Roth and Hejjel 2003). In the early reperfusion 
the release of inflammatory cytokines, such as tumor necrosis factor alpha (TNF) increase 
too. These events together with the elevated Ca2+ levels inside the attached cells threat the 
integrity of the whole organism, destroying the crucial macromolecules, proteins, lipids and 
nucleic acids (Arato et al. 2005), (Blaisdell FW  1989).  
Reactive oxygen species are Janus-faced agents. They have important role in eliminating 
pathogen microorganisms from the body, and can regulate cell growth and differentiation. 
ROS can act as important signalling molecules, in the circulation and participate in the 
maintenance of intra- and extracellular milieu. They can induce redox sensitive transcription 
factors, regulate redox sensitive signalization cascades and can act as secondary messengers 
(Kathy K et al 2000), (Dröge W, 2002). Oxygen free radicals can act as second messengers and 
they are able to influence the function of enzymes, and transcription factors, leading to the 
induction of genes are sensitive to them (Li W et al 2008). Their intra- and extracellular 
levels are regulated by SOD and catalase (the enzymes are present in almost all living 
organisms are exposed to oxygen) and other antioxidant, respectively. On the other hand 
they can cause endothelial dysfunction due to eliminating vital nitrogenous monoxides 
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(NO), which are absolutely necessary for the endothelium dependent relaxation of the 
vessels (Moncada et al 1991), for the proper function of cardiomyocytes (Umar S, van der 
Laarse A. 2010), and for the physiological function of circulating cells, such as thrombocytes 
(Massberg S 1998) and leukocytes, and red blood cells. It can be stated that free radicals are 
both our friends and enemy at the same time (Downey JM, and Cohen MV 2008). 
It is very difficult to monitor the cellular processes which influence the outcome of the 
surgical interventions, or serves as a marker of the postoperative events. A huge amount of 
data emerged for the characterization of ischemia reperfusion injury, but function of 
platelets and other circulating cells or their interaction with each other or with endothelial 
cells has been hardly investigated  (Buchholz AM, Bruch L 2003.). Limitation of reperfusion 
injury is inevitably important to prevent tissue damages, manifested in apoptosis, necrosis 
or both, and frequently occurred after restoration of circulation after stroke, myocardial 
infarction, organ transplantations, and in all types of revascularization surgeries. There are 
pharmacologic tools, and protective processes, which can reduce IR injury. Antioxidants, 
such as N-acetylcysteine, vitamin E, mannitol, thiols, alkaloids and endogenous 
antioxidants, such as superoxide dismutase, reduced glutathion, glutathione reductase, 
catalase, or ion chelators functions due to inactivation of free radicals, which are key 
element in IR induced tissue damages (Arato et al 2010), (Peto K,  et al 2007),  but leukocyte 
depletion, anti-cytokine or leukocyte adhesion molecule monoclonal antibody therapies 
ended with conflicting results (Arato et al 2010) (Loberg AG et al ,2011). Among other 
effective possibilities, ischemic postconditioning is one of the most effective processes in 
reducing IR caused damages, which was first introduced by Vinten-Johansen’s group in 
2003. The main essence of application of short (some seconds) repetitive interruption of 
early reperfusion by brief ischemic episodes resulting in reduced infarct size in the heart, 
diminished tissue edema, reduced infiltration of leukocytes into the area of injury, as they 
were improved in animal studies (Vinten-Johansen J 2007).  
Angioplasty with or without vascular stenting is an effective method, was developed by 
Dotter and Judkins (Misty M et al 2001) to reconstruct the proper flow within the narrowed 
or occluded vessels. The procedure is carried out mainly in the coronary arteries, but it is 
frequently applied in other parts of the circulation. The procedure itself is a typical example 
of I/R injury was characterized above, with main risks of endothelium dysfunction and 
reocclusion due to thrombus formation and/or smooth muscle proliferation. The potential 
role of the circulating cells, such as PLT, WBC, and RBC in the vessel closure is intensively 
studied, and their interactions with the components of vessel wall, mainly with the smooth 
muscle cells and the endothelial linage have special attention (Ming Wei Liu et al 1989). 
Platelet leukocyte interaction is also investigated, because of their unique role in reocclusion 
(Szabo S. et al 2005). 
In the present study we aimed to investigate the function of circulating cells in the course of 
acute (emergency) and elective revascularization surgery in lower limb of patients with 
Peripheral arterial disease (PAD). In our studies thrombocyte function, antioxidant and 
prooxidant status were investigated in two groups of patients, who were scheduled to elective 
revascularization surgery (Elective) and were compared to the patients with acute vessel 
closure and were undergone revascularization surgery in emergency, 4-6 hours after of vessel 
closure (Acute). Data obtained in the two patients groups were compared to the same 
parameters of healthy veterinary blood donors (Control). Patients of the two groups (Acute 
and Elective) have other chronic diseases too, such as diabetes mellitus. Diabetes is a disease 
when patients have high blood sugar concentration due to the inadequate production: DM1, or 
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inadequate effects on the tissues of otherwise physiological or high level of circulating insulin: 
DM2. In the second series of experiments, thrombocyte function and prooxidant/antioxidant 
status of DM1 and DM2 patients with PAD were also investigated. In vitro effects of 
exogenous insulin (Actrapid Insulin (Novo-Nordisk) In 0, 40, 80, 160 µU/ml) were also 
investigated on collagen induced platelet aggregation and phorbol – 12 myristate-13 acetate 
(PMA) induced reactive oxygen species (ROS) production in whole blood.  
2. Materials and methods 
Patients selection and investigation in this randomized, open, prospective studies was 
carried out according to the Helsinki declaration (1996), considering the statute of 
Hungarian Ministry of Health (32/2005. (VIII:26), with the permission of the local ethical 
board of the Pecs University, Medical School. (Permission No.: 2498). 
2.1 The first series of experiments 
The aim of this study was to investigate the effect of the duration of hypoxia on the 
thrombocyte function, free radical production and antioxidant/prooxidant statuses of the 
patients who were undergone revascularization surgery of lower limb.  
Patients: Two groups of patients were investigated:  
1. Acute group: n=12; 9 males and 3 female, age: 58.1±7.3 years, suffered from ischemia  
4-6 hours  before  revascularization surgery of lower limb because of  seriously ischemic 
extremities due to embolism, acute arterial thrombosis or rupture of infrarenal artery 
before the surgery. They were undergone revascularization surgery in emergency.  
2. Elective group n=10, (6 male 4 female) were scheduled to elective revascularization 
surgery because of chronic obliterative arterial stenosis. Ischemia was diagnosed by 
angiography, and Doppler test.  
Other chronic diseases accompanied by PAD in our patients are summarized in Table 1.  
Surgical interventions were carried out in General and Vascular Surgery Department of 
Baranya County Hospital (Pecs; Hungary), and were performed in spinal anaesthesia, with 
43.8±17 min ischemic time. Patients of both groups received similar anticoagulant and 
antiplatelet therapy (at least 75 mg Aspirin) and low molecular weight heparin was also 
prescribed in the perioperative period. Medication of the patients is summarized in Table 2. 
 
Disease Acute group Elective group 
Hypertension 6/12 8/10 
Ischemic heart disease 3/12 4/10 
Diabetes mellitus 4/12 5/10 
Lung complications 4/12 4/10 
Smooking 5/12 4/10 
Table 1. Chronic diseases accompanied with PAD in the first series of the study 
Blood sampling: Venous blood samples were obtained by venipuncture.  Samples of 10 
healthy blood donors (Blood Donation Center of Pecs, Hungary) served as Control. Venous 
blood samples of the two patients groups were obtained before and 2 and 24 hours and one 
week after the surgery. Blood samples were collected into three Vacutainer tubes containing 
trisodium citrate (3.8%) or K3-EDTA (7.5 %) (Becton Dickinson, UK). Informed consents 
were obtained from all patients and volunteers participated in the study.  
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Groups of medicine Acute Elective 
PLT aggregation inhibitors 
(Aspirin protect or Astrix) 12/12 10/10 
Anticoagulant 
(perioperative) 12/12 10/12 
Antihypertensive 6/12 8/10 
Antidiabetic 4/12 5/10 
Others 12/12 10/10 
Table 2. Medication of patients with PAD in the 1st series of the study 
Laboratory measurements: were carried out in Department of Surgical Research and 
Techniques of Pecs University Medical School, Hungary. Hematologic measurement: red 
and white blood cell numbers, haemoglobin concentration, platelet numbers were measured 
by Minitron automatic analysator (Diatron LTD Budapest, Hungary). Platelet aggregation 
measurements:  
1. in platelet rich plasma (PRP), according to Born’s turbidimetric method (Born 1965a), 
Born et al 1965b), by means of Carat aggregometer (Carat Diagnostic ltd, Budapest, 
Hungary), using ADP (5 µM; and 10 µM) and collagen (2 µg/ml) as inductors. 
Aggregation was followed for 8 minutes after its induction and expressed in %. 
2. in whole blood was measured by the method of Ingerman-Wojenski and Silver by 
Chrono-log lumino-aggregometer (type 560VS, USA), according to the user’s manual of 
the instrument (Ingerman-Wojenski CM and Silver MJ), using the same inductors as 
was used in PRP. In whole blood platelet aggregation was measured by impedance, and 
expressed in Ohm, and was followed for six minutes from its induction. 
Measurement of main antioxidants: SOD is an ancient antioxidant enzyme of pro- and 
eukaryotic organisms, containing metal (Cu, Zn, Fe, Mn Ni, respectively) in its active centre, 
and it has several isoforms,  which can be found intra- and extracellularly, in almost all 
living creature, as well. Measurement of SOD activity was carried out by the method of 
Misra and Fridovich (Misra and Fridovich 1972). Reduced glutathione (GSH) levels were 
determined in plasma were obtained after centrifugation of anticoagulated whole blood, 
using Ellman’s reagent (Sedlak and Lindsday 1968). GSH cystein is able to neutralize free 
radicals by donating one electron and stabilizes them. In the course of this reaction it 
became reactive, as well, but an other GSH can neutralize it, forming GSSG, which will be 
regenerated to GSH by glutathione reductase. Plasma proteins (such as albumin) contain 
sulphydril groups, as well and exert remarkable antioxidant capacity though its –SH 
groups, was measured also. 
Measurement of prooxidants: Reactive oxygen species (ROS) was measured in the mixture 
of whole blood (20 µl) and phosphate buffered saline (1400 µl) by chemiluminometric, 
kinetic method, by means of Chrono-Log lumino-aggregometer. The main sources of ROS in 
the blood are leukocytes.  ROS production was induced in whole blood by phorbol -12-
miristate-13-acetate (PMA) and was made detectable by luminol (Arato et al 2010b).) 
Malondialdehyde (MDA), the main lipid peroxidation marker, which signs the 
polyunsaturated fatty acid peroxidation of the biological membranes. It was measured in 
anticoagulated whole blood and in plasma (Ohkawa H (1979). Myeloperoxidase (MPO) 
produces hypochlorous acid (HOCl) from hydrogen peroxide (H2O2) and chloride anion  
(Cl-) (or the equivalent from a non-chlorine halide) during the neutrophil's respiratory burst. 
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It requires hem as a cofactor. Furthermore, it oxidizes tyrosine to tyrosyl radical using 
hydrogen peroxide as an oxidizing agent. MPO level was measured in plasma, according to 
the method of (Xia and Zweier 1997). 
2.2 The second series of experiments 
The aim of this study 
Insulin resistance and diabetes mellitus are causal or worsening factors in the peripheral 
arterial diseases (Jude EB 2001). In the second part of the study we intended to investigate 
thrombocyte function parallel with antioxidant prooxidant status of ambulant diabetic 
(DM1 and DM2)  patients with PAD were under the care of General and Vascular Surgery 
Department of Baranya County Hospital (Pecs; Hungary). Eleven healthy volunteers of 
Blood Donation Centre of Pecs served as controls   
Methods 
This study involved 24 patients with DM1 (18 male and 6 female; age: 62 ± 2.3 year), and 22 
with DM2 (18 male and 4 female; age: 65,7 ±3.7)  with PAD. Healthy blood donors served as 
control (8 male and 2 female; age: 33 ± 6.7 years). Anticoagulated whole blood of ambulant 
patients and volunteers were used. Informed consents were obtained from all participants. 
Regular medication of the two patients group is summarized in Table 3. 
 
Medication DM1 DM2 
Platelet aggregation inhibitors 
(Aspirinprotect or Astrix) 24/24 22/22 
Anticoagulant (Syncumar) 4/24 4/22 
Anticoagulant (LMWH) 12/24 10/22 
Antihypertensive 18/24 18/22 
Insulin 24/24 2/22 
Oral antidiabetic 0/24 20/22 
Other 24/24 22/22 
Table 3. Medication of the DM1 and DM2 patients. 
Parameters to be measured 
Clinical chemistry data: Glucose triglyceride, cholesterol was measured by commercial  
kits (Diagnosticum Ltd Budapest) by photometric method. Platelet aggregation was 
measured in whole blood and in PRP. PMA induced ROS production; endogenous 
antioxidant and prooxidant status of these patients were measured as it was described 
above. Platelet aggregation: Platelet aggregation was measured in PRP and in whole blood 
as it was described above. In the latter case area under the aggregation curves were 
calculated as well, using Origin 6.0 data analyzing and graphing software. Collagen 
induced platelet aggregation, and PMA induced ROS production were measured in the 
presence of 0, 40, 80, 160 µU/ml insulin (Actrapid), too. Statistical analyses: Student’s 
paired and unpaired t-test and one way analysis of variance were used. Differences were 
considered significant, when p was less than 0.05. The results were expressed as mean ± 
SD or in percentage. 
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3.1.1 Results of clinical chemistry measurements 
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Elective and Control ones, in the course of the study 
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ADP and Collagen were selected as aggregation inductors. These agents were used to 
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Fig. 1. ADP (5 and 10 µM) induced aggregation in platelet rich plasma. Antiplatelet therapy 
seemed to be effective in both patients groups using 5 and 10 µM ADP, as inductor in 




























































Fig. 2. Maximum values of collagen (2 g /ml) induced platelet aggregation in PRP, 
compared to Control. *= p<0,05, **=p<0.01 compared to controls. 
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Fig. 1. ADP (5 and 10 µM) induced aggregation in platelet rich plasma. Antiplatelet therapy 
seemed to be effective in both patients groups using 5 and 10 µM ADP, as inductor in 




























































Fig. 2. Maximum values of collagen (2 g /ml) induced platelet aggregation in PRP, 
compared to Control. *= p<0,05, **=p<0.01 compared to controls. 
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In figure 1 and 2 the ADP- and in figure 3 the collagen induced aggregation maximums 
were summarized, and compared to the values of healthy subjects. According to our data 
antiplatelet therapy received by both patients groups were effective on the level of isolated 
thrombocytes in the whole observation time.  Platelet aggregation in Control group was 
within the normal range either ADP or collagen was used as inductors (61-91% of ADP, and 
64-92 of collagen), contrarily in both groups of patients a significantly reduced response to 
ADP and Collagen were measured, signing an effective anti-platelet therapy. 
3.1.3 Investigation of platelet aggregation in whole blood 
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Fig. 4. ADP induced aggregation in Acute group, compared to Control (red line). 
ADP induced platelet aggregation in whole blood was similar in Acute and Elective and 
Control groups before the surgery. In the Elective group ADP induced platelet aggregation 
did not changed significantly in the course of the study. In the Acute group a significant 
gradual increase was observed in the function of time, with a four times increase at the end 
of the week (Figure 4). 
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Fig. 6. Collagen induced aggregation in whole blood in Acute group.  
In whole blood of healthy subjects, the collagen induced platelet aggregation started  
with one minute delay. In the patient groups, collagen induced aggregation started 
without delay, mainly in Acute group, one week after the surgery. Application of  
the inductor in this case resulted in an immediate induction of platelet aggregation. The 
effect of antiplatelet therapy was detected in platelet- rich plasma was missed in whole 
blood.  
3.1.4 Investigation of antioxidants   
3.1.4.1 GSH level 
Before surgery GSH levels were similar in the three groups. In patients groups a transient 
reduction occurred 2 hours after and one day after the surgery, but returned to the baseline 
level one week after the surgery. 
3.1.4.2 Plasma thiol groups 
Before the surgery the plasma SH-group concentration of the patient groups did not differed 
from each other or the healthy controls, but a transient, significant reduction was measured 
2 hours and 24 hours after surgery in both patients groups, which returned to the normal 
level 1 week later. 
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3.1.4.3 SOD activity 
Before surgery SOD activity was lower in both patients groups, compared to Control, 
however SOD activity in Elective group was higher than in Acute group, and remained 
unchanged during the study. In Acute group SOD level decreased further 24 hours after the 
surgery. SOD levels of patients groups remained below the normal range in the course of 


























Fig. 7. Changes in SOD activity. *= p<0.05, **=p<0.01, **=p<0.005, +=p<0.05 vs. elective, 
#=p<0,05 vs. before surgery 
Before surgery SOD activity in both patients groups were lower compared to healthy 
volunteers. This low level decreased further significantly n Acute group until the 24th hour 
of reperfusion and remained in this low level during the study. In elective group SOD level 
was on a constant low-level during the study. I/R injury was described almost 50 years ago, 
but the correct mediation, the way of prevention or treatment is under investigation in 
nowadays, as well. The inflammatory responses can be detected following reperfusion 
varies greatly and depends on the time and severity of ischemia, as it was measured in our 
cases too. Restoration of blood flow of ischemic tissues initiates a chain reaction of 
complications which can categorize into two main groups: regional and systemic. In our 
case restoration of blood flow in lower limb, generated a systemic response, which had been 
detected in blood samples (in serum, haemolysate, plasma) obtained in a great distance from 
the intervention. 
3.1.5 Investigation of prooxidants 
3.1.5.1 PMA induced free radical production 
Before surgery PMA induced ROS production was higher in Acute than in Elective and 
Control groups. This value elevated further in the course of the study. Free radical generation 
was characterized with four parameters: 1. the lag-time: the time elapsed between the 
induction and the beginning of the free radical production, 2. maximum of free radical 
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production corrected to the WBC numbers, 3. the Slope: the rate of rise of  the ascending part 
































































































































































Fig. 8. Upper left panel: white blood cell numbers, upper right panel: lag time, bottom left 
panel: slope of free radical curve, bottom right panel: maximal free radical production. 
***=<0.001 vs. control, +++=p<0.001 vs. elective, #= p< 0.01 vs. before surgery). 
In Acute group WBC numbers were significantly higher (upper left panel) and Lag time was 
significantly shorter (upper right panel) before and one week after the surgery, than the 
similar values in Elective and Control Groups (*=p<0.05 vs. Control, # = p<0.05 vs. Elective 
groups). Slope of the free radical producing curves became steeper in acute and elective 
groups, signing that more and more active WBC are present before and one week after the 
surgery, but in Acute group this free radical generation was significantly higher, than in the 
other two groups. The maximum of free radical production continuously elevated both in 
acute and in elective groups, but these elevation in acute group was several times higher 
than it was measured in elective group (figure 8.). 
3.1.5.2 Investigation of lipid peroxidation due to measurement of MDA in plasma and in 
red blood cell haemolysate 
It is a well known fact, that one of the main consequence of long-lasting atherosclerosis is 
the significant decrease in the polyunsaturated fatty acid (PUFA) content of the membranes, 
due to saturation of the membrane lipids which responsible for the rigidity of the 
membranes. MDA is one of the lipid peroxydation end products, generated in the course of 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
72
3.1.4.3 SOD activity 
Before surgery SOD activity was lower in both patients groups, compared to Control, 
however SOD activity in Elective group was higher than in Acute group, and remained 
unchanged during the study. In Acute group SOD level decreased further 24 hours after the 
surgery. SOD levels of patients groups remained below the normal range in the course of 


























Fig. 7. Changes in SOD activity. *= p<0.05, **=p<0.01, **=p<0.005, +=p<0.05 vs. elective, 
#=p<0,05 vs. before surgery 
Before surgery SOD activity in both patients groups were lower compared to healthy 
volunteers. This low level decreased further significantly n Acute group until the 24th hour 
of reperfusion and remained in this low level during the study. In elective group SOD level 
was on a constant low-level during the study. I/R injury was described almost 50 years ago, 
but the correct mediation, the way of prevention or treatment is under investigation in 
nowadays, as well. The inflammatory responses can be detected following reperfusion 
varies greatly and depends on the time and severity of ischemia, as it was measured in our 
cases too. Restoration of blood flow of ischemic tissues initiates a chain reaction of 
complications which can categorize into two main groups: regional and systemic. In our 
case restoration of blood flow in lower limb, generated a systemic response, which had been 
detected in blood samples (in serum, haemolysate, plasma) obtained in a great distance from 
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was characterized with four parameters: 1. the lag-time: the time elapsed between the 
induction and the beginning of the free radical production, 2. maximum of free radical 
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production corrected to the WBC numbers, 3. the Slope: the rate of rise of  the ascending part 
































































































































































Fig. 8. Upper left panel: white blood cell numbers, upper right panel: lag time, bottom left 
panel: slope of free radical curve, bottom right panel: maximal free radical production. 
***=<0.001 vs. control, +++=p<0.001 vs. elective, #= p< 0.01 vs. before surgery). 
In Acute group WBC numbers were significantly higher (upper left panel) and Lag time was 
significantly shorter (upper right panel) before and one week after the surgery, than the 
similar values in Elective and Control Groups (*=p<0.05 vs. Control, # = p<0.05 vs. Elective 
groups). Slope of the free radical producing curves became steeper in acute and elective 
groups, signing that more and more active WBC are present before and one week after the 
surgery, but in Acute group this free radical generation was significantly higher, than in the 
other two groups. The maximum of free radical production continuously elevated both in 
acute and in elective groups, but these elevation in acute group was several times higher 
than it was measured in elective group (figure 8.). 
3.1.5.2 Investigation of lipid peroxidation due to measurement of MDA in plasma and in 
red blood cell haemolysate 
It is a well known fact, that one of the main consequence of long-lasting atherosclerosis is 
the significant decrease in the polyunsaturated fatty acid (PUFA) content of the membranes, 
due to saturation of the membrane lipids which responsible for the rigidity of the 
membranes. MDA is one of the lipid peroxydation end products, generated in the course of 
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free radical induced peroxydation of PUFA. MDA is frequently used as a lipid peroxydation 









































































Fig. 9. MDA level in red blood cell (RBC) hemolysate (left panel) and in plasma (right 
panel), *= p<0.05 vs. Control,   **= p<0.01 vs. Control, ***= p<0.0051 vs. Control +=p<0.05 vs. 
Elective, #=p<0.05 vs. before surgery 
Surprisingly, in our case MDA concentration of erythrocyte membrane remained in a 
standard, relatively low level during the whole study, in the Acute group. We speculated 
about the background of this phenomenon, and finally we concluded that the long-lasting 
hypoxia preceeded the surgery may exhausted of the PUFA contents of the lipidmembranes. 
At the same time, plasma MDA of Acute group (right panel) were significantly higher than 
in Elective and Control groups, and elevated further 24 hours after the surgery, and 
returned to the baseline one week after the surgery. In Elective group a bell-shaped 
elevation appeared which peaked 2 hours after surgery (Figure 9. right panel). 
3.1.5.3 Changes in MPO 
In spite of MPO have not been evaluated in routine clinical chemistry studies, according to a 
recent study of Brevetti and coworkers its elevated level, but not C-reactive protein, predicts 
cardiovascular risk in peripheral arterial disease (Brevetti G , 2008). According to an other 
study it is a marker of myocardial infarction too. The base-line myeloperoxidase level 





























Fig. 10. Myeloperoxidase level in Control, Elective and Acute groups. MPO level both in 
Elective and Acute groups were significantly higher than in Control before surgery, than 
after a transient decrease in the postoperative period returned to the preoperative level. 
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(Brennan ML et al 2003). MPO is a hydrogen peroxide oxidoreductase, specifically found on 
mammalian polymorphonuclear leukocytes (PMN), responsible for the bactericidal 
capability of these cells. PMN activation and mediator release are partially responsible for 
the morbidity and mortality of revascularization of ischemic lower limb, regardless of the 
mode of intervention, surgery or application of thrombolytics. 
3.1.5.4 Conclusion of the first series of the experiments 
Ischemia/reperfusion injury, accompanied by revascularization surgeries of lower limb, 
was in the focus of the present study. This problem has great importance in the clinical 
practice because of its poor outcome (postoperative mortality is 15-60%). Tissue injury 
appears not only under ischemia, but after restoration of the blood flow in the formerly 
ischemic areas, due to the reperfusion injury, as well (Yasin) NM et al. 2002), (Arato et al 
2009). Ischemia reperfusion injury of lower limb is accompanied by muscle changes with 
progressive micro-vascular damage, and affects all circulating cells (RBC, WBC, and PLT), 
as well. These cells are in connection with each other and with cells of the vessel walls, too. 
Inflammatory response following reperfusion varies greatly, and depends on the time and 
severity of ischemia. According to our results in accordance with several other studies, the 
duration and severity of ischemia is proportional to the damage occurred after it. Studying 
thrombocyte function and antioxidant prooxidant status of our unique patient groups, 
several new aspects of ischemia reperfusion injury were revealed. Peripheral arterial disease 
is a common progressive disorder that attaches the circulation of the legs, particularly in 
people over 55 years, strengthening in these patients the greatly increased risk of heart 
attack or stroke, and of dying within a decade. Several aspects of the problem were 
intensively studied, but platelet function during the restoration of the circulation of ischemic 
lower limb was hardly investigated before. It was revealed in this study that an effective 
antiaggregating therapy was applied in these patients, and effectively reduced the 
aggregation induced by ADP and collagen in PRP, but this reduction in whole blood was 
completely disappeared, both in ADP and collagen induced aggregation in Acute and 
Elective groups too. Above this a highly significant increase in platelet aggregation was 
measured in whole blood, in response to both types of inductors, one week after the surgery 
in Acute group. We concluded on the basis of our result that the long-lasting hypoxia is 
responsible for the increased PLT aggregation in whole blood, as the consequence of the 
shift of the antioxidant-prooxidant balance to the prooxidant direction lead to the increased 
response to aggregation inductors. 
3.2 Results of the second series of experiments 
3.2.1 Clinical chemistry data 
Monitoring thrombocyte function and antioxidant prooxidant status of diabetic patients 
with peripheral arterial disease is inevitably important, because of the increased risk of 
complication. Patients suffering from both diabetes and PAD are at risk of developing 
critical limb ischemia, ulceration and potentially requiring limb amputation. In addition, 
diabetes complicates surgical treatment of PAD and impairs vascular functions. The 
presence of diabetes increases the frequency of intermittent claudication. The relative risk of 
amputation in diabetic population is 12,4-fold higher compared to the non diabetic patients 
(95%, 10,9-14,9), and this value doubles above 65 years. Diabetes increases the sensing of 
shear stress and the response to vasoconstrictor stimuli, reducing the recruitment and 
dilatation of collateral arteries (Brennan ML et al 2010).  
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Group of  
patients Glucose Triglyceride Cholesterol 
DM1 11.4 ±1.6 1.9 ± 0.3 4.3±0.6 
DM2 7.3 ±0.7 4.3 ±1.4 5.2 ±0.7 
Healty 4.82 ±0.27 1.1±0.15 4.2 ±0.5 
Normal values 4.2-6.1 mmol/l 0.4-1.7 mmol/l 3.7-5.2 mmol/l 
Table 4. Clinical Chemistry of Control subjects and DM1 and DM2 patients. 
Glucose and triglyceride levels of diabetic patients were higher than the normal values. The 
mean value of cholesterol level was within the normal range, but individually high values 
were measured, as well.  
3.2.2 Investigation of platelet aggregation 
3.2.2.1 Investigation of PLT function in platelet rich plasma 
Investigation of platelet function by turbidimetric method in PRP is a more frequently  
used method, than impedance measurement in whole blood. Our own investigations 
focused our attention on the usefulness of the parallel measurements. There are several 
advantages using both methods parallel, e.g. in PRP platelet function can be measured 
independently from other circulating cells. It is very advantageous if we investigate  
the effect of antiplatelet drug in a specific direction. Contrary, in whole blood the effects of 
the other components of circulating cells of blood (leukocytes, red blood cells) can be 
studied together. 
 





















Fig. 11. ADP induced platelet aggregation in PRP of diabetic patients with PAD.  
All parameter were measured in DM1 and DM2 Patients were reduced, compared to 
Control. In DM2 patients Slope of the aggregation curve was significantly higher compared 
to Elective groups.  
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Fig. 12. Collagen induced platelet aggregation in PRP of diabetic patients with PAD.  
3.2.2.2 Investigation of ADP induce platelet aggregation in whole blood in control and 


























Fig. 13. ADP induced platelet aggregation of healthy and diabetic patients with PAD in the 
function of time. However patient’s data were higher in every time points compared to 





















Fig. 14. Area under the ADP induced platelet aggregation curves (AUC). AUC of patients 
with PAD were significantly higher (p<0.05), than that of Control 
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Fig. 14. Area under the ADP induced platelet aggregation curves (AUC). AUC of patients 
with PAD were significantly higher (p<0.05), than that of Control 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
78
3.2.2.3 Investigation of PLT function in whole blood in control and diabetic patients  































Fig. 15. Collagen induced platelet aggregation in whole blood of healthy and diabetic subjects 
with PAD in the function of time. Platelet aggregation of diabetic patients was higher in each 




























Fig. 16. AUC of the platelet aggregation curves of healthy and diabetic patients. Significant 
differences were measured among DM1 and DM2 groups, compared to each other (#)., and 
between DM1 and Control. 
3.2.3 Antioxidant and prooxidant levels 
Plasma GHS levels were similar in the three groups, however SOD activity was significantly 
lower in both patients groups, compared to Control (Figure 17). WBC numbers in the DM1 
group was the double and ROS production/103 WBC was 20 times higher in DM1 group 





















Fig. 17. SOD activity was significantly lower in patients groups than in Control. 
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Fig. 18. PMA induced ROS production was higher in patients then in Control 
3.2.4 In vitro effects on insulin on platelet aggregation in whole blood 
3.2.4.1 In vitro effect of actrapid insulin on collagen induced platelet aggregation in 
whole blood of healthy volunteers, DM1 and DM2 patients with PAD was investigated 
Actrapid insulin exerts its effect within a short time in patients too, that was the reason why 
we chose this. Platelet aggregation was expressed in Ohm, and area under the curves was 




































Fig. 19. Collagen induced aggregation in healthy volunteer’s whole blood in the function of 
time, in the presence or absence of Actrapid insulin. A significant decrease occurred in the 

































Fig. 20. AUC in healthy subjects. Significant decrease was detected in the presence of 80 
µU/ml of insulin, considering 100% of AUC without insulin 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
78
3.2.2.3 Investigation of PLT function in whole blood in control and diabetic patients  































Fig. 15. Collagen induced platelet aggregation in whole blood of healthy and diabetic subjects 
with PAD in the function of time. Platelet aggregation of diabetic patients was higher in each 




























Fig. 16. AUC of the platelet aggregation curves of healthy and diabetic patients. Significant 
differences were measured among DM1 and DM2 groups, compared to each other (#)., and 
between DM1 and Control. 
3.2.3 Antioxidant and prooxidant levels 
Plasma GHS levels were similar in the three groups, however SOD activity was significantly 
lower in both patients groups, compared to Control (Figure 17). WBC numbers in the DM1 
group was the double and ROS production/103 WBC was 20 times higher in DM1 group 





















Fig. 17. SOD activity was significantly lower in patients groups than in Control. 
Investigation of the Oxidative Stress, the Altered Function  


























Fig. 18. PMA induced ROS production was higher in patients then in Control 
3.2.4 In vitro effects on insulin on platelet aggregation in whole blood 
3.2.4.1 In vitro effect of actrapid insulin on collagen induced platelet aggregation in 
whole blood of healthy volunteers, DM1 and DM2 patients with PAD was investigated 
Actrapid insulin exerts its effect within a short time in patients too, that was the reason why 
we chose this. Platelet aggregation was expressed in Ohm, and area under the curves was 




































Fig. 19. Collagen induced aggregation in healthy volunteer’s whole blood in the function of 
time, in the presence or absence of Actrapid insulin. A significant decrease occurred in the 

































Fig. 20. AUC in healthy subjects. Significant decrease was detected in the presence of 80 
µU/ml of insulin, considering 100% of AUC without insulin 
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Fig. 21. Collagen induced platelet aggregation in the function of time on whole blood in 
DM1 patients. DM1 patient’s blood was sensitive to each concentration of insulin, without 































Fig. 22. AUC of collagen induced platelet aggregation curves in DM1. The three insulin 
concentration caused similar, but significant decrease in the aggregation. 
 
 
Fig. 23. Collagen induced platelet aggregation in DM2 patients. Insulin was ineffective on 
collagen induced platelet aggregation. 
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3.2.5 Effect of exogenous insulin on PMA induced ROS production in whole blood 
Insulin effect on the maximum of PMA induced ROS production was investigated, as well.  
The presence of insulin in whole blood was able to reduce PMA induced ROS production in 
whole blood in healthy subjects and that of DM1 patients’ blood too, but not in DM 2 
patients (Figure 24.) 
 
 
Fig. 24. Insulin was not able to reduce area under platelet aggregation curve in blood 





































Fig. 25. Effect of insulin on PMA induced ROS production on whole blood of Control, DM1 
and CM2 patients’ whole blood, in vitro. 
3.3 Summary of data obtained from investigation of diabetic patients blood 
The presence of DM1 or DM2 diabetes differently influenced the thrombocyte function and 
antioxidant status of PAD patients, and the in vitro effects of insulin on collagen induced 
platelet aggregation and PMA induced ROS generation.  
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Investigating platelet aggregation in whole blood of patients neither in ADP, nor  
in collagen induced aggregation curves differed significantly from each other or the control.  
Calculating area under curves (AUC), significant differences were revealed, showing that 
platelets of DM1 patients was more sensitive to both inductors than that of  
in other two groups (Figure 13-16). This increased sensitivity was accompanied by lower 
SOD activity (Figure 17.) and highly significant increase in PMA induced ROS generation 
(Figure 18.). 
In vitro effects of insulin on collagen induced platelet aggregation, and PMA induced ROS 
generation were also investigated in the presence of 0, 40, 80, 160 U/ml insulin in the 
whole blood. A U-shaped inhibition in collagen induced aggregation was detected in 
healthy subjects, a constant decrease in DM1 patients, without dose dependence, but insulin 
was ineffective in DM2 patients blood (figure 19-25). The maximum values of PMA induced 
ROS generation was significantly higher than in other two groups, but insulin pre-treatment 
was able to reduce it. Insulin was able to reduce the low ROS levels were induced by PMA 
in the blood donor’s blood, but not in DM2 patient’s blood.  
4. Conclusion  
Reconstruction of blood flow in the formerly ischemic tissues induces chain reactions, which 
affect not only the tissues are involved, but threats the integrity of the whole organism, 
causing multiorgan failure and death. The irreversible muscle cell damage begins 3 hour 
after ischemia and completed about within 6 hours (Blaisdell W. 2002). Tissue damage 
induced by the revascularization surgery of lower limbs had been in the focus of our 
studies. Our main aims were to study and characterize the role of the duration of the 
hypoxia on the thrombocyte function, and on the other circulating cells, especially on the 
leukocytes. ADP and collagen were used as platelet aggregation inductors. ADP is able to 
potentate the effects of other inductors, such as thrombin, due to stimulate and stabilize the 
thrombus. Collagen appears in the blood steam in the course of the injury of endothelial 
lineage. Collagen directly acts due to GPIIbIIIa receptors, and indirectly by Von-Willebrand 
factor, induces platelet aggregation and increases the adherence of platelet to the vessel 
wall, too.  
Our studies can be considered new, in the respects of the parallel measurement of 
aggregation in platelet rich plasma and in whole blood within the same samples, at the same 
time. We revealed significant differences using the two methods. In isolated thrombocyte 
the effectiveness of antiplatelet therapy can be tested directly on the thrombocyte itself, 
during the hospitalization. In whole blood, the modulating effects of other cellular and non 
cellular components of blood can be studied. The disturbances in antioxidant/prooxidant 
balance are in the background of this phenomenon. The most surprising results were in our 
studies, that in PRP a satisfactory aggregation inhibition was detected in both the Acute and 
Elective groups (Figure1 and 3), but in whole blood (Figure 3., 4.,5., 6.) a highly significant 
elevation in ADP and collagen induced aggregation were revealed in the Acute group, 
compared to the Elective and Control ones. We concluded that the increased leukocyte 
numbers, the elevated free radical production of the individual leukocytes, and the 
exhausted antioxidant capacity, mainly the significant reduction in SOD activity, had 
important role (Figure 7. and 8). We pointed out the importance of the increase of 
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prooxidants, while antioxidant capacity decreases especially in Acute group and in a less 
extensive way in Elective group too. 
It has to be mentioned that SOD deficiency is a highly important determinant of the 
increased ROS production and the increase in platelet aggregation one week after the 
surgery. Pipinos and co-workers published that, the SOD enzyme mutation of 
gastrocnemius muscle of rats is a risk factor of PAD, (Pipinos II and Swanson SA 2008). 
Intracellular GSH and the plasma –SH groups possess remarkable antioxidant capacities. 
Before the surgery their levels were almost equal in the three groups, but after surgery a 
small but significant transient reduction was measured in their levels, mainly in the Acute 
group. Conflicting results are published about the effects of volatile anaesthetics on 
oxidative stress, and some local anaesthetics can cause transient decrease in GSH level in 
skeletal muscles (Jia-Li Luo, et al 1996). It can be supposed that transient decrease in GSH 
level is partially caused by the surgical intervention. Further alterations are caused by the 
disease itself, due to the sclerotic vessels, and/or the presence of hypertension, and other 
disturbances. These states also complicated by increased free radical generation, which 
usually increased further by the surgical intervention. Activated platelets play definitive 
role in the development of atherosclerosis and increase of the risk of surgical 
interventions. In spite of these there are only few data which can highlight the 
background of the poor prognosis of PAD and the role of thrombocytes in these processes. 
Other risk-factors which have definitive role, the activated complement system (Beinrohr 
L), leukocyte-thrombocyte interaction, and the increased endothelin release. The 
consequences of IR affect not only the great conduit vessels, but microcirculation is also 
affected (Kaszaki et al 2006). In the course of the animal studies they improved the 
protective effects of endothelin-A receptor antagonists and preconditioning against IR 
induced micro-vascular alterations. 
Diabetes is also a well defined risk factor which worsens the outcome the surgical 
intervention. In the second series of our study thrombocyte function and antioxidant 
prooxidant status of diabetic patients with peripheral arterial disease were investigated 
and effects of exogenous insulin were tested. Platelet aggregation of PRP in diabetic 
patients was reduced compared to healthy blood donors signing the efficacy of their 
antiplatelet treatment. This difference failed to appear in whole blood. Free radical 
productions were significantly higher and SOD enzyme activities were significantly lower 
in diabetic patients compared to control. Low concentrations of insulin reduced the 
aggregation and free radical production in healthy and Type 1 diabetic patient’s blood but 
failed to induce such effects in Type 2 diabetic ones. Insulin resistance is developed 
against not only the metabolic effects of insulin, but against other activities of this 
important hormone, as well. Revealing the alterations caused by surgical intervention in the 
function of circulating cells is inevitably important to improve the outcome of these 
procedures and reduce the complication of surgical intervention and facilitate recovery. 
Insulin is a vital hormone which essential for the glucose uptake of skeletal muscle and 
the heart. Insulin resistance increases the harmful effect of IR. Insulin effect can be 
improved and free radical production can be decreased by antioxidant, signing the 
important roles of free radicals in the pathogenesis of IR. Mice overexpressing 
extracellular SOD are less sensitive to IR (Sheng H et al 1999), signing that endogenous 
antioxidants have important role in tissue protection.  
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Investigating platelet aggregation in whole blood of patients neither in ADP, nor  
in collagen induced aggregation curves differed significantly from each other or the control.  
Calculating area under curves (AUC), significant differences were revealed, showing that 
platelets of DM1 patients was more sensitive to both inductors than that of  
in other two groups (Figure 13-16). This increased sensitivity was accompanied by lower 
SOD activity (Figure 17.) and highly significant increase in PMA induced ROS generation 
(Figure 18.). 
In vitro effects of insulin on collagen induced platelet aggregation, and PMA induced ROS 
generation were also investigated in the presence of 0, 40, 80, 160 U/ml insulin in the 
whole blood. A U-shaped inhibition in collagen induced aggregation was detected in 
healthy subjects, a constant decrease in DM1 patients, without dose dependence, but insulin 
was ineffective in DM2 patients blood (figure 19-25). The maximum values of PMA induced 
ROS generation was significantly higher than in other two groups, but insulin pre-treatment 
was able to reduce it. Insulin was able to reduce the low ROS levels were induced by PMA 
in the blood donor’s blood, but not in DM2 patient’s blood.  
4. Conclusion  
Reconstruction of blood flow in the formerly ischemic tissues induces chain reactions, which 
affect not only the tissues are involved, but threats the integrity of the whole organism, 
causing multiorgan failure and death. The irreversible muscle cell damage begins 3 hour 
after ischemia and completed about within 6 hours (Blaisdell W. 2002). Tissue damage 
induced by the revascularization surgery of lower limbs had been in the focus of our 
studies. Our main aims were to study and characterize the role of the duration of the 
hypoxia on the thrombocyte function, and on the other circulating cells, especially on the 
leukocytes. ADP and collagen were used as platelet aggregation inductors. ADP is able to 
potentate the effects of other inductors, such as thrombin, due to stimulate and stabilize the 
thrombus. Collagen appears in the blood steam in the course of the injury of endothelial 
lineage. Collagen directly acts due to GPIIbIIIa receptors, and indirectly by Von-Willebrand 
factor, induces platelet aggregation and increases the adherence of platelet to the vessel 
wall, too.  
Our studies can be considered new, in the respects of the parallel measurement of 
aggregation in platelet rich plasma and in whole blood within the same samples, at the same 
time. We revealed significant differences using the two methods. In isolated thrombocyte 
the effectiveness of antiplatelet therapy can be tested directly on the thrombocyte itself, 
during the hospitalization. In whole blood, the modulating effects of other cellular and non 
cellular components of blood can be studied. The disturbances in antioxidant/prooxidant 
balance are in the background of this phenomenon. The most surprising results were in our 
studies, that in PRP a satisfactory aggregation inhibition was detected in both the Acute and 
Elective groups (Figure1 and 3), but in whole blood (Figure 3., 4.,5., 6.) a highly significant 
elevation in ADP and collagen induced aggregation were revealed in the Acute group, 
compared to the Elective and Control ones. We concluded that the increased leukocyte 
numbers, the elevated free radical production of the individual leukocytes, and the 
exhausted antioxidant capacity, mainly the significant reduction in SOD activity, had 
important role (Figure 7. and 8). We pointed out the importance of the increase of 
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prooxidants, while antioxidant capacity decreases especially in Acute group and in a less 
extensive way in Elective group too. 
It has to be mentioned that SOD deficiency is a highly important determinant of the 
increased ROS production and the increase in platelet aggregation one week after the 
surgery. Pipinos and co-workers published that, the SOD enzyme mutation of 
gastrocnemius muscle of rats is a risk factor of PAD, (Pipinos II and Swanson SA 2008). 
Intracellular GSH and the plasma –SH groups possess remarkable antioxidant capacities. 
Before the surgery their levels were almost equal in the three groups, but after surgery a 
small but significant transient reduction was measured in their levels, mainly in the Acute 
group. Conflicting results are published about the effects of volatile anaesthetics on 
oxidative stress, and some local anaesthetics can cause transient decrease in GSH level in 
skeletal muscles (Jia-Li Luo, et al 1996). It can be supposed that transient decrease in GSH 
level is partially caused by the surgical intervention. Further alterations are caused by the 
disease itself, due to the sclerotic vessels, and/or the presence of hypertension, and other 
disturbances. These states also complicated by increased free radical generation, which 
usually increased further by the surgical intervention. Activated platelets play definitive 
role in the development of atherosclerosis and increase of the risk of surgical 
interventions. In spite of these there are only few data which can highlight the 
background of the poor prognosis of PAD and the role of thrombocytes in these processes. 
Other risk-factors which have definitive role, the activated complement system (Beinrohr 
L), leukocyte-thrombocyte interaction, and the increased endothelin release. The 
consequences of IR affect not only the great conduit vessels, but microcirculation is also 
affected (Kaszaki et al 2006). In the course of the animal studies they improved the 
protective effects of endothelin-A receptor antagonists and preconditioning against IR 
induced micro-vascular alterations. 
Diabetes is also a well defined risk factor which worsens the outcome the surgical 
intervention. In the second series of our study thrombocyte function and antioxidant 
prooxidant status of diabetic patients with peripheral arterial disease were investigated 
and effects of exogenous insulin were tested. Platelet aggregation of PRP in diabetic 
patients was reduced compared to healthy blood donors signing the efficacy of their 
antiplatelet treatment. This difference failed to appear in whole blood. Free radical 
productions were significantly higher and SOD enzyme activities were significantly lower 
in diabetic patients compared to control. Low concentrations of insulin reduced the 
aggregation and free radical production in healthy and Type 1 diabetic patient’s blood but 
failed to induce such effects in Type 2 diabetic ones. Insulin resistance is developed 
against not only the metabolic effects of insulin, but against other activities of this 
important hormone, as well. Revealing the alterations caused by surgical intervention in the 
function of circulating cells is inevitably important to improve the outcome of these 
procedures and reduce the complication of surgical intervention and facilitate recovery. 
Insulin is a vital hormone which essential for the glucose uptake of skeletal muscle and 
the heart. Insulin resistance increases the harmful effect of IR. Insulin effect can be 
improved and free radical production can be decreased by antioxidant, signing the 
important roles of free radicals in the pathogenesis of IR. Mice overexpressing 
extracellular SOD are less sensitive to IR (Sheng H et al 1999), signing that endogenous 
antioxidants have important role in tissue protection.  
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
84
Present study support the importance of antioxidant prooxidant  equilibrium and the role of 
endogenous antioxidants. 
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1. Introduction 
Peripheral arterial disease affects approximately 12% of adults and 20% of adults over 70 
years (Hiatt et al., 1995). This disease results from one or more lesions in the arterial system 
of the lower extremity that restrict blood flow. The restriction of blood flow during 
ambulation may cause intermittent claudication, i.e. muscular pain due to lack of blood 
supply. About one fifth of people with peripheral arterial disease have intermittent 
claudication. About half of people with peripheral arterial disease are asymptomatic. A 
small part of people with peripheral arterial disease (< 10%) have critical limb ischemia, i.e. 
rest muscular pain and/or ischemic ulceration or gangrene of toes. Based on the severity of 
symptoms, the stages of the disease are classified as Fontaine stages I-IV, where stage I is 
asymptomatic, stage IIa is the occurrence of intermittent claudication after a pain-free 
walking distance of more than 200 m, stage IIb is intermittent claudication after less than 200 
m, stage III is rest pain, and stage IV is the presence of ischemic ulcers.  
Patients with peripheral arterial disease, which is an expression of systemic atherosclerosis, 
have an increased risk of cardiovascular events (Hankey et al., 2006). 
Medical therapy should include modification or elimination of atherosclerotic risk factors 
(cigarette smoking, diabetes mellitus, hypertension, hyperlipidemia), and antiplatelet 
therapies  to decrease  the risk of cardiovascular events and to improve survival. Moreover, 
the initial approach to the treatment of limb symptoms should focus to relieve discomfort, to 
improve exercise performance, and daily functional abilities by means of structured exercise 
and, in selected patients, pharmacotherapies to treat the exercise limitation of claudication 
(Norgren et al, 2007). Lower extremity revascularization is indicated for patients with a 
lifestyle-limiting disability due to intermittens claudication or with chronic critical limb 
ischemia (Hirsch et al., 2006; Norgren et al., 2007). 
There are two types of revascularization procedure: endovascular or surgical. Percutaneous 
transluminal angioplasty with or without stenting is an endovascular technique for 
revascularizing obstructed arteries. It was first introduced by Dotter and Judkins (Dotter & 
Judkins, 1964), and subsequently improved by Grüntzig (Grüntzig & Hopff, 1974). 
In peripheral transluminal angioplasty the recanalization of obstructed arteries is obtained by 
dilatation of a stenosis (i.e. a narrowing of the vessel diameter) or recanalization of a total 
occlusion, using a wire-guided inatable balloon catheter. Usually the femoral artery in the 
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groin is cannulated and a deflated balloon catheter is inserted and pushed forward along the 
guide-wire to the sites of obstruction. Stenting is usually added to reduce the risk of 
reocclusion, especially if there is a major endothelial damage, arterial dissection or non-
satisfactory dilatation with relevant residual stenosis. Self-expanding metallic stents are 
mainly applied at the aortic bifurcation or iliac segments, whereas the femoropopliteal level, 
until recently, was associated with a higher risk for reocclusion due to smaller vessel diameters 
in distal arteries (Do et al., 1992; Mahler et al., 1999; Palmaz et al., 1985; Strecker et al., 1988). 
The implantation of drug-eluting stents, nitinol stents, paclitaxel-coated angioplasty 
balloons, or treatment by intravascular brachytherapy following peripheral angioplasty of 
the femoropopliteal arteries have been considered as interventions with the capacity of 
reducing the occurrence of restenosis/reocclusion  (Schillinger et al., 2006;  Gray et al., 2008). 
In patients with peripheral arterial disease endovascular procedures are generally the 
treatment of choice for short-segment iliac or femoral-popliteal artery lesions (TASC-A, 
single stenosis less than 3 cm long). Longer segment iliac or femoral-popliteal artery lesions 
(TASC-B, single iliac stenosis 5-10 cm long, two iliac lesions 3-5 cm long, single occlusion of 
an iliac artery, tandem femoral-popliteal stenoses less than 3 cm long, single femoral-
popliteal lesion 3-5 cm in length) are frequently treated by endovascular techniques 
(Norgren et al., 2007). 
Restenosis (or reocclusion) is the main complication of peripheral transluminal angioplasty. 
Balloon angioplasty has been shown to induce endothelial injury and oxidative stress with 
subsequent endothelial dysfunction, platelet aggregation, macrophage activation, and 
smooth muscle cell proliferation (McBride et al., 1988; Taniyama & Griendling, 2003). 
Peripheral transluminal angioplasty induces a prothrombotic condition: atherosclerotic 
plaques are disrupted and platelets aggregate at the site of the damaged arterial wall (Fuster 
et al., 1995). Thus, as a result of platelet aggregation, activated blood clotting in the damaged 
atheromatous artery and low shear stress, restenosis (or reocclusion) is frequent (Schwartz, 
1998; Wentzel et al., 2003). 
In particular, the effects of balloon angioplasty on the platelet activation have been studied 
previously in vitro and in vivo. Peripheral transluminal angioplasty has been shown to 
result in significant imbalance between the production of prostacyclin, an effective 
vasodilatator and platelet antiaggregator produced in endothelial cells, and thromboxane 
A2, a potent smooth muscle constrictor and platelet aggregator formed in platelets, with 
shift more toward increased thromboxane A2 production. This finding is suggestive of 
significant platelet activation and may have implication for future failure of peripheral 
angioplasty (Parmar et al., 2010). An increased formation of thromboxane A2 was also seen 
in other two studies, one in patients undergoing peripheral angioplasty and one in patients 
after coronary angioplasty (Rossi et al., 1997; Peterson et al., 1986). 
In addition, in the initial phase after balloon and stent procedures, coagulation system is 
activated, as demonstrated by increased serum levels of thrombin-antithrombin complexes, 
D-dimer and fibrinopeptide A. This condition favours early thrombotic occlusion, where 
’early’ is usually defined as a period covering the first 4 weeks after the intervention 
(Tsakiris et al., 1999; Tschöpl et al., 1997). Subsequently, intimal hyperplasia, a redundant 
healing of the arterial wall, which is responsible for restenosis and reocclusion in the mid- 
and long-term, may follow. Intimal hyperplasia occurs as a result of denudation (tearing off 
of the inner lining) of the endothelium caused by damage to the vessel wall with the 
catheter. Smooth muscle cells in the medial layer are stimulated to grow and migrate into 
the intimal layer (Haudenschild, 1995; Jørgensen et al., 1990). 
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Risk factors for restenosis/reocclusion include severity of atherosclerosis in run-off arteries, 
length of diseased segments, number of treated lesions, stage of disease, and presence of 
cardiovascular risk factors (Norgren et al., 2007). Female gender may be an independent 
predictor of decreased primary patency of external iliac artery stents (Timaran et al., 2001). 
Inflammation, revealed by an elevated C-reactive protein, was also considered as a risk 
factor for restenosis at six months after successful femoropopliteal angioplasty (Schillinger 
et al., 2002). 
The rate of restenosis/reocclusion of suprainguinal (iliac) arteries after peripheral 
transluminal angioplasty ranges from 14% after one year to 29% after 5 years, while the rate 
of restenosis/reocclusion of infrainguinal (femoropopliteal) arteries after peripheral 
transluminal angioplasty with or without stenting ranges from 23-35% after one year to  
45-58% after 5 years (Norgren et al., 2007). Patients with stenoses or occlusions of 
infrainguinal arteries of less than 3 cm had a favourable long-term patency rate of 74% 
(Gallino et al., 1984). 
Patients subjected to local thrombolysis show higher incidences of restenosis/reocclusion 
(Decrinis et al., 1993). 
It is important to define the lesion suitable for balloon angioplasty in both the suprainguinal 
and infrainguinal districts. 
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) 
redefined the indications for endovascular or surgical revascularization on the basis of 
anatomical characteristics of the lesions. Endovascular interventions are recommended  
for: i) unilateral or bilateral stenosis of common iliac artery; unilateral or bilateral single 
short (  3 cm) stenosis of external iliac artery; ii) single stenosis  10 cm in length of 
femoropopliteal arteries; single occlusion  5 cm in length of femoropopliteal arteries (TASC 
Type A lesions) (Norgren et al., 2007). 
Endovascular interventions are the preferred treatments for: i) short (  3 cm) stenosis of 
infrarenal aorta; unilateral common iliac artery occlusion; single or multiple stenosis totaling 
3-10 cm involving the external iliac artery not extending into the common femoral artery; 
unilateral external iliac artery occlusion not involving the origin of internal iliac or common 
femoral artery; ii) multiple lesions (stenoses or occlusions), each  5 cm of femoropopliteal 
segment; single stenosis or occlusion  15 cm not involving the infra geniculate popliteal 
artery; single or multiple lesions in the absence of continuous tibial vessels to improve 
inow for a distal bypass; heavily calcied occlusion  5 cm in length; single popliteal 
stenosis (TASC Type B lesions) (Norgren et al., 2007). 
Provisional stent placement is indicated for iliac arteries as salvage therapy for a suboptimal 
or failed result from balloon dilatation (persistent translesional gradient, residual stenosis 
greater than 50%, flow-limiting dissection). Stenting is effective as primary therapy for 
common and external iliac artery stenoses and occlusions. Moreover, stents can be useful in 
the femoral, popliteal and tibial arteries as a salvage therapy for suboptimal or failed results 
from balloon dilatation (Hirsch et al., 2006). 
As mentioned above, the implantation of drug-eluting stents, nitinol stents, paclitaxel-
coated angioplasty balloons, or treatment by intravascular brachytherapy following 
peripheral angioplasty have been considered as interventions with the capacity of reducing 
the occurrence of restenosis/reocclusion. A study by Schillinger et al. showed better results 
at one year with self-expanding nitinol stent in femoropopliteal segments (Schillinger et al., 
2006). Use of paclitaxel-coated angioplasty balloons during percutaneous treatment of 
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femoropopliteal disease has been shown to be associated with significant reductions in late 
lumen loss (Tepe et al., 2008). Endovascular brachytherapy has been proposed as a 
promising treatment modality to reduce restenosis after angioplasty (Minar et al., 2000). 
However, the phenomenon of late acute thrombotic occlusion in patients receiving 
endovascular brachytherapy after stenting of the femoropopliteal arteries may compromise 
the benets of endovascular radiation. The fact that late acute thrombotic occlusions occurs 
concomitantly with stopping clopidogrel in patients treated with a double antiplatelet 
regimen (aspirin 100 mg / day and clopidogrel 75 mg / day) suggests an intensive and 
prolonged antithrombotic prevention in these patients (Bonvini et al., 2003). 
There are much few data concerning antithrombotic therapy after peripheral arterial 
revascularization, and patients with peripheral arterial disease are often treated on the basis 
of experiences extrapolated from coronary arteries (Visonà et al., 2009). 
Antithrombotic therapy has been shown to lower the incidence of associated cardiovascular 
events (Sobel & Verhaeghe, 2008). A meta-analysis of 42 trials has shown a statistically 
significant 23% reduction of vascular events (vascular death, nonfatal myocardial infarction 
or stroke) in 9,214 patients with peripheral arterial disease treated with antiplatelet therapy. 
Even patients having peripheral angioplasty benefited to a similar degree (Antithrombotic 
Trialists' Collaboration, 2002). Clopidogrel seems to be superior to aspirin in reducing 
cardiovascular events, particularly in patients with peripheral arterial disease (relative risk 
reduction of 23%) (CAPRIE Steering Committee, 1996), but this advantage is minimal. Life-
long antiplatelet therapy is usually recommended for all patients with peripheral arterial 
disease to prevent death and disability from stroke and myocardial infarction.  
Antithrombotic drugs to prevent restenosis would make an important contribution to the 
sustained success of endovascular treatment. The main questions concern the most effective 
and safe antithrombotic therapy and its duration. 
2. Methods 
We performed a Medline search of English language studies published between 1976 and 
2010 with the keywords “antithrombotic therapy, peripheral angioplasty”. We also 
considered the reviews and meta-analyses. We selected two meta-analyses, two reviews, 
and fifteen original articles. 
3. Results 
Two meta-analyses and two reviews evaluated the efficacy and safety of antithrombotic 
agents for the prevention of restenosis after balloon angioplasty in patients with peripheral 
arterial disease (Girolami et al., 2000; Dörfer-Melly et al., 2005; Watson & Bergqvist, 2000; 
Visonà et al. 2009). 
The first meta-analysis evaluated the efficacy of conservative adjuvant therapy after 
endovascular or surgical revascularization procedures. The meta-analysis, including thirty-
two studies, showed that, compared to non-active control, aspirin (100-300 mg daily) with 
dipyridamole (225-450 mg daily) improves patency (odds ratio 0.69) and mortality (odds 
ratio 0.57). Similarly, ticlopidine has been shown to improve patency and amputation rates 
(odds ratio 0.53 and 1.01, respectively), and therefore may be used when aspirin is 
contraindicated. Data on the effectiveness of vitamin K inhibitors were not conclusive 
(Girolami et al., 2000). 
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The second meta-analysis is a Cochrane review of 14 randomized trials comparing different 
antithrombotic drugs (anticoagulants, antiplatelet agents and others) with no treatment or 
placebo to prevent restenosis/reocclusion following peripheral vascular treatment. The 
trials included patients with symptomatic peripheral arterial disease treated by 
endovascular revascularization of the iliac or femoropopliteal arteries. Various 
pharmacological interventions were analysed: anticoagulants, antiplatelet agents and other 
vasoactive drugs were compared with no treatment, placebo, or any other vasoactive drug. 
Clinical endpoints were reocclusion, amputation, death, myocardial infarction, stroke and 
major bleeding. The efficacy and safety of acetylsalcylic acid and low molecular weight 
heparins have been shown. Aspirin (50-300 mg daily) started prior to femoropopliteal 
peripheral transluminal angioplasty has been shown to be the most effective prophylactic 
treatment. Low molecular weight heparins seem to be more effective in preventing 
restenosis or reocclusion than unfractionated heparin (Dörfer-Melly et al., 2005). 
Watson and Bergqvist identified eleven randomized trials with antithrombotic agents, but 
they didn’t clarify their usefulness in reducing the likelihood of restenosis or reocclusion 
after balloon angioplasty of femoropopliteal lesions (Watson & Bergqvist, 2000). 
Our group recently conducted a review on antithrombotic therapy after peripheral 
angioplasty (Visonà et al., 2009). 
We analyse the studies identified in the following paragraphs (Table 1). 
3.1 Aspirin with or without dipyridamole 
Two studies compared aspirin combined with dipyridamole to placebo (Heiss et al., 1990; 
Study Group, 1994). 
In a single-center trial 199 patients undergoing balloon angioplasty of femoropopliteal 
arteries were randomized to high dose aspirin (990 mg) combined with dipyridamole (225 
mg), low dose aspirin (300 mg) plus dipyridamole (225 mg), or placebo. Clinical and 
angiographic improvement was observed in both treatment groups in comparison with 
placebo, but this was statistically significant only in the high-dose aspirin group (Heiss et al., 
1990). 
A multicenter study randomized 223 patients undergoing balloon angioplasty of iliac or 
femoropopliteal arteries to receive either placebo or aspirin (50 mg) plus dipyridamole (400 
mg). No difference was observed between the two groups. A possible explanation of this 
result may be a higher percentage of patients with more favourable iliac lesions in the 
placebo group (65% versus 51%). Moreover, use of metallic stents was not performed (Study 
Group, 1994). 
According the conclusions of the Cochrane review, a 60% reduction of restenosis/ 
reocclusion was found with aspirin 330 mg combined with dipyridamole as compared to 
placebo up to 12 months after angioplasty of femoropopliteal arteries. A similar positive 
effect on patency was found with aspirin 50 to 100 mg combined with dipyridamole as 
compared to placebo at 6 months, but this was not significant (Dörfer-Melly et al., 2005). 
Aspirin/dipyridamole showed a superior effect on patency after femoropopliteal 
angioplasty compared to vitamin K antagonists at 3, 6, and 12 months, but even this effect 
was not significant (Do & Mahler, 1994; Pilger et al. 1991). 
Aspirin 50 to 330 mg, with or without dipyridamole, started before femoropopliteal 
endovascular treatment, appeared to be the most effective and safest strategy, and reduced 
the incidence of restenosis/reocclusion at 6 and 12 months when compared with no therapy 
or vitamin K antagonists. Three trials compared the efficacy and safety of different doses of 
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femoropopliteal disease has been shown to be associated with significant reductions in late 
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agents for the prevention of restenosis after balloon angioplasty in patients with peripheral 
arterial disease (Girolami et al., 2000; Dörfer-Melly et al., 2005; Watson & Bergqvist, 2000; 
Visonà et al. 2009). 
The first meta-analysis evaluated the efficacy of conservative adjuvant therapy after 
endovascular or surgical revascularization procedures. The meta-analysis, including thirty-
two studies, showed that, compared to non-active control, aspirin (100-300 mg daily) with 
dipyridamole (225-450 mg daily) improves patency (odds ratio 0.69) and mortality (odds 
ratio 0.57). Similarly, ticlopidine has been shown to improve patency and amputation rates 
(odds ratio 0.53 and 1.01, respectively), and therefore may be used when aspirin is 
contraindicated. Data on the effectiveness of vitamin K inhibitors were not conclusive 
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or vitamin K antagonists. Three trials compared the efficacy and safety of different doses of 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
94
aspirin after peripheral angioplasty. The doses tested ranged from 50 mg / day to 1000 mg / 
day. The three studies showed that higher doses of aspirin had no advantage on early 
reocclusion (within one month) and were more likely to cause gastrointestinal side effects 
including peptic ulcer (Weichert et al., 1994; Minar et al., 1995;  Ranke et al., 1994). 
3.2 Oral anticoagulants 
Anticoagulation is frequently combined with antiplatelet therapy after femoropopliteal or 
tibial artery balloon angioplasty, although the results of three randomized controlled trials 
do not support this practice (Schneider et al., 1987, as cited in Sobel & Verhaeghe, 2008; 
Pilger et al., 1991; Do & Mahler, 1994). In fact, in all three studies no significant difference 
was observed in arterial patency rate between the anticoagulation groups and the 
antiplatelet therapy groups (only slightly lower patency rate and more bleeding 
complications in the anticoagulation groups). 
3.3 Low molecular weight heparins 
Intimal hyperplasia is responsible for restenosis and reocclusion after angioplasty in the 
mid- and long-term. Low molecular weight heparins have been shown in experimental 
studies to have antiproliferative effects in addition to their antithrombotic properties 
(Wilson et al., 1991). Their potential to reduce restenosis remains to be established. The 
hypothesis that low molecular weight heparins plus aspirin are more effective than aspirin 
alone in reducing incidence of restenosis after peripheral transluminal angioplasty was 
tested in two trials. Nadroparin, administered at a dose adjusted to weight for 7 days after 
femoropopliteal angioplasty, has been shown to be more effective to prevent reocclusion at 
6 months than unfractionated heparin, without causing increased bleeding (Schweizer et al., 
2001). Despite this interesting result, dalteparin 2500 UI, administered for 3 months after 
femoropopliteal angioplasty plus aspirin 100 mg/day versus aspirin alone, failed to reduce 
incidence of restenosis/reocclusion at 12 months. However, dalteparin appeared to be 
beneficial at the 12-month follow-up in the subgroup of patients with critical limb ischemia 
(Koppensteiner et al., 2006). 
3.4 New antiplatelet drugs (abciximab, thienopyridines) 
There are few studies available on potent new antiplatelet drugs such as abciximab and 
thienopyridines. 
3.4.1 Abciximab 
In one study in high-risk patients with long segmental femoropopliteal interventions 
adjunctive administration of abciximab had a favorable effect on patency and clinical 
outcome in patients undergoing complex femoropopliteal catheter interventions not 
hampered by serious bleeding. Treatment effect of abciximab observed at 30 days was 
maintained at 6 months (Dörfer-Melly et al., 2005). 
In another study adjunctive abciximab after nitinol stenting of the superficial femoral artery 
did not appear to demonstrate any identifiable effect on functional outcomes at 9 months 
(Ansel et al., 2006). 
3.4.2 Thienopyridines 
The thienopyridines, ticlopidine and clopidogrel, interfere with the adenosine diphosphate 
(ADP) pathway. They might represent a useful alternative to aspirin, when it is not 
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tolerated, and might be combined with aspirin, when increased risk factors for 
restenosis/reocclusion are detected, although specific data are lacking. 
In one study ticlopidine was compared to vitamin K inhibitors. No significant difference in 
efficacy was found between the two drugs (Schneider et al., 1987, as cited in Sobel & 
Verhaeghe, 2008). 
The administration of clopidogrel and aspirin leads to a potent platelet inhibition, whose 
benefits have been demonstrated for patients with acute coronary syndrome, symptomatic 
vascular disease, and presence of multiple cardiovascular risk factors. A randomized double-
blind trial showed that the administration of clopidogrel and aspirin significantly suppresses 
platelet function up to 30 days after lower limb angioplasty, compared to aspirin and placebo 
(Cassar et al., 2005a). On the other hand, addition of clopidogrel to the standard 
antithrombotic therapy with aspirin had no effect on the levels of markers of coagulation 
activation, such as D-dimer and thrombin-antithrombin III, in patients with intermittent 
claudication before or after endovascular intervention (Cassar et al., 2005b). Moreover, therapy 
with clopidogrel and aspirin had no significant effect on markers of vascular smooth muscle 
cell proliferation before and after peripheral angioplasty (Wilson et al., 2009). 
3.4.3 Dual antiplatelet therapy 
Dual antiplatelet therapy (clopidogrel plus aspirin), leading to a potent platelet inhibition, 
has been shown to be more effective than aspirin alone in reducing cardiovascular events in 
patients with acute non-ST coronary syndrome. This finding has not been confirmed in 
patients at high cardiovascular risk but not in the acute phase, where risk-benefit ratio is less 
favourable (Keller et al., 2007). A potential benefit of clopidogrel and aspirin versus aspirin 
alone in patients with symptomatic vascular disease has been suggested by the CHARISMA 
trial, which enrolled more than 15,000 patients with either evident clinical cardiovascular 
disease or multiple risk factors (Bhatt et al., 2006). 
The benefit of more potent platelet inhibition with dual therapy, aspirin and clopidogrel, has 
been shown in a trial on acute coronary syndromes (CURE) (Fox et al., 2004). However, the 
efficacy and safety of this dual antiplatelet therapy after peripheral angioplasty have not 
been evaluated in a randomized controlled trial. The Clopidogrel and Aspirin in the 
Management of Peripheral Endovascular Revascularization study (CAMPER) was designed 
to evaluate this outcome after femoropopliteal angioplasty, but it was stopped, due to 
difficulties of randomization, perhaps because many patients were already treated off-label 
with clopidogrel and aspirin (Patrono et al., 2004).  
The administration of ticlopidine and acetylsalicylic acid has been shown to improve 
neurological outcome after carotid stenting without an additional increase in bleeding 
complications in patients undergoing carotid stenting, compared to acetylsalicylic acid alone 
(Dalainas et al., 2006). 
Aspirin and clopidogrel were used as standard therapy in two major randomized controlled 
trials of carotid stenting (preprocedure and at least for 30 days) (SPACE Collaborative 
Group, 2006; Mas et al., 2006). 
Although it is questionable to extrapolate experience from one anatomic region to another, in 
the absence of data on peripheral interventions, dual antiplatelet therapy seems to be a 
reasonable approach to reduce thrombotic complications after lower extremity balloon 
angioplasty and stenting, especially in the femoropopliteal and tibial districts. In fact, many 
physicians in the world use dual antiplatelet therapy with aspirin (100 mg / day) and 
clopidogrel (75 mg / day) before and after peripheral transluminal angioplasty and stenting of 
peripheral arteries. Dual antiplatelet therapy is continued for 4 weeks after the intervention. 
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patients at high cardiovascular risk but not in the acute phase, where risk-benefit ratio is less 
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Then aspirin is continued indefinitely (Visonà et al., 2009). Treatment with a loading dose of 
clopidogrel 6-24 hours before angioplasty seems to improve the clinical outcome (Verheugt et 
al., 2007), and a 600 mg loading dose versus 300 mg at least 12 hours before the procedure 
provides greater benefit in coronary syndromes (Cuisset et al., 2006). In addition, an intra-
arterial bolus of heparin (3000 to 5000 U) is often administered at the time of the procedure. 
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Currently, for patients undergoing lower extremity balloon angioplasty (with or without 
stenting), the American College of Chest Physicians (ACCP) recommends long-term aspirin 
(75-100 mg / day) (grade 1C), and recommends against anticoagulation with heparin or 
vitamin K inhibitors (grade 1A) (Sobel & Verhaeghe, 2008).     
Randomized, prospective studies with dual therapy are needed for resolving some issues, 
such as real efficacy of dual therapy in peripheral district, the optimal loading dose in 
patients undergoing endovascular revascularization, and the optimal duration of dual 
therapy following peripheral angioplasty and stenting (Plosker & Lyseng-Williamson, 2007). 
3.5 Vasoactive drugs 
Some drugs have interesting vasoactive properties, that may improve outcome after 
peripheral angioplasty. Iloprost, the prostacyclin analogue, and cilostazol, a 
phosphodiesterase type 3 inhibitor, have multiple effects, such as inhibition of platelet 
activation, vasodilation, antiproliferation of vascular smooth muscle cells, and improvement 
of endothelial cell function. These effects may lead to the inhibition of neointimal 
hyperplasia after stenting. 
Iloprost was investigated in a small study in conjunction with aspirin. A 3-day 
periinterventional intravenous infusion of iloprost plus long-term aspirin didn’t reduce 
incidence of restenosis, compared to aspirin alone (Horrocks et al., 1997). 
Cilostazol after endovascular therapy for femoropopliteal lesions was more effective in 
reducing restenosis than ticlopidine (Iida et al., 2008). 
Further studies are needed. 
4. Conclusion 
Patients with peripheral arterial disease benefit from receiving life-long aspirin at a daily 
dose of 75 mg to 100 mg or clopidogrel at a daily dose of 75 mg. Patients undergoing 
peripheral transluminal angioplasty should receive aspirin at a daily dose of 75 mg to 100 
mg, started before the intervention and continued life-long. Thienopyridines, e.g. 
clopidogrel, might represent a useful alternative to aspirin in cases of intolerance to aspirin. 
Although randomized clinical trials are lacking, it is reasonable to consider short-term dual 
antiplatelet therapy with aspirin and thienopyridines for infrainguinal stenting, given the 
relatively high rate of restenosis/reocclusion after interventions. It is reasonable to 
administer a 300-600 mg loading dose 6-24 hours before angioplasty, and to continue dual 
therapy for 4 weeks. If a drug-eluting peripheral stent was placed, dual therapy is 
maintained for 6-12 months. Use of low molecular weight heparins may be reserved for 
patients with critical limb iischemia. Abciximab may be useful after extended 
femoropopliteal interventions in patients at high risk of restenosis/reocclusion. 
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Then aspirin is continued indefinitely (Visonà et al., 2009). Treatment with a loading dose of 
clopidogrel 6-24 hours before angioplasty seems to improve the clinical outcome (Verheugt et 
al., 2007), and a 600 mg loading dose versus 300 mg at least 12 hours before the procedure 
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Currently, for patients undergoing lower extremity balloon angioplasty (with or without 
stenting), the American College of Chest Physicians (ACCP) recommends long-term aspirin 
(75-100 mg / day) (grade 1C), and recommends against anticoagulation with heparin or 
vitamin K inhibitors (grade 1A) (Sobel & Verhaeghe, 2008).     
Randomized, prospective studies with dual therapy are needed for resolving some issues, 
such as real efficacy of dual therapy in peripheral district, the optimal loading dose in 
patients undergoing endovascular revascularization, and the optimal duration of dual 
therapy following peripheral angioplasty and stenting (Plosker & Lyseng-Williamson, 2007). 
3.5 Vasoactive drugs 
Some drugs have interesting vasoactive properties, that may improve outcome after 
peripheral angioplasty. Iloprost, the prostacyclin analogue, and cilostazol, a 
phosphodiesterase type 3 inhibitor, have multiple effects, such as inhibition of platelet 
activation, vasodilation, antiproliferation of vascular smooth muscle cells, and improvement 
of endothelial cell function. These effects may lead to the inhibition of neointimal 
hyperplasia after stenting. 
Iloprost was investigated in a small study in conjunction with aspirin. A 3-day 
periinterventional intravenous infusion of iloprost plus long-term aspirin didn’t reduce 
incidence of restenosis, compared to aspirin alone (Horrocks et al., 1997). 
Cilostazol after endovascular therapy for femoropopliteal lesions was more effective in 
reducing restenosis than ticlopidine (Iida et al., 2008). 
Further studies are needed. 
4. Conclusion 
Patients with peripheral arterial disease benefit from receiving life-long aspirin at a daily 
dose of 75 mg to 100 mg or clopidogrel at a daily dose of 75 mg. Patients undergoing 
peripheral transluminal angioplasty should receive aspirin at a daily dose of 75 mg to 100 
mg, started before the intervention and continued life-long. Thienopyridines, e.g. 
clopidogrel, might represent a useful alternative to aspirin in cases of intolerance to aspirin. 
Although randomized clinical trials are lacking, it is reasonable to consider short-term dual 
antiplatelet therapy with aspirin and thienopyridines for infrainguinal stenting, given the 
relatively high rate of restenosis/reocclusion after interventions. It is reasonable to 
administer a 300-600 mg loading dose 6-24 hours before angioplasty, and to continue dual 
therapy for 4 weeks. If a drug-eluting peripheral stent was placed, dual therapy is 
maintained for 6-12 months. Use of low molecular weight heparins may be reserved for 
patients with critical limb iischemia. Abciximab may be useful after extended 
femoropopliteal interventions in patients at high risk of restenosis/reocclusion. 
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1. Introduction 
Starting in 1984, the technique of angioplasty was no longer confined to only the treatment 
of peripheral and coronary arteries.  In the original paper investigating the technique of 
angioplasty in cerebral arteries after cerebral vasospasm from aneurysmal subarachnoid 
hemorrhage (aSAH) , Zubkov et al. found an overall decrease in headaches and focal 
neurological deficits after the procedure (Zubkov et al, 1984). Despite advances in both 
medical and endovascular treatment of cerebral vasospasm since then, vasospasm remains a 
prominent source of morbidity and mortality for patients in the Neuro-Intensive Care Unit. 
At an estimated incidence rate of 10-28/100000 people, aSAH is associated with a 20% to 
40% risk of development of symptomatic, cerebral vasospasm. Of these patients 
experiencing symptomatic vasospasm, an estimated 10-15% will die before medical therapy 
while the other 85-90% will have an overall mortality rate of 32-67% (Weant et al, 2010; 
Frontera et al, 2009).  
In a review of the literature investigating endovascular treatment of cerebral vasospasm, an 
absence of standardization is present across these studies. Starting from the basics, the 
literature has not produced a “gold standard” definition of vasospasm. While some groups 
define vasospasm by a clinical ,neurological deterioration (Andaluz et al, 2002), others use a 
variety of diagnostic modalities, such as Transcranial Doppler Velocities (Oskouian et al, 
2002), digital subtraction angiography (Frontera et al, 2009), and narrowing of vessel 
diameter via CT angiography (Coenen et al, 1998), to make the same diagnosis. Therefore, 
assessing the overall efficacy of angioplasty for cerebral vasospasm is difficult when the 
literature provides different indications for the same treatment.  
Once a diagnosis of cerebral vasospasm is confirmed, a lack of standardization continues 
throughout its treatment. While some groups have associated a good neurological grade 
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define vasospasm by a clinical ,neurological deterioration (Andaluz et al, 2002), others use a 
variety of diagnostic modalities, such as Transcranial Doppler Velocities (Oskouian et al, 
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upon admission to the hospital and an early, clinical response to initial treatment for 
vasospasm with improved outcomes, a treatment regimen for vasospasm is far from 
standardized (Charpentier et al, 1999; Frontera et al, 2010). Although treatment for 
vasospasm differs from hospital to hospital, most studies examining the management of 
vasospasm use a combination of hypervolemia, hemodilution, and hypertension (triple-H) 
therapy as well as the calcium channel blocker nimodipine as their first-line treatments 
(Frontera et al, 2009). Besides applying these two “core” therapies, recent studies have 
tried various combinations of endovascular therapies, such as intra-arterial papaverine 
and verapamil, as well as transluminal balloon angioplasty, first described by Zubkov in 
1984 (Frontera et al, 2009; Zubkov et al, 1984). Despite evidence of improved outcomes 
from papaverine, verapamil, and angioplasty therapies, the absence of a large, 
prospective, multi-center, randomized, controlled trial, evaluating these treatments has 
prevented the creation of a gold standard protocol for treatment of vasospasm (Frontera 
et al, 2009; Zubkov et al, 1984). 
2. Definition of vasospasm 
Zubkov set the stage for investigating the endovascular treatments of vasospasm after 
aneurysmal subarachnoid hemorrhage. Epidemiologically, aneurysms are estimated to be 
present in between 1% and 9% of the population; the incidence of aSAH is around 1 per 
10,000 people and increases with age and female sex (Dupont et al, 2010). While the cause of 
aneurysms and subsequent ruptures are not completely elucidated, risk factors for aSAH 
include smoking, alcohol use, cocaine use, and hypertension (Dupont et al, 2010).  
Cerebral vasospasm after aSAH, macroscopically, is a contraction of smooth muscle in 
cerebral arteries (Al-Tamimi et al, 2010). This contraction, however, is difficult to measure 
and define from direct observation. From the articles reviewed, vasospasm definitions can 
be divided into three categories; groups have defined vasospasm by either clinical 
indications, Transcranial Doppler Velocity measurements, or by angiographic vessel 
diameter evidence. While Kaku et al. define vasospasm as a Transcranial Doppler mean 
flow velocity greater than 100 cm/sec or an increase of more than 30 cm/sec (Kaku et al, 
1992) , Firlik et al. report vasospasm by measuring percentage stenosis through angiogram 
analysis (Firlik et al, 1997). Frontera et al. include a definition for vasospasm, which is 
defined by the development of new focal neurological symptoms or deficits after other 
causes have been excluded (Frontera et al, 2011). Below, Table 1 reports the variation in 
definitions of vasospasm used by different studies in this literature review. 
3. Pharmaceutical, non-endovascular treatments of vasospasm 
While studies investigating endovascular therapy for cerebral vasospasm are mostly 
retrospective with a small sample size, a group of prospective, randomized, controlled trials 
on the efficacy of non-endovascular, pharmaceutical treatment of vasospasm does exist. 
Recent trials have investigated the efficacy of statins, calcium channel blockers, a 
nonglucocorticoid aminosteroid, recombinant tissue plasminogen activator, and an 
endothelin receptor antagonist in vasospasm therapy. Although this review focuses on 
endovascular treatments for vasospasm, the future of vasospasm therapy also involves non-
endovascular treatments. 
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First Author Date/Journal Definition of Vasospasm 
Keuskamp 2008, J Neurosurg Angiographic CT 0, no vasospasm. Mild <20%, Mild Moderate 21-40%, moderate 41-60%, moderate-severe 61-80%. Severe >81%  constriction 
Firlik 1997, J Neurosurg Angiographic CT 0, no vasospasm. Mild, <50% stenosis. Moderate 50% stenosis. Severe >50% stenosis. 
Kaku 1992, J Neurosurg Symptomatic (new neurological deficit not attributable to other causes) and TCD velocity >100 cm/sec 





25% decrease in the vessel diameter was defined as mild, moderate 





on TCD measurements alone, VMCA >120 cm/s and HR 
VMCA/VEC-ICA of more than 3. 
Eskridge 1998, Neurosurgery TCD and Angiography, unclear scales used 
Jestaedt 2008, Neurosurgery 
TCD > 120 cm/s 
Retrospective CT angiography 0 , no vasospasm; 1, vessel narrowing 
less than 70%; 2, vessel narrowing greater than 70%; or 3, subtotal 
occlusion with high-grade hemodynamic compromise 
Symptomatic (50% decrease in somatosensory evoked potential 
amplitutde, increase in somatosensory evoked potential latency or 
increase of greater than 150 cm/second, or clinical vasospasm by new 
neurological deficit or loss of two points on GCS), decrease to less than 
15 mmHg in tissue oxygenation; also verified via digital subtraction 
angiography 
Beck 2006, J Neurosurg TCD velocity >120 cm/s in presence of Lindegaard index of>3 and severe vasospasm recorded was >200 cm/s 
Zweinenberg
-Lee 2008, Stroke Symptomatic and angiographic >50% narrowing 
Frontera 2011, Acta Neurochir Suppl 
Symptomatic (delayed neuronal deficits not explained by 
hydrocephalus, cerebral edema, infection, or other causes) 
Katoh 1999, Neurological Focus 
TCD velocities; between 150 and 200 cm/s mild vasospasm and >200 
moderate and >250 severe 
Muizelaar 2001, Acta Neurochir Suppl 
Angiographic (mild vasospasm <50% reduction in vessel diameter, 
moderate = 50% reduction, severe >50% reduction 
Kassell 1992, J Neurosurg Angiographic >50% reduction in diameter 
Fujii 1995, Neurosurg Rev 
Angiographic; <30% luminal narrowing mild, between 30 and 60% 
moderate, and over 60% severe 
Jun 2010, AJNR Angiographic; decrease in 50% or more in diameter of vessel segment 
Choi 2011, J Korean Neurosurg 
Symptomatic (new focal neurological deficit not attributable to seizure, 
hematoma, brain edema, or hydrocephalus) 
Santillan 2011, Neurosurgery 
 Symptomatic and Angiographic (clinical, not defined greater than 50% 
constriction of vessel for angiographic) 
Murai 2005, Surgical Neurology 
Symptomatic defined by onset of delayed neurological deficit with 2 or 
more decrease on GCS 
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a. Statin therapy 
The statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors, 
have been theorized to have a protective role in the development of cerebral vasospasm. In 
addition to inhibiting the synthesis of cholesterol, statins are also thought to regulate 
endothelial and nitric oxide synthase function (Al-Tamimi et al, 2010), and therefore might 
affect the spasticity of the cerebral vasculature. Two statins, specifically simvastatin and 
pravastatin, have been investigated in randomized, placebo-controlled, trials. The results on 
simvastatin treatment of cerebral vasospasm have been mixed. While Vergouwen et al.  find 
that simvastatin treatment provided no improvement on TCD-defined vasospasm 
(Vergouwen et al, 2009), Chou et al. report that angiographic vasospasm was present in 
5/19 patients treated with simvastatin compared with 8/20 patients given a placebo (Chou 
et al, 2008). No differences, however, are statistically significant.  In their meta-analysis, 
Etminan et al. include only 190 patients and find this number to be too small to make 
conclusions about the efficacy of statin therapy (Etminan et al, 2011). 
b. Calcium antagonist therapy 
Nimodipine, a calcium antagonist and part of the current standard of care for treatment of 
cerebral vasospasm, inhibits calcium entry. However, other pathways exist within the cell 
that affect calcium utilization and also serve as possible targets for the treatment of 
vasospasm. In a prospective, randomized, placebo-controlled, double-blind trial, Shibuya et 
al. investigated the efficacy of AT877, an inhibitor of myosin light-chain kinase, of protein 
kinases A,G, and C, and of the actions of free intracellular calcium ions (Shibuya et al, 1992). 
With intravenous therapy of AT877, Shibuya et al. report a statistically significant reduction 
of angiographic vasospasm by 38% as well as a reduction in symptomatic vasospasm by 
30%. Clinically, Shibuya et al. find AT877’s effect on outcomes to be similar to nimodipine’s; 
the article reports a significant reduction in poor outcomes associated with vasospasm by 
54% and finds no significant adverse side effects (Shibuya et al, 1992). A possible downside 
of treatment with AT877 is its short half-life. Although Shibuya et al. report that AT877’s 
metabolite still shows spasmolytic qualities, the parent compound has an estimated half-life 
of under fifteen minutes.  
c. Treatment with tirilizad mesylate 
In response to the possible connection between free radical-induced lipid peroxidation and 
vasospasm, the 21 aminosteroid, tirilazad meslyate, was created to inhibit this pathway 
(Kassell et al, 1996). In a prospective, randomized, double-blind, controlled trial of 1023 
patients, Kassell et al. investigated the efficacy of tirilazad mesylate, using symptomatic 
vasospasm and Glasgow Outcome Scale scores at three months as outcome measures. 
Although Kassell et al. do not report a statistically significant reduction in symptomatic 
vasospasm with aSAH after treatment with tirilazad mesylate, they argue for the presence 
(p=.048) of a decrease in vasospasm at higher doses of tirilazad mesylate. The most 
promising statistics from this article, however, concern the three month outcomes for 
patients in the treatment group. Kassell et al. report in the highest dosage of tirilazad 
mesylate,  63% of patients had a good recovery, compared to 53% of the vehicle treated 
group (Kassell et al, 1996). This difference was statistically significant. Despite minor 
injection site phlebitis, tirilazad mesylate was not associated with life-threatening or adverse 
medical events.  
d. Endothelin receptor antagonist therapy 
Systemic vasoconstriction is controlled by many physiological hormones, including 
adrenergic agonists, angiotensin II, and antidiuretic hormone.  Endothelin, a powerful 
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vasoconstrictor possibly increased after aSAH (Macdonald et al, 2008) and its pathway to 
vasoconstriction have been investigated for possible targets in the treatment of vasospasm. 
Specifically, Macdonald et al. looked at the efficacy of the endothelin receptor antagonist, 
clazosentan, in the prospective, randomized, double-blind, placebo-controlled 
CONSCIOUS-1 trial. While Macdonald et al. report no significant difference between the 
treatment and control groups with respect to morbidity and mortality, they find a reduction 
of moderate or severe vasospasm from 66% in the placebo group to 23% in the highest 
dosage treatment group (Macdonald et al, 2008). Complications associated with clazosentan 
administration included anemia, hypotension and pulmonary issues including pneumonia, 
pleural effusions, pulmonary edema, and acute respiratory distress syndrome. The results of 
the CONSCIOUS-1 trial point to the disconnect between vasospasm and clinical outcome. 
While Macdonald et al. report a decrease in vasospasm from digital subtraction 
angiography after treatment, they find no effect on morbidity and mortality (Macdonald et 
al, 2008). Like other studies in this review of the literature, this trial calls for further 
exploration in the connection between vasospasm and clinical consequences.  
e. Fibrinolytic therapy 
The correlation between subarachnoid clot thickness and degree of vasospasm led to the 
possibility of fibrinolytic therapy in the treatment of cerebral vasospasm. In a prospective, 
randomized, blinded, placebo-controlled trial by Findlay, the efficacy of intracisternal, 
recombinant tissue plasminogen activator for prevention of vasospasm was investigated 
with angiographic vasospasm serving as the primary endpoint (Findlay, 1995)  Although 
Findlay reports angiographic vasospasm in 74.4% of placebo patients and 64.6% of 
treatment patients, the difference between the two groups was not statistically significant 
(P=.31) An interesting, significant finding from the same study comes from the treatment of 
patients with thick subarachnoid clots. In this group, Findlay finds a 56% relative risk 
reduction  of severe vasospasm in the treatment group, suggesting a very specific indication 
for treatment with recombinant tissue plasminogen activator. While Findlay also reports a 
pattern of lower mean velocities on transcranial Doppler, reduced delayed neurological 
worsening, a lower 14 day mortality rate, and improved 3 month outcome in the treatment 
group, none of these findings was statistically significant (Findlay, 1995). As with all 
fibrinolytic treatment, the possibility of treatment associated hemorrhage presents as a risk.  
While these studies, investigating the efficacy of pharmaceutical, non-endovascular 
treatments of vasospasm, are well-designed and have promising results, future larger scale, 
multi-center trials, with mortality serving as a primary outcome measure, would help 
determine which therapies should be added to the standard protocol for treatment of 
cerebral vasospasm.  
4. Current institutional protocols for treatment of aSAH and vasospasm 
While a standard of care has not been completely established for the treatment of cerebral 
vasospasm, common themes are ubiquitous throughout a review of the literature. After 
diagnosis of aSAH, the following treatment can be divided into two sections, common to 
most recent studies.  The first part of therapy involves stabilizing the patient’s aSAH while 
the second focuses on the prevention or management of cerebral vasospasm. Before cerebral 
vasospasm is even considered, the aSAH is ideally treated surgically by either endovascular 
coiling or clipping.  However, the timing of surgery, similar to the definition of cerebral 
vasospasm, has not been completely standardized. While Choi et al.’s protocol (Choi et al, 
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vasoconstrictor possibly increased after aSAH (Macdonald et al, 2008) and its pathway to 
vasoconstriction have been investigated for possible targets in the treatment of vasospasm. 
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dosage treatment group (Macdonald et al, 2008). Complications associated with clazosentan 
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pleural effusions, pulmonary edema, and acute respiratory distress syndrome. The results of 
the CONSCIOUS-1 trial point to the disconnect between vasospasm and clinical outcome. 
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recombinant tissue plasminogen activator for prevention of vasospasm was investigated 
with angiographic vasospasm serving as the primary endpoint (Findlay, 1995)  Although 
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While these studies, investigating the efficacy of pharmaceutical, non-endovascular 
treatments of vasospasm, are well-designed and have promising results, future larger scale, 
multi-center trials, with mortality serving as a primary outcome measure, would help 
determine which therapies should be added to the standard protocol for treatment of 
cerebral vasospasm.  
4. Current institutional protocols for treatment of aSAH and vasospasm 
While a standard of care has not been completely established for the treatment of cerebral 
vasospasm, common themes are ubiquitous throughout a review of the literature. After 
diagnosis of aSAH, the following treatment can be divided into two sections, common to 
most recent studies.  The first part of therapy involves stabilizing the patient’s aSAH while 
the second focuses on the prevention or management of cerebral vasospasm. Before cerebral 
vasospasm is even considered, the aSAH is ideally treated surgically by either endovascular 
coiling or clipping.  However, the timing of surgery, similar to the definition of cerebral 
vasospasm, has not been completely standardized. While Choi et al.’s protocol (Choi et al, 
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2011) calls for surgery within twenty four hours of the aSAH, Murai et al. include patients 
whose aneurysms had been clipped or coiled within forty eight hours of aSAH (Murai et al, 
2005). After the subarachnoid hemorrhage has been managed surgically, the goal of therapy 
begins to focus on the treatment of cerebral vasospasm.  
Typically after surgery today, patients are then treated with oral nimodipine and a 
combination of induced hypertension, hemodilution, and volume expansion (“Triple-H”) 
therapy to minimize the effects of cerebral vasospasm (Komotar et al, 2008). Nimodipine, a 
dihydropyridine calcium channel blocker, which blocks L-type, slow conducting, voltage-
dependent, calcium channels, has been shown to reduce cerebral infarction, when compared 
to untreated patients (Weant et al, 2010) , while triple-H therapy focuses on maintaining 
high cerebral perfusion pressures to increase cerebral blood flow during vasospasm 
(Komotar et al, 2008). 
These treatments, however, are not applied without controversy. With Triple-H therapy 
comes the risk of possible organ damage, pulmonary edema, and organ ischemia. On the 
other hand, the use of nimodipine in the treatment of cerebral vasospasm has raised 
questions about the connection between cerebral vasospasm and poor outcomes. 
Mechanistically, the administration of a calcium channel blocker “makes sense”; prevention 
of an increasing concentration of intracellular calcium should reduce smooth muscle 
contraction within the cerebral vasculature.   
While Pickard et al. do report a significant reduction in cerebral infarction events in those 
treated with nimodipine after aSAH (Pickard et al, 1989), they do not find a change in 
Transcranial Doppler Velocities between those treated and the controls. It has been 
suggested that antithrombotic actions of nimodipine might be responsible for its therapeutic 
effects (Weant et al, 2010). Nimodpine’s clinical benefits without changing Transcranial 
Doppler Velocities suggests that vasospasm may be correlated with adverse clinical 
outcomes but may not cause them. Similarly, Frontera et al. report that a Transcranial 
Doppler Velocity greater than 120 cm/sec, a measurement indicative of vasospasm, is not 
necessarily a predictor of clinical outcome (Frontera et al, 2009).  A recent meta-analysis by 
Etminan et al., investigating the efficacy of pharmaceutical treatment on delayed cerebral 
ischemia (DCI), also reported a decrease in radiographic vasospasm without clinical benefit 
(Etminan et al, 2011). The exact relationship between vasospasm and clinical outcome must 
still be fully elucidated.  
Although nimodipine and Triple-H therapy have been shown to improve clinical outcome, 
even administration of these therapies are not standardized. While Zweinenberg-Lee et al. 
report a protocol (Zwienenberg-Lee et al, 2008) of maintaining hematocrit levels between 30-
35%, Oskouian et al.’s protocol (Oskouian et al, 2002) calls for a target of 31-35%. Similarly, 
across these studies on the treatment of vasospasm, a common, unifying goal of 
hypertensive therapy is not present.  Rosenwasser et al. report elevating mean arterial 
pressure to 130-140 mm Hg (Rosenwasser et al, 1999), while Oskouian et al. present a 
protocol calling for a perfusion pressure of 70 mm Hg (Oskouian et al, 2002) and Coyne et 
al. report a maintenance level of 240 mm Hg for systolic blood pressure (Coyne et al, 1994). 
The methods to achieve high levels of cerebral blood flow and hypertension are also not 
standardized.  While Keuskamp et al. report using neosynephrine, ephedrine, and 
dopamine in their triple-H therapy (Keuskamp et al, 2008), Murai et al. use dobutamine 
alone (Murai et al, 2005).  Therefore, the current “gold standard,” a combination of Triple-H 
therapy and nimodipine, is not uniformly executed.  
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5. Experimental endovascular treatments for vasospasm 
Besides medical therapy with intravenous or oral nimodipine and Triple-H therapy, cerebral 
vasospasm after aSAH, has been experimentally treated with methods that are theoretically 
sound. While nitric oxide donors, phosphodiesterase inhibitors, endothelin antogonists, 
statins, and magnesium (Weant et al, 2010; Fathi et al, 2001; Shankar et al, 2011) have all 
been investigated for treating cerebral vasospasm through expected vasodilatory effects, the 
focus of current endovascular studies has predominantly remained on intra-arterial medical 
therapy with the calcium channel antagonist ,verapamil ,or the posphodiesterase inhibtor, 
papaverine, or transluminal balloon angioplasty of the affected vessels. 
a. Intra-arterial medical treatment and its efficacy 
The methods of administering intra-arterial medical therapy differ slightly from group to 
group and depend on the specific article from the review of the literature. A representative 
technique, however, is described by Feng et al . A 5F or 6F guiding catheter is used to infuse 
the specified drug in the internal carotid or vertebral arteries. With this technique, the 
physician hopes to deliver medical therapy to the spastic vessels (Feng et al, 2002). Some 
groups, such as Jun et al., report a slightly different protocol if severe vasospasm is present 
in the ACA or MCA.; they describe using a microcatheter  to reach the spastic portions of 
the ACA and MCA to deliver medical therapy (Jun et al, 2010). 
Although most studies evaluating the efficacy of intra-arterial medical therapy and 
angioplasty are retrospective with a relatively small sample size, they do show some 
promise in the treatment of cerebral vasospasm. While Kaku et al. report an improvement in 
neurological function in 80% of patients treated with intra-arterial papaverine (Kaku et al, 
1992), Keuskamp et al. describe a median reduction of 2 units on their vasospasm scale after 
treatment with intra-arterial verapamil (Keuskamp et al, 2008). However, the data on intra-
arterial medical treatment of cerebral vasospasm are not completely straightforward; 
Coenen et al. report that the benefits from intra-arterial papaverine administration are 
neither reliable nor sustained. Another problem that arises in comparing studies, evaluating 
the efficacy of intra-arterial medical treatment, is the dosage of drug administered (Coenen 
et al,  1998). While Kassell et. al use 100-300 mg of papaverine in their protocol (Kassell et al, 
1992) , Firlik et al. report using between 300 and 600 mg of the same drug (Firlik et al, 1997). 
It is difficult to generalize the efficacy of intra-arterial medical therapy given the variety of 
dosage protocols across studies in this literature review. 
However, intra-arterial treatment of cerebral vasospasm does not come without risk.  
Investigating the risks of intra-arterial verapamil infusion and papaverine therapy 
respectively, Feng et al. and Keuskamp et al. find no significant changes in intracranial 
pressure, heart rate, or hemodynamic parameters after intra-arterial treatment (Feng et al, 
2002; Keuskamp et al, 2008).  These are not the only parameters, however, by which safety of 
intra-arterial therapies should be assessed. Intra-arterial administration of papaverine and 
verapamil have both been associated with case reports of seizures (Zubkov et al, 1984) while 
papaverine alone has been linked to aphasia, mental status changes, and even respiratory 
arrest. On the cellular level, papaverine might also adversely affect neuronal mitochondrial 
respiration (Weant et al, 2010). Although Feng et al. and Keuskamp et al. report that intra-
arterial therapy is safe, further research should be conducted before verapamil or 
papaverine use is widely accepted as treatment for vasospasm.  
b. Angioplasty for cerebral vasospasm and its efficacy 
Beginning in 1984, the treatment of cerebral vasospasm after aSAH came to include the 
physical dilation of cerebral arteries using transluminal balloon angioplasty. The original 
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technique of angioplasty, described by Zubkov et al., involved puncturing the common 
carotid artery and placing a balloon catheter in the internal carotid artery. In an X-ray room, 
the balloon catheter was then repetitively inflated and deflated in the proximal part of the 
affected artery. This procedure then continued distally and after this technique, cerebral 
blood flow was monitored with a Xe-133 administration (Zubkov et al, 1984).  
Since Zubkov’s original paper, the actual technique of angioplasty has progressed at a 
relatively slow rate; today, angioplasty very much resembles the original procedure 
performed by Zubkov, including the repetitive inflation-deflation cycles.  Similar to the 
description of intra-arterial medical treatment for vasospasm, the current techniques of 
angioplasty differ slightly from group to group and depend on the specific article from the 
literature. A representative method of angioplasty for cerebral vasospasm is described by 
Jun et al (Jun et al, 2010).  In this study, Jun et al. report intravenous heparinization prior to 
angioplasty. Unlike Zubkov et al., they begin treating the distal portions of the spastic artery 
before the proximal portions.  Although angioplasty for cerebral vasospasm has shown 
promise with respect to clinical outcomes, the technique is not without limitations. Terada et 
al. and Jun et al. both exclude smaller, distal cerebral arteries as targets of treatment with 
angioplasty for fear of vessel rupture (Terada et al, 1997; Jun et al, 2010). While each group 
“sets their own limits” with respect to the smallest vessel they will treat with angioplasty, 
Jun et al. report treating vasospasm in the supraclinoid ICA, M1 MCA, A1 ACA, intracranial 
vertebral artery, basilar artery, and P1 PCA (so called “proximal vessels”), while they find 
treatment of M2 MCA, A2 ACA, P2 PCA (so called “distal vessels”) to be too risky (Jun et al, 
2010). With every procedure comes the possibility of complications. While the risks of 
mechanical dilation of spastic cerebral vessels by transluminal angioplasty are lessened by a 
skilled physician, they are still present. Vessel rupture, thrombosis, and occlusion are 
possible complications during the angioplasty procedure (Weant et al, 2010). 
Since Zubkov’s paper, studies have investigated the efficacy of his technique.  Overall, the 
results of cerebral angioplasty have been promising; in a 50 patient pilot study, Eskridge et 
al. report a 61% sustained neurological improvement after angioplasty (Eskridge et al, 1998). 
Although most studies in this literature review look positively upon angioplasty for cerebral 
vasospasm, not all trials have proven to be efficacious. While Fujii et al. and Eskridge et al., 
respectively, describe an 83% increase in diameters of affected cerebral arteries (Fujii et al, 
1995) and a 73% recovery in patients experiencing focal neurological deficits after treatment 
(Eskridge et al, 1990), Coenen et al. find angioplasty to be an unreliable method of treating 
cerebral vasospasm. Similar to other conclusions made in this literature review, the results 
of these retrospective angioplasty trials do not provide a straightforward judgment on its 
efficacy (Coenen et al, 1998).  
Once again, comparing these studies, which assess the efficacy of angioplasty for cerebral 
vasospasm, is difficult given the absence of standardization of the procedure. One 
difference, amongst groups, lies in the type and size of balloon used during angioplasty. For 
example, while Eskridge et al. use a 3 mm. x 12 mm. silicone balloon from Target 
Therapeutics (Eskridge et al, 1998) , Bejjani et al. report using a 3.5 mm. Cirrus balloon 
(Bejjani et al, 1998).  While these differences might not practically affect the procedure or its 
results, they should be considered when evaluating the efficacy of this technique. 
c. Comparison of angioplasty with intra-arterial medical therapy 
Although retrospectively, the efficacy of intra-arterial medical therapy and angioplasty for 
vasospasm have been compared. Similar to the studies on the efficacy of both of these 
modes of treatment, the groups comparing these two therapies have produced mixed 
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results.  Elliott et al. report a favorable clinical outcome in 67% of patients after angioplasty 
compared with a 62% favorable outcome after treatment with papaverine (Elliott et al, 1998), 
while Katoh et al. report a 58% clinical improvement after angioplasty compared with a 25% 
improvement after papaverine (Katoh et al, 1999). Elliiott et al. also report an increase in 
Transcranial Doppler velocities on Day 2 after treatment with papaverine, suggesting an 
absence of sustainable effect from the papaverine (Elliott et al, 1998). Although these studies 
suggest that angioplasty is a more effective endovascular treatment for cerebral vasospasm, 
the data are not all one-sided. Coenen et al. report that both angioplasty and papaverine are 
equivalently ineffective in producing reliable and sustained results (Coenen et al, 1998). 
Theoretically, an interesting procedure would be combining both angioplasty and intra-
arterial medical therapy in the same treatment. 
d. Combination therapy with angioplasty and intra-arterial medical treatment 
Since it is believed that angioplasty in smaller, more distal vessels, is too risky, it is logical 
that a combination of intra-arterial medical treatment with angioplasty might be effective in 
treating both proximal and distal cerebral vasospasm. In a retrospective study by Frontera et 
al. the group compares combined therapy with chemical vasodilation alone. Frontera et al. 
find that while 39% of patients undergoing combination therapy developed recurrent 
angiographic and symptomatic vasospasm, 82% of patients receiving chemical vasodilation, 
alone, developed vasospasm (Frontera et al, 2011).  Future, large-scaled and multicenter 
trials on the efficacy of combination therapy should help elucidate the most effective 
combinations of medical endovascular treatment with angioplasty. 
Amongst these experimental, endovascular treatments, angioplasty seems beneficial for the 
larger, more proximal, and more accessible cerebral vessels while treatment with intra-
arterial papaverine and verapamil is more appropriate for smaller, more distal, and less 
accessible arteries where a large risk of rupture is present.  
6. Limitations to efficacy comparisons across studies 
However, problems with these studies, investigating the efficacy of experimental treatments 
for cerebral vasospasm, do exist. The small sample sizes and retrospective nature of a vast 
majority of these studies make it difficult to establish definitive conclusions with respect to 
efficacy of different endovascular treatments. Also, the criteria to begin endovascular 
treatment differ from group to group. For example, while Bejjani et al report treating 
vasospasm with angioplasty only after Triple-H therapy has failed (Bejjani et al, 1998) , 
Santillan et al. use a decrease in vessel diameter via angiography as one if their indications 
for treatment (Santillan et al, 2011). Therefore, constructing a meta-analysis, combining the 
results of these studies, is difficult as different groups make their own decisions about when 
to treat patients endovascularly. Table 2, below, lists the criteria to treat cerebral vasospasm, 
from several groups, reviewed in the literature.  
7. Recommendations for invasive treatments 
Although most experimental studies investigating the efficacy of invasive treatments for 
cerebral vasospasm after aSAH are retrospective in nature, effective patterns can be 
extracted from these studies. From the studies in this literature review, it appears that 
Triple-H therapy combined with administration of nimodipine is the first line of treatment 
or prevention of cerebral vasospasm. Once the vasospasm is deemed refractory to this  
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results.  Elliott et al. report a favorable clinical outcome in 67% of patients after angioplasty 
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or prevention of cerebral vasospasm. Once the vasospasm is deemed refractory to this  
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Author/Date Indication for Endovascular Treatment 
Feng, 2002 Verapamil was given  “to prevent catheter-induced vasospasm,”  for treatment 
of mild vasospasm that did not warrant angioplasty, and for the treatment of 
moderate to severe vasospasm that could not be safely treated with angioplasty 
Firlik, 1997 CBF new region < 20 ml/100 g/minute were treated with angioplasty 
Bejjani, 1998 Do angioplasty after failed HHH therapy; digital subtraction angiography 
performed first. 
Kaku 1992 Angioplasty (to deliver papaverine) if onset of new neurological deficit 
not attributable to other causes,  no evidence of infarction on CT, unsuccessful 
treatment of neurological deficit by conventional medical and pharmacological 
therapies, mean flow velocity 100 cm/sec or increase in mean flow 
velocity greater than 30 cm/sec w/in 24 hours in affected vessel by TCD, and 
vasospasm seen angiographically in location consistent with neurological 
deficit. 
Terada, 1997 Endovascular therapy if  new neurological signs appear after SAH, not deriving 
from hematoma, brain edema, or hydrocephalus, neurological signs are related 
to vascular territory of vasospasm, vessel diameter is less than 50% of initial 
diameter angiographically, no low density area is related to vasospasm on CT, 
clinical signs progress despite medical treatment, and ruptured aneurysm has 
been treated 
Andaluz, 2002 Refractory vasospasm (not clearly defined) to HHH therapy; included if  all 
aneurysm clipped or coiled before Day 3 after SAH, clinical vasospasm defined 
by the presence of a new neurologic deficit not explained by hydrocephalus, 
infection, electrolyte imbalance, or other medical complication, clinical 
vasospasm in patients treated with nimodipine and with symptoms not 
reversed by maximal HHH treatment, and endovascular therapy instituted 
w/in 12 hours of onset of symptoms 
Eskridge, 1998 hypertensive therapy started if suspicion of vasospasm; angioplasty if  new 
onset of a neurological deficit not attributable to other causes, no evidence of 
established cerebral infarction on CT scans, deficit persisting despite 
hypertensive, hypervolemic therapy, and angiographic evidence of vasospasm 
in a distribution that could explain the deficit 
Rosenwasser, 1999 If new deficit, CT scan to eliminate hydrocephalus or bleeding. HHH therapy 
maximized to elevate MAP to 130-140 mm Hg. If not reversible then go to get 
angioplasty 
Jestaedt, 2008 Clinical symptoms or high grade vessel narrowing (>70%) 
Beck, 2006 HHH protocol; symptoms still then get MR;  if PW DW mismatch then continue 
HHH; then DS angiography then TBA 
Zwienenberg-Lee, 
2008 
Randomized to either angioplasty or no angioplasty 
Frontera 2011 All patients digital subtraction angiography; vessels which responded to IACV 
and could not be treated with angioplasty only IACV; accessible vessels with 
residual vasospasm  after IACV then TBA 
Eskridge, 1990 Inclusion criteria included  new onset of a neurologic deficit after subarachnoid 
hemorrhage that was not attributable to other causes, such as hydrocephalus, 
hematoma, mass effect,  no evidence of infarction on CT scan, neurologic deficit 
not reversed by hypervolemic and hypertensive therapy, and angiographically 
apparent vasospasm in location responsible for deficit 
Muizelaar, 2001 All patients had SAH and Fisher Grade III on CT scan w/in first two days of 
SAH; had to have surgical or neurointerventional treatment of ruptured 
aneurysm; then TBP could be performed 
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Fujii, 1995 developed symptomatic vasospasm in spite of intensive medical supportive 
therapy including hypertension, volume expansion, and administration of brain 
protective agents, the cases whose showed either consciousness deterioration 
worse than 30 in Japan Coma Scale and/or distinct neurological deficit, and 
cases whose angiogram performed as early as possible after emergence of 
symptoms showed the responsible narrowing in intracranial arteries. 
Jun, 2010 Severe proximal CV (luminal narrowing >60%) treated with PTA and distal CV 
(luminal narrowing >30%) with verapamil 
Choi, 2011 CT scan in patients with clinical deterioration; vasospasm defined as increase in 
TCD flow to 150 cm/second. If greater than 150 cm/second, MRI, DWI and 
MRA; if infraction or narrowing by MRA, angioplasty was recommended 
Santillan, 2011 Indication for TBA  neurological deficits were referable to vascular territory of 
the VSP angiographically, vessel diameter less than 50% of initial diameter 
angiographically, no evidence of hypodensity on non-contrast head CT scan 
suggestive of ischemic infarct due to VSP prior to angiogram, and baseline 
diameter of vessel on initial cerebral angiogram or CT was not less than 
approximately 2 mm in size. 
Murai, 2005 DINDs assumed vasospasm if between 3-14 days after SAH; some had 
angiograms to determine vasospasm (50% or more narrowing when compared 
to admission CT); heparinization w/angioplasty if deficit could be related to 
distribution of vasospasm 
Coyne, 1994 Symptomatic vasospasm defined as onset of delayed neurological deficit (2 or 
more decrease on Glasgow Coma Scale); treated initially with hypervolemia, 
hypertensive therapy; maintain a capillary wedge pressure of 14 to 18 mm Hg. 
Maintain a systolic BP of 240 mm HG in clipping or 160 mm HG in unclipped; 
angioplasty if neurological deficit/CT showed no improvement 
Table 2. 
treatment, invasive treatments should be employed next. A combination of verapamil or 
papaverine to treat distal vasospasm with angioplasty to treat proximal vasospasm in larger, 
more available vessels falls in line with conclusions of many of the studies reviewed. Timing 
of invasive treatments may also prove to be critical. Rosenwasser’s retrospective study finds 
improved clinical and angiographic outcomes in patients treated with angioplasty within a 
two hour window (Rosenwasser et al, 1999). Therefore, combined intra-arterial treatment 
with either papaverine or verapamil and angioplasty within a timely manner appears to be 
the most effective treatment.  
8. Unclear role of vasospasm in clinical outcomes 
A review of the literature on invasive treatments for cerebral vasospasm has highlighted a 
possible disconnect between the presence of cerebral vasospasm and clinical outcome. 
Frontera’s group and Macdonald’s group respectively find that Transcranial Doppler 
Velocities (Frontera et al, 2009) and angiography (Macdonald et al, 2008), consistent with 
cerebral vasospasm, are not necessarily predictors of a specific clinical outcome. These 
findings have led to the hypothesis that other mechanisms, after aSAH, may be responsible 
for poor clinical outcomes. Specifically, early brain injury, before the onset of vasospasm, 
has been explored. Classically, cerebral vasospasm is thought to occur between four and 
nine days after the ictus. Early brain injury, defined as injury within 72 hours of the aSAH, 
may provide insight into poor clinical outcomes after aSAH (Pluta et al, 2009). Within these 
72 hours, early brain injury has been associated with an elevation of intracranial pressure, a 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
114 
Author/Date Indication for Endovascular Treatment 
Feng, 2002 Verapamil was given  “to prevent catheter-induced vasospasm,”  for treatment 
of mild vasospasm that did not warrant angioplasty, and for the treatment of 
moderate to severe vasospasm that could not be safely treated with angioplasty 
Firlik, 1997 CBF new region < 20 ml/100 g/minute were treated with angioplasty 
Bejjani, 1998 Do angioplasty after failed HHH therapy; digital subtraction angiography 
performed first. 
Kaku 1992 Angioplasty (to deliver papaverine) if onset of new neurological deficit 
not attributable to other causes,  no evidence of infarction on CT, unsuccessful 
treatment of neurological deficit by conventional medical and pharmacological 
therapies, mean flow velocity 100 cm/sec or increase in mean flow 
velocity greater than 30 cm/sec w/in 24 hours in affected vessel by TCD, and 
vasospasm seen angiographically in location consistent with neurological 
deficit. 
Terada, 1997 Endovascular therapy if  new neurological signs appear after SAH, not deriving 
from hematoma, brain edema, or hydrocephalus, neurological signs are related 
to vascular territory of vasospasm, vessel diameter is less than 50% of initial 
diameter angiographically, no low density area is related to vasospasm on CT, 
clinical signs progress despite medical treatment, and ruptured aneurysm has 
been treated 
Andaluz, 2002 Refractory vasospasm (not clearly defined) to HHH therapy; included if  all 
aneurysm clipped or coiled before Day 3 after SAH, clinical vasospasm defined 
by the presence of a new neurologic deficit not explained by hydrocephalus, 
infection, electrolyte imbalance, or other medical complication, clinical 
vasospasm in patients treated with nimodipine and with symptoms not 
reversed by maximal HHH treatment, and endovascular therapy instituted 
w/in 12 hours of onset of symptoms 
Eskridge, 1998 hypertensive therapy started if suspicion of vasospasm; angioplasty if  new 
onset of a neurological deficit not attributable to other causes, no evidence of 
established cerebral infarction on CT scans, deficit persisting despite 
hypertensive, hypervolemic therapy, and angiographic evidence of vasospasm 
in a distribution that could explain the deficit 
Rosenwasser, 1999 If new deficit, CT scan to eliminate hydrocephalus or bleeding. HHH therapy 
maximized to elevate MAP to 130-140 mm Hg. If not reversible then go to get 
angioplasty 
Jestaedt, 2008 Clinical symptoms or high grade vessel narrowing (>70%) 
Beck, 2006 HHH protocol; symptoms still then get MR;  if PW DW mismatch then continue 
HHH; then DS angiography then TBA 
Zwienenberg-Lee, 
2008 
Randomized to either angioplasty or no angioplasty 
Frontera 2011 All patients digital subtraction angiography; vessels which responded to IACV 
and could not be treated with angioplasty only IACV; accessible vessels with 
residual vasospasm  after IACV then TBA 
Eskridge, 1990 Inclusion criteria included  new onset of a neurologic deficit after subarachnoid 
hemorrhage that was not attributable to other causes, such as hydrocephalus, 
hematoma, mass effect,  no evidence of infarction on CT scan, neurologic deficit 
not reversed by hypervolemic and hypertensive therapy, and angiographically 
apparent vasospasm in location responsible for deficit 
Muizelaar, 2001 All patients had SAH and Fisher Grade III on CT scan w/in first two days of 
SAH; had to have surgical or neurointerventional treatment of ruptured 
aneurysm; then TBP could be performed 
Evidence-Based Invasive Treatments for Cerebral  
Vasospasm Following Aneurysmal Subarachnoid Hemorrhage 
 
115 
Fujii, 1995 developed symptomatic vasospasm in spite of intensive medical supportive 
therapy including hypertension, volume expansion, and administration of brain 
protective agents, the cases whose showed either consciousness deterioration 
worse than 30 in Japan Coma Scale and/or distinct neurological deficit, and 
cases whose angiogram performed as early as possible after emergence of 
symptoms showed the responsible narrowing in intracranial arteries. 
Jun, 2010 Severe proximal CV (luminal narrowing >60%) treated with PTA and distal CV 
(luminal narrowing >30%) with verapamil 
Choi, 2011 CT scan in patients with clinical deterioration; vasospasm defined as increase in 
TCD flow to 150 cm/second. If greater than 150 cm/second, MRI, DWI and 
MRA; if infraction or narrowing by MRA, angioplasty was recommended 
Santillan, 2011 Indication for TBA  neurological deficits were referable to vascular territory of 
the VSP angiographically, vessel diameter less than 50% of initial diameter 
angiographically, no evidence of hypodensity on non-contrast head CT scan 
suggestive of ischemic infarct due to VSP prior to angiogram, and baseline 
diameter of vessel on initial cerebral angiogram or CT was not less than 
approximately 2 mm in size. 
Murai, 2005 DINDs assumed vasospasm if between 3-14 days after SAH; some had 
angiograms to determine vasospasm (50% or more narrowing when compared 
to admission CT); heparinization w/angioplasty if deficit could be related to 
distribution of vasospasm 
Coyne, 1994 Symptomatic vasospasm defined as onset of delayed neurological deficit (2 or 
more decrease on Glasgow Coma Scale); treated initially with hypervolemia, 
hypertensive therapy; maintain a capillary wedge pressure of 14 to 18 mm Hg. 
Maintain a systolic BP of 240 mm HG in clipping or 160 mm HG in unclipped; 
angioplasty if neurological deficit/CT showed no improvement 
Table 2. 
treatment, invasive treatments should be employed next. A combination of verapamil or 
papaverine to treat distal vasospasm with angioplasty to treat proximal vasospasm in larger, 
more available vessels falls in line with conclusions of many of the studies reviewed. Timing 
of invasive treatments may also prove to be critical. Rosenwasser’s retrospective study finds 
improved clinical and angiographic outcomes in patients treated with angioplasty within a 
two hour window (Rosenwasser et al, 1999). Therefore, combined intra-arterial treatment 
with either papaverine or verapamil and angioplasty within a timely manner appears to be 
the most effective treatment.  
8. Unclear role of vasospasm in clinical outcomes 
A review of the literature on invasive treatments for cerebral vasospasm has highlighted a 
possible disconnect between the presence of cerebral vasospasm and clinical outcome. 
Frontera’s group and Macdonald’s group respectively find that Transcranial Doppler 
Velocities (Frontera et al, 2009) and angiography (Macdonald et al, 2008), consistent with 
cerebral vasospasm, are not necessarily predictors of a specific clinical outcome. These 
findings have led to the hypothesis that other mechanisms, after aSAH, may be responsible 
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reduction in cerebral blood flow, blood-brain barrier disruption and neuronal cell death 
(Pluta et al, 2009). These changes, and not cerebral vasospasm, may be responsible for the 
subsequent clinical outcome.  
Another recently proposed mechanism for the development of poor clinical outcomes has 
also been suggested. A mixture, similar to that of cerebrospinal fluid after SAH, has been 
shown to cause spreading cortical depolarization after application to the subarachnoid space 
(Pluta et al, 2009). This, in turn, has led to eventual ischemia and cortical necrosis. Similarly, 
13 out of 18 patients, receiving surgical treatment after aSAH, have been shown to have 
similar waves of depolarization, consistent with the start of clinical deterioration (Pluta et al, 
2009). Therefore, in addition to vasospasm, early brain injury and spreading cortical 
depolarization should be investigated for their importance in clinical outcomes.  
9. Future directions in the treatment of cerebral vasospasm 
Theoretically, endovascular therapy for cerebral vasospasm may include treatments other 
than intra-arterial pharmaceutical administration and cerebral artery angioplasty. Komotar 
et al. mention the possibility of using intra-aortic balloon counterpulsation to treat 
vasospasm. In this technique, an aortic balloon is placed distally to the origin of the left 
subclavian artery endovascularly. During diastole, the balloon inflates, redirecting blood to 
the coronary, carotid, and vertebral arteries in this part of the cardiac cycle (Komotar et al, 
2008). The balloon then deflates during systole. The authors of this study report an average 
increase in cerebral blood flow by 69.3% (Nussbaum et al, 1998). Since the goal of Triple-H 
therapy is to improve cerebral blood flow, the intra-aortic balloon might be used in 
combination therapy with medical treatment for the reduction of cerebral vasospasm and 
ischemia after aSAH.  As this device is implanted in the femoral artery, risks such as 
hemorrhage and dissection of the femoral artery are present (Komotar et al, 2008). A case 
report, by Appelboom et al., describes a similar procedure with a Neuroflo, intra-aortic, dual 
balloon catheter. In this report, two balloons, one above and one below the renal arteries, are 
inflated to redirect blood flow to the cerebral arteries during refractory vasospasm. An 
advantage of this technique is the avoidance of complications associated with direct 
manipulation of cerebral vasculature (Appelboom et al, 2010).  
The future of cerebral vasospasm therapy depends on further elucidation of the 
pathophysiology of this condition. Komotar et al. report initial success with another free 
radical trapping agent. Just like tirilizad mesylate, disodium 2,4-disulfophenyl-N-tert-
butylnitrone inhibits lipid peroxidation and has been associated with improvement in 
neurological function in primates (Komotar et al, 2008). Other evidence has suggested that 
the pathogenesis of vasospasm may depend on the immune system. Preventing the 
interaction between leukocytes and endothelial cells with blocking antibodies has also 
inhibited vasospasm after aSAH (Baybek et al, 1998). Similarly, patients undergoing therapy 
with steroids have a lower risk of developing delayed ischemic deficits after aSAH (Chyatte 
et al, 1987). The interplay between the immune system and development of cerebral 
vasospasm needs to be further investigated before immune modulating therapy can be 
directed towards the treatment of vasospasm.  
10. Conclusion 
A review of the literature on endovascular treatment for cerebral vasospasm has suggested 
the need for commonly used protocols and definitions to determine the efficacy of these 
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therapies. Although most studies in this review provided protocols that used Triple-H  
therapy and nimodipine as a first line treatment for cerebral vasospasm, the variation in 
institutional protocols in these studies made comparisons difficult. Similarly, the absence of 
a unifying or “gold standard” definition of vasospasm suggests that different indications in 
each study might call for the same treatment. Given that studies in this analysis use either 
CT angiography, symptoms, or Transcranial Doppler Velocities to assess for vasospasm, it is 
difficult to know if each study would treat the same patient for the same degree of 
vasospasm.  It is therefore difficult to compare the results of different studies, investigating 
the same treatment. Similarly, the actual endovascular therapy, either intra-arterial medical 
treatment or transluminal angioplasty, was not the same in each study. Both the dosage of 
intra-arterial drug administered and the type and size of angioplasty balloon differed 
amongst the studies in this review of the literature.  
The retrospective nature and small sample size of an overwhelming majority of the studies 
in this review call for a newly designed, novel study in the endovascular treatment of 
vasospasm. Zweinenberg-Lee et al. provide data from a Phase II, Multicenter, Randomized, 
Clinical Trial assessing the effects of prophylactic angioplasty on infarction rates after 
cerebral vasospasm. The results of this trial, that prophylactic angioplasty provided an 
absolute risk reduction of 5.9% for developing an infarction after cerebral vasospasm 
(Zweienenberg-Lee et al, 2008), may serve as a model for future trials assessing the efficacy 
of endovascular treatments of vasospasm although not all the data were statistically 
significant. Future research on endovascular treatment of vasospasm should also follow the 
study design of trials investigating non-endovascular, pharmaceutical therapy for 
vasospasm. These studies, included in Etminan’s meta-analysis, are prospective, 
randomized, adequately blinded, and placebo or vehicle controlled (Etminan et al, 2011).  
This literature review has highlighted the need for a highly controlled, randomized, 
multicenter, clinical trial, assessing the efficacy of endovascular treatment. A randomized, 
controlled, clinical trial placing patients into either an intra-arterial papaverine group, an 
intra-arterial verapamil group, an intra-arterial papaverine and angioplasty group, an intra-
arterial verapamil and angioplasty group, and an angioplasty group alone would provide 
the groundwork for a standardized protocol for effectively treating cerebral vasospasm 
endovascularly. Similarly, future studies should investigate vasospasm’s role in affecting 
clinical outcomes and possible novel treatments. The future of vasospasm treatment, 
however, depends on further elucidation of the pathophysiology of vasospasm after aSAH. 
The role of the immune system and lipid peroxidation after aSAH should be investigated in 
the pathogenesis of this condition.  
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however, depends on further elucidation of the pathophysiology of vasospasm after aSAH. 
The role of the immune system and lipid peroxidation after aSAH should be investigated in 
the pathogenesis of this condition.  
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Angiography for Peripheral  
Vascular Intervention 
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Cardiology, Kishiwada Tokushuaki Hospital, Osaka 
Japan 
1. Introduction  
The use of endovascular technique for peripheral vascular disease (PVD) has evolved and 
new devices and techniques were being developed. Even after recent development of 
noninvasive diagnosis of PVD, angiography is still the gold standard for the evaluation of 
stenotic and occluded lesions. Without precise angiographic information, endovascular 
therapy can not be performed. In this chapter, the angiographic technique to visualize major 
arteries of atherosclerotic disease is described.  
2. Angiography suite for peripheral vascular intervention  
Excellent imaging is the key for the success of endovascular therapies. Flat-panel X ray 
image detectors for use in digital fluoroscopy and angiography are essential for peripheral 
artery intervention. The ability of three-dimensional (3D) visualization techniques and bolus 
chasing are also required. Various types of imaging sizes are available but we have to 
compromise considering of function on the machine. Careful planning and professional 
expertise is a key factor for choosing every endovascular suite.  
2.1 Single plane vs. biplane system 
We have two types of our peripheral angiography suite. One is single plane arm with 31cm 
X 31cm flat panel detector (Fig. Suite1A). And the other biplane with the 30cm X 40cm flat 
panel detector (Fig. Suite1B). Both machines have its merit and demerit. Single plane 
machine has the versatile function and more suited for intervention. Biplane system could 
obtain the multiple images and reduce the dosage of dye. But except for cerebral 
angiography, it takes time to adjust two images in centred position. For the diagnostic 
purpose, biplane System has the advantage, but interventional work, the single plane 
system has more versatile function and much safer for the patient’s care during procedure.  
2.2 Extra monitor 
In angiographic table, operators usually stand on the right side, but for left limb 
intervention or left brachial approach, operator needs to be positioned on the left side of the 
table. In these circumstances, the extra monitor is useful for left side operator. Without 
moving central image monitor, main operator can do the procedure with assistant who are 
seeing central monitor from right side (Fig. Suite2A). This is the convenient way to intervene 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
120 
Nussbaum ES, Sebring LA, Ganz WF, Madison MT (1998) Intra-aortic balloon counterpulsation 
augments cerebral blood flow in the patient with cerebral vasospasm: a xenon-
enhanced computed tomography study. Neurosurgery 42(1):206-13. 
Oskouian RJ, Martin NA, Lee JH, Glenn TC, Guthrie D, Gonzalez NR, Afari A, Viñuela F  
(2002) Multimodal Quantitation of the Effects of Endovascular Therapy for 
Vasospasm on Cerebral Blood Flow, Transcranial Doppler Ultrasonographic 
Velocities, and Cerebral Artery Diameters. Neurosurgery  51:1 30-43. 
Pickard JD, Murray GD, Illingowrth R, Shaw MD, Teasdale GM, Foy PM, Humphrey PR, Lang 
DA, Nelson R, Richards P (1989) Effect of oral nimodipine on cerebral infarction and 
coutcome after subarachnoid hemorrhage: British aneurysm nimodipine trial. Br Med 
J 298: 636-642. 
Pluta RM, Hansen-Schawrtz J, Dreier J, Vajkoczy P, Macdonald RL, Nishizawa S, Kasuya H, 
Wellman G, Keller E, Zauner A, Dorsch N, Clark J, Ono S, Kiris T, Leroux P, Zhang 
JH (2009) Cerebral vasospasm following subarachnoid hemorrhage: time for a new 
world of thought. Neurol Res  31(2):151-8. 
Rosenwasser RH, Armonda RA, Thomas JE, Benitez RP, Gannon PM, Harrop J (1999) 
Therapeutic modalities for the management of cerebral vaso- spasm: timing of 
endovascular options. Neurosurgery 44: 975–979. 
Santillan A, Knopman J, Zink W, Patsalides A, Gobin YP (2011)  Transluminal balloon 
angioplasty for symptomatic distal vasospasm refractory to medical therapy in 
patients with aneurysmal subarachnoid hemorrhage. Neurosurgery [Epub ahead of 
print]. 
Shankar JJ, dos Santos MP, Deus-Silva L, Lum C (2011)  Angiographic evaluation of the effect 
of intra-arterial milrinone therapy in patients with vasospasm from aneurysmal 
subarachnoid hemorrhage. Neuroradiology  53(2): 123-128. 
Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, 
Hidaka H (1992) Effect of AT877 on cerebral vasospasm after aneurysmal 
subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind 
trial. J Neurosurg  76(4): 571-7. 
Terada T, Kinoshita Y, Yokote H, Tsuura M, Nakai K, Itakura T, Hyotani G, Kuriyama T, Naka 
Y, Kido T (1997) The Effect of Endovascular Therapy for Cerebral Artery Spasm, its 
Limitation and Pitfalls. Acta Neurochir (Wien) 139:227-234. 
Vergouwen MD, Meijers JC, Geskus RB, Coert BA, Horn J, Stroes ES, van der Poll T, 
Vermeulen M, Roos YB (2009)  Biologic effects of simvastatin in patients with 
aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled 
randomized trial.  J Cereb Blood Flow Metab  29(8): 1444-53. 
Weant KA,  Ramsey CN, and Cook AM (2010) Role of Intraarterial Therapy for Cerebral 
Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage. Pharmacotherapy  
30:4 , 405-417.  
Zubkov YN, Nikirov BM, Shustin VA (1984) Balloon catheter technique for dilatation of 
constricted cerebral arteries after aneurysmal SAH. Acta Neurochir  70(1-2): 65-79 
Zwienenberg-Lee M, Hartman J, Rudisill N, Madden LK, Smith K, Eskridge J, Newell D, 
Verweij B, Bullock MR, Baker A, Coplin W, Mericle R, Dai J, Rocke D, Muizelaar JP 
(2008) Effect of Prophylactic Transluminal Balloon Angioplasty on Cerebral 
Vasospasm and Outcome in Patients With Fisher Grade III Subarachnoid 
Hemorrhage: Results of a Phase II Multicenter, Randomized, Clinical Trial Stroke 
39: 1759-1765. 
7 
Angiography for Peripheral  
Vascular Intervention 
 Yoshiaki Yokoi 
Cardiology, Kishiwada Tokushuaki Hospital, Osaka 
Japan 
1. Introduction  
The use of endovascular technique for peripheral vascular disease (PVD) has evolved and 
new devices and techniques were being developed. Even after recent development of 
noninvasive diagnosis of PVD, angiography is still the gold standard for the evaluation of 
stenotic and occluded lesions. Without precise angiographic information, endovascular 
therapy can not be performed. In this chapter, the angiographic technique to visualize major 
arteries of atherosclerotic disease is described.  
2. Angiography suite for peripheral vascular intervention  
Excellent imaging is the key for the success of endovascular therapies. Flat-panel X ray 
image detectors for use in digital fluoroscopy and angiography are essential for peripheral 
artery intervention. The ability of three-dimensional (3D) visualization techniques and bolus 
chasing are also required. Various types of imaging sizes are available but we have to 
compromise considering of function on the machine. Careful planning and professional 
expertise is a key factor for choosing every endovascular suite.  
2.1 Single plane vs. biplane system 
We have two types of our peripheral angiography suite. One is single plane arm with 31cm 
X 31cm flat panel detector (Fig. Suite1A). And the other biplane with the 30cm X 40cm flat 
panel detector (Fig. Suite1B). Both machines have its merit and demerit. Single plane 
machine has the versatile function and more suited for intervention. Biplane system could 
obtain the multiple images and reduce the dosage of dye. But except for cerebral 
angiography, it takes time to adjust two images in centred position. For the diagnostic 
purpose, biplane System has the advantage, but interventional work, the single plane 
system has more versatile function and much safer for the patient’s care during procedure.  
2.2 Extra monitor 
In angiographic table, operators usually stand on the right side, but for left limb 
intervention or left brachial approach, operator needs to be positioned on the left side of the 
table. In these circumstances, the extra monitor is useful for left side operator. Without 
moving central image monitor, main operator can do the procedure with assistant who are 
seeing central monitor from right side (Fig. Suite2A). This is the convenient way to intervene 
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right femoropopliteal artery or left subclavian artery. In left below the knee procedure via 
cross over approach, C-arm is rotated to the left side. Cranial side operator may not see the 
central image. In this situation, extra monitor can be placed in left cranial side (Fig. Suite2B). 
 
 
Fig. Angiosuite 1: Peripheral angiography suite 
A: Single plane flat panel system.  
A single plane system has more versatile function compared to the biplane system. Single 
system is suited for interventional work  
B: Biplane system: Biplane system allows the two images both on fluoro and images. Dye 
consumption could reduce. However, lateral tube might limit the patient’s care. Mostly 
employed for neuroangiography.  
 
 
Fig. Angiosuite 2: Extra monitor 
A: Operators usually stand on the right side of the table. But for left limb intervention or left 
brachial approach, operator needs to be positioned on the left side of the table. In these 
circumstances, the extra monitor is useful for left side standing operator without moving 
central image monitor 
B: In left below the knee procedure via cross over approach, C-arm is rotated to the left side. 
Cranial side operator may not see the central image. In this situation, extra monitor can be 
placed in left cranial side. Primary operator could see the image on the cranial side monitor 
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2.3 Power injectors 
For most of small vessel and selective angiography, hand injection is adequate. However, 
for the optimal opacification of high-flow blood vessels like aorta, the use of power 
injector is mandatory.  Constant and high volume of dye should be injected through 
electronically calibrated power injector. There are two types of injector. One is  
old fashioned power injector and the other is the assisted device which could give the 
small or large amount of dye by the injector attached to catheter table. Any contrast 
volume is adjusted by manually. Even a small dose of dye can be injected. However, the 
space of left side of table is occupied by this assisted device. We prefer conventional 
power injector which is mounted to the celling. This method gives us more space around 
catheter table. 
In the assisted device, the operator is supposed to stand only on the right side of the table 
and can not be away from the table during injection. To prevent for radiation exposure, 
conventional use of power injector is more preferable (Fig. Suite4).  
 
 
Fig. Angiosuite 3: Celling mounted Power injector  
Celling mounted power injector gives more space around catheter table 
2.4 Image size and contrast volume 
Contrast volume for opacification of the major arteries were listed in Table 1.was listed. 
These injection volumes are mainly used in our catheter laboratory. But, real contrast 
volume depends on the patient’ condition, catheter size, amount of contrast, speed of 
injection and et al. Therefore contrast dose should be individurized on each case 
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Fig. Angiosuite4: Radiation exposure 
Radiation exposure should be minimalized during injection of dye by using power injector 
2.5 Table 1 Commonly used imaging size, injection rates and contrast volume for 
major arteries  
 
Angiogram Image size Injection rate Contrast volume 
Aortic Arch 30cm 20cc/s 20-30cc 
Carotid (Selective) 20cm 4-6cc/s 7-9cc 
Cerebral: AP 20cm 4-6cc/s 7-9cc 
Cerebral: Lateral 30cm 4-6cc/s 7-9cc 
Abdominal aorta 20-40cm 16-20cc/s 16-25cc 
Renal (Selective) 20cm 4-6cc/s (by hand) 4-6cc 
Iliac (Selective) 20cm 6-10cc/s 8-10cc 
Femoropopliteal-Tibial (Bolus) 30cm 4cc/s 16-20  
SFA 30cm 4-6cc/s 10cc 
SFA (Selective) 20—30cm 4-6cc/s 10cc 
Below the knee (Bolus) 30cm 3cc/s 7-9cc 
Tibial 20cm 3cc/s 5cc 
Tibial (Selective) 20cm 1-2cc/s (by hand) 2-3cc 
Table 1. Commonly used imaging size, injection rates and contrast volume 
AP: antero-posterior, SFA: superficial femoral artery 
3. Carotid artery angiography 
The atherosclerotic plaque accumulates at the carotid bifurcation. There are a number of 
factors, including geometry, velocity profile, and shear stress. The carotid bulb forms a focal 
dilatation.  The flow at the bifurcation is considered to be a complex hemodynamics and 
postulated to lead carotid artery stenosis (Fig. Carotid 1) (1). Carotid disease is one of 
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important cause of ischemic stroke. In symptomatic patients, carotid revascularization is 
indicated in the presence of a stenosis 50~70% or more (2). There are many arguments about 
the indication for asymptomatic patients. But asymptomatic stenoses are usually treated 
only if luminal narrowing exceeds 60%(2). Carotid artery stenting (CAS) is a preferred 
treatment strategy in high-risk patients requiring Carotid endoatherectomy (CEA). Even 
though indication of CAS is still controversial, CAS is a less invasive and attractive way for 
revascularization for carotid artery disease. To indicate carotid artery revascularization, 
meticulous angiographic approach should be taken to evaluate of carotid artery stenosis. 
 
 
Fig. Carotid 1: Progression of carotid artery disease 
A: The carotid bulb forms a focal dilatation  
B: Mostly lesion starts at the bifurcation. Mild stenosis is seen 
C: In progressive form of atherosclerosis. 
Carotid bulb is filled with plaque and the flow at the bifurcation show thc complex 
hemodynamics. This hemodynamics is postulated to lead carotid artery stenosis  
3.1 Aortic arch type 
Engagement of catheter to the brachiocephalic or left CCA is required to perform carotid 
artery angiography. In selecting catheter, the aortic arch anatomy plays an important role 
for the success of the procedure. In CAS, not only engaging the catheter, guiding sheath 
have to be placed into common CCA. It does mean the technique of the deep engagement of 
diagnostic catheter to CCA or external carotid artery (ECA) is the important procedure for 
carotid artery angiography. 
There are classifications that categorize aortic arch anatomy (3) (Fig. Carotid 2).  
The aortic arch angiography in left anterior oblique view shows three type of aortic arch 
(Fig. Carotid 3). The vertical distance from the origin of the innominate artery to the top of 
the arch determines the arch type. In type 3, engagement of catheter, particularly to left 
common carotid artery is difficult and may account for the failure of carotid artery stenting.  
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the arch determines the arch type. In type 3, engagement of catheter, particularly to left 
common carotid artery is difficult and may account for the failure of carotid artery stenting.  
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Fig. Carotid 2: Schematic classification of aortic arch (3). 
Above figures are quoted from reference 3 
A: Type 1 arch: The origins of the great vessels to be catheterized are at the level of the 
superior arch line  
B: Type 2 arch: The origins of the great vessels to be catheterized are between the superior 
and the inferior arch line  
C: Type 3 arch: The origins of the great vessels to be catheterized below the level of the 
inferior arch line. 
 
 
Fig. Carotid 3: Angiographic classification of aortic arch 
In Type 1(A) and Type 2(B), catheter can be easily selected. In Type 3(C), steep curve 
between the top of aortic arch and the origin of arch vessel is shown. This type 3 arch is 
difficult to negotiate to access to common carotid artery 
The anomalies of bovine arch can frequently occur and may lead to prolonged fluoroscopy 
time to select left common carotid artery (Fig. Carotid 4). Fig. Carotid 4 A and B are the typical 
bovine arch. Access to left common carotid artery is easy in Fig. Carotid 4A, but In Fig. Carotid 
4B, selection to left common may be difficult due to the sharp bend from top of aortic arch 
Most of the type 3 aortic arch is shaggy and cannulation of selective catheter carries the risks 
of embolization (Fig. Carotid 5). Even in type 1 aortic arch, horizontally angulated left 
common carotid artery makes it difficult to engage the catheter from transfemoral approach 
(Fig. Carotid 6). In recent multi-detector CT angiography, the similar information of aortic 
arch can be obtained (Fig. Carotid 7). 
Type Type 2 Type 3
A B C 
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Since an aortic arch angiogram or CT angiography can accurately reveal aortic arch type, 
complex anatomic variations and angulated takeoff. The assessment of aortic arch type is 





Fig. Carotid 4: Bovine arch 
A and B are the typical bovine arch. Access to left common carotid artery is easy in A, but In 






Fig. Carotid 5: Type 3 arch 
A and B are typical type 3 arch. Cannulation of catheter to common carotid artery is 
difficult. Manipulation in these shaggy aortic arch carries the risks of embolization and a 
predictor of periprocedural complications. 
A B 
A B 
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Fig. Carotid 6: Difficult aorta of type 1 
Even in type 1 aortic arch, horizontaly angulated left common carotid artery makes it 
difficult to engage the catheter from transfemoral approach 
 
 
Fig. Carotid 7: Aortic arch assessment by 3D CT angiography and aortic arch angiography 
Aortic arch angiogram on the same patient. Similar aortic arch assessment can be obtained 
on either CT angiography (A) or angiogram(B) 
3.2 Selective carotid angiography  
3.2.1 CTA vs. DSA 
To evaluate carotid stenosis, selective carotid angiography remains the golden standard. 
But multidetector CT angiography is rapidly becoming the preferred examination for the 
initial evaluation of carotid artery stenosis (4). CT angiography correlates to DSA. CTA 
(Fig. Carotid 8A) and DSA (Fig. Carotid 8B) images of left carotid stenosis were compared. 
A B 
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In both images, tight stenosis were seen but CTA overestimates the stenosis. In calcified 
lesion, CTA does not reveal the real lumen. In Fig.8C,D, CTA image does not clarify the 




Fig. Carotid 8: Comparison of carotid artery stenosis between CT angiography and 
angiography 
Left internal carotid artery (ICA) stenosis by CT angiography (A) was confirmed by digital 
subtraction angiography (B). CT angiography overestimates the stenosis. 
In calcified lesion, CT angiography failed to show the ICA stenosis (C) and DSA revealed 
the ulcerated ICA stenosis (D). 
3.2.2 Quantitative stenosis measurement 
The percentage of stenosis is expressed using the NASCET criteria (5). The NASCET criteria 
of 70% stenosis is the indication for CEA in symptomatic carotid stenosis. In NASCET, the 
stenosis calculated as the ratio of the diameter at the narrowest point to the diameter point 
at which beyond the area of post stentic dilatation. Before intervening carotid artery 
stenosis, quantitative angiographic assessment is required to measure the stenosis. So called 
NASCET measurement causes some confusion about the reference point of distal internal 
carotid artery. To avoid this confusion, minimal lumen Diameter (MLD) should be 
measured in mm (Carotid 9). In this case, % stenosis based on NASCET was calculated at 
87% with MLD 0.7mm.   
3.2.3 Angiographic view for carotid artery stenosis 
Basic angiographic view for carotid bifurcation can be obtained by anterior-posterior and 
lateral view. In most of the cases, lateral view shows the stenosis (Fig. Carotid 10). To 
indicate CAS or CEA, angiographic significant stenosis has to be found in multiple views. In 
these circumstances, 3D angiography is employed. In Fig Carotid 11, moderate stenosis was 
seen on either anterior or lateral view. In 3D angiography,  right anterior oblique view at 
60°could reveal the tight stenosis. 
A C B D 
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Fig. Carotid 9: Quantitative stenosis measurement 
A: Distal internal carotid artery (ICA) 
B: minimal lesion diameter (MLD) 
C: Common carotid artery (CCA) 
D: Reference catheter outer diameter 
MLD should be express in mm. Distal ICA, MLD and CCA with reference catheter 
outerdiametr are needed to caluculate stenosis.  
 
 
Fig. Carotid 10: Antero-posterior amd lateral view of left carotid artery bifurcation 
A: Antero-posterior view 
B: Lateral view 
Basic angiographic view for carotid bifurcation can be obtained by anterior-posterior (A) 















Fig. Carotid 11: 3D angiography for carotid artery stenosis assessment 
A: Anterior view 
B: Lateral view 
C: Right anterior oblique 60° view 
Moderate stenosis were seen on either anterior or lateral view. In 3D angiography, right 
anterior oblique view at 60° could see the tight stenosis. 
3.2.4 Level of carotid artery bifurcation and lesion 
Carotid artery bifurcates at the level of around C4. To indicate CAS, either anatomical or 
clinical high risks for CEA have to be clarified. One of the common indications is high 
position of bifurcation. The level of bifurcation or lesion level must be clearly demonstrated 
by lateral view. In Fig. Carotid 12A, bifurcation level is normal at the level of C4 In Fig. 
Carotid 12B, bifurcation is at the C3, but lesion extends to C2. In Fig. Carotid 12C shows the 
unusually low bifurcation.  
3.2.5 Plaque morphology 
Carotid artery plaque is evaluated by ultrasound or MRI, but angiogram also could  
show the large plaque burden (Fig. Carotid 13). Ulcer is commonly seen and the main 
source of cerebral emboli (Fig. Carotid 13A). Severe long stenosis is seen in Fig. Carotid 
13B. This suggests the large plaque burden and CEA is recommended. Severe tight 
stenosis shows the string sings (Fig. Carotid 13C). This is the near occlusion and  
shows the sluggish antegrade flow. Real vessel size of distal ICA cannot be determined. In 
these cases, CEA is better indicated than CAS for thinking of complex plaque 
morphology. 
3.2.6 Tortuosity of ICA 
Protection device is placed at distal ICA or petrous portion. Atherosclerotic ICA sometimes 
shows the tortuosity. To place the protection device by the filter,  the landing zone that was 
relative straight and 3~4 cm away from lesion site must be found. If there is no lamding  
B A C 
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Fig. Carotid 12: Level of bifurcation and lesion 
A: Bifurcation level is normal at the level of C4 
B: Bifurcation is at the level of C3, but lesion extends to C2. 





Fig. Carotid 13: Plaque morphology 
A: Typical ulcer. 
B: Severe long stenosis is seen and this suggests the large plaque burden 
C: String sing is the preocclusion and shows the sluggish antegrade flow. 
zone for filter, we have to consider proximal protection or balloon occlusion. In Fig. Carotid 
14A, there is a landing zone but thinking of stent distal and filter position could be a very 
close and have the risks of filter trouble.  In Fig. Carotid 14B, lesion show the directed to 
horizontally and upward bending of distal ICA. In this case, conformable stent is desirable 
and there is a risk of filter retrieval. In Fig. Carotid 14C, ICA shows the extreme tortuosity 











Fig. 14: Tortuosity of internal carotid artery (ICA) 
A: S curve of ICA.  
B: 90 degree rightward shift of proximal ICA.  
C: Marked tortuosity of ICA  
These cases suggest carotid artery stenting are not a good indication for anatomical reasons. 
3.3 Summary 
Internal carotid artery stenosis is an important cause of ipsilateral stroke. CAS is becoming a 
valid alternative to CEA. Therefore angiography should be taken for thinking of CAS can be 
possible or not. Precise angiographic stenosis assessment, lesion location and lesion 
morphology are suitable for CAS. And also, place for filter landing zone have to be taken 
account.  
4. Subclavian artery angiography  
Occlusive disease of the supra-aortic trunks still remains an angiographic challenge. Among 
the proximal supra-aortic trunk disease, atherosclerosis is the most common cause of large 
artery occlusive disorder in the upper extremity.  
In this chapter, angiographic approach for left subclavian artery disease will be discussed. 
4.1 Aortic arch angiography for branch disease 
Branch disease is defined of innominate, left common carotid, left subclavian artery (SCA) 
disease. In angiographic assessment of aortic branch disease, left anterior oblique (LAO) 
projection of aortography is the basic view. However, bony structure of thorathic cage and 
calcification of aorta made it difficult to obtain the clear image of arch. Severe proximal 
stenosis of three aortic arch vessels caused by atherosclerosis was shown in In Fig. SCA 1B, 
proximal left common carotid artery is stenosed. Stenosis or occlusion of innominate and 
ostium of left common carotid artery  are not suited for revascularization by endovascular 
technique (6). In three aortic arch branch, left SCA stenosis most commonly seen and can be 
intervened by endovascular approach (Fig. SCA 1C). Atherosclerotic right SCA stenosis is 
mostly located at the ostium at the bifurcation of right common carotid artery. Aortography 
by LAO view showed right subclavian artery stenosis at the ostium (Fig. SCA 2A). Selective 
innominate artery angiography by right anterior oblique (RAO) view reveals that stenosis is 
located at the bifurcation of right common carotid artery (Fig. SCA 2B). Angioplasty to the 
right SCA ostium might affect right common carotid artery ostium. Extra caution is needed 
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Fig. Carotid 12: Level of bifurcation and lesion 
A: Bifurcation level is normal at the level of C4 
B: Bifurcation is at the level of C3, but lesion extends to C2. 





Fig. Carotid 13: Plaque morphology 
A: Typical ulcer. 
B: Severe long stenosis is seen and this suggests the large plaque burden 
C: String sing is the preocclusion and shows the sluggish antegrade flow. 
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and there is a risk of filter retrieval. In Fig. Carotid 14C, ICA shows the extreme tortuosity 
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These cases suggest carotid artery stenting are not a good indication for anatomical reasons. 
3.3 Summary 
Internal carotid artery stenosis is an important cause of ipsilateral stroke. CAS is becoming a 
valid alternative to CEA. Therefore angiography should be taken for thinking of CAS can be 
possible or not. Precise angiographic stenosis assessment, lesion location and lesion 
morphology are suitable for CAS. And also, place for filter landing zone have to be taken 
account.  
4. Subclavian artery angiography  
Occlusive disease of the supra-aortic trunks still remains an angiographic challenge. Among 
the proximal supra-aortic trunk disease, atherosclerosis is the most common cause of large 
artery occlusive disorder in the upper extremity.  
In this chapter, angiographic approach for left subclavian artery disease will be discussed. 
4.1 Aortic arch angiography for branch disease 
Branch disease is defined of innominate, left common carotid, left subclavian artery (SCA) 
disease. In angiographic assessment of aortic branch disease, left anterior oblique (LAO) 
projection of aortography is the basic view. However, bony structure of thorathic cage and 
calcification of aorta made it difficult to obtain the clear image of arch. Severe proximal 
stenosis of three aortic arch vessels caused by atherosclerosis was shown in In Fig. SCA 1B, 
proximal left common carotid artery is stenosed. Stenosis or occlusion of innominate and 
ostium of left common carotid artery  are not suited for revascularization by endovascular 
technique (6). In three aortic arch branch, left SCA stenosis most commonly seen and can be 
intervened by endovascular approach (Fig. SCA 1C). Atherosclerotic right SCA stenosis is 
mostly located at the ostium at the bifurcation of right common carotid artery. Aortography 
by LAO view showed right subclavian artery stenosis at the ostium (Fig. SCA 2A). Selective 
innominate artery angiography by right anterior oblique (RAO) view reveals that stenosis is 
located at the bifurcation of right common carotid artery (Fig. SCA 2B). Angioplasty to the 
right SCA ostium might affect right common carotid artery ostium. Extra caution is needed 
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for right SCA ostium intervention, such as distal protection for right carotid artery territory. 
Among the three aortic arch branch vessels, atherosclerotic left SCA is commonly found in 
proximal to vertebral artery and left SCA is most favourable fort endovascular therapy. In 
this chapter, left SCA angiogram for interventional approach is discribed. 
 
 
Fig. SCA 1: Aortic arch angiogram of aortic branch disease 
A: Innominate, left common, left subclavian artery are diseased. 
B: A tight ostial stenosis of left common carotid artery in type 3 arch 
C: Typical left subclavian artery stenosis. Bovine arch is noted.  
 
 
Fig. SCA 2: Ostial location of right subclavian artery stenosis 
A: Aortography by left anterior oblique view showed right subclavian artery stenosis at the 
ostium  
B: Selective innominate artery angiography by right anterior oblique view reveals that 
stenosis is located at the bifurcation of right common carotid artery. 
4.2 Aortic arch angiogram for left subclavian artery stenosis 
In subclavian artery angiography, nonsubtracted image gives the anatomical information 
but does not show the detail of subclavian artery stenosis (Fig. SCA 3A). Digital  
subtraction angiography (DSA) clearly delineates subclavian artery from the background 
(Fig.SCA3B).  
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Fig. SCA 3: Non-substracted and subtracted angiogram of left subclavian stenosis 
A: Non subtracted angiography gives the anatomical information 
B: Digital subtraction angiography (DSA) clearly delineates subclaviar artery stenosis 
As the initial angiographic approach for left SCA stenosis or occlusion, aortic  
arch angiography should be taken in left anterior oblique (LAO) 30~45°view by DSA  
(Fig. SCA 4A). Contrast volume and speed are at least 18cc/s, total 20~30cc by using  
5Fr Pigtail catheter. In Fig. SCA 4A the image was taken by 30cm in size and delayed 
image reveals the distal SCA via collateral from right vertebral artery (Fig. SCA  
4B). Selective right vertebral angiogram proves the reversed flow of left vertebral  
artery through basal artery (Fig. SCA4C). Image size of aortic arch angiography is usually 
taken by 30-40cm image (Fig. SCA 5A). Thinking of interventional approach, 20cm  
image is more practical to cannulate catheter to left SCA (Fig. SCA 5B). But to confirm  
the exact location of stenosis, selective left subclavian artery angiogram is required (Fig. 
SCA 5C). In Fig. SCA 6A, aortogram showed the total occlusion of proximal left SCA, but  
 
 
Fig. SCA 4: Angiogram of left subclavian artery occlusion 
A: Aortography by LAO 45°by 30cm image size  
B: Delayed image reveals the distal SCA via a collateral from right vertebral artery  
C: Selective right vertebral angiogram proves the reversed flow of left vertebral artery 
through basal artery  
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stenosis is located at the bifurcation of right common carotid artery. 
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Fig. SCA 3: Non-substracted and subtracted angiogram of left subclavian stenosis 
A: Non subtracted angiography gives the anatomical information 
B: Digital subtraction angiography (DSA) clearly delineates subclaviar artery stenosis 
As the initial angiographic approach for left SCA stenosis or occlusion, aortic  
arch angiography should be taken in left anterior oblique (LAO) 30~45°view by DSA  
(Fig. SCA 4A). Contrast volume and speed are at least 18cc/s, total 20~30cc by using  
5Fr Pigtail catheter. In Fig. SCA 4A the image was taken by 30cm in size and delayed 
image reveals the distal SCA via collateral from right vertebral artery (Fig. SCA  
4B). Selective right vertebral angiogram proves the reversed flow of left vertebral  
artery through basal artery (Fig. SCA4C). Image size of aortic arch angiography is usually 
taken by 30-40cm image (Fig. SCA 5A). Thinking of interventional approach, 20cm  
image is more practical to cannulate catheter to left SCA (Fig. SCA 5B). But to confirm  
the exact location of stenosis, selective left subclavian artery angiogram is required (Fig. 
SCA 5C). In Fig. SCA 6A, aortogram showed the total occlusion of proximal left SCA, but  
 
 
Fig. SCA 4: Angiogram of left subclavian artery occlusion 
A: Aortography by LAO 45°by 30cm image size  
B: Delayed image reveals the distal SCA via a collateral from right vertebral artery  
C: Selective right vertebral angiogram proves the reversed flow of left vertebral artery 
through basal artery  
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selective injection revealed the 95% stenosis (Fig. SCA 6). To determine subtotal or 





Fig. SCA 5: Angiographic image size of for left subclavian artery disease 
A: Aortic arch angiography is usually taken by 30cm image 
B: To cannulate catheter selectively to left subclavian artery, 20cm image of angiogram is 
appropriate 





Fig. SCA 6: Aortography and selective angiography 
A: Aortagram showed the total occlusion of proximal left subclavian artery 
B: Selective left subclabian artery angiogram showed subtotal stenosis. 
Selective angiography is necessary to intervene the lesion. 
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4.3 Angiography for subclavian artery intervention.  
Although there is a paucity of long-term data of endovascular therapy, subclavian artery 
stenting is now the standard approach and offer many advantage over surgery in terms of 
morbidity and mortality. To succeed in left SCA stenting, a precise location of stenosis or 
occlusion must be visualized. 
Fig. SCA 7 shows the typical left SCA stenosis. Initial aortogam by LAO view reveals left 
SCA stenosis (Fig. SCA 7A). To intervene left SCA stenosis, stenosis should be exactly 
located. Selective angiography combined with brachial artery catheter injection of dye 
clearly demonstrates the tight stenosis of left SCA (Fig. SCA 7B). Based on this angiogram, 
further stenting became the straightforward procedure (Fig. SCA 7C). The simultaneous 
injection of dye from distal and proximal SCA is very useful technique for subclavian artery 
intervention. To confirm SCA occlusion, the similar technique is applied during 
aortography. Selective SCA angiogram by injecting dye through catheter from brachial 
artery at the time of aortography showed the exact occlusion site (Fig. SCA 8A). This kind of 
angiogram leads to the successful intervention. Same angiographic technique was taken 




Figure. SCA7: Angiographic technique to assess left subclavian stenosis 
A: Initial aortagram by LAO view reveals left SCA stenosis 
B: Selective angiography combined with brachial artery catheter injection of dye clearly 
demonstrates the tight stenosis 
C: Selective angiogram of post stenting. Distal and proximal injection of dye clearly 
demonstrate successful stent implantation 
Not all angiogram could show the clear image of subclavian stenosis. In these cases, 
hemodynamic assessment is the useful to confirm a significant stenosis. In Fig. SCA 9A, 
simultaneous pressure recording was performed and showed 40mmHg peak systolic 
gradient and left SCA stenosis was located at the ostium. After stenting, no gradient was 
detected and successful stent placement was confirmed (Fig. SCA 9B). 
4.4 Angiographic assessment for coronary- internal mammary steal 
The increased employment of internal mammary artery (IMA) grafts for coronary 
revascularization, proximal SCA stenosis is becoming well known cause of coronary- 
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selective injection revealed the 95% stenosis (Fig. SCA 6). To determine subtotal or 
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appropriate 





Fig. SCA 6: Aortography and selective angiography 
A: Aortagram showed the total occlusion of proximal left subclavian artery 
B: Selective left subclabian artery angiogram showed subtotal stenosis. 
Selective angiography is necessary to intervene the lesion. 
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4.3 Angiography for subclavian artery intervention.  
Although there is a paucity of long-term data of endovascular therapy, subclavian artery 
stenting is now the standard approach and offer many advantage over surgery in terms of 
morbidity and mortality. To succeed in left SCA stenting, a precise location of stenosis or 
occlusion must be visualized. 
Fig. SCA 7 shows the typical left SCA stenosis. Initial aortogam by LAO view reveals left 
SCA stenosis (Fig. SCA 7A). To intervene left SCA stenosis, stenosis should be exactly 
located. Selective angiography combined with brachial artery catheter injection of dye 
clearly demonstrates the tight stenosis of left SCA (Fig. SCA 7B). Based on this angiogram, 
further stenting became the straightforward procedure (Fig. SCA 7C). The simultaneous 
injection of dye from distal and proximal SCA is very useful technique for subclavian artery 
intervention. To confirm SCA occlusion, the similar technique is applied during 
aortography. Selective SCA angiogram by injecting dye through catheter from brachial 
artery at the time of aortography showed the exact occlusion site (Fig. SCA 8A). This kind of 
angiogram leads to the successful intervention. Same angiographic technique was taken 




Figure. SCA7: Angiographic technique to assess left subclavian stenosis 
A: Initial aortagram by LAO view reveals left SCA stenosis 
B: Selective angiography combined with brachial artery catheter injection of dye clearly 
demonstrates the tight stenosis 
C: Selective angiogram of post stenting. Distal and proximal injection of dye clearly 
demonstrate successful stent implantation 
Not all angiogram could show the clear image of subclavian stenosis. In these cases, 
hemodynamic assessment is the useful to confirm a significant stenosis. In Fig. SCA 9A, 
simultaneous pressure recording was performed and showed 40mmHg peak systolic 
gradient and left SCA stenosis was located at the ostium. After stenting, no gradient was 
detected and successful stent placement was confirmed (Fig. SCA 9B). 
4.4 Angiographic assessment for coronary- internal mammary steal 
The increased employment of internal mammary artery (IMA) grafts for coronary 
revascularization, proximal SCA stenosis is becoming well known cause of coronary- 
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Fig. SCA 8: Angiographic technique for left subclavian occlusion  
A: Aortography with simultaneous injection of dye through the catheter from brachial 
artery. This angiogram gives the precise morphologic information of occlusion.  
B: Aortography of post stenting.  
Same angiographic technique was taken and shows the successful stent placement.  
 
 
Fig. SCA 9: Simultaneous pressure tracing for subclavian artery stenosis 
A: Aortography with selective distal SCA angiogram. Angiogram does not clearly reveal 
SCA stenosis. Simultaneous pressure tracing confirmed the siginificant stenosis.  
B: Aortography of post stenting. Distal and proximal pressure were equalized  and 
successful stenting was proven by hemodynamic study. 
subclavial steal. Left SCA stenting is the good indication for coronary to left IMA steal (7). In 
coronary steal to left IMA, selective left coronary angiogram is needed to prove reversed 
flow of IMA. The 70-year-old patient with suspected coronary steal was shown in Fig. SCA 
10A. The left coronary angiogram showed the typical coronary steal which left IMA shows 
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reversed flow and draining into left SCA is seen. This image was taken by coronary mode, 
but point is to prove coronary to left SCA steal phenomenon and DSA image can be used 
with 30cm image (Fig. SCA10B). 
 
 
Fig. SCA10: Left coronary angiography for coronary-subclavian steal 
A: Suspected coronary steal patient. Left coronary angiogram showed revealed reversed 
flow of left IMA. This angiogram was taken by coronary mode. 
B: Similar left coronary angiogram was taken by digital subtraction angiography. IMA is 




Fig. SCA 11: Relation between proximal left subclavian artery stenosis and origin of left 
internal mammary artery (IMA) 
A: Left subclavian artery angiogram by left anterior oblique (LAO) view. Origin of left IMA 
is not identified by LAO view.  
B. Left subclavian artery angiogram by antero-posterior view. 
Relation between left IMA and proximal SCA stenosis is well seen. 
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Fig. SCA 8: Angiographic technique for left subclavian occlusion  
A: Aortography with simultaneous injection of dye through the catheter from brachial 
artery. This angiogram gives the precise morphologic information of occlusion.  
B: Aortography of post stenting.  
Same angiographic technique was taken and shows the successful stent placement.  
 
 
Fig. SCA 9: Simultaneous pressure tracing for subclavian artery stenosis 
A: Aortography with selective distal SCA angiogram. Angiogram does not clearly reveal 
SCA stenosis. Simultaneous pressure tracing confirmed the siginificant stenosis.  
B: Aortography of post stenting. Distal and proximal pressure were equalized  and 
successful stenting was proven by hemodynamic study. 
subclavial steal. Left SCA stenting is the good indication for coronary to left IMA steal (7). In 
coronary steal to left IMA, selective left coronary angiogram is needed to prove reversed 
flow of IMA. The 70-year-old patient with suspected coronary steal was shown in Fig. SCA 
10A. The left coronary angiogram showed the typical coronary steal which left IMA shows 
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reversed flow and draining into left SCA is seen. This image was taken by coronary mode, 
but point is to prove coronary to left SCA steal phenomenon and DSA image can be used 
with 30cm image (Fig. SCA10B). 
 
 
Fig. SCA10: Left coronary angiography for coronary-subclavian steal 
A: Suspected coronary steal patient. Left coronary angiogram showed revealed reversed 
flow of left IMA. This angiogram was taken by coronary mode. 
B: Similar left coronary angiogram was taken by digital subtraction angiography. IMA is 




Fig. SCA 11: Relation between proximal left subclavian artery stenosis and origin of left 
internal mammary artery (IMA) 
A: Left subclavian artery angiogram by left anterior oblique (LAO) view. Origin of left IMA 
is not identified by LAO view.  
B. Left subclavian artery angiogram by antero-posterior view. 
Relation between left IMA and proximal SCA stenosis is well seen. 
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Most of the initial left SCA angiogram is taken by LAO view. However, in this view, in some 
cases, left IMA origin is not well seen (Fig. SCA 11A). Relation between left SCA stenosis 
and IMA is very important for stent placement. The left SCA selective angiogram was taken 
by anterior-posterior (AP) view (Fig. SCA 11B). In AP view, origin of left IMA is visualized 
and relation between left SCA stenosis and IMA is well understood. This could lead to 
successful stent placement. 
 
 
Fig. SCA12: Pre and post left subclavian artery stenting in coronary-subclavian steal 
A: Aortic arch angiogram.  
A 65 year-old female post coronary bypass patient, lesion was located at left SCA ostium.  
B: Aortic arch angiogram post stenting. This angiogram showed the successful stenting. 
In left SCA ostium disease, precise lesion location is mandatory. In Fig. SCA 12, a 65 year-
old female post coronary bypass patient, lesion was located at left SCA ostium. This was 
confirmed aortography combined with brachial side simultaneous injection of dye (Fig. SCA 
12A). Based on the angiogram, stent was precisely implanted and same angiographic 
technique was repeated to confirm successful procedure.  
4.5 Summary 
Primary stenting for a symptomatic SCA stenosis can be performed with relatively safe 
procedure risks. However, to succeed SCA stenting, the stenosis or occlusion must be clearly 
visualized by angiography. Aortic arch angiography with selective angiography by using 
distal injection of dye gives the precise lesion location and could lead to successful 
intervention. When patient  presents after coronary bypass with coronary-subclavian steal, 
SCA stenting is the good option. But, origination of IMA must be precisely identified. 
Thereis no clinical randomized study about SCA stenting. To intervene to subclvian artery, a 
meticulous angiographic assessment is required. 
5. Renal artery angiography 
Atherosclerotic renal artery stenosis (ARAS) is an increasingly recognized cause of severe 
hypertension and declining kidney function (8). Typically involving the renal artery ostium 
or proximal segment of the renal artery. Patients with ARAS have been demonstrated to 
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have an increased risk of adverse cardiovascular events (9). However, the efficacy of renal 
artery stenting for ARAS is a bit of controversial since ASTRAL trial was published (10). 
Discordance exists between the procedural success rate and the equivocal clinical response 
rate after renal stent placement, which is likely to be a result of poor patients selection and 
inadequate angiographic assessment of lesion severity. Angiographic technique for ARAS 
will be discussed in this chapter. 
5.1 Aortography for renal artery stenosis 
Aortography and selective renal artery angiography considered to be the gold standard for 
assessing renal artery anatomy and renal artery stenosis. 3D CT angiography consists of a 
continuously overlapping transaxial images and is now replacing aortography for the 
diagnostic purpose. The drawback of aortography, only one shot image can be obtained and 
the image may not be in a single plane to see the both renal artery ostium. We usually take 
left anterior oblique view 15~30° for initial aortography (Fig. Renal 1). In Fig. Renal 1, 
bilateral renal artery stenosis is well visualized in one flame.  
 
 
Fig. Renal 1: Aortography for the assessment of renal artery stenosis 
Aortography was taken by left anterior oblique view 30°. Typical bilateral atherosclerotic 
renal artery stenosis is shown in one flame. 
• Multiple renal arteries: Computed tomography angiography (CTA) with multiple 
detector-row CT (MDCT) has evolved into an established technique for imaging of 
renal and mesenteric vessels. Particularly, in multiple renal arteries, MDCT is superior 
to DSA to detect all renal arteries. To make a correct diagnosis of multiple renal arteries, 
MDCT and DSA could be used complimentary. In Fig. Renal 2, a case of multiple renal 
arteries are shown in both MDCT and DSA. In DSA, many other arteries were shown 
and we might miss to identify all 4 renal arteries. With the information of MDCT image, 
all renal arteries were confirmed. 
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Most of the initial left SCA angiogram is taken by LAO view. However, in this view, in some 
cases, left IMA origin is not well seen (Fig. SCA 11A). Relation between left SCA stenosis 
and IMA is very important for stent placement. The left SCA selective angiogram was taken 
by anterior-posterior (AP) view (Fig. SCA 11B). In AP view, origin of left IMA is visualized 
and relation between left SCA stenosis and IMA is well understood. This could lead to 
successful stent placement. 
 
 
Fig. SCA12: Pre and post left subclavian artery stenting in coronary-subclavian steal 
A: Aortic arch angiogram.  
A 65 year-old female post coronary bypass patient, lesion was located at left SCA ostium.  
B: Aortic arch angiogram post stenting. This angiogram showed the successful stenting. 
In left SCA ostium disease, precise lesion location is mandatory. In Fig. SCA 12, a 65 year-
old female post coronary bypass patient, lesion was located at left SCA ostium. This was 
confirmed aortography combined with brachial side simultaneous injection of dye (Fig. SCA 
12A). Based on the angiogram, stent was precisely implanted and same angiographic 
technique was repeated to confirm successful procedure.  
4.5 Summary 
Primary stenting for a symptomatic SCA stenosis can be performed with relatively safe 
procedure risks. However, to succeed SCA stenting, the stenosis or occlusion must be clearly 
visualized by angiography. Aortic arch angiography with selective angiography by using 
distal injection of dye gives the precise lesion location and could lead to successful 
intervention. When patient  presents after coronary bypass with coronary-subclavian steal, 
SCA stenting is the good option. But, origination of IMA must be precisely identified. 
Thereis no clinical randomized study about SCA stenting. To intervene to subclvian artery, a 
meticulous angiographic assessment is required. 
5. Renal artery angiography 
Atherosclerotic renal artery stenosis (ARAS) is an increasingly recognized cause of severe 
hypertension and declining kidney function (8). Typically involving the renal artery ostium 
or proximal segment of the renal artery. Patients with ARAS have been demonstrated to 
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have an increased risk of adverse cardiovascular events (9). However, the efficacy of renal 
artery stenting for ARAS is a bit of controversial since ASTRAL trial was published (10). 
Discordance exists between the procedural success rate and the equivocal clinical response 
rate after renal stent placement, which is likely to be a result of poor patients selection and 
inadequate angiographic assessment of lesion severity. Angiographic technique for ARAS 
will be discussed in this chapter. 
5.1 Aortography for renal artery stenosis 
Aortography and selective renal artery angiography considered to be the gold standard for 
assessing renal artery anatomy and renal artery stenosis. 3D CT angiography consists of a 
continuously overlapping transaxial images and is now replacing aortography for the 
diagnostic purpose. The drawback of aortography, only one shot image can be obtained and 
the image may not be in a single plane to see the both renal artery ostium. We usually take 
left anterior oblique view 15~30° for initial aortography (Fig. Renal 1). In Fig. Renal 1, 
bilateral renal artery stenosis is well visualized in one flame.  
 
 
Fig. Renal 1: Aortography for the assessment of renal artery stenosis 
Aortography was taken by left anterior oblique view 30°. Typical bilateral atherosclerotic 
renal artery stenosis is shown in one flame. 
• Multiple renal arteries: Computed tomography angiography (CTA) with multiple 
detector-row CT (MDCT) has evolved into an established technique for imaging of 
renal and mesenteric vessels. Particularly, in multiple renal arteries, MDCT is superior 
to DSA to detect all renal arteries. To make a correct diagnosis of multiple renal arteries, 
MDCT and DSA could be used complimentary. In Fig. Renal 2, a case of multiple renal 
arteries are shown in both MDCT and DSA. In DSA, many other arteries were shown 
and we might miss to identify all 4 renal arteries. With the information of MDCT image, 
all renal arteries were confirmed. 
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Fig. Renal 2: CT angiography and angiography for multiple renal arteries 
A: CT angiography showed two renal arteries on both kidney. 
B: The same view was taken by angiography. 4 renal arteries were seen but many other 
arteries are included and might miss multiple renal arteries. 
• Right renal artery ostium and super mesenteric artery: Often times, right renal artery 
overraps to superior mesenteric artery (SMA) by antero-posterior view and proximal 
right renal is not visualized (Fig. Renal 3A). Selective right renal artery angiography 
confirmed the tight stenosis in right renal artery ostium (Fig. Renal 3B). There are 
reports about the detection of renal artery stenosis by aortography at the time of 
coronary angiography. But in reality, the simple aortogram might not identify the 
stenosis of right renal artery proximal stenosis. 
 
 
Fig. Renal 3: Relation between right renal artery ostium and super mesenteric artery 
A: In aortography of left anterior oblique view, right renal artery overraps to superior 
mesenteric artery and proximal right renal artery is not shown 
B: Selective right renal artery angiography confirmed tight stenosis in proximal right renal 
artery ostium  
• Access for selective renal artery catheter placement: Aortography gives the 
important information about the access to selective renal artery angiography. The 
straight aorta with minimal atherosclerotic change is seen in Fig. Renal 4A. This 
suggests easy access for left renal catheter engagement. In Fig. Renal 4B, there is a 
marked tortuosity of aorta and tranfemoral approach may face difficulty to reach 









Fig. Renal 4: Access for selective renal artery catheter placement 
A: The straight aorta with minimal atherosclerotic change is seen. This suggests easy access 
for left renal catheter engagement. 
B: There is a marked tortuosity of aorta. Selective angiography by tranfemoral approach 
might be difficult procedure to reach both renal artery. In this case, transbrachial or 
transradial approach is recommended. 
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Selective renal artery angiography is the definitive gold standard for the diagnosis of the 
significant renal artery stenosis. In aortography, clear relation between aorta and renal 
artery ostium is shown (Fig. Renal 5A). However, in aortography, information of intrarenal 
arteries is not obtained. Only selective renal artery angiography could show the picture of 
intrarenal artery as well as proximal stenosis (Fig. Renal 5B). 
 
 
Fig. Renal 5: Aortography and selective renal artery angiography 
A: Aortography shows the clear relation between aorta and renal artery ostium stenosis.  
B: Selective renal artery angiography could show precise renal artery stenosis and anatomy 
of intrarenal arteries. 
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5.2.1 Digital subtracted image 
By using digital subtraction angiography (DSA), the excellent renal artery angiography is 
Taken (Fig. Renal 6A). But in reality, it is very difficult to take excellent DSA image. Recent 
advances of digital image, distinction between subtracted and non subtracted image are 
relatively small (Fig. Renal 6B). Non DSA image is more important for renal artery 
intervention. In the near future, good quality digital image might replace DSA at least in 
renal artery.  
 
 
Fig. Renal 6: Digital subtracted and non subtracted selective renal artery angiography 
A: Digital subtracted renal artery angiography. 
B: Non subtracted image 
Digital subtraction angiography (DSA) gives excellent image of renal artery vasculature(A). 
Recent advances of digital angiography shows that image quality  between subtracted and 
non subtracted image are relatively small(B).  
5.2.2 Ideal renal artery angiography 
In selective renal artery angiography, catheter tip is in the renal artery ostium, but most of 
catheter goes into distal to stenosis and relationship between ostium and stenosis is not 
clarified. Aortagraphy of typical bilateral ARAS is shown in Fig. Renal 7A). In selective right 
renal artery angiography, catheter tip goes further to stenosis (Fig. Renal 7B) and 
relationship between ostium and stenosis is not clear. The ideal selective renal artery 
angiography is shown in Fig. Renal 8. In Fig. 8A, catheter tip attached to stenosis and is not 
recommended to inject dye. The ideal renal artery angiography is catheter tip located in 
aorta and could see the proximal stenosis (Fig. Renal 8B). To take the good quality renal 
artery angiogram, lesion is crossed by soft coil 0.014inc. wire. After confirming normal aortic 
pressure pattern, dye should be injected. If the catheter is too close to stenosis, slight 
drawback of catheter is needed to take the good quality angiogram. By doing this 
procedure, correct stenosis assessment can be made.  
5.2.3 Lesion location 
In ARAS, stenosis is basically localized in proximal renal artery. There are 3 types of lesion 
locations (11). One is typical ostial stenosis (Fig. Renal 9A). Lesion located in middle of the 
proximal renal artery is called renal type (Fig. Renal 9B). In most of the cases, mixed type of 
stenosis is seen (Fig. Renal 9C). 
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Fig. Renal 7: Catheter tip position of selective renal artery angiography 
A: Aortography of typical bilateral ARAS  
B: Selective right renal artery angiography. 
In selective angiography, catheter tip goes into further stenosis. Relation between ostium 
stenosis and aortic wall is not elucidated.  
 
 
Fig. Renal 8: Ideal selective renal artery angiography 
A: Catheter tip attached to stenosis and injection of dye at this place might damage the 
vessel. 
B: The ideal renal artery angiography. Catheter tip is located in aorta and could see the 
proximal stenosis with distal renal vasculature. 
 
 
Fig. Renal 9: Lesion location of atherosclerotic renal artery stenosis. Atherosclerotic renal artery 
stenosis is basically localized in proximal renal artery. There are 3 types of lesion locations. 
One is typical ostial stenosis (A).  Lesion located in middle of the proximal renal artery is 
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5.2.4 Reference vessel 
To select the correct stent size, accurate vessel diameter must be measured (12). To make a 
correct assessment of stenosis and vessel size, reference point is chosen. In Fig. Renal 10A, 
reference vessel is considered to be about 2cm distal to stenosis. However, in Fig. Renal 10B, 
post-stenostic dilatation is seen and bifurcation follows (Fig. Renal 10B). In this case, 
reference vessels cannot be determined. The bifurcation located at the ostium, real vessel 
size is not known (Fig. Renal 10C). This fact is not well understood and this is the main 
cause of recent confusion of stenosis evaluation.  
 
 
Fig. Renal 10: Reference vessel 
To calculate % diameter stenosis or minimal lesion diameter, reference vessel must be 
determined.  
A: Reference vessel can be determined about 2cm distal to stenosis. 
B: Typical post-stenostic dilatation is seen and bifurcation follows. In this case, reference 
vessels can not be determined.  
C: The bifurcation located at the ostium and real vessel size is not known. 
• Summary: Renal artery angiography is the gold standard diagnostic test. 
However, to make a correct diagnosis of ARAS, excellent visualization of renal vasculature 
should be performed. Aortography is now replacing to CT angiography. But in placing 
catheter to renal artery ostium, we still need aortography for the safe catheter manipulation. 
Selective angiography identifies the severity of stenosis with intra renal vasculature 
information. Confusion for the indication of renal artery stenting is mostly coming from 
poor angiographic image of renal artery stenosis. 
6. Iliac artery angiography 
Peripheral arterial disease at the level of iliac artery is well known for good indication  
of angioplasty. Currently, stenting for the treatment of iliac occlusive disease is the  
most effective modality and endovascular treatment of iliac artery disease should  
be considered as a first-line therapy for symptomatic PAD. The most commonly  
quoted classification of iliac lesions has been set forth by the TransAtlantic inter- 
Society Consensus (TASC II) group with recommended treatment options (13). The type A 
and B lesions are treated preferentially by endovascular techniques and typed C and D 
lesions are more suited for surgical treatment. However, recent development of 
endovascular technique, even type D lesions sometimes is treated by endovascular 
procedure. To maximize the success of iliac artery stenting, good quality angiogram is 
needed.  
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6.1 Aortography for iliac artery disease 
artery. The image field at least 30cm is needed. In Fig. Iliac 1, 31X31 cm and 30X40 cm 
image field are shown (Fig. Iliac 1). In both angiogram show from terminal aorta  
to common femoral artery. However, in 31cm image field, we are lifting a table to 
maximize image field ( Fig. Iliac 2). Typical long left iliac artery total occlusion is shown in 
Fig Iliac 2A. This image was taken by lifting table to obtained collateral vessels to 
common femoral artery (Fig. Iliac 2B). DSA image is considered to be the standard 
angiography for iliac artery disease, but pelvic vessels often times interfered by bowel 
movement and gas. In recent advanced digital angiography, similar image to subtracted 
angiogram can be obtained. In Fig. Iliac 3, subtracted (In Fig. Iliac 3A) and non- 




Fig. Iliac 1: Aortography for iliac artery 
A: 31X31cm image,  
B: 30X40cm image  
Both angiogram could show from terminal aorta to common femoral artery.  
6.2 Image size 
To visualize aorto iliac disease, more than 30 cm image field is required. But in reality, 
image of 30 cm often times misses the complicated stenostic lesion. In Fig. Iliac 4A, there is a 
tight stenosis in left external iliac artery. In 20cm image, ulcerated tight stenosis in left 
common iliac artery clearly visualized (Fig. Iliac 4B). To intervene the iliac artery disease, the 
information of vessels size and lesion length is needed. 30cm image could confirm the 
disease of common femoral artery, but to obtain the precise lesion morphology,  20cm image 
is better than 30cm image. 
6.3 Basic 3 views for iliac artery 
The anteriorposterior (AP) pelvic angiogram is the basic angiogram. The oblique images 
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Fig. Iliac 2: Aortography by 31X31cm image field 
A: Aortography of 31X31cm image. Left common femoral artery is visulaized through 
collateral. 





Fig. Iliac 3: Subtracted and non subtracted Aortography 
A: Image of digital subtraction angiography 
Image of digital subtraction angiography is considered to be the standard  for the 
visualization of iliac artery disease 
B: Non subtracted image 
Pelvic vessels are interfered by bowel movement and bowel gas. Recent digital angiography 
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Fig. Iliac 4: Image size of Iliac artery disease  
A: 31cm of image 
B: 20cm of image 
To visualize iliac artery disease, more than 30 cm image field is required. But for the 
purpose of interventional work, image of 30 cm often times misses the complicated stenotic 
lesion. There is a tight stenosis in left external iliac artery(A). In 20cm image, ulcerated tight 
stenosis in left common iliac artery clearly visualized (B).  
(Fig. Iliac 5). In a right anterior oblique view, the left iliac artery is best visualized and  
could separate bifurcation of internal iliac artery (Fig. Iliac 5A). Similarly, right iliac artery is 
taken by left anterior oblique (Fig. Iliac 5C) with the projection 30°. In complex disease 
anatomy, this approach is very important before intervention. In Fig. Iliac 6, severely 
diseased bilateral external iliac artery are shown in three views. In AP view, right external 
iliac artery over rap and left external iliac artery is not well visualized (Fig. Iliac 6B). The 
right internal anterior oblique view shows occlusion of left external iliac artery iliac artery 
(Fig. Iliac 6A). Left anterior view clearly delineate right external and internal iliac artery (Fig. 
Iliac 6C).    
6.4 Working image for intervention 
In iliac artery disease, primary iliac stenting is performed in most of the cases. To stent, exact 
lesion location must be visualized. In Fig. Iliac 7, left external iliac artery focal stenosis is 
shown (Fig. Iliac 7A). In DSA image, bony landmark is not seen and DSA image converted 
to non-subtracted image (Fig. Iliac 7B). By seeing femoral head, precise stenting was 
performed (Fig. Iliac 7C).  
6.5 Contrast injection from sheath 
Iliac artery stenting is becoming the routine procedure and angiography can be simplified. 
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Fig. Iliac 5: Basic 3 views for iliac artery  
A: 30° right anterior oblique view 
B: Anteriorposterior (AP) view 
C: 30° left anterior oblique view 
In a right anterior oblique view, the left iliac artery is best visualized and separate 
bifurcation of internal iliac artery (A). In AP view, both external iliac artery are shortened(B) 







Fig. Iliac 6: Basic 3 views for iliac artery diease 
A: 30° right anterior oblique view 
B: Anteriorposterior (AP) view 
C: 30° left anterior oblique view 
The right internal anterior oblique view shows occlusion of left external iliac artery iliac 
artery (A). In AP view, right external iliac artery over rap with right internal iliac artery and 
left external iliac artery is not well visualized (B). The left anterior view clearly delineate 
right external and internal iliac artery and shows diffusely diseased right external iliac 
artery (C).    
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Fig. Iliac 7: Working image for intervention 
A:  Subtracted image  
B: Non subtravted image 
C: Post stenting  
To stent, exact lesion location has to be visualized. Foca stenosis in left external iliac artery is 
shown by DSA image (A). Bony landmark is not seen and DSA image converted to non-
subtracted image (B). By seeing femoral head, precise stenting was performed (C). 
 
 
Fig. Iliac 8: Ipsilateral contrast injection from sheath  
A: Angiogram by injecting dye through left femoral artery sheath 
B: Post stenting angiogram 
In ipsilateral retrograde femoral approach, sheath can be used to injection of dye. There is a 
focal stenosis in left external iliac artery (A). Angiogram was performed through this sheath 
and ballooning and stenting was performed. (B).  
to injection of dye. There is a focal stenosis in left external iliac artery (Fig. Iliac 8A). 
Angiogram was performed through this sheath and ballooning and stenting was performed. 
(Fig. Iliac 8B). However, in retrograde approach, hand injection cannot visualize proximal 
iliac artery. Power injector should be employed and test injection is needed to check the tip 
of sheath position is in vessel lumen. 
A B 
A B C 
Angioplasty, Various Techniques and Challenges in  







Fig. Iliac 5: Basic 3 views for iliac artery  
A: 30° right anterior oblique view 
B: Anteriorposterior (AP) view 
C: 30° left anterior oblique view 
In a right anterior oblique view, the left iliac artery is best visualized and separate 
bifurcation of internal iliac artery (A). In AP view, both external iliac artery are shortened(B) 







Fig. Iliac 6: Basic 3 views for iliac artery diease 
A: 30° right anterior oblique view 
B: Anteriorposterior (AP) view 
C: 30° left anterior oblique view 
The right internal anterior oblique view shows occlusion of left external iliac artery iliac 
artery (A). In AP view, right external iliac artery over rap with right internal iliac artery and 
left external iliac artery is not well visualized (B). The left anterior view clearly delineate 
right external and internal iliac artery and shows diffusely diseased right external iliac 
artery (C).    
AP LAORAO
RAO AP LAO
A B C 
A B C 
 





Fig. Iliac 7: Working image for intervention 
A:  Subtracted image  
B: Non subtravted image 
C: Post stenting  
To stent, exact lesion location has to be visualized. Foca stenosis in left external iliac artery is 
shown by DSA image (A). Bony landmark is not seen and DSA image converted to non-
subtracted image (B). By seeing femoral head, precise stenting was performed (C). 
 
 
Fig. Iliac 8: Ipsilateral contrast injection from sheath  
A: Angiogram by injecting dye through left femoral artery sheath 
B: Post stenting angiogram 
In ipsilateral retrograde femoral approach, sheath can be used to injection of dye. There is a 
focal stenosis in left external iliac artery (A). Angiogram was performed through this sheath 
and ballooning and stenting was performed. (B).  
to injection of dye. There is a focal stenosis in left external iliac artery (Fig. Iliac 8A). 
Angiogram was performed through this sheath and ballooning and stenting was performed. 
(Fig. Iliac 8B). However, in retrograde approach, hand injection cannot visualize proximal 
iliac artery. Power injector should be employed and test injection is needed to check the tip 
of sheath position is in vessel lumen. 
A B 
A B C 
Angioplasty, Various Techniques and Challenges in  




Iliac artery stenting is recognized as an effective treatment and became the standard therapy 
for iliac artery disease. CTA and vascular echo can be utilized for diagnostic purpose and 
diagnostic angiography is less performed. But pelvic vessels are difficult to diagnose by 
echo. CTA can be misread by calcification. The angiogram is still the golden standard for 
final decision making of iliac artery stenting.  
7. Femoropopliteal artery angiography 
Patients with disease limited to superficial femoral artery (SFA) usually present with 
claudication. However, most of severe claudication shows multi level involvement. In SFA, 
popliteal and infrapopliteal artery disease could be a cause of critical limb. Interventional 
approach to SFA is much easier than infrapopliteal artery and precise assessment of 
femoropopliteal artery disease in very important to deal with severe claudication and 
critical limb. 
7.1 Proximal femoral artery 
proximal femoral artery disease. In AP view, profunda femoral override to SFA (Fig. SFA 
1A). In ipsilateral oblique view, separation between SFA proximal and profund femoral are 
well seen (Fig. SFA 1B). This view is particular important for diseased proximal femoral 
artery. The SFA proximal stenosis is not delineated by anterior posterior (AP) view (Fig. 
SFA 2A). Left anterior oblique view shows SFA ostial stenosis and found that lesion length 
of proximal profunda artery is longer than AP view (Fig. SFA2B). This angled view is 
particular useful to guide the wire into SFA ostial occlusion. In Fig SFA 3 shows the typical 
SFA long occlusion originating from SFA ostium (Fig. SFA 3A). In AP view, SFA ostium is 
not identified (Fig. SFA 3B). In left anterior oblique view, SFA ostium occlusion is well 
visualized (Fig. SFA 3C).   
7.2 Bolus chase for limb artery angiography 
To see the entire limb artery, a bolus chasing angiography is very useful method. In  
some angiographic system, this angiography can be done by digital subtraction with  
small amount contrast. We usually give 4cc/second, total 16~18cc of contrast to visualize 
from femoral to tibial artery. In Fig SFA 4A is the bolus chase of right limb. Infrapopliteal 
arteries are not well seen, but this angiogram give the right limb is not severely diseased. In 
Fig. SFA 4B shows the two focal stenosis with three tibial vessels run-off. The typical SFA 
occlusion with well developed collateral via profunda femoral artery is well seen (Fig. 
SFA4C). 
7.3 Lesion length 
marking is placed in SFA. Tape measurement is fairly consistent with marker wire and  
this tape can be used to measure lesion length (Fig. SFA 5). By using this tape, lesion  
length can be measured. Short focal lesion was measured at 1cm (Fig. SFA 6A). The  
lesion length of short CTO is measured at 6.5cm. In Fig. SFA 6C, 20cm long CTO is  
shown. In long diffuse lesion, another way to measure lesion length is to employ balloon 
marker. In Fig. SFA 7A, long SFA lesion is shown. By using 10cm balloon marker (Fig.  
SFA 7B), lesion was calculated about 20cm and two 6mmX100mm stent were implanted 
(Fig. SFA 7C). 
 




Fig. SFA 1: Anteroposterior view and left anterior  
oblique view for proximal left femoral artery 
A: AP view shows that profunda femoral override to SFA 




Fig. SFA 2: Anteroposterior view and left anterior  
oblique view for proximal left femoral diseased artery 
A: The SFA proximal stenosis is not delineated by anterior posterior (AP) view  
B: Left anterior oblique view shows SFA ostial stenosis and lesion length of proximal 
profunda artery is longer than AP view 
A B 
A B 
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Iliac artery stenting is recognized as an effective treatment and became the standard therapy 
for iliac artery disease. CTA and vascular echo can be utilized for diagnostic purpose and 
diagnostic angiography is less performed. But pelvic vessels are difficult to diagnose by 
echo. CTA can be misread by calcification. The angiogram is still the golden standard for 
final decision making of iliac artery stenting.  
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Fig. SFA 4B shows the two focal stenosis with three tibial vessels run-off. The typical SFA 
occlusion with well developed collateral via profunda femoral artery is well seen (Fig. 
SFA4C). 
7.3 Lesion length 
marking is placed in SFA. Tape measurement is fairly consistent with marker wire and  
this tape can be used to measure lesion length (Fig. SFA 5). By using this tape, lesion  
length can be measured. Short focal lesion was measured at 1cm (Fig. SFA 6A). The  
lesion length of short CTO is measured at 6.5cm. In Fig. SFA 6C, 20cm long CTO is  
shown. In long diffuse lesion, another way to measure lesion length is to employ balloon 
marker. In Fig. SFA 7A, long SFA lesion is shown. By using 10cm balloon marker (Fig.  
SFA 7B), lesion was calculated about 20cm and two 6mmX100mm stent were implanted 
(Fig. SFA 7C). 
 




Fig. SFA 1: Anteroposterior view and left anterior  
oblique view for proximal left femoral artery 
A: AP view shows that profunda femoral override to SFA 




Fig. SFA 2: Anteroposterior view and left anterior  
oblique view for proximal left femoral diseased artery 
A: The SFA proximal stenosis is not delineated by anterior posterior (AP) view  
B: Left anterior oblique view shows SFA ostial stenosis and lesion length of proximal 
profunda artery is longer than AP view 
A B 
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Fig. SFA 3: Anteroposterior view and left anterior  
oblique view for proximal left femoral artery occlusion 
A: Typical SFA long occlusion originating from ostium  
B: In AP view, SFA ostium is not clearly seen  
C: In left anterior oblique view, the stump of SFA ostium occlusion is well visualized  
 
 
Fig. SFA 4: Bolus chase for limb vessel angiography 
To see the entire limb artery, bolus chasing is very useful method. This angiogram can be 
obtained by digital subtraction with small amount dye.  
A: Bolus chase of right limb. Infrapopliteal arteries are not well seen, but this angiogram shows 
the right lower limb is not severely diseased.  
B: Two focal stenosis with three vessels run-off is shown 
C: Typical SFA occlusion with well developed collateral via profunda femoral artery is well seen 
A B C 
A CB
 




Fig. SFA 5: Marker wire and measure tape 
To measure lesion length, maker tape is attached to frontal leg muscle. This tape is validated 




Fig. SFA 6: Lesion length of SFA disease 
A: Focal lesion was measured at 1cm  
B: Short CTO was measured at 6.5cm.  
C: SFA long CTO was measured at 20cm  
A B C 
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Fig. SFA 3: Anteroposterior view and left anterior  
oblique view for proximal left femoral artery occlusion 
A: Typical SFA long occlusion originating from ostium  
B: In AP view, SFA ostium is not clearly seen  
C: In left anterior oblique view, the stump of SFA ostium occlusion is well visualized  
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A: Bolus chase of right limb. Infrapopliteal arteries are not well seen, but this angiogram shows 
the right lower limb is not severely diseased.  
B: Two focal stenosis with three vessels run-off is shown 
C: Typical SFA occlusion with well developed collateral via profunda femoral artery is well seen 
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Fig. SFA 5: Marker wire and measure tape 
To measure lesion length, maker tape is attached to frontal leg muscle. This tape is validated 




Fig. SFA 6: Lesion length of SFA disease 
A: Focal lesion was measured at 1cm  
B: Short CTO was measured at 6.5cm.  
C: SFA long CTO was measured at 20cm  
A B C 
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Fig. SFA 7: Lesion length measured by balloon marker 
A: SFA long diffuse lesion 
B: Measring lesion length by using 10cm balloon marker 
C: Lesion was calculated about 20cm and two 6mmX100mm stent were implanted 
7.4 TASC II Classification(13) 
Before intervening the lesion, lesion length and morphology can be classified according to 
TASC II guideline (13). It will give the standard indication of interventional treatment or 
bypass surgery. Fig. SFA 8A shows a single focal lesion less than 10 cm in length and did not 
involve the origins of SFA. This lesion is classified into type A (Fig. SFA8A). Fig. SFA 8B is a 
single CTO lesion less than 15cm and considered to be type B (Fig. SFA 8B). Fig. SFA 8C shows 
multiple stenosis more than 15cm lesion length and a typical example of type C (Fig. SFA 8C). 
Fig. SFA 8D shows the long CTO and lesion length is more than 20cm (Fig.SFA 8D). This is the 
typical type D and stenting for this kind of lesion could be a high chance of restenosis. 
7.5 Ballooning or stenting 
In iliac artery disease, primary stenting is firmly established. In femoropopliteal artery 
disease, it is still controversial about primary stenting. In short lesion, the initial approach is 
still balloon angioplasty (Fig. SFA 9A, B). Angiogram of post balloon angioplasty shows 
suboptimal result (Fig. SFA 9C). But in reality, most of the lesion needs to be stented. Fig. 
SFA 10A shows the typical 5cm stenostic lesion and balloon angioplasty was performed 
(Fig. SFA10B). Balloon dilatation resulted in dissection and bail out stenting was performed. 
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Fig. SFA 8: Lesion classification based on TASC ll guideline (13) 
TASC II guideline gives the standard indication of interventional treatment or bypass 
surgery.  
A: TASC A is a single focal lesion less than 10 cm in length 
B: TASC B is a single CTO lesion less than 15cm 
C: TASC C is multiple stenosis more than 15cm lesion length 
D: TASC D is a long CTO and lesion length is more than 20cm 
 
 
Fig. SFA 9: Balloon angioplasty 
In short lesion, initial approach is the balloon angioplasty  
A: A sort focal lesion in distal SFA 
B: Balloon angioplasty was performed 5X40mm balloon at 8 ATM 
C: Post balloon angioplasty showed a residual less than 50% stenosis at ballooning site 
A B C
A B C D 
Angioplasty, Various Techniques and Challenges in  






Fig. SFA 7: Lesion length measured by balloon marker 
A: SFA long diffuse lesion 
B: Measring lesion length by using 10cm balloon marker 
C: Lesion was calculated about 20cm and two 6mmX100mm stent were implanted 
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multiple stenosis more than 15cm lesion length and a typical example of type C (Fig. SFA 8C). 
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typical type D and stenting for this kind of lesion could be a high chance of restenosis. 
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In iliac artery disease, primary stenting is firmly established. In femoropopliteal artery 
disease, it is still controversial about primary stenting. In short lesion, the initial approach is 
still balloon angioplasty (Fig. SFA 9A, B). Angiogram of post balloon angioplasty shows 
suboptimal result (Fig. SFA 9C). But in reality, most of the lesion needs to be stented. Fig. 
SFA 10A shows the typical 5cm stenostic lesion and balloon angioplasty was performed 
(Fig. SFA10B). Balloon dilatation resulted in dissection and bail out stenting was performed. 
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Fig. SFA 9: Balloon angioplasty 
In short lesion, initial approach is the balloon angioplasty  
A: A sort focal lesion in distal SFA 
B: Balloon angioplasty was performed 5X40mm balloon at 8 ATM 
C: Post balloon angioplasty showed a residual less than 50% stenosis at ballooning site 
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Fig. SFA 10: Bail out stenting post balloon angioplasty 
A: 5cm stenostic lesion 
B: Balloon angioplasty was performed and resulted in dissection 
C: Nitinol stenting for bail out purpose succeeded to seal the dissection 
7.6 Stent fracture 
Stent fracture in SFA is a growing concern (14). In most of the cases, stent fracture are not 
related to restenosis. Wall stent was implanted at 8 years ago (Fig. 10A). The stent showed 
complete traverse liner separation without stent displacement. This is called type 3 stent 
fracture. But there is a stent fracture related to restenosis. In Fig. SFA 11A, there is a focal 
restenosis at SMART stent implanted site. In plain view, multiple separation of strut is seen 
(Fig. SFFA 11B). Magnified view shows, multiple stent strut were separated (Fig. SFA 11C). 
This stent fracture could be a cause of restenosis. 
7.7 Stent restenosis 
In recent years, studies have demonstrated the superiority of stents over balloon angioplasty 
as far as primary patency is concerned (15). In some center,  SFA Nitinol stent is empoloyed 
as primary use. However, stent restenosis is still the big issue for primary stenting. SFA long 
CTO originating from SFA ostium was shown in Fig. SFA 12A. Successful recanalization 
was obtained with stenting (Fig. SFA 12B). Angiogram at 6 months showed stent restenosis 
with new stenosis in profund femoral artery (Fig. SFA 12C). This restenosis is clearly seen in 
non subtracted angiogram (Fig. SFA12D). This suggest stent affecting to other vessel as the 
chronic cell proliferation. 
7.8 Summary 
SFA is the longest vessel and is difficult to visualize entire vessel. In proximal part of SFA 
should be taken by ipsilateral view. To evaluate lesion severity, lesion length is the 
important factor for endovascular approach. The precise lesion length measurement must be 
made. Stent restenosis after endovascular treatment of SFA obstructions is still the big 
concern. 
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Fig. SFA 11: Stent fracture  
A: Wall stent was implanted at 8 years ago. The stent showed complete traverse liner 
separation without stent displacement. This is called type 3 stent dissection.  
B: There is no restenosis at fractured site 
 
 
Fig. SFA 12: Stent fracture with restenosis 
A: There is a focal restenosis at SMART stent implanted site. 
B: In plain view, multiple separation of strut are seen 
C: More magnified view shows, multiple stent strut were separated 
8. Below the knee angiography 
Infrapopliteal atherosclerotic lesions are common in critical limb ischemia and to assess 
these lesions, a meticulous angiographic technique should be taken. In Below the knee 
(BTK) angiogram, 4 BTK arterial segments (tibioperoneal trunk, anterior tibial,  posterior 
tibial arteries and peroneal artery) must be separated and identified. And also, continuation  
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Fig. SFA 10: Bail out stenting post balloon angioplasty 
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B: Balloon angioplasty was performed and resulted in dissection 
C: Nitinol stenting for bail out purpose succeeded to seal the dissection 
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complete traverse liner separation without stent displacement. This is called type 3 stent 
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(Fig. SFFA 11B). Magnified view shows, multiple stent strut were separated (Fig. SFA 11C). 
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7.7 Stent restenosis 
In recent years, studies have demonstrated the superiority of stents over balloon angioplasty 
as far as primary patency is concerned (15). In some center,  SFA Nitinol stent is empoloyed 
as primary use. However, stent restenosis is still the big issue for primary stenting. SFA long 
CTO originating from SFA ostium was shown in Fig. SFA 12A. Successful recanalization 
was obtained with stenting (Fig. SFA 12B). Angiogram at 6 months showed stent restenosis 
with new stenosis in profund femoral artery (Fig. SFA 12C). This restenosis is clearly seen in 
non subtracted angiogram (Fig. SFA12D). This suggest stent affecting to other vessel as the 
chronic cell proliferation. 
7.8 Summary 
SFA is the longest vessel and is difficult to visualize entire vessel. In proximal part of SFA 
should be taken by ipsilateral view. To evaluate lesion severity, lesion length is the 
important factor for endovascular approach. The precise lesion length measurement must be 
made. Stent restenosis after endovascular treatment of SFA obstructions is still the big 
concern. 
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Fig. SFA 11: Stent fracture  
A: Wall stent was implanted at 8 years ago. The stent showed complete traverse liner 
separation without stent displacement. This is called type 3 stent dissection.  
B: There is no restenosis at fractured site 
 
 
Fig. SFA 12: Stent fracture with restenosis 
A: There is a focal restenosis at SMART stent implanted site. 
B: In plain view, multiple separation of strut are seen 
C: More magnified view shows, multiple stent strut were separated 
8. Below the knee angiography 
Infrapopliteal atherosclerotic lesions are common in critical limb ischemia and to assess 
these lesions, a meticulous angiographic technique should be taken. In Below the knee 
(BTK) angiogram, 4 BTK arterial segments (tibioperoneal trunk, anterior tibial,  posterior 
tibial arteries and peroneal artery) must be separated and identified. And also, continuation  
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Figure SFA 13: Stent restenosis 
A: SFA occlusion originating from ostium 
B: Succeful recanalization was obtained with Nitinol stenting 
C: At 6 months,  angiography showed SFA stent restenosis with a new stenosis in profund 
femoral artery.  
D: This restenosis is clearly seen in non subtracted angiogram  
from anterotibial artery to dorsal pedis and posetotibial to planter artery have to be 
delineated. BTK arteries are most complicated vessels and difficult to identify each three 
vessels. Meticulous angiographic approach should be taken to visualize three tibila arteries. 
8.1 Basic angiography for BTK 
Femoropopliteal artery angiogram must be taken to rule out inflow disease (Fig. BTK 1A). 
After confirming no inflow disease is present, BTK angiography is performed through the 
catheter located at distal popliteal artery (Fig. BTK 1B). This BTK angiogram is to show three 
tibial arteries and antero tibial artery is occluded. To locate exact lesion location, we take 4 
views. These are two right anterior oblique view (RAO) (Fig. BTK 1C, 1D)and two left 
anterior oblique view (LAO)  taken (Fig. BTK 1E, 1F). In upper RAO, proximal left 
anterotibial artery is well seen (Fig. BTK 1C). In lower RAO view, distal three tibial arteries 
are well seen (Fig. BTK 1D). In this case, distal anterotibial artery is occluded. In upper LAO, 
three tibial arteries are separated (Fig. BTK 1E). In lower LAO view, anterotibial and 
peroneal artery overrap and could not separate these two vessels (Fig. BTK 1F). 
8.2 Anatomical variation of infrapopliteal arteries 
Branching variations of the popliteal artery are not uncommon. A practical triad 
classification of the anatomical variation in the branching pattern is reported (17). Type 1 
indicates a normal level of popliteal arterial branching, including the usual pattern (Fig. BTK 
2A) and trifurcation (Fig. BTK 2B). Type 2 indicates a high division of popliteal artery 
branching. In Fig. BTK 2C, anterotibial artery arises at the knee joint. Type 3 indicates 
hypoplastic or branching with an altered distal supply, including a hypoplastic posterotibial 
(Fig. BTK 2D) and a hypoplastic antrotibial (Fig. BTK 2E) .There are more other variation, but 
we have to keep in mind variant tibial arteries are not uncommon. 
8.3 Numbers of patent tibial arteries 
After completing initial angiogram, we have to evaluate how many tibial arteries are patent. 
In normal BTK arteries, three vessels are patent (Fig. BTK 3A.) In Fig. BTK 3B, peroneal  
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Figure BTK 1: Basic below the knee angiography 
A: Ipsilateral left femoropopliteal to infrapoplital artery angiogram. This angiogram could 
rule out the inflow disease. 
B: BTK angiography shows the entire three tibial arteries.  
C: Upper right anterio oblique view.  
Proximal left anterotibial artery is well seen. But posterotibial and peroneal artery are over 
rapped. 
D: Lower right anterio oblique view. In this view, distal 3 tibial arteies are separated. 
E: Upper left anterior oblique view.  
Proximal three tibial arteries are well separated. 
F: Lower left anterior oblique view. 
Distal Posterotibial artery is well seen. 
artery is not seen and considered two vessels run off. In Fig. BTK 3C, peroneal and 
posterotibial artery are patent and means two vessel runoff., In Fig. BTK 3D, only personal 
artery is patent and shows the one vessel run off. 
8.4 Single vessel run off of peroneal artery 
In Fig. BTK 4, both cases are single vessel disease with peroneal artery patent. These 2 cases, 
one peroneal artery is patent, but have active ulcer. It means that peroneal artery is not good 
enough for supplying foot arteries.(Fig. BTK 4). Peroneal artery terminates at the ankle and 
gives collateral to planter artery (Fig. BTK 4A). In Fig. BTK 4B, peroneal artery gives the 
collateral to dorsal pedis. This means to revascularize either anterotibial or posteriotibial artery 
must be recanalaized for the successful angioplasty. 
8.5 BTK angiogram of pre and post balloon angioplasty 
Before intervening BTK vessels, target vessel have to be clearly identified. In Fig. BTK 5, 
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Figure SFA 13: Stent restenosis 
A: SFA occlusion originating from ostium 
B: Succeful recanalization was obtained with Nitinol stenting 
C: At 6 months,  angiography showed SFA stent restenosis with a new stenosis in profund 
femoral artery.  
D: This restenosis is clearly seen in non subtracted angiogram  
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three tibial arteries are separated (Fig. BTK 1E). In lower LAO view, anterotibial and 
peroneal artery overrap and could not separate these two vessels (Fig. BTK 1F). 
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2A) and trifurcation (Fig. BTK 2B). Type 2 indicates a high division of popliteal artery 
branching. In Fig. BTK 2C, anterotibial artery arises at the knee joint. Type 3 indicates 
hypoplastic or branching with an altered distal supply, including a hypoplastic posterotibial 
(Fig. BTK 2D) and a hypoplastic antrotibial (Fig. BTK 2E) .There are more other variation, but 
we have to keep in mind variant tibial arteries are not uncommon. 
8.3 Numbers of patent tibial arteries 
After completing initial angiogram, we have to evaluate how many tibial arteries are patent. 
In normal BTK arteries, three vessels are patent (Fig. BTK 3A.) In Fig. BTK 3B, peroneal  
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Figure BTK 1: Basic below the knee angiography 
A: Ipsilateral left femoropopliteal to infrapoplital artery angiogram. This angiogram could 
rule out the inflow disease. 
B: BTK angiography shows the entire three tibial arteries.  
C: Upper right anterio oblique view.  
Proximal left anterotibial artery is well seen. But posterotibial and peroneal artery are over 
rapped. 
D: Lower right anterio oblique view. In this view, distal 3 tibial arteies are separated. 
E: Upper left anterior oblique view.  
Proximal three tibial arteries are well separated. 
F: Lower left anterior oblique view. 
Distal Posterotibial artery is well seen. 
artery is not seen and considered two vessels run off. In Fig. BTK 3C, peroneal and 
posterotibial artery are patent and means two vessel runoff., In Fig. BTK 3D, only personal 
artery is patent and shows the one vessel run off. 
8.4 Single vessel run off of peroneal artery 
In Fig. BTK 4, both cases are single vessel disease with peroneal artery patent. These 2 cases, 
one peroneal artery is patent, but have active ulcer. It means that peroneal artery is not good 
enough for supplying foot arteries.(Fig. BTK 4). Peroneal artery terminates at the ankle and 
gives collateral to planter artery (Fig. BTK 4A). In Fig. BTK 4B, peroneal artery gives the 
collateral to dorsal pedis. This means to revascularize either anterotibial or posteriotibial artery 
must be recanalaized for the successful angioplasty. 
8.5 BTK angiogram of pre and post balloon angioplasty 
Before intervening BTK vessels, target vessel have to be clearly identified. In Fig. BTK 5, 
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Fig. BTK 2: Anatomical variation of tibial arteries 
A: Type 1-A 
A normal level of arterial branching and most common pattern. The first brach is antrotibial 
artery and peroneal trunk separate to peroneal and posterotibial artery. 
B: Type 1-B 
A normal level of arterial branching. The three tibial arteries show trifurcation.  
C: Type 2-A  
A high division of popliteal artery branching and antrotibial artery arises at the knee joint. 
D: Type3-A 
Hypoplastic posterotibial artery and peroneal artery is giving a distal supply. 
E: Type 3-B 
Hypoplastic anterotibial artery and peroneal artery is giving a distal supply. 
D: One vessel, peroneal arterry is patent 
 
 
Fig. BTK 3: Number of patent tibial arteries 
A: Three vessels are patent 
B: Two vessels are with occluded peroneal artery  
C: Two vessels are with occluded anterotibial artery 
A B C D
Type1-A Type1-B Type2-A Type3-A Type3-B 
A B C D E 
 




Fig. BTK 4: Single vesses runoff of peroneal artery in patients with critical limb 
A: Peroneal artery terminates at the ankle and gives collateral to planter artery 
B: Peroneal artery terminates at the ankle and gives collateral to dorsal pedis. 
In these  two cases, single vessel are patent but ulcer does not heal. Peroneal artery is not 
giving sufficient flow distal to ankle. 
 
 
Fig. BTK 5: Pre interventional BTK angiography for critical limb ischemia 
A 65 year old man with diabetes and presented with right 4th and 5th toe ulcer.  
A: Bolus chase 
Right anterotibial and posterotibial arteries were occluded and peroneal artery is patent 
B: The upper RAO view 
Three tibial arteries and right antrotibial artery was occluded at proximal portion 
C: The lower RAO view 
Right dorsal pedis was patent; D: The upper LAO view - Only peroneal artery is patent 
E: The lower LAO view - Right antrotibial artery was occluded at the ankle and dorsal pedis 
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Fig. BTK 2: Anatomical variation of tibial arteries 
A: Type 1-A 
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Right anterotibial and posterotibial arteries were occluded and peroneal artery is patent 
B: The upper RAO view 
Three tibial arteries and right antrotibial artery was occluded at proximal portion 
C: The lower RAO view 
Right dorsal pedis was patent; D: The upper LAO view - Only peroneal artery is patent 
E: The lower LAO view - Right antrotibial artery was occluded at the ankle and dorsal pedis 
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intervention angiography showed right anterotibial and posterotibial arteries were occluded 
(Fig. BTK 5A).  Two right anterior oblique view (RAO) (Fig. BTK 5B, C) and two left anterior 
oblique (LAO) (Fig. BTK 5D, E) views were taken. The upper RAO showed three tibial 
arteries and right antrotibial artery was occluded at proximal portion (Fig. BTK 5B). The 
lower RAO view showed right dorsal pedis was patent (Fig. BTK 5C). The upper LAO view 
showed only peroneal is patent t (Fig. BTK 5D). The lower LAO view revealed right 
antrotibial artery was occluded at the ankle and right planter artery is not well seen (Fig. 
BTK 5E). Based on these angiograms, right antrotibial artery occlusion was targeted. By 
using 2.5mmX10cm over the wire balloon system, occluded anteoritibial artery was 
recanalaized (Fig. BTK 6). Post angioplasty angiogram was shown in Fig. BTK 7. Post 
intervention angiography showed right anterotibial was successfully recanalaized.and (Fig. 
BTK 7A).  Two right anterior oblique view(RAO) (Fig. BTK 7B,C) and two left anterior 
oblique(LAO) (Fig. BTK 7D,E) views were taken to confirm the recanalized right antrotibial 
artery. The upper RAO showed three tibial arteries and right antrotibial artery was 
recanalized(Fig. BTK 5B). The lower RAO view showed peroneal override with anterotibial 
artery and could not separate two vessels(Fig. BTK 7C). The upper LAO view showed 
opened antrotibial artery(Fig. BTK 7D). The lower LAO view showed continuity between 






Fig. BTK 6: Balloon angioplasty to occluded anterotibial artery 
Based on these angiograms, right antrotibial artery occlusion was targeted.  
A: By using 2.5mmX10cm over the wire balloon system, the occluded proximal anteoritibila 
artery was recanalaized 
B: The wire advanced to dorsal pedis and succeeded to recanalization 
 




Fig. BTK 7: Post interventional BTK angiography for critical limb ischemia 
A: Bolus chase 
Right anterotibial artery was recanalized and straight line to dorsal pedis artery was 
established. 
B: The upper RAO view 
Right anterotibial artery was patent but midportion of anterotibial artery overrides with 
peroneal artery. 
C: The lower RAO view 
The continutity between anterotibial and dorsal pedis artery is confirmed. 
D: The upper LAO view 
Recanalized right anterotibial artey is well seen 
E: The lower LAO view 
Right anterotibial to dorsal pedis artey is shown.  
8.6 Foot artery angiogram 
In dealing with critical limb ischemia, precise knowledge of foot artery anatomy is needed. 
However, severe ischemic limb, foot artery angiogram is hard to obtain by the patient’s leg 
movement. To minimize this problem, injection of small amount of contrast with inflow 
revascularization is mandatory. In Fig. BTK 8, typical ischemic foot artery is shown. 
Basically two views are good enough. One is antero-posterior view and the other is lateral 
view. In lateral view, complete occlusion of poterotibial artery is well seen and dorsal pedis 
show the short occlusion (Fig. BTK 8A). In anterior view, plantaris medial and lateralis are 
well separated (Fig. BTK 8B). And in anterior view, dorsalis pedis is well seen and suited for 
Retrograde dorsal pedis puncture (Fig. BTK 8B). 
8.7 Summary 
The effectiveness of BTK angioplasty for revascularization is well known (18). However, 
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E: The lower LAO view 
Right anterotibial to dorsal pedis artey is shown.  
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8.7 Summary 
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Fig. BTK 8: Foot artery angiogram: 
A: Lateral view of left foot 
Complete occlusion of poterotibial artery is well seen and dorsal pedis show the short 
occlusion 
B: Anteroposterior view 
Plantaris medial and lateralis artery are well separated. In anterior view, occluded dorsalis 
pedis artery is well seen 
sized vessels with complicated anatomy. The amount of dye for injection is limited by 
patient’s leg movement. However, angiogram is the only way to get the correct information 
BTK. The meticulous approach for BTK angiography should be taken.  
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Arterial Angioplasty in Congential Heart Disease 
Thomas J. Forbes, Srinath Gowda and Daniel R. Turner   
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1. Introduction 
This chapter will describe the historical background, technical issues, outcomes, and future 
considerations of angioplasty to treat various congenital heart lesions in both the systemic 
and pulmonary arteries. Intravascular stent placement will be mentioned briefly, but the 
primary focus will be balloon angioplasty of arterial stenosis. Peripheral stenoses secondary 
to acquired arterial lesions will not be discussed. 
2. Coarctation of the aorta  
2.1 Historical background 
Coarctation of the aorta is a condition where the aorta is narrowed in the area where the 
ductus arteriosus inserts (Figure 1). Coarctation represents 5-10% of all congenital heart 
disease. Coarctation is more common in Caucasian than Asian individuals and is less 
common among Native Americans. Males are affected 1.6-1.8 times as often as females. The 
overall incidence of coarctation in the United States is 64 per 100,000. The presentation can 
range from shock in infancy after closure of the ductus arteriosus to systemic hypertension 
in early childhood to adulthood.  
The three treatment modalities for coarctation of the aorta are surgery, stent placement, and 
balloon angioplasty (BA). Candidates for BA will be discussed in detail below. In native 
coarctation of the aorta, the anatomy most suitable for BA is discrete, rather than diffuse, 
stenosis (Figures 2a and 2b). This is not necessarily the case in recurrent coarctation, where 
discrete or diffuse lesions secondary to surgical scarring are each amenable to BA. 1-3 
2.2 Neonates/infants 
Balloon angioplasty of coarctation of the aorta in neonates/infants can typically be 
performed with low-profile balloon angioplasty catheters due to the smaller final inflation 
diameter required in this age group. The most common diameter used in this age group is 6-
8 mm, although as the patient approaches 12 months of age, the diameter shifts to the 8-10 
mm range. The most commonly used balloons are the TyShak II balloons (NuMed Corp, 
Hopkington, New York). Up to 8 mm diameter balloons take an 0.021” wire, can be 
introduced through 4-Fr sheaths, and have a rated burst pressure (RBP) of at least 4 
atmospheres (ATMs). The 9-12 mm diameter balloons take an 0.025” (9-10 mm) or 0.035” (12 
mm) wire, can be introduced through 5-Fr sheaths, and have a RBP of 3.5 ATMs. TyShak 
Mini balloons (NuMed), with diameters from 4-10 mm, are even lower profile, using 3-Fr  
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Fig. 1. Coarctation 
 
 
Fig. 2. a-b. 
sheaths up to 8 mm diameter and 4-Fr sheaths for the 9-10 mm sizes. They take an 0.014” 
wire and can reach RBP of at least 3.5 ATMs. Most coarctations require 3 ATMs to obtain 
adequate dilation of the narrowed segment.  
On occasion, high-profile, non-compliant balloon angioplasty catheters may be required to 
adequately dilate the coarctation segment. There are numerous balloon angioplasty 
catheters available: PowerFlex series (4-12 mm diameter, Cordis Corp, Warren, New Jersey), 
Z-Med II balloons (4-30 mm diameter, NuMed), and Cook ATB (4-10 mm diameter, Cook 
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Corp, Bloomington, IN). Each are similar, although certain sizes of PowerFlex and ATB 
balloons can be advanced through sheaths that are 1-Fr size smaller than Z-Med II. Rarely, 
cutting balloons (CB) may be required for coarctation angioplasty.4 More specific 
information on CB will be given in the pulmonary angioplasty section. 
The standard approach for native or recurrent coarctation of the aorta is retrograde via 
femoral- or umbilical-arterial access. This approach offers the most direct route to treat the 
coarctation site. In very small infants (< 1.5 kg), alternative approaches have been reported 
(Figures 3a, 3b, and 3c).5 Angiograms of the coarctation and transverse aortic arch are 
performed prior to balloon angioplasty. In over 20% of patients, most commonly in cases of 
symptomatic neonatal/infant coarctation of the aorta, transverse aortic arch hypoplasia may 
be present. The definition of transverse aortic arch hypoplasia is a transverse arch-to-
descending aortic ratio of < 0.60.6-8  Measurements at the transverse aortic arch and 
descending aorta at the level of the diaphragm are made. The smaller of these diameters 
determines the size of the balloon catheter used to perform coarctation angioplasty. It is 
particularly important that the balloon be de-aired prior to inflation, as balloon rupture may 
cause air emboli into the brachiocephalic vessels. On initial inflation, one tries not to exceed 
a balloon-to-coarctation ratio of > 4:1.7 Pre- and immediately post-pressure measurements 
are obtained. After the angioplasty, it is extremely important to obtain standard and 
orthogonal angiographic views of the coarctation area to exclude a small dissection or 
aneurysm. If high pressure or cutting balloon catheters are required for adequate dilation of 
the coarctation segment, a covered stent should be available in the catheterization lab in case 
one encounters aneurysm formation, an acute dissection, or vessel tear.  
 
 
Courtesy of Prada F, et al. Rev Esp Cardiol. 2010 Jun;63(6):741-3. 
Fig. 3. a-c. Balloon angioplasty of a critical coarcation in a 1200 gram premature infant per 
the left carotid artery via a 3 Fr sheath using the Seldinger technique. A 4 mm TyShak Mini 
balloon was used with the coarctation segment increasing from 1.5 to 3.2 mm and a decrease 
in the systolic gradient from 35 to 7 mmHg. The infant developed recoarctation 2 months 
later and at 2200 grams underwent repeat balloon angioplasty from the femoral arterial 
system. At 6 months out from the procedure (5600 grams) the infant continues to do well 
with no evidence of recoarctation. 
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one encounters aneurysm formation, an acute dissection, or vessel tear.  
 
 
Courtesy of Prada F, et al. Rev Esp Cardiol. 2010 Jun;63(6):741-3. 
Fig. 3. a-c. Balloon angioplasty of a critical coarcation in a 1200 gram premature infant per 
the left carotid artery via a 3 Fr sheath using the Seldinger technique. A 4 mm TyShak Mini 
balloon was used with the coarctation segment increasing from 1.5 to 3.2 mm and a decrease 
in the systolic gradient from 35 to 7 mmHg. The infant developed recoarctation 2 months 
later and at 2200 grams underwent repeat balloon angioplasty from the femoral arterial 
system. At 6 months out from the procedure (5600 grams) the infant continues to do well 
with no evidence of recoarctation. 
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Infantile coarctation of the aorta typically occurs in conjunction with severe heart failure or 
shock. In this setting, coarctation is frequently associated with other congenital heart lesions 
(bicuspid aortic valve in 60-70%, ventricular septal defect in 40%, and other left-sided 
lesions, i.e. mitral valve stenosis, subaortic valve stenosis, and hypoplastic left ventricle 3% 
of the time). Performance of coarctation angioplasty is not recommended in patients with 
associated congenital lesions requiring surgery. The predominant treatment for isolated 
native coarctation of the aorta presenting in infancy is surgical repair with extended end-to-
end anastomoses. Although many believe that surgical repair is the standard of care, some 
have advocated that BA in high-risk patients is a reasonable initial procedure to improve 
their surgical candidacy.9 The overall outcome of BA is poor in infants presenting in heart 
failure or shock. Liang et al. performed a recent study where they evaluated 18 infants with 
native coarctation of the aorta and congestive heart failure who underwent balloon 
angioplasty. The mean age was just less than three months and the mean body weight was 4 
kg. Congestive heart failure symptoms improved markedly in all patients immediately after 
BA. The incidence of re-coarctation was high in infants, requiring surgery if the systolic 
pressure gradient > 10 mmHg from ascending to descending aorta or if the coarctation 
diameter measured < 3 mm. The recurrent coarctation rate was 44% (8/18 patients) and the 
conclusion was that balloon angioplasty, in this setting, was ineffective and not 
recommended as a primary treatment alternative.9  
In another recent study by Rau, et al., 51 infants less than 3 months of age who presented 
with heart failure underwent balloon coarctation angioplasty from the umbilical artery 
(16/51), femoral artery (26/51) and femoral venous antegrade across the inter-atrial 
communication (9/51). Findings included acute reduction in the peak gradient across the 
coarctation segment, increase in the diameter of the coarctation segment, and improved 
symptomatology following BA. Effective palliation was achieved in 47/51 infants (92%). At 
intermediate follow-up, 22/51 (43%) developed re-coarctation withn three months after 
balloon angioplasty, requiring either repeat BA (14/22) or surgical (8/22) intervention. 
Using avoidance of surgery for four weeks as the definition of success, the authors 
concluded that BA is an excellent alternative to surgical intervention for the management of 
native coarctation in the neonatal period. With > 50% of patients requiring reintervention 
within 10 months of initial BA, we believe that surgical treatment of this condition remains 
the standard of care in this subgroup of patients. 10 
2.4 Challenges for the future 
The development of bioabsorable stents could potentially change this treatment paradigm. 
There are two current challenges with bioabsorable stent technology: (1) to reliably make a 
stent that can reach 6-7 mm diameter with adequate radial strength to overcome the 
coarctation; and (2) to be able to deliver the stent though a low profile sheath (4-5-Fr if 
performed retrograde and up to 7-Fr if performed antegrade from the venous route). There 
are currently two bioabsorbable stents being evaluated with the potential to enter clinical 
use in Europe within the next several years. 
3. Aortic coarctation in children and adults 
3.1 Historical overview 
Balloon angioplasty for the treatment of native or recurrent coarctation of the aorta has been 
performed since the mid 1980s.11 There is excellent data to support BA to treat recurrent 
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coarctation of the aorta in this age group. Although BA is considered the treatment of choice 
for this lesion in children and adults,12 controversy surrounds the use of BA for native 
coarctation of the aorta in these patients presenting with hypertension. 
3.2 Technique 
BA is performed from the retrograde femoral arterial route in the majority of children and 
adults undergoing BA for either recurrent or native coarctation. Recently, there have been 
reports of using radial access for recognition and treatment of potential complications, some 
advocating for BA though we, and others, feel radial access is more appropriate for stent 
treatment of coarctation of the aorta. 13 After a complete right and left heart catheterization 
is performed, the coarctation segment is approached retrograde from the descending to 
ascending aorta. It is important to rule out any potential left-sided lesions, including mitral 
valve stenosis, subaortic valve stenosis, or aortic valve stenosis, as these lesions can be also 
associated with coarctation of the aorta. Furthermore, significant diastolic dysfunction and 
increased diastolic pressures can be encountered in this patient group. For severe or nearly 
atretic coarctation of the aorta, crossing the narrowed segment retrograde may be quite 
difficult. Under those circumstances, transseptal technique is used to enter the left heart 
antegrade and the coarctation can then be crossed more easily from the ascending to 
descending aorta. Typically, either an angled 0.035” glide wire (Cook Corp, Bloomington, 
Indiana) or Wholey wire (Covidian Inc. Mansfield, MA) are used. The wire is then snared 
retrograde from the distal descending aorta and an arterial-venous loop is created, then 
allowing retrograde delivery of the balloon to the coarctation segment.  
 
   
Fig. 4. a-b. Comparison between the Atlas and Z Med II balloon catheters. The tapered 
shoulder on the Atlas balloon significantly increases the actual balloon length as well as 
inflation/deflation time in comparison to the shorter Z Med II balloon. 
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Higher RBP for coarctation BA is more important as patients age. Although lower profile 
(TyShak II) balloons may be used, less compliant, higher profile balloon angioplasty 
catheters are usually required. PowerFlex, Maxi-Plus (Cordis corp, Warren, NJ), Z-Med II, 
Mullins (NuMed corp., Hopkington, NY), and Atlas (Bard Medical, Tempe, AZ) balloon 
angioplasty catheters have all been used. The Atlas balloon catheter has enhanced low 
profile (2-3 Fr sizes less than the others) and high RBP. The tapered shoulders of the Atlas 
balloon makes the balloon quite long and longer inflation/deflation times are required, 
making it more difficult to adequately position this balloon catheter across the coarctation 
segment (Figures 4a-b). 
As one exceeds 5-6 atmospheres of pressure to achieve successful dilation of the coarctation 
segment, there is an increased likelihood of creating an acute dissection, aneurysm, or in 
rare cases, rupture of the aorta.7 It has been recommended that one not exceed four times the 
narrowest coarctation segment during dilation in the initial setting. Patients with extremely 
tight coarctation segments therefore require a staged approach. 
3.3 Outcomes 
Balloon angioplasty of native coarctation of the aorta is part of the treatment paradigm in 
children and adults. In the Congenital Cardiovascular Interventional Study Consortium 
(CCISC) registry comparing surgical vs. stent vs. balloon angioplasty treatment of native 
coarctation of the aorta in children and adults, BA appeared to have an increased risk  
of aneurysm formation and dissection at short-term and intermediate follow-up (Tables 1 
and 2) (Journal American College of Cardiology, in press). The overall hemodynamic 
outcome related to blood pressure management and upper to lower extremity blood 
pressure gradient appear to be equal between the three groups at short-term and 
intermediate follow-up. In the subgroup of patients undergoing balloon angioplasty, the 
incidence of aneurysm formation was as high as 43% at intermediate follow-up, some 
patients requiring placement of a covered stent (Figures 5a-b). Cowley et al., in comparing 
surgery with balloon angioplasty for native coarctation of the aorta, showed that aneurysm 
formation and the need for re-intervention was significantly higher in the balloon 
angioplasty group compared to the surgical group.14 Hassan, et.al., looked at balloon 
angioplasty in the older adolescent and young adult populations only, age range from 14-54 
years. In this age group, the aneurysm rate was much lower (7%) at intermediate follow-
up.15, 16 The difference between these studies may be related to the age group of patients 
treated with balloon angioplasty. In the Forbes study, the mean age was 6.8 years vs. 22 
years in Hassan’s study. Perhaps older patients are more likely to have successful outcomes 
and less likely to have aneurysm formation following BA.  
The most severe complication, aortic rupture or large dissection, is rare, but occurs with 
increased incidence in older patients. As expected, it is the non compliant, adult aorta where 
this is more likely to occur. Aortic rupture or large aneurysm formation does not appear to 
be related to exceeding the balloon:coarctation ratios of 4:1, but may be related to exceeding 
6 ATMs during initial balloon inflation. In one case, a 43 yo lady with moderate 
hypertension and coarctation of the aorta presented for transcatheter treatment of the 
coarctation segment. BA was unsuccessful in relieving the gradient. Stent placement was 
performed using a high pressure balloon angioplasty catheter. At the end of the procedure, 
a small amount of contrast was observed outside of the stent posteriorly. CT scan revealed 
near complete transection of the aorta. One month and one year follow-up CT imaging 
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noted complete resolution of the peri-aortic hematoma with no evidence of dissection or 
aneurysm formation (Figures 6a-d). 
 
Outcomes Surgery (n = 26) 
Balloon 
(n = 28) 
Stent 
(n = 97) 
p-value 
(2-sided) 
Any Complications1 23.1% 32.1% 8.3% 0.003* 
Aortic Wall Injury (%) 11.5% 21.4% 3.1% 0.004* 
   Dissection / Intimal Tear (%) 0.0% 7.1% 0.0% 0.062 
   Aneurysm (%)  11.5% 14.3% 3.1% 0.040* 
Coarct / Dao ratio (mean) 0.91 0.73 0.82 0.003* 
Coarct / Dao  0.6 87% 79% 90% 0.247 
Any Re-obstruction 19.2% 32.1% 15.4% 0.057 
   Mild2 7.7% 17.9% 11.3%  
   Moderate 7.7% 3.6% 4.1%  
   Severe 3.9% 10.7% 0%  
1Defined as any moderate to severe reobstruction, aortic wall injury (aneurysm, dissection, intimal tear) 
or stent fracture.  
2Mild reobstruction was not considered as a complication in our analysis.  
* P- value < 0.05 




(n = 16) 
Balloon 
(n = 16) 
Stent 
(n = 56) 
p-value 
(2-sided) 
Any Complications1 25.0% 43.8% 12.5% 0.020* 
Aortic Wall Injury (%) 12.5% 43.8% 7.1% 0.003* 
   Dissection / Intimal Tear (%) 0.0% 6.3% 1.8% 0.598 
   Aneurysm (%)  12.5% 43.8% 5.4% <0.001 
Coarct / Dao ratio (mean) 0.98 0.79 0.80 0.011* 
Coarct / Dao  0.6 88% 93% 89% 1.000 
Any Re-obstruction 18.8% 18.8% 14.3% 0.923 
   Mild2 6.3% 18.8% 12.5%  
   Moderate 6.3% 0% 1.8%  
   Severe 6.3% 0% 0%  
1Defined as any moderate to severe reobstruction, aortic wall injury (aneurysm, dissection, intimal tear) 
or stent fracture.  
2Mild reobstruction was not considered as a complication in our analysis.  
* P- value < 0.05 
Table 2. Intermediate Follow-up Outcomes by Integrated Imaging 
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Fig. 6. d. 
Re-obstruction, as defined as an upper to lower blood pressure gradient > 20 mmHg or 
narrowed segment > 50% of the native vessel diameter, appears to be less common as the 
age at the time of initial treatment increases. Re-obstruction frequency ranges from 3-20% in 
older children/adults undergoing primary BA of native coarctation compared to the nearly 
50% re-obstruction rate seen in infant balloon angioplasty of their native coarctation. 9, 10, 15 
3.4 Challenges for the future 
Stent treatment, particularly in older children and adults, appears to be the treatment of 
choice in treatment of native and recurrent coarctation of the aorta.7, 8, 13, 17 Permeating 
balloons, where a drug is injected into the vessel wall during angioplasty to prevent the 
development of re-stenosis, have not been successful for adequate drug delivery in animal 
studies. The primary challenge involves unintentional delivery of the drug directly into the 
blood stream, and not into the vessel wall. Placement of markers 5 mm apart, marking the 
permeating holes within the balloon catheter may assist us in delivering the treatment drug 
directly into the vessel wall, though this remains to be seen. The length of time for inflation 
required to deliver the medication (1-3 minutes) would require adequate collateralization 
around the coactation lesion to decrease the likelihood of encountering lower 
Peri-aortic 
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extremity/bowel ischemia. The current medications that may have a role in this are similar 
to the current medications being placed on drug eluting stents. These can be broken down 
into cytotoxic/cytostatic drugs, which have recently been undergoing head-to-head trials in 
applications to coronary stenting 18, 19 20 or “pro-healing” drugs such as endogenous growth 
factors or endothelial progenotor cells.21 What role, if any, in this approach to coarctation of 
the aorta, remains to be seen.  
4. Pulmonary artery stenosis 
4.1 Historical background 
Balloon angioplasty, first described for use in pulmonary valve stenosis in 1983,22 has 
become the treatment of choice for balloon angioplasty of branch pulmonary artery stenosis 
in most pediatric cardiology centers. 23, 24 Surgical repair of branch pulmonary artery 
stenosis has been sub-optimal, associated with increased morbidity, especially in young 
infants and children. 
4.2 Technique 
As with any interventional procedure, the first step in evaluating a pulmonary artery for BA 
is to understand the anatomy and pathophysiology of the stenotic lesion to be addressed. 
Generally, as in coarctation of the aorta, discrete lesions tend to be more amenable to BA 
compared to long segmental lesions. In Figures 7a-c, a patient with Tetralogy of Fallot with 
pulmonary valve atresia has multiple discrete and long segment stenosis of the right upper 
lobe segment. BA is performed both in the distal discrete stenosis and the more proximal 
long segment stenosis. Follow up imaging noted resolution of the distal discrete stenosis 
with persistence of the proximal stenosis, which required stent placement. In another patient 
with RPA stenosis following the arterial switch procedure (Figure 8), MRI imaging shows 
the RPA stenosis to be secondary to posterior compression from the aorta. Therefore stent 
placement, not BA, was necessary to treat this mechanical RPA stenosis.  
Performance of branch pulmonary artery BA is relatively straightforward and can be 
through a short sheath. The most difficult part of the procedure is usually crossing the 
stenotic segment. Accurate angiographic imaging is essential. For proximal stenosis (prior to 
the takeoff of the upper lobe branch), the lesion is crossed with either a 0.025 or 0.035” wire 
where, depending on patient size, a 4-5 Fr pigtail or multipurpose catheter is advanced over 
the wire into the stenosed pulmonary artery. Hand or power angiography is performed. For 
distal branch stenosis, the stenotic lesion is usually crossed with a glide wire and then a 4-Fr 
JB-1 or similar glide catheter (Cook Corp, Bloomington, IN) is advanced over the wire distal 
to the lesion. Hand injections can be performed through the catheter with the wire 
remaining in place. BA is usually carried out over that same wire. If multiple lobar segments 
are involved, the BA catheter is pulled back into the proximal pulmonary arterial segment 
and the soft tipped 0.018” wire is used to cross other stenoses. Stent treatment of multiple 
branch PA stenosis is usually not recommended, as many of the affected branch vessels 
would be “jailed off” by the stent (Figure 9a-b). 
The balloons typically required for branch pulmonary artery BA are the higher-pressure, 
non-compliant balloon catheters. Typically, the more distal or peripheral the stenosis, the 
greater the need for higher atmosphere balloons or cutting balloons (or both) to achieve 
adequate BA of the stenotic segment.  
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branch PA stenosis is usually not recommended, as many of the affected branch vessels 
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adequate BA of the stenotic segment.  
Angioplasty, Various Techniques and Challenges in  










Fig. 7. a-c. Patient with Pulmonary Atresia and Ventricular Septal Defect with multiple 
distal stenosis of the RPA segment. BA is performed up to 19 ATMs with a 4 mm balloon 
angioplasty catheter. Left lower panel notes resolution of the distal discrete stenosis, though 
persistence of the proximal stenosis.  
The cutting balloon (CB) is a dilation balloon made of noncompliant modified polyethylene 
terephthalate with available balloon diameters from 2-8 mm and lengths 10, 15, and 20 mm 
(Boston Scientific Corp., Natick, Massachusetts, Figure 10 a-b). The incremental increase in 
balloon size is 0.25 mm from 2-4 mm and 1 mm from 5-8 mm. Depending on the balloon 
diameter, 3 or 4 microsurgical blades are attached every 90 or 120 degrees, each blade with a 
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working height of 0.11-0.18 mm. Prior to dilation, the folds of the balloon cover the 
microsurgical blades and following dilation, the blades wrap into the folds of the balloon with 
deflation. Use of the CB requires a long sheath, 4-Fr for a 4 mm CB, 6-Fr for a 5 mm CB, and 7-
Fr for a 6-8 mm CB. Wires are 0.014” up to 4 mm diameter and 0.018” from 5-8 mm diameter. 
These balloons reach full inflation at 6 ATMs with burst pressure at 10 ATMs. Aggressive 
balloon angioplasty of the vessel (up to 22 ATM pressure) with a standard balloon angioplasty 
catheter is usually performed prior to performing CB. (Figure 11a-d). The CB is usually dilated 
1-2 mm larger than the narrowest segment of the stenosis. Following this, standard BA is 
performed up to the native vessel size. The balloons may undergo repeat dilation, but it is 
recommended that no more than 10 inflation/deflation cycles be used for one balloon catheter. 
Rapid inflation and deflation of CB should not be performed; rather slowly inflating and 
deflating these balloons over a one minute period of time is recommended. Finally, exceeding 
the burst pressure of these balloons should never be undertaken. Balloon rupture, which 
typically is longitudinal, prevents the proper folding of the balloon and subsequent coverage 
of the microblades, thereby making it more likely to strip a blade off the balloon catheter 
during removal of the CB. CB angioplasty is performed via either long flexor sheaths (Cook 




Patients with multiple bilateral peripheral pulmonary artery stenoses can suffer from re-
perfusion injury following dilation of multiple affected lung segments. This situation can be 
life threatening in patients who are already compromised with severe elevation of the right 
ventricular pressure. Multiple techniques have been addressed in an attempt to avoid this 
circumstance. One is to dilate one segment or pulmonary arterial side with no treatment of 
the contralateral side at the same cath procedure.  Another is selectively ventilating the 
contralateral lung segment during the BA procedure, thereby decreasing blood flow to the 
treated lung and theoretically decreasing the likelihood of encountering re-perfusion injury 
of those involved segments. 25 
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Courtesy Allison Cabalka, Mayo Clinic, Rochester, MN 
Fig. 9. a-b. Multiple right and left pulmonary artery stenosis of the distal branches. Patient 
has systemic right sided pressures and is planning on undergoing multiple balloon 
angioplasty dilations. One can see discrete as well as diffuse stenosis of the distal branch 
vessels.  
 




Fig. 10. a-b. 
4.3 Outcomes 
The performance of pulmonary balloon valvuloplasty to treat pulmonary valve stenosis has 
been an extremely effective procedure. Unfortunately, balloon dilation of stenoses of the 
pulmonary arteries distal to the pulmonary valve has not been as satisfactory.23, 26 Although 
the stenotic vessels often can be dilated with angioplasty balloons, even to three or four 
times the original size, the stenoses frequently recur immediately after balloon deflation. 
The recurrence of obstruction following dilation is thought to be due to the natural elastic 
recoil of the tissue in native pulmonary arterial stenosis or to resilience and resistance of scar 
tissue in postoperative cases. Rothman, et al. reported the only large series of balloon 
pulmonary artery dilations in 135 patients. 27 They noted that previous reports of surgery for 
the direct relief of pulmonary artery lesions was difficult and often ineffective.28 The mean 
diameter of the lesion increased from 3.8 +/- 1.7 to 5.5 +/- 2.1 mm with dilation (p = 0.001). 
The overall success rate was 58% (127/218 dilations), assessed by the following criteria: an 
increase greater than or equal to 50% of predilation diameter, an increase greater than 20% 
in flow to the affected lung, or a decrease greater than 20% in systolic right ventricular to 
aortic pressure ratio. A pulmonary artery aneurysm occurred in 5% of the pulmonary 
arteries dilated. Two patients died at angioplasty. Restenosis occurred in 16% of the 
restudied patients with initial successful dilation. They concluded that balloon angioplasty 
was an established, highly useful procedure in the management of branch pulmonary artery 
stenosis. 27 
The use of cutting balloons (CB) has increased the success rate of pulmonary artery BA from 
50-60% to 80%, irrespective of whether CB were used de novo or following failure of 
standard balloon angioplasty.26 One area where CB have been particularly effective is in 
severe, multiple discrete stenosis of the distal pulmonary arterial branches (Figure 9a-b). 29, 30  
Angioplasty, Various Techniques and Challenges in  






Courtesy Allison Cabalka, Mayo Clinic, Rochester, MN 
Fig. 9. a-b. Multiple right and left pulmonary artery stenosis of the distal branches. Patient 
has systemic right sided pressures and is planning on undergoing multiple balloon 
angioplasty dilations. One can see discrete as well as diffuse stenosis of the distal branch 
vessels.  
 




Fig. 10. a-b. 
4.3 Outcomes 
The performance of pulmonary balloon valvuloplasty to treat pulmonary valve stenosis has 
been an extremely effective procedure. Unfortunately, balloon dilation of stenoses of the 
pulmonary arteries distal to the pulmonary valve has not been as satisfactory.23, 26 Although 
the stenotic vessels often can be dilated with angioplasty balloons, even to three or four 
times the original size, the stenoses frequently recur immediately after balloon deflation. 
The recurrence of obstruction following dilation is thought to be due to the natural elastic 
recoil of the tissue in native pulmonary arterial stenosis or to resilience and resistance of scar 
tissue in postoperative cases. Rothman, et al. reported the only large series of balloon 
pulmonary artery dilations in 135 patients. 27 They noted that previous reports of surgery for 
the direct relief of pulmonary artery lesions was difficult and often ineffective.28 The mean 
diameter of the lesion increased from 3.8 +/- 1.7 to 5.5 +/- 2.1 mm with dilation (p = 0.001). 
The overall success rate was 58% (127/218 dilations), assessed by the following criteria: an 
increase greater than or equal to 50% of predilation diameter, an increase greater than 20% 
in flow to the affected lung, or a decrease greater than 20% in systolic right ventricular to 
aortic pressure ratio. A pulmonary artery aneurysm occurred in 5% of the pulmonary 
arteries dilated. Two patients died at angioplasty. Restenosis occurred in 16% of the 
restudied patients with initial successful dilation. They concluded that balloon angioplasty 
was an established, highly useful procedure in the management of branch pulmonary artery 
stenosis. 27 
The use of cutting balloons (CB) has increased the success rate of pulmonary artery BA from 
50-60% to 80%, irrespective of whether CB were used de novo or following failure of 
standard balloon angioplasty.26 One area where CB have been particularly effective is in 
severe, multiple discrete stenosis of the distal pulmonary arterial branches (Figure 9a-b). 29, 30  
Angioplasty, Various Techniques and Challenges in  





   
 
 
   
Courtesy Jaqueline Kreutzer, Children’s Hospital of Pittsburgh, Pittsburgh, PA 
Fig. 11. a-d. Cutting balloon angioplasty of distal branch left lower lobe pulmonary artery 
stenosis. Upper left panel notes the stenotic segments of the left lower lobe branches. Right 
upper panel notes failed aggressive balloon angioplasty at 18 ATMs. Left lower panel, 
successful cutting balloon dilation of the stenotic segment. Right lower panel, resolution of 
the left lower lobe stenosis following cutting balloon angioplasty.  
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This is a rare condition that can be idiopathic or associated with William’s/Alagille 
syndrome. 29, 31 Primary stenting is generally not recommended for these lesions due to the 
likelihood of jailing off adjacent pulmonary arterial branches. Balloon angioplasty of these 
lesions almost always requires high-pressure balloons and in many cases is resistant to 
standard BA. 23 Aneurysm, dissection, and vessel perforation have been associated with BA 
of pulmonary artery stenosis, with one patient having a late rupture of an aneurysm with 
subsequent death. 32 These procedures can be tedious but the outcomes, over time, can be 
dramatic. 
Surgical repair of pulmonary arterial stenosis has also been ineffective and carries 
considerably greater morbidity and probably greater mortality. 28 Surgical problems with 
these lesions relate to the location of the narrowings, often in the distal branch pulmonary 
arteries, an area difficult to reach from a standard midline sternotomy or lateral 
thoracotomy. Recurrent stenosis has been reported in up to 31% of patients who had 
surgical repair of the right pulmonary artery after Waterston shunt placement.28 
4.4 Challenges for the future 
Although BA has its limitations, it remains a very important treatment modality for 
pulmonary and systemic arterial stenosis. CBs have improved the treatment of resistant 
lesions. The improvement of balloon technology has significantly decreased the number of 
vascular complications over the past 15 years. Drug delivery through permeable balloons 
(see section under Challenges for the Future in Coarctation) has significant potential 
application for the treatment of stenosis in the pulmonary arterial system. The tolerance of 
longer inflation times and smaller vessel size observed in the pulmonary arterial system 
makes this a technically easier undertaking in comparison to attempting drug delivery in 
the systemic arterial system.  
5. Conclusion 
Balloon angioplasty has proven to be successful in the treatment of pulmonary artery 
stenosis and coactation of the aorta. Significant challenges remain, primarily in the 
prevention of recurrent stenosis. The development of biodegradable stents and permeable 
balloon catheters will undoubtedly improve outcomes for both pulmonary artery and aortic 
coarctation angioplasty, most importantly in the area of restenoses. 
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1. Introduction 
Carotid intervention for the amelioration of symptoms due to carotid stenosis has been a 
controversial therapeutic concept for much of its history. Operative carotid surgery 
(carotid endarterectomy) underwent considerable turmoil and challenge during the late 
20th century, eventually becoming a generally accepted approach in the management of 
symptomatic critical carotid artery stenosis. A similar circumstance currently confronts 
carotid angioplasty. Carotid endarterectomy (CEA) now represents the clinical standard 
against which any carotid intervention is compared and carotid angioplasty must 
“measure up” to this reference procedure. However, it must be recognized that the time 
line for acceptance of CEA measured approximately 40 years suggesting that the clinical 
community must exercise patience in the evaluation of carotid angioplasty which enjoys a 
relatively short history. Conversely, there is considerable vested interest by several 
specialties for carotid angioplasty to be accepted (cardiology, radiology) or rejected 
(vascular surgery) indicating the need for critical analysis of this procedure’s efficacy. 
This process of procedure assessment remains a difficult task in view of the constantly 
changing technological advances that surround this field. This chapter focuses on the key 
elements of technique and clinical experience which represent the status of carotid 
angioplasty today. 
2. History 
The association of carotid artery blood flow to the brain as a vital element to  
sustain neurologic function dates back to Hippocrates (Figure). As a corollary, it has 
become accepted that atherosclerotic disease of the carotid artery is associated with 
stroke. This concept was first described by Ramsay Hunt in 1914 and subsequently 
popularized as one of the most significant risk factors for developing stroke. It wasn’t 
until the 1950’s, when durable reconstructive carotid surgery was described and further 
refined and popularized by Debakey, Eastcott, Rob, Thompson, Moore, Baker and  
Wylie, that the field of carotid intervention was popularized. Some of the landmark  
large randomized controlled trials like North American Symptomatic Carotid 
Endarterectomy (NASCET)1, Asymptomatic Carotid Atherosclerosis Study (ACAS)2 and 
European Carotid Surgery Trial (ECST)3 showed statistically significant reductions in 
stroke in the patients undergoing carotid endarterectomy versus medical treatment alone. 
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Currently, there are approximately 165,000 carotid endarterectomy (CEA) procedures 
performed across United States annually and this procedure is considered the “gold 




Adapted From Hippocrates to Palmaz-Schatz, the history of carotid surgery. 4 
Robicsek F, Roush TS, Cook JW, Reames MK. Eur J Vasc Endovasc Surg. 2004 Apr;27(4): 
389-97.  
Moniz described carotid and cerebral angiography in 1927 and thereafter, further 
improvements in the extracranial carotid imaging facilitated more patients being 
diagnosed with occlusive carotid diseases and hence treatment advancement. Debakey 
and his coworkers described intraluminal angioplasty of the internal carotid artery in 
1968 for fibromuscular dysplasia.5 Percutaneous transluminal angioplasty of carotid 
artery was described in 1977 by Mathias and subsequently Diethrich  reported the first 
large series of carotid angioplasty and stenting in 1995, although the risk of neurological 
complication was as high as 10.7% in his report. Subsequently, multiple technical 
advances have taken place in percutaneous carotid artery interventions including stent 
augmentation of carotid angioplasty, routine use of cerebral embolic protection and 
improved patient selection.  
Carotid angioplasty and stenting (CAS) provides a few advantages over traditional  
CEA including avoidance of a neck incision, general anesthesia and freedom from cranial 






3. Technical aspects of carotid angioplasty and stenting 
Key for successful endoluminal intervention is patient evaluation and proper patient 
selection, choice of optimum vascular access site, a thorough evaluation of the access route, 
any anatomic or morphologic anomalies, appropriate selection of devices and accurate 
sizing of the target lesion and vessels.  
Pre-procedural assessment of carotid artery disease is obtained by duplex ultrasound (DU). 
DU allows an assessment of the degrees of stenosis and extent of calcification. Highly 
calcified lesions may be more embologenic or unyielding to balloon angioplasty resulting in 
a suboptimal dilatation. Further information on the target lesion may be obtained by 
magnetic resonance (MR) or computed tomographic (CT) arteriography. These two imaging 
modalities are useful confirmatory studies following duplex imaging and offer an 
assessment of unsuspected occlusive disease outside the DU imaging window. Furthermore, 
these non-invasive means evaluate access site, aortic arch morphology and any incidental 
pathology in the access route which are invaluable in the planning of a procedure.  
4. Aortic arch configuration 
Initially, a 4 or 5 Fr sheath access is obtained in the common femoral artery. A flush 
pigtail catheter may be positioned in the ascending aorta for the initial arch aortogram 
which is performed in left anterior oblique (LAO) position. Depending on the degree of 
tortuosity and configuration of the aortic arch, we like to have between 30 degrees to as 
much as 60 degrees of LAO projection. The performance of the arch angiogram is useful 
to identify the target vessel origin. In difficult anatomic arrangements, the aortogram is 
very helpful but it may also increase procedure morbidity. Utilizing diffusion weighted 
MRI imaging, silent microembolic lesions are detectable in up to two-thirds of patients 
undergoing CAS8. At least half of these lesions can be identified in the cerebral 
hemisphere contralateral to the target lesion. This suggests that manipulation of devices, 
including diagnostic catheters used for arch angiography, are a substantial source of 
embolic events during CAS. 
The aortic arch configuration varies due to multiple patient factors. Probably the dominant 
factor is age since the aorta tends to elongate with increasing age contributing to a 
worsening of the arch type. There are mainly three arch types depending on the 
radiographic morphology (Figure).  
5. Diagnostic catheters 
Safe selective cannulation of the great vessels is the rate-limiting step. Usually the 
appropriate diagnostic catheters are available in 100 cm to 125 cm lengths. The longer 
lengths are required should one use the telescoping technique (vida infra). 
For the Type I aortic arch, the standard angled catheters like the angle taper Glidecath® 
(Terumo Medical Corporation, Somerset, NJ, USA) or a Berenstein catheter (Boston 
Scientific, Natick, MA, USA) or Headhunter or JB 1 (Cook Medical, Bloomington, IN, USA) 
are usually successful.  
For more challenging aortic arch morphology, with types II and III configuration, reverse-
curve catheters like Simmons type catheters (I or II), JB 2 or the VTK catheter (Cook Medical, 
Bloomington, IN, USA) may be used. 
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A Type IV arch is a term that may be applied to an exaggerated Type III arch with severe 
angulation of the great vessels. 
Type I – The great vessels originate 
from the same horizontal plane of 
the outer curvature of the arch  
Type II – Innominate artery 
originates between the horizontal 
planes of outer and inner curvature 
of the arch 
Type III – Innominate artery 
originates below the horizontal 










These are the configurations of some of the catheters commonly used in the carotid 
angioplasty procedure. 
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6. Sheath access 
Positioning of a sheath in the CCA is a prerequisite to CAS. Typically, this requires 
placement of a diagnostic catheter into the CCA followed by advancement of a glide-wire 
into the ECA. This allows introduction of the catheter into the ECA followed by a wire 
exchange for a stiff wire forming the guide for a 6 Fr Shuttle sheath. Occasionally, the ECA 
is occluded or severely diseased requiring the use of a stable stiff wire access into common 
carotid artery (CCA) alone and a 6 Fr sheath is advanced and parked into proximal CCA. 
7. Cannulation of internal carotid artery 
After obtaining stable sheath access into proximal CCA, the embolic protection device (EPD) 
is deployed into the appropriate position. The pros and cons of different cerebral EPDs are 
discussed in next section.  
The different approches of obtaining ICA access depend upon the degree of stenosis, 
amount of tortuosity and type of EPD used. Usual access to the ICA is obtained with a 
standard 0.014” wire or EPD dedicated wire followed by delivery of the balloon and stent 
system. 
8. Telescoping catheter technique 
Positioning of the Shuttle sheath system into the CCA is a prerequisite for the CAS 
procedure. Typically, this is performed over a stiff wire anchored in the ECA. However, 
advancement of the stiff wire into the CCA through a diagnostic catheter may be a 
challenge. If tortuous anatomy prevents this maneuver, a softer, 125 cm 6 or 6.5 Fr catheter 
is used to replace the obturator of the Shuttle sheath. The additional 35 cm lead portion of 
this catheter which is telescoped into the 90 cm Shuttle serves as a sufficient support over 
which to slide the sheath once the catheter tip is introduced into the CCA. Thus, the inner 
catheter effectively serves as a “stiff guide”. 
9. Right brachial/axillary artery access technique (double wire technique) 
Access to the right carotid system can be achieved under essentially all anatomically 
difficult circumstances with this technique. This approach has been successful even with an 
exaggerated Type III aortic arch configuration (effectively a Type IV arch). The technique 
requires gaining access to the brachial or axillary artery on the right with passage of an 
exchange length glide wire retrograde into the thoracic aorta. The wire is snared from a 
femoral access point for through and through wire control. A 7 or 8 Fr sheath is now 
advanced into the innominate artery. The wire may be changed out for a smaller wire to 
reduce occupied space within the sheath while stabilizing it. This is then followed by the 
transfemoral advancement of a second steerable 0.014” wire into the CCA. The second wire 
now permits the delivery of a cerebral protection system and completion of the CAS 
procedure.  
10. Transtemporal technique 
Access to the CCA can be quite difficult if the carotid anatomy is tortuous or the aortic arch 





greatest utility on the left since the right CCA can be cannulated using the double wire 
technique noted above. The transtemporal approach involves ultrasound guided access or 
direct dissection of the superficial temporal artery followed by retrograde placement of a 
coronary wire into the aorta where it is snared from the femoral artery. This provides 
through and through access permitting advancement of a Shuttle sheath into proper 
position for the CAS procedure. The remainder of the procedure is then performed in the 
usual fashion. 
11. Ultra-critical stenosis 
Sometimes the standard 0.014” wire is not successful in traversing an ultra-critical 
stenosis, in which case a 0.012” Headliner® Glidewire® (45 degrees, 200 cm) (Terumo 
Medical Corporation, Somerset, NJ, USA), supported by 1.9 Fr (0.026”) Prowler® 
microcatheter (Cordis, Miami Lakes, FL, USA) may be successful. Following traversal  
of the lesion with the microcatheter, the 0.012” wire is replaced with a more supportive 
0.014” wire which can be parked in the treatment area. The new wire may now be used  
to deliver a balloon, EPD or a flow arrest/reversal system (vida infra) for completion of  
the CAS. 9 
 
 
This figure shows a pre-occlusive lesion of the right internal carotid artery which would not 
accept a 0.014” wire. 
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The lesion has been passed using an 0.012” wire followed by replacement with an 0.014” 
wire and placement of a MOMA flow arrest device within the external carotid artery  
balloon inflated (long arrow).  
 
The ICA angioplasty is complete. The MOMA flow arrest device is still in place with the 





12. Transcervical occlusion and protective shunting technique 
This technique uses a partially open operative approach. The procedure is performed under 
local anesthesia utilizing a small incision just above the clavicle. A large (9 Fr) and medium 
(6 Fr) sheath are introduced into the CCA directed in a cephalad orientation through the 
incision. Additionally, a 6 Fr sheath is introduced into the jugular vein directed caudally. An 
over-the-wire fogerty catheter is used to occlude the external carotid artery and the 
proximal CCA is clamped following anticoagulation. Flow reversal in the carotid system is 
established by connecting the sideports of the 9 Fr arterial and 6 Fr venous sheaths and flow 
direction is verified using a small injection of contrast. Now, the angioplasty is performed 
through the 9 Fr sheath and any loose debris that results is carried into the venous system or 
trapped by any interposed filter. The arterial puncture sites are sutured at the time of final 
sheath removal. This approach appears fairly labor intensive within a small field and the use 
of a partially open portion of the angioplasty procedure seems to defeat the minimally 
invasive nature of CAS. Nonetheless, it has been suggested as a reliable means of controlling 
embolization. 
13. Review of literature 
Mathias first described the percutaneous carotid artery angioplasty (CA) technique in 
1977.10 Subsequently he reported a case series of 3 high surgical risk patients undergoing 
percutaneous carotid angioplasty.11 During this time, percutaneous carotid intervention was 
limited to fibromuscular dysplasia and was not applied to atherosclerotic diseases due to 
risk of embolic events and secondly, CEA was considered a very safe procedure and its 
utilization was widespread. There were occasional case reports of CA, but it wasn’t until 
1990’s when this technique was more systematically studied for its feasibility, safety and 
outcomes. The summary of early clinical studies is shown in Table 1. The most feared 
complication of CA is embolic phenomenon and evidence of early and delayed embolization 
after percutaneous CA was reported by Markus et al. 12  
 





Diethrich EB13 (1996) 110 (7.6 months) 99% 12 (10.9%) 12 (10.9%) 
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Yadav JS16 (1997) 107 (6 months) 100% 9 (8.4%) 10(9.3%) 
Jordan WD, Jr17 (1997) 107 (6 months) NA 9 (8.4%) 10 (9.3%) 
Vozzi CR18 (1997) 22 (10 months) NA 2 (9%) 2 (9%) 
Teitelbaum GP19 (1998) 25 (6 months) 96.2% 2 (7.7%) 6 (27%) 
Table 1. 
In 1992, Brown20 reviewed approximately 100 cases reported in the literature with stroke 
rate of 4%. In May 1998, Wholey21 published a review of 2,048 cases of carotid stents across 
24 centers world-wide and reported a 98.6% technical success rate. Also the complication 
rates were 3.08% for minor strokes, 1.32% major strokes and 1.37% peri-procedural 
mortality. The 6-month re-stenosis rate was 4.8% by duplex-ultrasound or angiographic 
method. The stents being utilized for carotid stenting at the time were Palmaz (Cordis) or 
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Palmaz-Schatz (Johnson and Johnson) balloon expandable stents (53%), followed by 
Wallstent (Schneider, Minneapolis, MN) (39%), Strecker (8%) and Inegra (1%) (Medi-Tech) 
stents. Subsequently, he reported updated data for 5,210 cases across 36 centers in June 2000. 
This showed a rapid rise in global popularity of this procedure. The incidence of major and 
minor stroke remained 1.49% and 2.72%. This review observed lower stroke rates in the 
centers with more than 50 procedures performed indicating the importance of a learning 
curve. Overall procedure-related complication rates declined from 5.72% in 1998 to 4.75% in 
2000. Since the cerebral protection technology had not yet evolved, these results derived 
from “unprotected” procedures. 
Theron et al22 first reported the use of cerebral embolic protection in carotid artery angioplasty 
and stenting procedures. There were no procedure related complications in 136 cases of 
carotid artery stenting with use of the cerebral embolic protection for atherosclerotic stenosis. 
The Carotid Revascularization using Endarterectomy or Stenting Systems (CaRESS)23 was a 
non-randomized prospective trial designed for high-risk patients with or without 
symptoms. Total of 397 patients were studied and the outcomes at 4-years showed a stroke 
incidence of 9.6% in CAS group versus 8.6% in CEA group (p=0.444) and an overall 
complication (death/stroke) rate of 26.5% in CEA versus 21.8% (p=0.361) in CAS. However, 
at the long-term follow-up, there were significantly higher re-stenosis and re-intervention 
rates in the CAS arm. 
14. Randomized controlled trials 
14.1 CAVATAS 
In 1996, the European Carotid Angioplasty trial group reported the rationale, design and 
protocol of the first multicenter randomized trial, the Carotid and Vertebral Artery 
Transluminal Angioplasty Study (CAVATAS).24 Preceding this trial, a single center trial in 
the UK was stopped after enrolling 20 patients due to unacceptable rate of stroke in the 
carotid angioplasty arm (7/10 patients).25 The CAVATAS trial involved 22 centers across 
Europe, Canada and Australia and the patient enrollment was between March 1992 and July 
1997. Five hundred and four patients were randomized to either CEA or CAS. The majority 
of patients (90%) in both arms had symptoms within 6 months of randomization and 
exhibited >70% carotid stenosis. Because the stents suitable for CAS were developed during 
the course of this study, all the patients before 1994 had primary balloon angioplasty alone 
versus the cases thereafter, which utilized stenting with Wallstent (Schneider, Minneapolis, 
MN), Streker (Medi-Tech, USA) and Palmaz (Johnson and Johnson, USA) stents. High-risk 
patients were excluded from the study. The major stroke and death rates were not 
statistically significantly different between two groups (30-day: 10% for CAS versus 10% for 
CEA; 3-years: 14.3% in CAS versus 14.2% in CEA). The primary limitation of this study is 
that very low number of patients (26%) who underwent carotid artery stenting and that the 
stroke and death rates were unusually high. However, subgroup analysis showed the 
incidence of stroke was only 2% in the stented patients, which lead to more widespread use 
of stent application after balloon angioplasty of a carotid artery stenosis. 
15. WALLSTENT26 
The Carotid WALLSTENT trial enrolled 223 patients with symptomatic carotid artery 
stenosis > 60%. No cerebral embolic protection was used. The trial was stopped due to 





16. Stenting and Angioplasty with Protection of the Patients at High Risk for 
Endarterectomy (SAPPHIRE)27 
This multicenter, industry-supported randomized trial enrolled 747 patients from 29 centers 
between 2000 and 2002. The major “high-risk”criteria were significant cardiac or pulmonary 
disease, contralateral carotid occlusion, prior neck radiation or radical neck surgery, 
recurrent stenosis, contralateral recurrent laryngeal nerve palsy or age greater than 80 years. 
The study showed that CAS was non-inferior to CEA when evaluating the cumulative 
incidence of major stroke, MI or death in 30-day period and at 1-year.  
17. Stent-supported Percutaneous Angioplasty of the Carotid artery versus 
Endarterectomy (SPACE)28 
The SPACE trial was designed as non-inferiority trial for CAS versus CEA. 1214 patients 
with symptomatic high grade stenosis of carotid artery (>70%) were randomized into CAS 
or CEA between March 2001 and February 2006. The primary end-point of ipsilateral stroke 
or death rate was 6.45% in CEA group versus 6.92% in CAS group which did not reach the 
statistical significance level (p=0.09) for non-inferiority for CAS. At 2-year follow-up, the 
overall mortality was 6.3% in CAS versus 5% in CEA (p=0.68), and the ipsilateral ischemic 
stroke rate was 2.2% vs 1.9%. However, recurrent stenosis (>70% by ultrasound criteria) was 
10.7% in CAS versus 4.6% in CEA group (p=0.0009). The subgroup analysis showed patients 
greater than 68 years of age had higher event rates with CAS compared to CEA, whereas the 
younger patients did better with CAS compared to CEA. 
18. Endarterectomy Versus Angioplasty in patients with Symptomatic Severe 
Carotid Stenosis (EVA-3S) trial29 
This trial was a French multicenter, prospective randomized non-inferiority trial. The 
patient enrollment started in November 2000 and ended in September 2005. A total of 527 
patients were enrolled and randomized into two arms. All the CAS cases after January 2003 
were done with approved EPDs at the time, which left initial 73 cases being done without 
any cerebral protection. The 30-day risk of stroke or death was 3.9% in CEA group versus 
9.6% in CAS group, and risk of any peri-procedural disabling stroke or death was 1.5% in 
CEA group versus 3.4% in CAS group. The 4-year hazard ratio (HR) of any disabling or fatal 
stroke or death was 2.0 (p=0.17) slightly favoring endarterectomy. Although the peri-
procedural risk was unusually higher in the stenting group, overall long-term secondary 
prevention of stroke was similar in both arms. The major criticism of this study was that 
despite a requirement of a minimum procedure volume performed prior to enrollment in 
the study as an operator, overall operator experience was too limited and may have 
influenced the outcomes. 
19. The International Carotid Stenting Study (ICSS)30 
The ICSS study, also known as CAVATAS-2, was designed. A meta-analysis of 3 trials, 
EVA-3S (2008), SPACE (2008) and the ICSS (2010) showed significantly lower event rate in 
the CEA group (OR 1.73, 95% CI: 1.29 – 2.32)20. Age, greater than 70 years, was a risk factor 
for poorer outcomes with CAS (12%) compared to CEA (5.9%), RR = 2.04. However, the 
patients younger than 70 years had no difference in outcomes.31 
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20. Carotid Revascularization Endarterectomy versus Stenting Trial 
(CREST)32 
This North American prospective randomized controlled trial enrolled 2502 patients from 117 
centers (symptomatic and asymptomatic). The primary end-points of any stroke, MI or death 
were similar in both groups of CEA (6.8%) and CAS (7.2%). Although there was a lower 
incidence of MI in the CAS group versus lower stroke rate in the CEA group, these rates did 
not reach statistical significance. Also the younger patients had slightly better outcomes with 
CAS whereas the older patients did slightly better after CEA. At one year, subgroup analysis 
revealed that stroke had a lasting effect on quality of life as opposed to the effects of MI. 
Nonetheless, overall, both procedures were safe when done by a skilled operator. 
21. Cerebral embolic protection devices 
The first safety and feasibility study of the ICA filter devices for cerebral embolic protection was 
done by Reimers et al.33 The 3-types of the filter devices used in that study are shown below. 
 
Subsequently, the EPD field has expanded with the addition of other filtration systems such 


















            
 
Overall, there are three major functional principles upon which all EPDs are based. (1) Distal 
ICA balloon occlusion with flow arrest (2) filtration with continuous flow through (as noted 
in the above figures), and (3) proximal balloon occlusion with flow stagnation or flow 
reversal. The pros and cons of these devices are enumerated in Table 2. 
Rx Accunet 
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Type Pros Cons Currently available in Market in the US 
Filter Maintains flow throughout 
the procedure 
 
Can perform angiogram 
during the procedure 
Risk of embolism 








(smaller than pore 
size of the filter) 
 
Risk of filter 
thrombosis 







Offers complete distal 
embolic protection 
Risk of embolism 
while traversing the 
lesion 
 
Potential for arterial 
injury by balloon 
 
Inability of some 
patients to tolerate 
ICA occlusion 
 






Does not require traversing 
the lesion unprotected 
 
Offers complete distal 
embolic protection 
Complete flow 




Potential for arterial 








22. Filter protection 
All filter devices have similar design. The filter is mounted on a 0.014” wire with floppy tip. 
The filter is made up from nitinol (nickel-titanium alloy) covered with polyurethane 
membrane. The porous size of the filter ranges from 30 to 140 microns. Each filter comes in 
with its own deployment and retrieval sheaths. The filter basket and the sheath are flushed 
carefully with heparinized saline with particular attention to avoid any air-bubbles. Once 
the filter is deployed in the distal straight portion of the ICA, the more proximal diseased 





diameter of the distal ICA. At the conclusion of the procedure, the filter is retrieved and 
then the entire system is removed. The currently available filter-devices have a crossing 
profile between 3Fr and 4Fr and accommodate the vessels from 3mm to 7mm diameter.  
23. Flow arrest or flow reversal technique 
Embolic protection during CAS can be accomplished with carotid flow arrest or reversal. The 
MOMA device is a 9 Fr sheath incorporating a small compliant balloon introduced into the 
ECA and a larger balloon located on the distal main body of the device used for CCA 
occlusion. Intubation of the ECA is performed using a 0.035” wire placed during a standard 
initial approach. The ECA wire serves as a guide for initial device placement. Following 
anticoagulation, the ECA and CCA balloons are inflated providing for carotid flow arrest. Any 
standard 0.014” wire may now be used to deliver angioplasty balloons and stents to the target 
lesion. An advantage to this system is that the working wire does not need to be advanced 
deep into the ICA territory thereby making this a favorable method when there is severe 
tortuosity to the ICA which will not accept distally placed filtration EPDs. Debris in the carotid 
bulb and ICA is aspirated at the conclusion of the procedure prior to balloon deflation.  
Initial data in a multicenter, intention-to-treat trial, ARMOUR Trial(Proximal Protection 
with the MO.MA Device During Carotid Stenting), showed that the major 30-day event rate 
(major cardiac and cerebrovascular) was 2.7% and 30-day major stroke rate was 0.9% in the 
patients undergoing CAS with MO.MA cerebral protection device.34  
 
 
MO.MA device. (Source: Invatec Inc., Italy)  
Flow reversal uses a similar principal of ECA and CCA occlusion during the angioplasty 
procedure but with dynamic flow reversal of blood from the carotid bulb into the femoral 
vein via a system side port. The flow reversal is encouraged by the higher arterial back 
pressure from the ICA compared to the venous system once the balloon system is inflated. 
This device is called the Parodi antiembolism system (PAES). Both devices serve the role of 
EPD as well as access sheath. 
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24. Neurorescue during carotid artery stenting 
24.1 Procedural embolization 
Embolization can occur during the carotid artery stenting procedure and that can be in the 
form of micro- or macro-embolization. However, the risk of embolization is particularly 
high during the diagnostic phase, deployment of EPD period and during retrieval of the 
EPD. Most cases with micro-embolization are asymptomatic at the time of the procedure 
and in the immediate post-procedural phase, but their impact on long-term functional 
outcome (eg., cognitive function) is largely unknown.  
The risk of embolization can be minimized by peri-procedural antiplatelet therapy (oral or 
intravenous GPIIB-IIIA inhibitors) and anticoagulation. These agents reduce platelet 
aggregation when subintimal tissue or stent material is exposed to the blood system during 
CAS. However, should macro-embolization occur, mainly due to technical error or failure of 
EPD, one should be prepared with mechanical retrieval/aspiration systems or catheter-
directed thrombolysis.  
24.2 Thrombosis 
Thrombosis during the CAS procedure is associated with the use of EPDs. This is usually 
treated with direct aspiration of thrombus and/or direct administration of a thrombolytic 
(ie. Alteplase) or GPIIb-IIIa inhibitor intra-arterially, if possible. Also, distal embolization 
can be prevented by adopting an incomplete filter-retrieval technique in which case the filter 
retrieval system is not closed completely upon removal in order to prevent thrombus from 
being squeezed out of the system.  
Acute stent thrombosis is rare (< 2%) and can be further minimized by appropriate 
periprocedural antiplatelet and anticoagulation strategy. The treatment consists of direct 
infusion of thrombolytic agent and/or GPIIb-IIIa inhibitor. This latter maneuver must be 
weighed against the risk of precipitating embolization during the lysis of an established ICA 
clot. In rare circumstances, when endoluminal techniques fail, the patient should 
immediately be taken to operating room and thrombectomy should be performed after 
appropriate anticoagulation and obtaining distal control to prevent progression of 
thrombosis and distal embolization. 
24.3 Dissection 
Dissection is fortunately a rare phenomenon and is usually related to stent insertion and/or 
balloon dilation. If the dissection does not limit the flow-lumen significantly, “wait-and-
observe” strategy can be employed with or without use of continued anticoagulation. In 
case of significant flow-limiting dissection, the deployment of second stent may be 
advocated versus open surgical repair. 
25. CAS surveillance 
25.1 Carotid restenosis 
The need for post-procedure surveillance is typically recommended by physicians who 
perform CAS. Surveillance options include duplex ultrasound (DU), MRA and CTA. MRA 
suffers from signal degradation due to the presence of a metallic stent and CTA involves 
significant ionizing radiation and the use of iodinated contrast, which may cause 
nephrotoxicity and allergic reactions35. Consequently, because of the absence of risk, DU 





Post-procedure sonography is performed in order to (1) identify undetected procedural 
faults associated with residual stenosis, (2) evaluate the occurrence of neointimal 
hyperplasia at the stented site, and (3) monitor the progression of contralateral disease. The 
incidence of significant contralateral disease ranges 25-50% making this the most compelling 
reason for ongoing duplex surveillance. Assessment of restenosis at the angioplasty site 
represents the second most frequent need for longitudinal surveillance.35 
Risk factors for restenosis after CAS largely remain undefined. When various factors are 
analyzed, a history of head and neck cancer and prior carotid endarterectomy (CEA) were 
found to be marginally significant for the development of early in-stent restenosis (ISR).36,37 
The time line for the occurrence of ISR is somewhat variable but the majority (>70%) of these 
cases are identified within 12 months following the index procedure3. However, this disease 
process may be ongoing as evidenced by an increasing incidence over a five year follow-up. 
Lal et al38, reported ISR rates of 2.7% and 6.4% at 1 and 5 years, respectively. These data utilize 
80% stenosis as a measure of disease with this frequency rising if lower degrees of restenosis 
criteria are selected. Interestingly, ISR may regress over time but the temporal profile of this 
process as well as factors predictive of regression remain undefined. 
25.2 Duplex ultrasound criteria 
The baseline post-procedural duplex velocities for stented vessels tend to exhibit higher 
values than unstented vessels of normal luminal caliber. This may result from either 
under dilatation of the ICA during CAS or a change in the mechanical properties of the 
ICA. A common notion is that the purpose of balloon dilatation is to ensure an adequate 
ICA lumen and not an anatomically cosmetic perfect result. This conservative approach 
may predispose to a minor residual stenosis exemplified by a peak systolic velocity (PSV) 
higher than normal. Alternatively, some authorities have reported that the introduction of 
a stent into the carotid bulb and ICA alters the biomechanical properties of the vessel 
resulting in a stent-arterial complex with decreased compliance. This translates into an 
elevated PSV because energy normally applied to dilate the artery is now expended as 
increased flow velocity39. Consequently, recommendations have been advocated for the 
increase of velocity criteria corresponding to higher degrees of stenosis following CAS.  
Table 3 shows current recommendations by several clinical laboratories.  
The variability of the recommended criteria values depends upon the balance between 
sensitivity and specificity desired by the laboratory performing the studies. Surveillance is 
usually performed every six months following CAS for at least two years. If the patient 
exhibits contralateral disease, this surveillance may be continued indefinitely. 
 
Stenosis              PSV (cm/sec)        EDV (cm/sec)        ICA/CCA ratio 
 >50%                   >225                              -                           >2.540
                              >240                             -                           >2.4542    
 
 >70%                     >170                         >12041                           -   
                             >350                               -                           >4.7540 
                             >450                              -                           >4.342
 
 >80%                   >340                              -                          >4.1538 
                              >325                         >119                         >4.5339
PSV=peak systolic velocity; EDV=end diastolic velocity  
Table 3. Recommended Velocity Criteria for Restenosis of the ICA following CAS 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
204 
24. Neurorescue during carotid artery stenting 
24.1 Procedural embolization 
Embolization can occur during the carotid artery stenting procedure and that can be in the 
form of micro- or macro-embolization. However, the risk of embolization is particularly 
high during the diagnostic phase, deployment of EPD period and during retrieval of the 
EPD. Most cases with micro-embolization are asymptomatic at the time of the procedure 
and in the immediate post-procedural phase, but their impact on long-term functional 
outcome (eg., cognitive function) is largely unknown.  
The risk of embolization can be minimized by peri-procedural antiplatelet therapy (oral or 
intravenous GPIIB-IIIA inhibitors) and anticoagulation. These agents reduce platelet 
aggregation when subintimal tissue or stent material is exposed to the blood system during 
CAS. However, should macro-embolization occur, mainly due to technical error or failure of 
EPD, one should be prepared with mechanical retrieval/aspiration systems or catheter-
directed thrombolysis.  
24.2 Thrombosis 
Thrombosis during the CAS procedure is associated with the use of EPDs. This is usually 
treated with direct aspiration of thrombus and/or direct administration of a thrombolytic 
(ie. Alteplase) or GPIIb-IIIa inhibitor intra-arterially, if possible. Also, distal embolization 
can be prevented by adopting an incomplete filter-retrieval technique in which case the filter 
retrieval system is not closed completely upon removal in order to prevent thrombus from 
being squeezed out of the system.  
Acute stent thrombosis is rare (< 2%) and can be further minimized by appropriate 
periprocedural antiplatelet and anticoagulation strategy. The treatment consists of direct 
infusion of thrombolytic agent and/or GPIIb-IIIa inhibitor. This latter maneuver must be 
weighed against the risk of precipitating embolization during the lysis of an established ICA 
clot. In rare circumstances, when endoluminal techniques fail, the patient should 
immediately be taken to operating room and thrombectomy should be performed after 
appropriate anticoagulation and obtaining distal control to prevent progression of 
thrombosis and distal embolization. 
24.3 Dissection 
Dissection is fortunately a rare phenomenon and is usually related to stent insertion and/or 
balloon dilation. If the dissection does not limit the flow-lumen significantly, “wait-and-
observe” strategy can be employed with or without use of continued anticoagulation. In 
case of significant flow-limiting dissection, the deployment of second stent may be 
advocated versus open surgical repair. 
25. CAS surveillance 
25.1 Carotid restenosis 
The need for post-procedure surveillance is typically recommended by physicians who 
perform CAS. Surveillance options include duplex ultrasound (DU), MRA and CTA. MRA 
suffers from signal degradation due to the presence of a metallic stent and CTA involves 
significant ionizing radiation and the use of iodinated contrast, which may cause 
nephrotoxicity and allergic reactions35. Consequently, because of the absence of risk, DU 





Post-procedure sonography is performed in order to (1) identify undetected procedural 
faults associated with residual stenosis, (2) evaluate the occurrence of neointimal 
hyperplasia at the stented site, and (3) monitor the progression of contralateral disease. The 
incidence of significant contralateral disease ranges 25-50% making this the most compelling 
reason for ongoing duplex surveillance. Assessment of restenosis at the angioplasty site 
represents the second most frequent need for longitudinal surveillance.35 
Risk factors for restenosis after CAS largely remain undefined. When various factors are 
analyzed, a history of head and neck cancer and prior carotid endarterectomy (CEA) were 
found to be marginally significant for the development of early in-stent restenosis (ISR).36,37 
The time line for the occurrence of ISR is somewhat variable but the majority (>70%) of these 
cases are identified within 12 months following the index procedure3. However, this disease 
process may be ongoing as evidenced by an increasing incidence over a five year follow-up. 
Lal et al38, reported ISR rates of 2.7% and 6.4% at 1 and 5 years, respectively. These data utilize 
80% stenosis as a measure of disease with this frequency rising if lower degrees of restenosis 
criteria are selected. Interestingly, ISR may regress over time but the temporal profile of this 
process as well as factors predictive of regression remain undefined. 
25.2 Duplex ultrasound criteria 
The baseline post-procedural duplex velocities for stented vessels tend to exhibit higher 
values than unstented vessels of normal luminal caliber. This may result from either 
under dilatation of the ICA during CAS or a change in the mechanical properties of the 
ICA. A common notion is that the purpose of balloon dilatation is to ensure an adequate 
ICA lumen and not an anatomically cosmetic perfect result. This conservative approach 
may predispose to a minor residual stenosis exemplified by a peak systolic velocity (PSV) 
higher than normal. Alternatively, some authorities have reported that the introduction of 
a stent into the carotid bulb and ICA alters the biomechanical properties of the vessel 
resulting in a stent-arterial complex with decreased compliance. This translates into an 
elevated PSV because energy normally applied to dilate the artery is now expended as 
increased flow velocity39. Consequently, recommendations have been advocated for the 
increase of velocity criteria corresponding to higher degrees of stenosis following CAS.  
Table 3 shows current recommendations by several clinical laboratories.  
The variability of the recommended criteria values depends upon the balance between 
sensitivity and specificity desired by the laboratory performing the studies. Surveillance is 
usually performed every six months following CAS for at least two years. If the patient 
exhibits contralateral disease, this surveillance may be continued indefinitely. 
 
Stenosis              PSV (cm/sec)        EDV (cm/sec)        ICA/CCA ratio 
 >50%                   >225                              -                           >2.540
                              >240                             -                           >2.4542    
 
 >70%                     >170                         >12041                           -   
                             >350                               -                           >4.7540 
                             >450                              -                           >4.342
 
 >80%                   >340                              -                          >4.1538 
                              >325                         >119                         >4.5339
PSV=peak systolic velocity; EDV=end diastolic velocity  
Table 3. Recommended Velocity Criteria for Restenosis of the ICA following CAS 
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Carotid angioplasty and stenting is very slowly increasing in popularity. Currently, 
approximately 12% of carotid interventions in the United States involve CAS. The major 
limitation in its adaption is the reimbursement climate. Presently, the Center for Medicare 
Services restricts reimbursement for CAS to high risk, symptomatic patients (stenosis > 50%) 
and high risk asymptomatic patients (stenosis >80%) who are on a clinical trial or registry. 
At least one private insurance carrier has elected to support payment for high risk 
asymptomatic patients (>80%) indicating that reimbursement restrictions are gradually 
relaxing. Furthermore, the FDA has approved the use of the Acculink/Accunet carotid stent 
system in asymptomatic patients. These changes in regulatory requirements for CAS 
suggest that eventually, in the not too distant future, this procedure will be approved for all 
patients exhibiting carotid stenosis. Whether CAS should be performed in asymptomatic 
patients remains a controversial issue and will remain a topic in evolution as pharmaceutical 
therapy and life-style changes become increasingly aggressive. 
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Carotid angioplasty and stenting is very slowly increasing in popularity. Currently, 
approximately 12% of carotid interventions in the United States involve CAS. The major 
limitation in its adaption is the reimbursement climate. Presently, the Center for Medicare 
Services restricts reimbursement for CAS to high risk, symptomatic patients (stenosis > 50%) 
and high risk asymptomatic patients (stenosis >80%) who are on a clinical trial or registry. 
At least one private insurance carrier has elected to support payment for high risk 
asymptomatic patients (>80%) indicating that reimbursement restrictions are gradually 
relaxing. Furthermore, the FDA has approved the use of the Acculink/Accunet carotid stent 
system in asymptomatic patients. These changes in regulatory requirements for CAS 
suggest that eventually, in the not too distant future, this procedure will be approved for all 
patients exhibiting carotid stenosis. Whether CAS should be performed in asymptomatic 
patients remains a controversial issue and will remain a topic in evolution as pharmaceutical 
therapy and life-style changes become increasingly aggressive. 
27. References 
 
[1] North American Symptomatic Carotid Endarterectomy Trial Collaborators, Beneficial 
effect of carotid endarterectomy in symptomatic patients with high grade carotid 
stenosis. N Engl J Med. 1991 Aug 15;325(7):445-53 
[2] Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the 
Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995 May 10;273(18):1421-8. 
[3] European Carotid Surgery Trialists’ Collaborative Group, Ran-domised trial of 
endarterectomy for recently symptomatic carotid stenosis: final results of the MRC 
European Carotid Surgery Trial (ECST). Lancet. 1998 May 9;351(9113):1379-87. 
[4] Robicsek F, Roush TS, Cook JW, Reames MK. From Hippocrates to Palmaz-Schatz, the 
history of carotid surgery. Eur J Vasc Endovasc Surg. 2004 Apr;27(4):389-97. 
[5] Morris GC Jr, Lechter A, DeBakey ME. Surgical treatment of fibromuscular disease of 
the carotid arteries. Arch Surg. 1968 Apr;96(4):636-43.  
[6] Mathias K. [A new catheter system for percutaneous transluminal angioplasty (PTA) of 
carotid artery stenoses]. Fortschr Med. 1977 Apr 21;95(15):1007-11. German. 
[7] Diethrich EB, Ndiaye M, Reid DB. Stenting in the Carotid artery. Initial experience in 
110 patients. J Endovasc Surg. 1996 Feb;3(1):42-62. 
[8] Hammer FD, Lacroix V, Duprez T, et al: Cerebral microembolization after protected 
carotid artery stenting in surgical high-risk patients: Results of a 2-year prospective 
study. J Vasc Surg 2005;42:847-53. 
 
[9] Dahn M, Cheema M, Bozeman P, Divinagracia T. Crossing an ultracritical carotid 
stenosis for carotid angioplasty. Vasc Endovascular Surg. 2009 Dec;43(6):589-91. 
Epub 2009 Oct 14.  
[10]  Mathias K. [A new catheter system for percutaneous transluminal angioplasty (PTA) 
of carotid artery stenoses]. Fortschr Med. 1977 Apr 21;95(15):1007-11. German. 
[11] Bockenheimer SA, Mathias K. Percutaneous transluminal angioplasty in arteriosclerotic 
internal carotid artery stenosis. AJNR Am J Neuroradiol. 1983 May-Jun;4(3):791-2. 
[12] Markus HS, Clifton A, Buckenham T, Brown MM. Carotid angioplasty. Detection of 
embolic signals during and after the procedure. Stroke. 1994 Dec;25(12):2403-6. 
[13] Diethrich EB, Ndiaye M, Reid DB. Stenting in the Carotid artery. Initial experience in 






[14] Roubin GS, Yadav S, Iyer SS, Vitek J. Carotid stent-supported angioplasty: a 
neurovascular intervention to prevent stroke. Am J Cardiol. 1996 Aug 14;78(3A):8-12. 
[15] Gil-Peralta A, Mayol A, Marcos JR, Gonzalez A, Ruano J, Boza F, Duran F. 
Percutaneous transluminal angioplasty of the symptomatic atherosclerotic carotid 
arteries. Results, complications, and follow-up. Stroke. 1996 Dec;27(12):2271-3. 
[16] Yadav JS, Roubin GS, King P, Iyer S, Vitek J. Angioplasty and stenting for restenosis 
after carotid endarterectomy. Initial experience. Stroke. 1996 Nov;27(11):2075-9. 
[17] Jordan WD Jr, Schroeder PT, Fisher WS, McDowell HA. A comparison of angioplasty 
with stenting versus endarterectomy for treatment of carotid artery stenosis. Ann 
Vasc Surg. 1997 Jan;11(1):2-8. 
[18] Vozzi CR, Rodriguez AO, Paolantonio D, Smith JA, Wholey MH. Extracranial carotid 
angioplasty and stenting. Initial results and short term follow-up. Tex Heart Inst J. 
1997;24(3):167-72. 
[19] Teitelbaum GP, Lefkowitz MA, Giannotta SL Carotid angioplasty and stenting in high-
risk patients. Surg Neurol. 1998 Oct;50(4):300-11; discussion 311-2. 
[20] Brown MM. Balloon angioplasty for cerebrovascular disease. Neurol Res 1992; 
14(suppl): 159-173 
[21] Wholey MH, Wholey M, Bergeron P, Diethrich EB, Henry M, Laborde JC, Mathias K, 
Myla S, Roubin GS, Shawl F, Theron JG, Yadav JS, Dorros G, Guimaraens J, 
Higashida R, Kumar V, Leon M, Lim M, Londero H, Mesa J, Ramee S, Rodriguez 
A, Rosenfield K, Teitelbaum G, Vozzi C. Current global status of carotid artery 
stent placement. Cathet Cardiovasc Diagn. 1998 May;44(1):1-6. 
[22] Theron JG, Payelle GG, Coskun O, Huet HF, Guimaraens L. Carotid artery stenosis: 
treatment with protected balloon angioplasty and stent placement. Radiology. 1996 
Dec;201(3):627-36. 
[23] Zarins CK, White RA, Diethrich EB, Shackelton RJ, Siami FS; CaRESS Steering Committee 
and CaRESS Investigators. Carotid revascularization using endarterectomy or stenting 
systems (CaRESS): 4-year outcomes. J Endovasc Ther. 2009 Aug;16(4):397-409. 
[24] Sivaguru A, Venables GS, Beard JD, Gaines PA. European Carotid Angioplasty Trial. J 
Endovasc Surg. 1996 Feb;3(1):16-20. 
[25] Naylor AR, Bolia A, Abbott RJ, Pye IF, Smith J, Lennard N, Lloyd AJ, London NJ, Bell 
PR. Randomized study of carotid angioplasty and stenting versus carotid 
endarterectomy: a stopped trial. J Vasc Surg. 1998 Aug;28(2):326-34. 
[26] Alberts MJ. Results of a multicenter prospective randomized trial of carotid artery 
stenting vs. carotid endarterectomy. Stroke 2001. 
[27] Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Whitlow 
P, Strickman NE, Jaff MR, Popma JJ, Snead DB, Cutlip DE, Firth BG, Ouriel K; 
Stenting and Angioplasty with Protection in Patients at High Risk for 
Endarterectomy Investigators. Protected carotid-artery stenting versus 
endarterectomy in high-risk patients. N Engl J Med. 2004 Oct 7;351(15):1493-501. 
[28] Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke W, Hennerici M, 
Stingele R, Fiehler J, Zeumer H, Jansen O. Results of the Stent-Protected Angioplasty 
versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 
years: a multinational, prospective, randomised trial. Lancet Neurol. 2008 
Oct;7(10):893-902. Epub 2008 Sep 5. Erratum in: Lancet Neurol. 2009 Feb;8(2):135. 
[29] Mas JL, Trinquart L, Leys D, Albucher JF, Rousseau H, Viguier A, Bossavy JP, Denis B, 
Piquet P, Garnier P, Viader F, Touzé E, Julia P, Giroud M, Krause D, Hosseini H, 
Becquemin JP, Hinzelin G, Houdart E, Hénon H, Neau JP, Bracard S, Onnient Y, 
Angioplasty, Various Techniques and Challenges in  




Padovani R, Chatellier G; EVA-3S investigators. Endarterectomy Versus 
Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: 
results up to 4 years from a randomised, multicentre trial. Lancet Neurol. 2008 
Oct;7(10):885-92. Epub 2008 Sep 5. 
[30] International Carotid Stenting Study investigators, Ederle J, Dobson J, Featherstone RL, 
Bonati LH, van der Worp HB, de Borst GJ, Lo TH, Gaines P, Dorman PJ, Macdonald 
S, Lyrer PA, Hendriks JM, McCollum C, Nederkoorn PJ, Brown MM. Carotid artery 
stenting compared with endarterectomy in patients with symptomatic carotid 
stenosis (International Carotid Stenting Study): an interim analysis of a randomised 
controlled trial. Lancet. 2010 Mar 20;375(9719):985-97. Epub 2010 Feb 25. 
[31] Bonati LH, Fraedrich G; Carotid Stenting Trialists' Collaboration. Age modifies the 
relative risk of stenting versus endarterectomy for symptomatic carotid stenosis--a 
pooled analysis of EVA-3S, SPACE and ICSS. Eur J Vasc Endovasc Surg. 2011 
Feb;41(2):153-8. Epub 2011 Jan 26. 
[32] Brott TG, Hobson RW, Howard G, Roubin GS, Clark WM, Brooks W, et al: Stenting 
versus endarterectomy for treatment of carotid artery stenosis. N Engl J Med 
2010;363:11-23. 
[33] Reimers B, Corvaja N, Moshiri S, Saccà S, Albiero R, Di Mario C, Pascotto P, Colombo 
A. Cerebral protection with filter devices during carotid artery stenting. 
Circulation. 2001 Jul 3;104(1):12-5. 
[34] Ansel GM, Hopkins LN, Jaff MR, Rubino P, Bacharach JM, Scheinert D, Myla S, Das T, 
Cremonesi A; Investigators for the ARMOUR Pivotal Trial. Safety and effectiveness 
of the INVATEC MO.MA proximal cerebral protection device during carotid artery 
stenting: results from the ARMOUR pivotal trial. Catheter Cardiovasc Interv. 2010 
Jul 1;76(1):1-8. 
[35] Rizzo JA, Dodge A, White P, Martin ED. Magnetic resonance angiography in the 
evaluation of carotid stent patency. Perspect Vasc Surg Endovasc Ther 2010;22:261-3. 
[36] Skelly CL, et al. Risk factors for restenosis after carotid artery angioplasty and stenting. 
J Vasc Surg 2006;44:1010-5. 
[37] Zhou W, et al. Management of in-stent restenosis after carotid artery stenting in high 
risk patients. J Vasc Surg 2006;43:305-12. 
[38] Lal BK, et al. In-stent recurrent stenosis after carotid artery stenting: Life table analysis 
and clinical relevance. J Vasc Surg 2003;38:1162-9. 
[39] Abu Rahma AF, et al. Optimal carotid duplex velocity criteria for defining the severity 
of carotid in-stent restenosis. J Vasc Surg 2008;48:589-94. 
[40] Stanziale SF, et al. Determining in-stent restenosis of carotid arteries by duplex 
ultrasound criteria. J Endovasc Ther 2005;12:346-53. 
[41] Peterson BG, et al. Duplex ultrasound remains a reliable test even after carotid 
stenting. Ann Vasc Surg 2005;19:793-7. 
[42] Chi YN, White CJ, Woods TC, Goldman CK. Ultrasound velocity criteria for carotid in-
stent restenosis. Catheter Cardiovasc Interv 2006;69:349-54. 
10 
Revascularization of Tibial and Foot Arteries: 
Below the Knee Angioplasty for Limb Salvage 
Marco Manzi, Luis Mariano Palena and Giacomo Cester 
Interventional Radiology Unit -Policlinico Abano Terme, Padua 
Italy 
1. Introduction 
Advanced atherosclerosis with extended tibial arteries lesions is a common concern, especially 
in diabetic patients having critical-limb ischemia (CLI) and skin wounds. Chronic critical limb 
ischemia is a major worldwide cause of morbidity and, especially when threatening the limb, 
mortality (Faglia E. et al. 2006).  Certainly, major and minor amputations are associated with 
significant increases in mortality risk, and every efforts should be pursued to minimize 
amputations and ensure limb salvage (Norgen L. et al. 2007). 
Infragenicular atherosclerotic is the most common cause of CLI, usually due to multilevel 
and diffuse arterial disease with compromised foot arteries run-off.  Vascular disease is very 
often associated with arterial wall calcifications, that are usually severe and diffuse. The 
combination of severe peripheral arterial occlusion with the increased blood flow 
requirement necessary to achieve the healing of the skin wounds or surgical incisions, 
makes this population very challenging. Additionally, diabetics and CLI population have a 
high rate of comorbidities (Bargelini I, et al. 2008). 
Clinical manifestations range from Intermittent claudication to limb-threatening ischemia, 
with rest pain, non healing ulcers and gangrene. 
Despite the benefits of pharmacologic therapy (e.g. Angiotensin-converting enzyme 
inhibitors, antidiabetic drugs, antiplatelet agents and statins), arterial revascularization 
remains a mainstay in the management of CLI, with restoration of arterial blood flow to the 
foot, achieving a relief of rest pain and improving wound healing. 
In the last decade surgical revascularization has been adopted as the elective treatment 
option in patients with suitable anatomical conditions, however surgical by-pass is not 
always feasible due to the involvement of the foot arteries by the atherosclerotic disease, or 
recommended because of high surgical risk or contraindications in several cases, lack of 
venous conduits or poor vessels run-off, that compromise surgical by-pass patency 
(HerstenNR, et al. 2007; Norgen L, et al. 2007; Walsh Db, et al. 1991).  
In recent years, related to good technical and clinical results, endovascular treatment options 
growing acceptance as the primary therapeutic strategy, especially in subjects with 
significant risk factors for surgical by-pass. In fact, since its initial applications, endovascular 
recanalization of tibial vessels and foot arteries has proven to be feasible and safe. Actually it 
is an established treatment option for limb salvage, avoiding amputations in lot of cases and 
improving wound healing(Adam DJ, et al. 2005; Balmer H, et al. 2002; Dorros G, et al. 2001;  
Faglia E, et al. 2005, 2006; Ferraresi R, et al. 2009; Romiti M, et al. 2008; Soder HR, et al 2000; 
Wack C, et al. 1994). 
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is an established treatment option for limb salvage, avoiding amputations in lot of cases and 
improving wound healing(Adam DJ, et al. 2005; Balmer H, et al. 2002; Dorros G, et al. 2001;  
Faglia E, et al. 2005, 2006; Ferraresi R, et al. 2009; Romiti M, et al. 2008; Soder HR, et al 2000; 
Wack C, et al. 1994). 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
210 
The development of new technologies, such as dedicated guide-wire or low profile catheter 
balloons helps the interventionists to achieve technical and clinical results. Nevertheless, the 
knowledge of the most important techniques should be indispensable to obtain the 
procedural success and clinical outcome. In fact, the advances in distal lower extremity 
revascularization have revolutionized salvage of the ischemic limb.  
2. Epidemiology of peripheral arterial disease 
The management of the patient with peripheral arterial disease (PAD) has to be planned in 
the context of the epidemiology of the disease, its natural history and, in particular, the 
modifiable risk factors for the systemic disease as well as those that predict deterioration of 
the circulation to the limb (Norgen L, et al. 2007). 
2.1 Incidence of peripheral arterial disease 
Total disease prevalence based on objective testing has been evaluated in several 
epidemiologic studies and is in the range of 3-10%, increasing to 15% to 20% in persons over 
70 years (Criqui MH et al. 1985; Hiatt WR, et al. 1995; Norgen et al. 2007; Selvin E, et  
al. 2004). 
Intermittent claudication (IC) s usually diagnosed by a history of muscular leg pain on 
exercise that is relieved by a short rest. This symptom does not always predict the presence 
or absence of PAD. A patient with quite severe PAD may not have the symptom of IC 
because some other condition limits exercise or they are sedentary. In contrast, some 
patients with what seems to be IC may not have PAD. Likewise, patients with very mild 
PAD may develop symptoms of IC only when they become very physically active. 
Black ethnicity increases the risk of PAD by over two-fold, and this risk is not explained by 
higher levels of other risk factors such as diabetes, hypertension or obesity (Criqui MH, et al. 
2005). A high prevalence of arteritis affecting the distal arteries of young black South 
Africans has also been described. 
3. Risk factors of peripheral arterial disease 
Although the various factors described in this section are usually referred to as risk factors, 
in most cases the evidence is only for an association. The criteria used to support a risk 
factor require a prospective, controlled study showing that altering the factor alters the 
development or course of the PAD, such as has been shown for smoking cessation or 
treatment of dyslipidemia. Risk may be conferred by other metabolic or circulatory 
abnormalities associated with diabetes (Norgen L, et al. 2007). 
3.1 Race, gender and age 
The National Health and Nutrition Examination Survey in the United States found that an 
ABI 0.90 was more common in non-Hispanic Blacks (7.8%) than in Whites (4.4%). Such a 
difference in the prevalence of PAD was confirmed by the recent GENOA (Genetic 
Epidemiology Network of Arteriopathy) study (Kullo IJ, et al. 2003), which also showed that 
the difference was not explained by a difference in classical risk factors for atherosclerosis. 
The prevalence of PAD, symptomatic or asymptomatic, is slightly greater in men than 
women, particularly in the younger age groups. In patients with IC, the ratio of men to 
women is between 1:1 and 2:1. This ratio increases in some studies to at least 3:1 in more 
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severe stages of the disease, such as chronic CLI. Other studies have, however, shown  
a more equal distribution of PAD between genders and even a predominance of women 
with CLI. 
The striking increase in both the incidence and prevalence of PAD with increasing age is 
apparent from the earlier discussion of epidemiology (Norgen L, et al. 2007). 
3.2 Smoking 
The relationship between smoking and PAD has been recognized since 1911, when Erb 
reported that IC was three-times more common among smokers than among non-smokers. 
It has been suggested that the association between smoking and PAD may be even stronger 
than that between smoking and coronary artery disease (CAD). Furthermore, a diagnosis of 
PAD is made approximately a decade earlier in smokers than in non-smokers. The severity 
of PAD tends to increase with the number of cigarettes smoked. Heavy smokers have a four-
fold higher risk of developing IC compared with non-smokers. Smoking cessation is 
associated with a decline in the incidence of IC (Norgen L, et al. 2007).  
Results from the Edinburgh Artery Study found that the relative risk of IC was 3.7 in 7 
smokers compared with 3.0 in ex-smokers (who had discontinued smoking for less than 5 
years). 
3.3 Diabetes mellitus 
Many studies have shown an association between diabetes mellitus and the development of 
PAD. Overall, IC is about twice as common among diabetic patients than among non-
diabetic patients. In patients with diabetes, for every 1% increase in hemoglobin A1c there is 
a corresponding 26% increased risk of PAD (Selvin E, et al. 2004). 
Over the last decade, mounting evidence has suggested that insulin resistance plays a key 
role in a clustering of cardiometabolic risk factors which include hyperglycemia, 
dyslipidemia, hypertension and obesity. Insulin resistance is a risk factor for PAD even in 
subjects without diabetes, raising the risk approximately 40% to 50%. PAD in patients with 
diabetes is more aggressive compared to non-diabetics, with early large vessel involvement 
coupled with distal symmetrical neuropathy. The need for a major amputation is five- to 
ten-times higher in diabetics than non-diabetics. This is contributed to by sensory 
neuropathy and decreased resistance to infection. Based on these observations, a consensus 
statement from the American Diabetes Association recommends PAD screening with an ABI 
every 5 years in patients with diabetes (Norgen L, et al. 2007). 
3.4 Hypertension 
Hypertension is associated with all forms of cardiovascular disease, including PAD. 
However, the relative risk for developing PAD is less for hypertension than diabetes or 
smoking (Norgen L, et al. 2007). 
3.5 Dyslipidemia 
In the Framingham study, a fasting cholesterol level greater than 7 mmol/L (270 mg/dL) 
was associated with a doubling of the incidence of IC but the ratio of total to high-density 
lipoprotein (HDL) cholesterol was the best predictor of occurrence of PAD. In another 
study, patients with PAD had significantly higher levels of serum triglycerides, very low-
density lipoprotein (VLDL) cholesterol, VLDL triglycerides, VLDL proteins, intermediate 
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density lipoprotein (IDL) cholesterol, and IDL triglycerides and lower levels of HDL than 
controls (Attinder CE, et al. 2001; Criqui MH, et al. 1985; Fowkes FG, et al. 2004; Norgen L, et 
al. 2007; Selvin E, et al. 2004; Senti M, et al. 1992). 
Although some studies have also shown that total cholesterol is a powerful independent 
risk factor for PAD, others have failed to confirm this association. It has been suggested that 
cigarette smoking may enhance the effect of hypercholesterolemia. There is evidence that 
treatment of hyperlipidemia reduces both the progression of PAD and the incidence of IC. 
An association between PAD and hypertriglyceridemia has also been reported and has been 
shown to be associated with the progression and systemic complications of PAD. 
Lipoprotein(a) is a significant independent risk factor for PAD.  
3.6 Hyperviscosity and hypercoagulable states 
Raised hematocrit levels and hyperviscosity have been reported in patients with PAD, 
possibly as a consequence of smoking. Increased plasma levels of fibrinogen, which is also a 
risk factor for thrombosis, have been associated with PAD in several studies. Both 
hyperviscosity and hypercoagulability have also been shown to be markers or risk factors 
for a poor prognosis (Norgen L, et al. 2007).  
3.7 Hyperhomocysteinemia 
The prevalence of hyperhomocysteinemia is as high in the vascular disease population, 
compared with 1% in the general population. It is reported that hyperhomocysteinemia is 
detected in about 30% of young patients with PAD. The suggestion that 
hyperhomocysteinemia may be an independent risk factor for atherosclerosis has now been 
substantiated by several studies. It may be a stronger risk factor for PAD than for CAD 
(Norgen L, et al. 2007). 
3.8 Chronic renal insufficiency 
There is an association of renal insufficiency with PAD, with some recent evidence 
suggesting it may be causal. In the HERS study (Heart and Estrogen/Progestin Replacement 
Study), renal insufficiency was independently associated with future PAD events in 
postmenopausal women (O’Hare AM, et al. 2004; Norgen L, et al. 2007). 
4. Vascular anatomy and angiosome concept - The first step toward pedal 
recanalization 
Knowledge of vascular anatomy of the leg, ankle and foot, and an understanding of the 
dynamic nature of that vasculature are essential for limb salvage (Taylor G, et al. 1992). 
The concept that divides the body into three-dimensional vascular territories supplied by 
specific source arteries, known as the angiosome principle, was introduced by Taylor and 
expanded for the clinical treatment of ischemic lesions at the foot and ankle level by 
Attinger (Attinger CE, et al. 2001). The foot and the ankle can be divided into six distinct 
angiosomes; each fed by a specific arterial branch. Recent data suggest a different clinical 
outcome of successful revascularization procedures based on the possibility of providing 
inline vascular supply to the specific angiosome of the ischemic wound. 
By combining the anatomic and functional aspects of foot circulation, the angiosome theory 
can be useful in planning the endovascular revascularization strategy in cases of ischemic 
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wounds at foot and ankle level. In particular, the angiosome concept can help to select the 
target vessel for revascularization, that is, the artery which will yield the best local results. 
4.1 Normal vascular anatomy and main variations 
By definition the popliteal artery ends at the origin of the first tibial artery, which typically is 
the Anterior Tibial Artery. In about 4% of cases we find a so-called high origin of the 
Anterior tibial Artery at the level of the knee joint or even some centimetres more proximal. 
Similarly, in a small proportion of the population (1-2%) a high origin of the posterior tibial 
artery has been described. Normally, the direct continuation of the popliteal artery, after the 
branch of the anterior tibial artery, is the tibioperoneal trunk. This vascular segment splits 
into the posterior tibial artery and the peroneal artery (Fig. 1). 
As a variation, a triforcation of the popliteal artery into all three lower leg arteries at the 
same point has been observed in 0.4% of patients. The posterior tibial artery may be missing 
completely in 1-5% of a normal adult population. 
The vascular anatomy of the foot is composed of the anterior and posterior circulation, 
connected through the pedal arches. The anterior tibial artery continues into the dorsal 
pedal artery. The posterior tibial artery continues into the common plantar artery and then 
in the lateral and medial plantar arteries. The peroneal artery splits above the ankle joint 
into and anterior and posterior branch, the ramus perforans that anastomoses with the 
dorsal pedal artery, and the ramus communicans that anastomoses with the plantar arteries. 
The dorsalis pedis artery and the lateral plantar artery communicate via the plantar arch 
(Fig. 2 and Fig. 3). 
The digital branches origin from the plantar arch and there are a dorsal and plantar 
branches for each toe. The plantar digital branch for first toe ususally origin from medial 
plantar artery. 
Both tibial arteries, together with the peroneal artery, supply different portions of the foot 
and ankle. The plantar foot and the medial ankle are fed by the posterior tibial artery, the 
anterior ankle and the dorsum of the foot by the anterior tibial artery, and the antero-lateral 
ankle and rear foot by the peroneal artery. 
As a anatomic variations of the foot dorsalis pedis artery may be absent in 6-12% of cases; in 
this patient the lateral tarsal artery often became predominant and develop anastomosis 
through the plantar arch to the plantar circulation.  
In some cases the lateral plantar artery, through plantar arch, is the predominant artery for 
the I toe. In a few cases has been described the absence of plantar arch, in this situation the 
dorsalis pedis is the predominant artery for the I and II toe and the lateral plantar artery, is 
the predominant artery supplying the III, IV and V toe.  
4.2 Angiosome and wound related artery concept 
The angiosome principle was defined by Ian Taylor’s landmark anatomic study and divides 
the body into individual angiosomes: three-dimensional blocks of tissue fed by “source” 
arteries. He defined an angiosome as a three-dimensional anatomic unit of tissue fed by a 
source artery and defined at least 40 angiosomes in the body, including six in the foot and 
ankle region. Adjacent angiosomes are bordered by choke vessels, which link neighboring 
angiosomes to one another and demarcate the border of each angiosome. In addition, these 
choke vessels are important safety conduits that allow a given angiosome to provide blood 
flow to an adjacent angiosome if the latter’s source artery is damaged (Calligari PR, et al. 
1992; Taylor GI, et al. 1992a, 1992b). 
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The concept that divides the body into three-dimensional vascular territories supplied by 
specific source arteries, known as the angiosome principle, was introduced by Taylor and 
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wounds at foot and ankle level. In particular, the angiosome concept can help to select the 
target vessel for revascularization, that is, the artery which will yield the best local results. 
4.1 Normal vascular anatomy and main variations 
By definition the popliteal artery ends at the origin of the first tibial artery, which typically is 
the Anterior Tibial Artery. In about 4% of cases we find a so-called high origin of the 
Anterior tibial Artery at the level of the knee joint or even some centimetres more proximal. 
Similarly, in a small proportion of the population (1-2%) a high origin of the posterior tibial 
artery has been described. Normally, the direct continuation of the popliteal artery, after the 
branch of the anterior tibial artery, is the tibioperoneal trunk. This vascular segment splits 
into the posterior tibial artery and the peroneal artery (Fig. 1). 
As a variation, a triforcation of the popliteal artery into all three lower leg arteries at the 
same point has been observed in 0.4% of patients. The posterior tibial artery may be missing 
completely in 1-5% of a normal adult population. 
The vascular anatomy of the foot is composed of the anterior and posterior circulation, 
connected through the pedal arches. The anterior tibial artery continues into the dorsal 
pedal artery. The posterior tibial artery continues into the common plantar artery and then 
in the lateral and medial plantar arteries. The peroneal artery splits above the ankle joint 
into and anterior and posterior branch, the ramus perforans that anastomoses with the 
dorsal pedal artery, and the ramus communicans that anastomoses with the plantar arteries. 
The dorsalis pedis artery and the lateral plantar artery communicate via the plantar arch 
(Fig. 2 and Fig. 3). 
The digital branches origin from the plantar arch and there are a dorsal and plantar 
branches for each toe. The plantar digital branch for first toe ususally origin from medial 
plantar artery. 
Both tibial arteries, together with the peroneal artery, supply different portions of the foot 
and ankle. The plantar foot and the medial ankle are fed by the posterior tibial artery, the 
anterior ankle and the dorsum of the foot by the anterior tibial artery, and the antero-lateral 
ankle and rear foot by the peroneal artery. 
As a anatomic variations of the foot dorsalis pedis artery may be absent in 6-12% of cases; in 
this patient the lateral tarsal artery often became predominant and develop anastomosis 
through the plantar arch to the plantar circulation.  
In some cases the lateral plantar artery, through plantar arch, is the predominant artery for 
the I toe. In a few cases has been described the absence of plantar arch, in this situation the 
dorsalis pedis is the predominant artery for the I and II toe and the lateral plantar artery, is 
the predominant artery supplying the III, IV and V toe.  
4.2 Angiosome and wound related artery concept 
The angiosome principle was defined by Ian Taylor’s landmark anatomic study and divides 
the body into individual angiosomes: three-dimensional blocks of tissue fed by “source” 
arteries. He defined an angiosome as a three-dimensional anatomic unit of tissue fed by a 
source artery and defined at least 40 angiosomes in the body, including six in the foot and 
ankle region. Adjacent angiosomes are bordered by choke vessels, which link neighboring 
angiosomes to one another and demarcate the border of each angiosome. In addition, these 
choke vessels are important safety conduits that allow a given angiosome to provide blood 
flow to an adjacent angiosome if the latter’s source artery is damaged (Calligari PR, et al. 
1992; Taylor GI, et al. 1992a, 1992b). 
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Fig. 1. A. Anteroposterior view of the tibial trifurcation show anterior tibial artery ( ), tibio-
peroneal trunk ( ), peroneal artery ( ) and posterior tibial artery ( ). B. Lateral view at the 
distal leg and ankle level show the anterior ( ) and posterior ( )tibial arteries and the 
peroneal artery ( ) with the collateral branches. 
 




Fig. 2. Anterior and dorsal circulation. The major arteries are visualized in the lateral-




Fig. 3. Posterior and plantar circulation. The major arteries are visualized in antero-posterior 
view (left side) and in the lateral-oblique view (right side) angiographic projections. 
The choke vessel system links the angiosomes to one another. A unified network is created 
so that one source artery can provide blood flow to multiple angiosomes beyond its 
immediate border. 
While the choke vessels provide an indirect connection among angiosomes, there are also 
direct arterial-arterial connections that allow blood flow to immediately bypass local 
obstructions in the vascular tree. 
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The six angiosomes of the foot and ankle originate from the three main arteries to the foot 
and ankle. The posterior tibial artery supplies the medial ankle and the plantar foot, the 
anterior tibial artery supplies the dorsum of the foot, and the peroneal artery supplies the 
anterolateral ankle and the lateral rear foot. The large angiosomes of the foot can be further 
broken into angiosomes of the major branches of the above arteries. The three main 
branches of the posterior tibial artery each supply distinct portions of the plantar foot: the 
calcaneal branch (heel), the medial plantar artery (instep), and the lateral plantar artery 
(lateral midfoot and forefoot). The two branches of the peroneal artery supply the 
anterolateral portion of the ankle and rear foot, the anterior perforating branch (lateral 
anterior upper ankle) and the calcaneal branch (plantar heel). The anterior tibial artery 
supplies the anterior ankle and then becomes the dorsalis pedis artery that supplies the 
dorsum of the foot (Attinger CE, et al. 1997; Attinger CE, et al. 2001; Sarrafain SK. 1993; 
Taylor GI, et al. 1998). 
The dorsalis pedis artery follows a curved pathway on the forefoot to join the first plantar 
space, where meets the posterior circulation through the perforating deep artery. 
In according with angiosome concept, the foot lesion location is related to an specific 
angiosome and the revascularization of this specific angiosome is our target vessel or 
wound related artery. 
5. Endovascular intervention 
Endovascular recanalization of tibial vessels and foot arteries should be the first line 
treatment in patients with CLI, because of its good technical and clinical outcomes. 
Endovascular treatment is possible in most cases, with the known low complication rate of 
PTA. In cases in which endovascular revascularization failed, all surgical options remain 
open. 
The primary indications for tibial and foot arteries intervention is limb salvage, to avoid 
amputations. Patients with chronic leg ischemia face a gloomy future, in fact, long-term 
survival rate with CLI is significantly lower than that of a matched population.  
Limb salvage is of more importance to these patients. The most plausible explanation for 
this is that healing the wounds and/or infection will reduce the oxygenation demand. 
5.1 Vessel features 
Calcified vessels are the most difficult situation in endovascular treatment, especially when 
calcifications are very dark and thick, in a visual evaluation. We propose intraluminal 
approach in very heavy calcified vessels, using dedicated 0.014' guide wire and short, low-
profile OTW dedicated catheter balloons, like coronary balloons. OTW catheter balloon are 
necessary in order to be able to inject contrast material and check the position and to change 
the wire, when necessary.  
Non calcified vessel allows different recanalization alternative, as endoluminal or 
subintimal approach. It the occluded tract is short, may be endoluminal approache could be 
the first alternative. In long occlusions, especially when there is a good distal re-entry, 
subintimal approach could be a good alternative.  
In calcified vessel, when is imposible to cross the lesion trough the true lumen and vascular 
situation are dramatic and the indications to revascularization, related to wounds on the 
foot are present, a more aggressive strategy could be adopted. A subintimal attempt is 
justified in these cases and could bring to good result. 
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5.2 Technical strategies 
Antegrade access in the common femoral artery is, in our experience, the best approach to 
perform tibial and foot arteries revascularization, with excellent guide-ability of the guide-
wire and good push-ability of the catheter balloons due to this access is closer to the lesions. 
Contra-lateral approach is indicated in cases in which iliac treatment is required or is 
possible to treat contro-lateral common femoral artery or Superficial femoral artery. In cases 
of BTK interventions makes the procedure more difficult, require long shafts catheter 
balloons, limits some technical strategies and makes complications management 
considerably more complex.  
In some selected cases antegrade access in the popliteal artery could be useful, because it is 
closer to the lesions and ensure more push-ability of the devices, but the prone position of 
the patient is required. 
Previously to begging the procedure are injected, systematically, a intra-arterial bolus of 
5.000 I.U of heparin. The patients are undergo to double anti-platelets therapy with 
ticlopidine, 250 mg daily and acetylsalicylic acid 100 mg daily, 3 days before the procedure. 
The double antiaggregation is continued for 6 weeks after the procedure and acetylsalicylic 
acid is prescribed quoad vitam.  
5.2.1 Transluminal recanalization 
Transluminal recanalization is the preferred techniques to treat stenotic lesions, very short 
occlusions (<1 cm)  (Hauser H, et al. 1996) or lesions that involve the bifurcations. In our 
experience, is the best technical strategy to recanalize calcified vessels and it could be the 
first choice in CTO lesions with very heavy calcified arteries. 
The classic approach to intraluminal recanalization use a guide-wire in conjunction with a 
support catheter to cross the lesion (Patel PJ, et al. 2010). 
In our experience we prefer to use a 0.014”-in. guide-wire (Pilot®200 - Abbott) with an 
angulated tip (45° angle), that allows to guide the guide-wire, avoiding subintimal 
progression or vessel spills. A straight CTO dedicated guide-wire can also be used, with 
good results, in calcified and insuperable lesions. 
The first step is to penetrate the proximal occlusion followed by negotiation the full extent of 
the occlusion, until the distal patent lumen. A drilling motion of the guide-wire is performed 
to properly penetrate and cross the lesion. Often times, a short and low profile coaxial catheter 
balloon can be used as a support catheter (Patel PJ, et al. 2010).  Coaxial catheter balloon 
system is preferred to monorail system, because monorail system work well when the sheath 
tip can be placed close to the lesion. Coaxial system allows to remove the guide-wire, inject 
contrast media and check the position of the catheter and, if necessary, change the guide-wire . 
When the recanalization is completed, we perform a pre-dilatation with the support catheter 
balloon. A definitive dilatation is performed with a long catheter balloon, and based in the 
authors experience, in a heavy calcified vessels we prefer to avoid dissections during PTA 
dilating the crural vessels to 2.5 mm and the foot arteries to 2 mm in diameter (Fig 4 and 5). 
Diagnostic angiography. (A-B) Obstruction of the anterior and posterior arteries, patency of 
the tibio-peroneal trunk and peroneal artery. (C-D) patency of common plantar artery, 
dorsalis pedis artery and plantar arch, in a heavy calcified vessels.  
(E-H) Intraluminale recanalization of the posterior tibial artery, lateral plantar artery, 
plantar arch and the digital branch for the first toe and angioplasty of the digital branch (1.5 
x 20 mm catheter balloon). (I-J) Intraluminal PTA of the posterior and anterior tibial arteries 
(2.5 x 220 mm catheter balloon).  
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angulated tip (45° angle), that allows to guide the guide-wire, avoiding subintimal 
progression or vessel spills. A straight CTO dedicated guide-wire can also be used, with 
good results, in calcified and insuperable lesions. 
The first step is to penetrate the proximal occlusion followed by negotiation the full extent of 
the occlusion, until the distal patent lumen. A drilling motion of the guide-wire is performed 
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Fig. 4. Case 1. Diabetic patient with apical ulcer on the first toe, TcPO2: 13 mmHg. 
Diagnostic angiography. (A-B) Obstruction of the anterior and posterior arteries, patency of 
the tibio-peroneal trunk and peroneal artery. (C-D) patency of common plantar artery, 
dorsalis pedis artery and plantar arch, in a heavy calcified vessels.  
(E-H) Intraluminale recanalization of the posterior tibial artery, lateral plantar artery, plantar 
arch and the digital branch for the first toe and angioplasty of the digital branch  
(1.5 x 20 mm catheter balloon / FlexeCTO – Clearstream). (I-J) Intraluminal PTA of the 
posterior and anterior tibial arteries (2.5 x 220 mm catheter balloon / Bantam  – Clearstream).  
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Fig. 5. Case 1. Technical and clinical results. 
(A-D) Angiographic results of the intraluminal recanalization of the anterior and posterior 
tibial arteries; lateral plantar and dorsali pedis arteries, plantar arch and the first digital 
branch, with excellent blood flow in the target vessel. 
Clinical follow up at 4 months show increased of the TcPO2 to  42 mmHg and ulcer healing, 
avoiding amputation. 
5.2.2 Subintimal recanalization 
On the other hand, when the arteries are not calcified or low and incomplete calcifications are 
observed, a subintimal recanalization is proposed as the first technical strategy. Subintimal 
angioplasty was first described by Bolia (Bolia A et al. 1990) and since them there have been a 
lot of publications confirming the value and assess the clinical results of this technique to treat 
tibial vessels (Alexandrescu V, et al. 2009; Bolia A, et al. 1994, Bown MJ, et al. 2009; Chun JY, et 
al. 2010; Ingle H, et al. 2002; Met R, et al. 2008; Reekers J, et al. 1994, Spinosa DJ, et al. 2004). 
A subintimal recanalization in a heavy calcified crural vessels can also be considered, after 
failure of intraluminal attempts, with the impossibility to cross the lesion (Bolia A. 1998.) 
This technical strategy could also be used in Pedal arteries and a published paper described 
this technical option to recanalize the Pedal arch (Fusaro M, et al. 2007). 
The principal advantages of this technique are the ability to cross long chronic occlusions 
and the option of recanalization of more than one crural vessel. In our experience, the failure 
of this technical strategy is related to heavy calcified vessels, with fissuring the arterial wall 
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during the subintimal progression of the guide-wire, rupture of the arterial wall and failure 
of the recanalization. 
We perform a subintimal recanalization in crural arteries with a 0.018”-in guide-wire (V18® 
- Boston Scientific) or, less frequent, with 0.014”-in guide-wire (Pilot®200 - Abbott).  
The 0.014”-in guide-wire should be preferred to perform a subintimal recanalization in the 
Pedal arteries.  
Is also possible to perform a subintimal dissection using a 0.035”-in hydrophilic guide-wire, 
but in our opinion this more aggressive approach in reserved for cases with heavy calcified 
vessel and is not indicated for Pedal arteries recanalization. A diagnostic catheter 
(Berenstain II® - Cordis) or a balloon catheter, is used to support the guide-wire during 
subintimal progression.  
We prefer to avoid a pre-dilatations of the subintimal dissection before to reach the distal 
patent lumen and check the re-entry. This is just a modification of Bolia technique, in order to 
avoid the risk of potential bleeding secondary to vessel perforation or to prevent the dilatation 
of the subintimal dissection that could not re-entry and could need to change the subintimal 
way to obtain technical success.  When the re-entry is achieve, we change a guide-wire with a 
new one, usually 0.014”-in to avoid spasm in the foot arteries and Pedal arch.   
After pedal distal patent lumen recanalization, we deploy a low profile catheter balloon and 
perform a pre-dilatations of the crural vessel. After short balloon pre-dilatation, a longer one 
can be placed and a final dilatation performed. We usually dilate crural vessels with a 3 mm 
diameter balloon and Pedal arteries, including Pedal arch with 2.5 mm diameter balloon. 
When the result is still not satisfactory, dilatation can be repeated. 
In a recent published study (Met R, et al. 2005) a systematic review showed that subintimal 
recanalization can be a useful option in the treatment of patients with CLI, with primary 
success rate of 80-90% and 1 year limb salvage rate as high as 90% and conclude that despite 
the moderate long-term patency rates of the revascularized segments, subintimal angioplasty 
may serve as a “temporary by-pass”, providing wound healing and limb salvage. 
5.3 Antegrade and retrograde recanalization 
In our experience antegrade approach should be the first choice to treat tibial vessels and 
foot arteries and a retrograde recanalization should be seen as a support or problem solving 
strategy, in cases of antegrade failure, such as the inability to re-enter in the true patent 
distal lumen after subintimal recanalization. 
In this context, the retrograde recanalization can be performed and there are different 
technical options, such as trans-collateral navigation and retrograde recanalization, Pedal-
Plantar Loop technique or, retrograde distal access and recanalization.  
In our opinion, perform a distal retrograde access is the last technical strategy in order to 
create a re-entry or resolve problems. 
5.3.1 Trans-collateral recanalization 
In many cases of extreme vascular intervention, it is not possible to perform regular 
antegrade recanalization of occluded tibial arteries, which makes even the most expert 
interventionist resort to unusual techniques (Bolia A, 2005; Fusaro M, et al. 2008; Graziani L, 
et al. 2008, 2011) to restore direct blood flow to the foot. Combined retrograde-antegrade 
arterial recanalization through collateral vessels, essentially combined retrograde and 
antegrade arterial recanalization using a single entry site. 
This technical strategy, largely tested by the authors, has been described in published papers 
(Fusaro M, et al 2008, Graziani L, et al. 2011) and is intended as option to recanalize tibial arteries.  
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of the subintimal dissection that could not re-entry and could need to change the subintimal 
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new one, usually 0.014”-in to avoid spasm in the foot arteries and Pedal arch.   
After pedal distal patent lumen recanalization, we deploy a low profile catheter balloon and 
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the moderate long-term patency rates of the revascularized segments, subintimal angioplasty 
may serve as a “temporary by-pass”, providing wound healing and limb salvage. 
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technical options, such as trans-collateral navigation and retrograde recanalization, Pedal-
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This technical strategy, largely tested by the authors, has been described in published papers 
(Fusaro M, et al 2008, Graziani L, et al. 2011) and is intended as option to recanalize tibial arteries.  
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In our experience it could also be used to recanalize foot arteries, using a natural anastomoses 
in the foot, such as the so-called “Deep arch” of the foot, that communicate medial plantar 
artery with lateral tarsal branch and can be tracking in each other sense, to recanalize anterior 
or posterior tibial artery or in order to arrive to the Pedal arch, through the tarsal branch. 
In the same way, there is a natural anastomoses between peroneal artery and the “Deep 
arch” of the foot (Palena LM, et al. 2011), through a perforating deep branch and tracking 
this way  is possible to retrogradely racanalize the other tibial arteries,  via peroneal artery, 
using a “Deep arch” of the foot.  
The vessels are finally recanalized by antegrade PTA (Fig. 6 and 7). 
There are another collateral ways or natural anastomoses between tibial and foot arteries 
that allows to perform retrograde-antegrade recanalization of the tibial and the foot arteries, 
and its represent an alternative option to recanalize the target vessel.  
However, the use of this technique may be considered selectively, even in last-attempt 
efforts, when other options are not possible or are contraindicated. This technique may be of 
value specifically when a proximal occlusion stump is not evident, when a dissection flap or 
a perforation in the proximal tract of the target vessel impairs guide-wire advancement. 
This technique may represent a feasible endovascular option to avoid more invasive, time-
consuming or riskier procedures. 
 
 
Fig. 6. Case 2. Diabetic patient with amputation of the II and V toes, previously undergone 
to endovascular treatment with poor outcome and guide-wire fracture at the origin of the 
dorsalis pedis artery with loss the rest of the wire in a subintimal lumen. TcPO2: 6 mmHg.  
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(A-D) Diagnostic angiography shown patency of the posterior tibial artery and obstruction 
of the peroneal and anterior tibial arteries. On the foot patency of the first tract of the medial 









Fig. 6. (cont). (F-H) recanalization of the peroneal artery and, through the “deep arch”, 
retrogradely recanalization of the anterior tibial artery. After antegrade catheterization of the 
anterior tibial artery, (I) injection of the contrast material shown patency of the lateral tarsal 
branch. (J-K) PTA of the lateral tarsal branch (2 x 40 mm / FlexeCTO – Clearstream) and PTA 
of the anterior tibial artery (2.5 x 220 mm catheter balloon / Bantam  – Clearstream). 
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(A-D) Diagnostic angiography shown patency of the posterior tibial artery and obstruction 
of the peroneal and anterior tibial arteries. On the foot patency of the first tract of the medial 









Fig. 6. (cont). (F-H) recanalization of the peroneal artery and, through the “deep arch”, 
retrogradely recanalization of the anterior tibial artery. After antegrade catheterization of the 
anterior tibial artery, (I) injection of the contrast material shown patency of the lateral tarsal 
branch. (J-K) PTA of the lateral tarsal branch (2 x 40 mm / FlexeCTO – Clearstream) and PTA 
of the anterior tibial artery (2.5 x 220 mm catheter balloon / Bantam  – Clearstream). 
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Fig. 7. Angiographic results. (A-B) Recanalization of the anterior and peroneal arteries, 
patency of the posterior tibial artery. (C-D) Recanalization of the lateral tarsal branch and 
plantar arch, with good blood flow for the foot and the toes. 
Clinical follow up. TcPO2 increased to 37 mmHg with healing the surgical treatment. 
5.3.2 Pedal-Plantar LOOP technique 
In a high percentage of cases the success rate of PTA remains suboptimal, particularly when 
the atherosclerotic disease involving also the distal run-off. In these cases the support of 
Pedal-Plantar LOOP technique could be necessary. 
This technical approach, intended for the recanalization of challenging below-the-knee and 
below-the-ankle lesions,  has been  already described (Fusaro M, et al 2007) and the clinical 
results of its application in revascularization of tibial and foot vessels has thoroughly been 
described in a recent paper (Manzi M, et al. 2009).  
Specifically, this technique consist in either one or both the following two approaches: 
antegrade recanalization of the anterior tibial artery and the pedal artery, including the 
pedal arch, followed by retrograde recanalization of the lateral plantar artery and then of the 
posterior tibial artery; or antegrade recanalization of the posterior tibial artery and the 
lateral plantar artery, including pedal arch, followed by retrograde recanalization of the 
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pedal artery and then of the anterior tibial artery. After successfully crossing the target 
lesion with the guide-wire, usually 0.014”-in (Pilot® 200 - Abbott), a dedicated low-profile 
over-the-wire catheter balloon should be deployed for PTA and the check to confirm the 
position of the tip of the catheter in the distal true lumen should be done, injecting contrast 
media through the catheter. 
Pedal-Plantar LOOP technique is based on the creation of a loop with the guide-wire from 
the anterior tibial to the posterior tibial arteries (or vice versa) by means of guide-wire 
tracking through the pedal arch of the foot. 
Clearly, this strategy can be adapted case by case and a combination of other technical 
possibilities, such as subintimal recanalization of the tibial vessel recanalized antegradely, 
followed by a re-entry on the foot artery or a subintimal recanalization of the foot and tibial 
artery recanalized retrogradely, followed by a re-entry at the origin of the tibial vessel, could 
help to reach both, technical and clinical success. 
This technique may be of particular value whenever a proximal occlusion stump is 
unavailable, when dissection flap or a perforation in the proximal tract of the target vessel 
impairs the guide-wire advancement, as well as when distal disease makes retrograde 
percutaneous puncture impossible. 
5.3.3 Retrograde percutaneous revascularization 
In our opinion this should be the last technical strategy, considered when the possible 
solutions before described failed.  
It is intended as a direct percutaneous retrograde puncture of the distal tract of the  
tibial vessel or foot arteries, in order to retrogradely recanalization of the target vessel  
(Fig. 8 and 9). 
This approach has been described as a solution for the re-entry in a subintimal 
recanalization (Gandini R, et al. 2007; Spinosa DJ, et al 2003, 2005), that in a small 
percentage of patients in whom antegrade subintimal recanalization is unsuccessful or 
there is a limited distal target vessel “landing” zone, a retrograde distal puncture can be 
performed and a retrograde recanalization, following by antegrade PTA  and haemostasis 
may be a solution. 
The possible retrograde access site may be different, such as distal tract of the posterior 
tibial artery, pedal artery (Fusaro M, et al. 2006, 2007) or peroneal artery, but the 
difficulties to perform the puncture increase from each other site and the risk to damage 
the distal patent vessel, compromising the possibility to perform a distal by-pass, should 
be considered. 
In our experience, in selected and very challenging cases in whom a distal by pass is 
contraindicated, antegrade revascularization attempts failed and retrograde percutaneous 
distal access on the target vessel is not possible or failed too, an antegrade percutaneous 
distal access on the Pedal artery or in the common plantar artery, followed by antegrade 
recanalization of the foot artery, pedal arch and retrograde recanalization of the target 
vessel, is possible, but should be considered as indication in cases in whom every other 
endovascular or surgical strategy failed or are contraindicated. 
Endovascular recanalization of the tibial vessels and foot arteries, especially in diabetics 
with CLI is actually an excellent treatment option and, in our experience, should be 
considered as the first treatment option for revascularization. Different clinical studies 
and registries show that technical success rate is between 80% and 90% and clinical 
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help to reach both, technical and clinical success. 
This technique may be of particular value whenever a proximal occlusion stump is 
unavailable, when dissection flap or a perforation in the proximal tract of the target vessel 
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percentage of patients in whom antegrade subintimal recanalization is unsuccessful or 
there is a limited distal target vessel “landing” zone, a retrograde distal puncture can be 
performed and a retrograde recanalization, following by antegrade PTA  and haemostasis 
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The possible retrograde access site may be different, such as distal tract of the posterior 
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difficulties to perform the puncture increase from each other site and the risk to damage 
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distal access on the Pedal artery or in the common plantar artery, followed by antegrade 
recanalization of the foot artery, pedal arch and retrograde recanalization of the target 
vessel, is possible, but should be considered as indication in cases in whom every other 
endovascular or surgical strategy failed or are contraindicated. 
Endovascular recanalization of the tibial vessels and foot arteries, especially in diabetics 
with CLI is actually an excellent treatment option and, in our experience, should be 
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success rate, intended as limb salvage, is about 70% at 12 months. These technical and 
clinical outcomes are obtained in a dedicated centers, combining all technical strategies 
described before. 
Stent deployment in the below-the-knee district, in our opinion, should be considered  
as the last treatment option, because in-stent re-stenosis and occlusion related to neo-
intimal hyperplasia or struts fractures, is a frequent complication and the presence of 




































Fig. 8. Case 3. Diabetics patient, previously underwent to TMA, with apical ischemic 
wound. The patient was underwent to endovascular treatment and stenting in the tibio-
peroneal trunk, without any stump of the posterior tibial artery origin. TcPO2: 4 mmHg. (A-
E) Oclussione of the SFA with stent, occluded in the distal tract. Patency of the popliteal 
artery and the tibio-peronel trunk, with in-stent re-stenosis and patency of the peroneal 
artery and the distal truck of the posterior tibial artery. On the foot patency of the plantar 
arteries. (F-I) Retrograde puncture of the distal tract of the posterior tibial artery and 
retrograde recanalization. Antegrade long balloon PTA (2.5 x 220 mm catheter balloon / 
Bantam  – Clearstream). 
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Fig. 9. (A-F) After PTA of the SFA and Popliteal arteries, the angiographic study show 
patency of the femoro-popliteal tract, patency of the tibio-peroneal trunk and posterior tibial 
artery with excellent flow for the plantar arteries and for the apical lesion on the foot. 
Clinical follow up. TcPO2 increased to 33 mmHg with wound healing. 
6. Materials 
During the last years the development of the BTK techniques and the increasing rate of BTK 
interventionists have led a continuous expansion of the dedicated materials. 
Actually, there are a huge different type of dedicated guide-wire, from 0.014”-in and 0,018”-
in to the 0,035”-in or CTO guide-wire, from different manufacturers, all usefully and 
necessary in the interventional suite. 
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In the same context, a lot of dedicated catheter balloons are actually available, from long 
balloons such as 22 cm or longer, to short and coronary-like such as 2 cm; and from 1.25 mm 
in diameter to 3 mm.  
The selection of the guide-wire and the catheter balloons should be done on the personal 
preferences and experience, but the availability of different materials, from different 
manufacturer would be useful and necessary to perform very challenging cases. 
7. New frontiers and devices 
Current results of minimally invasive endovascular techniques, with 2-years patency rate 
between 40 and 60%, low primary patency and increased repeat intervention rates, has 
oriented toward new alternative techniques. 
7.1 Atherectomy 
Percutaneous angioplasty of below-the-knee arteries is an accepted therapy for patients with 
critical limb ischemia (Buckenham TM, et al. 1993; Hanna GP, et al. 1997; Saab MH, et al. 
1992; Soder HK, et al. 2000).  
However, below-the-knee interventions are limited by a considerable number of re-stenosis, 
especially in lesions with heavy calcified plaque. Directional atherectomy may be an 
alternative option to improve the procedural success and reduce the re-stenosis rate and the 
re-intervention rate (McKinseyJF, et al. 2008; Zeller T, et al. 2004, 2007).  
In our opinion this debulking device is indicated especially in cases of re-stenosis, but also is 
an excellent option to treat bifurcations and could be used to treat in-stent re-stenosis, 
despite this indication (in-stent treatment) is contraindicated by the manufacturer. 
Atherectomy should be prefer to traditional PTA in the popliteal artery, because of excellent 
technical results, avoiding dissection and stenting (Fig. 10).  
New dedicated BTK devices, with range from 2 to 4 mm in diameter, very small caliber 
design and excellent push-ability allow the recanalization of long occlusion, involving tibial 
vessels and/or foot arteries.  
The atherectomy cutter catheter usually need a 6F sheath and is designed to track over a 
0.014”-in guide-wire. Is recommended to use atherectomy crossing the lesion intraluminally, 
because of the potential risk of perforation during subintimal debulking. Cases of stenosis 
can be treated with primary atherectomy whereas occlusions should be pre-dilated with an 
undersized catheter balloon, to be sure that the guide-wire crosses the occlusion 
intraluminally and to guaranty the progression of the cutter catheter through the occlusion.  
Rotational atherectomy is also a useful technical strategy for calcified vessels. The limits of 
this technique is the push-ability of the device, that usually require long sheath deployment 
into the tibial vessel. 
After atherectomy, usually, is not necessary perform catheter balloon dilatation, because the 
atherectomy results  are satisfactory when the debulking procedure is performed correctly, 
cutting in the four faces of the artery wall. 
This technique present low rate of complications and could be the option to avoid stent 
deployment with significant advantage in cases of re-stenosis, allowing the endovascular re-
intervention.  
Promising acute and long-term clinical results, with a high rate of limb salvage and high rate 
of primary and secondary patency (McKinsey, et al. 2008), makes this technical strategy an 
excellent option for endovascular treatment in the below-the-knee district. 
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The other possible solution to fight re-stenosis in the BTK district could be Drug eluting 
balloons. This new technology, Paclitaxel-coated balloons should be a potential role in the 
peripheral district (Manzi M, et al. 2010; Sharma S, et al. 2010; Waksman P, et al. 2009) to 
avoid re-stenosis due to the antiproliferative effect. The use of DEB is not technically 
complex and there are, actually, a wide range of different devices. Despite the encouraging 
data on coronary arteries where drug eluting devices have shown promising antirestenotic 
effects in experimental and clinical trials, a clinical results in BTK district, early experimental 
and clinical data are promising but a randomized controlled trials, comparing DEB and 
traditional angioplasty or DEB and atherectomy must be produced. 
The limits of DEB’s, in our experience, is the use of this device in a subintimal 
recanalization. DEB’s are preferred to be used in intraluminal recanalization, due to the risk 
of pseudo-aneurism formation during subintimal recanalization. 
7.3 Cryoplasty 
The rational to use this technology is based in the presumed more uniform and less 
traumatic immediate performance of cryoplasty, in synergy with the induction of  
the apoptotic effect , that would result in less neo-intimal hyperplasia and, as consequence, 
better immediate and long-term angiographic and clinical results (Sipiliopoulos S, et  
al. 2010). 
The data about 12-months follow-up from the BTK Chill trial (Das TS, et al. 2009), which 
evaluated cryoplasty in the infra-popliteal district of CLI patients, reported high rates of acute 
technical  success and major amputation-free interval (97.3% and 78.5%, respectively) followed 
by a low percentage of repeated procedure due to clinically deterioration (21% at 12 months). 
We simply report the data published in the actual literature, because we do not have 
experience with this technical strategy, but the technical and clinical result are encouraging. 
It seem to avoids stent deployment, with the mentioned benefits in the BTK district. 
However, more experience are expected and could be useful more data about bigger cohort 
of patients. 
7.4 Laser 
The excimer laser technology is based on a cold-tipped laser that delivers intense bursts of 
energy in the ultraviolet range (308 nm) carried out in ultra-short pulse duration (0.05 nm 
per pulse vs 0.3-2.0 mm per pulse in the hot-tip laser). The energy delivered elicits 
photochemical, photothermal and photomechanical actions, which break molecular bonds, 
and produce vapor bubbles that generate kinetic energy (Serino F, et al. 2010). 
This technology has been studied in below-the-knee lesions, with improved results over 
standard PTA alone and exhibited excellent limb salvage rate (Bosier M, et al 2005; Laird JR, 
et al.2006). The use of the excimer laser represents a great opportunity to pursue a true 
endoluminal recanalization with potential long-term efficacy and decreased need for 
stenting.  The LACI and LACI Belgium study have both proven that laser-assisted 
angioplasty is a low risk, successful treatment strategy in CLI patients. Primary patency rate 
range from 83% at 6-months to 97.6% at 12-months and the limb salvage rate range from 
92.5% at 6-months to 94% at 12-months. However, the reported rate of stent deployment in 
the mentioned study was in a range from 21% to 52.9%, and this seem to be a contradiction 
between the opportunity to pursue the reduction of stent deployment that is at the bases of 
the use of this device and the real data reported about stent placement. 
 




Fig. 10. Case 4. Diabetic patient with claudication intermittens (50 m). (A-B) Diagnostic 
angiography shows occlusion in the popliteal artery. (C) shows directional atherectomy of 
the occluded tract. (D-F) angiographic result shows excellent recanalization of the popliteal 
artery, without dissection, avoiding stenting and patency in flexion position. 
8. Stent deployment 
Finally, we want to express our opinion about stent deployment in the BTK district. In 
literature is reported the use of stent for various indications such as dissections, calcified re-
stenosis, recoiling and thrombus formation ( Tepe G, et al. 2007), with good clinical results.  
We are in accord with the concept that stent use translates in acute high technical success 
and good short-term patency rate, but the re-stenosis rate related to neo-intimal hyperplasia 
is very high and the presence of stent appear as a foreign body in the true or in a subintimal 
lumen, that makes re-intervention more complex or, sometimes, impossible. Our stent 
deployment rate in the BTK district in the last year, was less than 3% and it was related to 
very flow limiting dissection, especially in the bifurcations, thrombus formation with 
unsuccessful attempts to perform thrombus-aspiration and in 1 case the stent deployment 
was related to artery perforation with acute bleeding.  
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The fear that early thrombosis and late luminal loss due to intimal hyperplasia formation 
potentially leads to insufficient long-term patency rates can explain the reluctance on 
implanting stents in small diameter below-the-knee (BTK) arteries. Drug-eluting stent (DES) 
technology was developed to prevent early thrombosis and late luminal loss to potentially 
improve long-term patency rates (Bosier M, et al. 2011).  
Currently, the first level 1 evidence from prospective, randomized, controlled DESTINY and 
ACHILLES studies indicate that the implantation of DES in short lesion in the infrapopliteal 
arteries leads to favorable outcomes with high primary patency rates and a published paper 
(Rosales OR, et al. 2008.) conclude that DES is a safe and effective long-term option for CLI 
due to severe infrapopliteal arterial disease. Long-term vascular patency led to a high rate of 
limb preservation and low amputation rate.  
May be in the future, a resorbable dedicated stent conceived for the BTK district will change 
the indications for stent deployment in tibial arteries. 
9. Conclusions 
Endovascular treatment of critical limb ischemia in diabetics with crural and pedal disease 
can be an exceedingly challenging and complex problem. Technical success rate and clinical 
outcomes, with a high rate of limb salvage and amputation-free survival are encouraging, 
support the endovascular revascularization as the first treatment option and demonstrate 
that is a reasonable and effective approach. The rapid pace of development of various 
endovascular devices and techniques often allow the interventionalist to treat increasingly 
complex and diffuse patterns of disease.  
Is essential for endovascular specialist, in order to reach these technical and clinical success, 
a thorough knowledge of the wide range of endovascular techniques and options. 
Usually only one technical strategy is not enough to treat crural and foot arteries  and a 
combination of the previously described techniques improve the results of the procedures 
and allow to achieve excellent clinical outcomes. 
10. References 
Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. (2005). Bypass versus 
angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised 
controlled trial. Lancet. 3;366(9501):1925-34. 
Alexandrescu V, Hubermont G, Philips Y, Guillaumie B, Ngongang Ch, Coessens V, et al. ( 
2009). Combined primary subintimal and endoluminal angioplasty for ischaemic 
inferior-limb ulcers in diabetic patients: 5-year practice in a multidisciplinary 
'diabetic-foot' service. Eur J Vasc Endovasc Surg. 37(4):448-56.  
Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Ganotakis ES, Symeonidis 
AN, et al. (2004). METS-GREECE Collaborative Group. Prevalence of atherosclerotic 
vascular disease among subject with the metabolic syndrome with or without 
diabetes mellitus: the METS-GREECE Multicentre study. Curr Med Res Opin. 
20:1691-701. 
Attinger, C. E., Cooper, P. & Blume, P. ( 1997). Vascular anatomy of the foot and ankle. Oper. 
Tech. Plast. Reconstr. Surg. 4: 183. 
Attinger, C. E., Cooper, P., Blume, P. & Bulan, E. ( 2001). The safest surgical incision and 
amputations applying the angiosomes principle and using the Doppler to assess the 
arterialarterial connections of the foot and ankle. Foot Ankle Clin. North Am. 6: 745. 
 
Revascularization of Tibial and Foot Arteries: Below the Knee Angioplasty for Limb Salvage 
 
233 
Balmer H, Mahler F, Do DD, Triller J & Baumgartner I. (2002). Balloon angioplasty in chronic 
critical limb ischemia: factors affecting clinical and angiographic outcome. J Endovasc 
Ther. 9(4):403-10. 
Bargellini I, Petruzzi P, Scatena A, Cioni R, Cicorelli A, Vignali C, et al. (2008). Primary 
infrainguinal subintimal angioplasty in diabetic patients. Cardiovasc Intervent radiol. 
31:713-22. 
Beckman JA, Creager MA & Libby P. (2002). Diabetes and atherosclerosis. Epidemiology, 
pathophysiology and management. JAMA 287:2570-81. 
Boiser M, Deloose K, Callaert J, Keirse K, Verbist J & Peeters P.  (2011). Drug-eluting stents 
below the knee. J Cardiovasc Surg (Torino) 52(2):231-4. 
Boiser M, Peeters P, Elst FV, Vermassen F, Maleux G, Fourneau I, et al. (2005). Excimer laser 
assisted angioplasty for critical limb ischemia: results of the LACI Belgium study. Eur 
J Vasc Endovasc Surg  29:613-9. 
Bolia A, Miles KA, Brennan J & Bell PR. (1990). Percutaneous transluminal angioplasty of 
occlusions of the femoral and popliteal arteries by subintimal dissection. Cardiovasc 
Intervent Radiol. 13(6):357-63. 
Bolia A, Sayers RD, Thompson MM & Bell PR. (1994). Subintimal and intraluminal 
recanalisation of occluded crural arteries by percutaneous balloon angioplasty. Eur J 
Vasc Surg. 8(2):214-9. 
Bolia A. (1998). Percutaneous intentional extraluminal (subintimal) recanalization of crural 
vessels in lower limb ischemia: long-term results. J Endovasc Ther 9:411-16. 
Bolia A. (2005). Subintimal angioplasty in lower limb ischaemia. J Cardiovasc Surg (Torino) 
46:385–394. 
Bown MJ, Bolia A & Sutton AJ. (2009). Subintimal angioplasty: meta-analytical evidence of 
clinical utility. Eur J Vasc Endovasc Surg. 38(3):323-37.  
Buckenham TM, Loh A, Dormandy JA & Taylor RS. (1993). Infrapopliteal angioplasty for limb 
salvage. Eur J Vasc Surg 7:21-5. 
Calligari, P.R., Taylor, G. I., Caddy, C. M. & Minabe, T. (1992). An anatomic review of the 
delay phenomenon: I. Experimental studies. Plast. Reconstr. Surg. 89: 397. 
Chun JY, Markose G & Bolia A. (2010). Developments in subintimal angioplasty in the 
infrainguinal segment. J Cardiovasc Surg (Torino) 51(2):213-21.  
Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S & Goodman D. (1985). The 
prevalence of peripheral arterial disease in a defined population. Circulation 
71(3):510-551. 
Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, et al. (2005). Ethnicity and 
peripheral arterial disease: the San Diego Population Study. Circulation 112(17):2703-
2707. 
Das TS, McNamara T, Gray B, Sedillo GJ, Turley BR, Kollmeyer K, et al. (2009). Primary 
cryoplasty therapy provides durable support for limb salvage in critical limb 
ischemia patients with infrapopliteal lesions: 12-months follow-up results from chill 
trial. J Endovasc Ther 16(suppl 2):I119-I130. 
Dorros G, Jaff MR, Dorros AM, Mathiak LM & He T. (2001). Tibioperoneal (outflow lesion) 
angioplasty can be used as primary treatment in 235 patients with critical limb 
ischemia: five-year follow-up. Circulation 23;104(17):2057-62. 
Faglia E, Dalla Paola L, Clerici G, Clerissi J, Graziani L, Fusaro M. et al. (2005). Peripheral 
angioplasty as the first-choice revascularization procedure in diabetic patients with 
critical limb ischemia: prospective study of 993 consecutive patients hospitalized and 
followed between 1999 and 2003. Eur J Vasc Endovasc Surg. 29(6):620-7. 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
232 
The fear that early thrombosis and late luminal loss due to intimal hyperplasia formation 
potentially leads to insufficient long-term patency rates can explain the reluctance on 
implanting stents in small diameter below-the-knee (BTK) arteries. Drug-eluting stent (DES) 
technology was developed to prevent early thrombosis and late luminal loss to potentially 
improve long-term patency rates (Bosier M, et al. 2011).  
Currently, the first level 1 evidence from prospective, randomized, controlled DESTINY and 
ACHILLES studies indicate that the implantation of DES in short lesion in the infrapopliteal 
arteries leads to favorable outcomes with high primary patency rates and a published paper 
(Rosales OR, et al. 2008.) conclude that DES is a safe and effective long-term option for CLI 
due to severe infrapopliteal arterial disease. Long-term vascular patency led to a high rate of 
limb preservation and low amputation rate.  
May be in the future, a resorbable dedicated stent conceived for the BTK district will change 
the indications for stent deployment in tibial arteries. 
9. Conclusions 
Endovascular treatment of critical limb ischemia in diabetics with crural and pedal disease 
can be an exceedingly challenging and complex problem. Technical success rate and clinical 
outcomes, with a high rate of limb salvage and amputation-free survival are encouraging, 
support the endovascular revascularization as the first treatment option and demonstrate 
that is a reasonable and effective approach. The rapid pace of development of various 
endovascular devices and techniques often allow the interventionalist to treat increasingly 
complex and diffuse patterns of disease.  
Is essential for endovascular specialist, in order to reach these technical and clinical success, 
a thorough knowledge of the wide range of endovascular techniques and options. 
Usually only one technical strategy is not enough to treat crural and foot arteries  and a 
combination of the previously described techniques improve the results of the procedures 
and allow to achieve excellent clinical outcomes. 
10. References 
Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. (2005). Bypass versus 
angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised 
controlled trial. Lancet. 3;366(9501):1925-34. 
Alexandrescu V, Hubermont G, Philips Y, Guillaumie B, Ngongang Ch, Coessens V, et al. ( 
2009). Combined primary subintimal and endoluminal angioplasty for ischaemic 
inferior-limb ulcers in diabetic patients: 5-year practice in a multidisciplinary 
'diabetic-foot' service. Eur J Vasc Endovasc Surg. 37(4):448-56.  
Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Ganotakis ES, Symeonidis 
AN, et al. (2004). METS-GREECE Collaborative Group. Prevalence of atherosclerotic 
vascular disease among subject with the metabolic syndrome with or without 
diabetes mellitus: the METS-GREECE Multicentre study. Curr Med Res Opin. 
20:1691-701. 
Attinger, C. E., Cooper, P. & Blume, P. ( 1997). Vascular anatomy of the foot and ankle. Oper. 
Tech. Plast. Reconstr. Surg. 4: 183. 
Attinger, C. E., Cooper, P., Blume, P. & Bulan, E. ( 2001). The safest surgical incision and 
amputations applying the angiosomes principle and using the Doppler to assess the 
arterialarterial connections of the foot and ankle. Foot Ankle Clin. North Am. 6: 745. 
 
Revascularization of Tibial and Foot Arteries: Below the Knee Angioplasty for Limb Salvage 
 
233 
Balmer H, Mahler F, Do DD, Triller J & Baumgartner I. (2002). Balloon angioplasty in chronic 
critical limb ischemia: factors affecting clinical and angiographic outcome. J Endovasc 
Ther. 9(4):403-10. 
Bargellini I, Petruzzi P, Scatena A, Cioni R, Cicorelli A, Vignali C, et al. (2008). Primary 
infrainguinal subintimal angioplasty in diabetic patients. Cardiovasc Intervent radiol. 
31:713-22. 
Beckman JA, Creager MA & Libby P. (2002). Diabetes and atherosclerosis. Epidemiology, 
pathophysiology and management. JAMA 287:2570-81. 
Boiser M, Deloose K, Callaert J, Keirse K, Verbist J & Peeters P.  (2011). Drug-eluting stents 
below the knee. J Cardiovasc Surg (Torino) 52(2):231-4. 
Boiser M, Peeters P, Elst FV, Vermassen F, Maleux G, Fourneau I, et al. (2005). Excimer laser 
assisted angioplasty for critical limb ischemia: results of the LACI Belgium study. Eur 
J Vasc Endovasc Surg  29:613-9. 
Bolia A, Miles KA, Brennan J & Bell PR. (1990). Percutaneous transluminal angioplasty of 
occlusions of the femoral and popliteal arteries by subintimal dissection. Cardiovasc 
Intervent Radiol. 13(6):357-63. 
Bolia A, Sayers RD, Thompson MM & Bell PR. (1994). Subintimal and intraluminal 
recanalisation of occluded crural arteries by percutaneous balloon angioplasty. Eur J 
Vasc Surg. 8(2):214-9. 
Bolia A. (1998). Percutaneous intentional extraluminal (subintimal) recanalization of crural 
vessels in lower limb ischemia: long-term results. J Endovasc Ther 9:411-16. 
Bolia A. (2005). Subintimal angioplasty in lower limb ischaemia. J Cardiovasc Surg (Torino) 
46:385–394. 
Bown MJ, Bolia A & Sutton AJ. (2009). Subintimal angioplasty: meta-analytical evidence of 
clinical utility. Eur J Vasc Endovasc Surg. 38(3):323-37.  
Buckenham TM, Loh A, Dormandy JA & Taylor RS. (1993). Infrapopliteal angioplasty for limb 
salvage. Eur J Vasc Surg 7:21-5. 
Calligari, P.R., Taylor, G. I., Caddy, C. M. & Minabe, T. (1992). An anatomic review of the 
delay phenomenon: I. Experimental studies. Plast. Reconstr. Surg. 89: 397. 
Chun JY, Markose G & Bolia A. (2010). Developments in subintimal angioplasty in the 
infrainguinal segment. J Cardiovasc Surg (Torino) 51(2):213-21.  
Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S & Goodman D. (1985). The 
prevalence of peripheral arterial disease in a defined population. Circulation 
71(3):510-551. 
Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, et al. (2005). Ethnicity and 
peripheral arterial disease: the San Diego Population Study. Circulation 112(17):2703-
2707. 
Das TS, McNamara T, Gray B, Sedillo GJ, Turley BR, Kollmeyer K, et al. (2009). Primary 
cryoplasty therapy provides durable support for limb salvage in critical limb 
ischemia patients with infrapopliteal lesions: 12-months follow-up results from chill 
trial. J Endovasc Ther 16(suppl 2):I119-I130. 
Dorros G, Jaff MR, Dorros AM, Mathiak LM & He T. (2001). Tibioperoneal (outflow lesion) 
angioplasty can be used as primary treatment in 235 patients with critical limb 
ischemia: five-year follow-up. Circulation 23;104(17):2057-62. 
Faglia E, Dalla Paola L, Clerici G, Clerissi J, Graziani L, Fusaro M. et al. (2005). Peripheral 
angioplasty as the first-choice revascularization procedure in diabetic patients with 
critical limb ischemia: prospective study of 993 consecutive patients hospitalized and 
followed between 1999 and 2003. Eur J Vasc Endovasc Surg. 29(6):620-7. 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
234 
Faglia E, Clerici G, Clerissi J, Gabrielli L, Losa S, Mantero M, et al. (2006). Early and five-year 
amputation and survival rate of diabetic patients with critical limb ischemia: data of a 
cohort study of 564 patients. Eur J Vasc Endovasc Surg. 32(5):484-90.  
Ferraresi R, Centola M, Ferlini M, Da Ros R, Caravaggi C, Assaloni R, et al. (2009). Long-term 
outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients 
with critical limb ischaemia. Eur J Vasc Endovasc Surg. 37(3):336-42. 
Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV & Prescott RJ. (1991). 
Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral 
arterial disease in the general population. Int J Epidemiol 20(2):384-392 
Fusaro M, Agostoni P & Biondi-Zoccai G. (2008). ‘‘Trans-Collateral’’ Angioplasty for a 
Challenging Chronic Total Occlusion of the Tibial Vessels: A Novel Approach to 
Percutaneous Revascularization in Critical Lower Limb Ischemia. Catheterization and 
Cardiovascular Interventions 71:268-72  
Fusaro M, Dalla Paola L & Biondi-Zoccai G. (2007). Pedal-Plantar LOOP Technique for a 
challenging below-the-knee chronic total occlusion: a novel approach to percutaneous 
revascularization in critical lower limb ischemia. J Invasive Cardiol 19:E34-7. 
Fusaro M, Dalla Paola L & Biondi-Zoccai G. (2006). Retrograde posterior tibial artery access for 
below-the-knee percutaneos revascularization by means of sheathless approach and 
double wire technique. Minerva Cardioangiol. 54:773-7. 
Fusaro M, Dalla Paola L, Brigato C, Marangotto M, Nicolini S, Rripay R, et al. (2007). Plantar to 
dorsalis pedis artery subintimal angioplasty in a patient with critical foot ischemia: a 
novel technique in the armamentarium of the peripheral interventionist. J Cardiovasc 
Med (Hagerstown) 8(11):977-80. 
Fusaro M, Tashani A, Mollicheli N, Medda M, Inglese L & Biondi-Zoccai G. (2007). Retrograde 
pedal artery access for below-the-knee percutaneous revascularisation. J Cardiovasc 
Med (Hagerstown) 8:216-8. 
Gandini R, Pipitone V, Stefanini M, Maresca L, Spinelli A, Colangelo V, et al. (2007). The 
‘‘Safari’’ Technique to Perform Difficult Subintimal Infragenicular Vessels. 
Cardiovasc Intervent Radiol 30:469-73. 
Graziani L, Silvestro A, Monge L, Boffano GM, Kokaly F, Casadidio I, et al. (2008). 
Transluminal angioplasty of peroneal artery branches in diabetics: initial technical 
experience. Cardiovasc Interv Radiol 31:49–55 
Graziani L & Morelli LG. (2011). Combined Retrograde–Antegrade Arterial Recanalization 
Through Collateral Vessels: Redefinition of the Technique for Below-the-Knee 
Arteries. Cardiovasc Intervent Radiol 34:S78–S82 
Hanna GP, Fujise K, Kjellgren O, GP, Feld S, Fife C, Schroth G, et al. (1997). Infrapopliteal 
transcatheter interventions for limb salvage in diabetic patients: importance of 
aggressive interventional approach and role of transcutaneous oximetry. J Am Coll 
Cardiol 30:664-9. 
Häuser H, Bohndorf K, Wack C, Tietze W, Wölfle KD & Loeprecht H. Percutaneous 
transluminal angioplasty (PTA) of isolated crural arterial stenoses in critical arterial 
occlusive disease. Rofo. 164(3):238-43. 
Hiatt WR, Hoag S & Hamman RF. (1995). Effect of diagnostic criteria on the prevalence of 
peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 
91(5):1472-1479. 
Ingle H, Nasim A, Bolia A, Fishwick G, Naylor R, Bell PR, et al. (2002). Subintimal angioplasty 
of isolated infragenicular vessels in lower limb ischemia: long-term results. J 
Endovasc Ther. 9(4):411-6. Erratum in: J Endovasc Ther 9(5):A-6.  
 
Revascularization of Tibial and Foot Arteries: Below the Knee Angioplasty for Limb Salvage 
 
235 
Kullo IJ, Bailey KR, Kardia SL, Mosley TH, Jr., Boerwinkle E &Turner ST. (2003). Ethnic 
differences in peripheral arterial disease in the NHLBI Genetic Epidemiology 
Network of Arteriopathy (GENOA) study. Vasc Med 8(4):237-242. 
Laird JR, Zeller T, Gray BH, Scheinert D, Vranic M, Reiser C, et al. (2006). LACI investigators. 
Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of 
the LACI multicenter trial. J Endovasc Ther. 13:1-11. 
Manzi M, Cester G & Palena LM. (2010). Paclitaxel-coated balloon angioplasty for lower 
extremity revascularization: a new way to fight in-stent restenosis. J Cardiovasc Surg 
51:567-71. 
Manzi M, Fusaro M, Ceccacci T, Erente G, Dalla Paola L & Brocco E. (2009). Clinical results of 
below-the-knee intervention using pedal-plantar loop technique for the 
revascularization of foot arteries. J Cardiovasc Surg 50:331-7. 
McKinsey JF, Goldstein L, Khan HU, Graham A, Rezeyat C, Morrissey NJ, et al. (2008). Novel 
Treatment of Patients With Lower Extremity Ischemia: Use of Percutaneous 
Atherectomy in 579 Lesions. Ann Surg 248:519-28. 
Met R, Van Lienden KP, Koelemay MJ, Bipat S, Legemate DA & Reekers JA. (2008). Subintimal 
angioplasty for peripheral arterial occlusive disease: a systematic review. Cardiovasc 
Intervent Radiol. 31(4):687-97 
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working 
Group et al. (2007). Inter-society consensus for the management of peripheral arterial 
disease (TASC II). J Vasc Surg 45(Suppl.S):S5-S67. 
O'Hare AM, Vittinghoff E, Hsia J & Shlipak MG. (2004). Renal insufficiency and the risk of 
lower extremity peripheral arterial disease: results from the Heart and 
Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol 15(4):1046- 1051. 
Palena LM, Cester G & Manzi M. (2011). Revascularisacion endovascular del pie y de las arterias 
tibiales a traves de caminos alternativos, utilizando la arcada profunda del pie. 
Presented at IX SITE- Symposio Internacional sobre Terapeuticas Endovasculares. 
Barcelona 4-7 May 2011. Published at Tecnicas Endovasculares. 14(1): 3739. 
Patel PJ, Hieb RA & Bhat AP. (2010). Percutaneous revascularization of chronic total 
occlusions. Tech Vasc Interv Radiol. 13(1):23-36. 
Reekers JA, Kromhout JG & Jacobs MJ. (1994). Percutaneous intentional extraluminal 
recanalisation of the femoropopliteal artery. Eur J Vasc Surg. 8(6):723-8. 
Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA & De Luccia N. (2008). Meta-
analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 
47(5):975-81. 
Rosales OR, Mathewkutty S & Gnaim C. (2008). Drug eluting stents for below the knee lesions 
in patients with critical limb ischemia : long-term follow-up. Catheter Cardiovasc 
Interv. 72(1):112-5. 
Saab MH, Smith DC, Aka PK, Browlee RW & Killeen JD. (1992). Percutaneous transluminal 
angioplasty of tibial arteries for limb salvage. Cardiovasc Intervent Radiol. 15:211–6. 
Sarrafian, S. K. (1993). Anatomy of the Foot and Ankle. Philadelphia: Lippincott.. Pp. 294–355. 
Selvin E & Erlinger TP. (2004). Prevalence of and risk factors for peripheral arterial disease in 
the United States: results from the National Health and Nutrition Examination 
Survey, 1999-2000. Circulation 110(6):738-743. 
 Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. (2004). Meta-
analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. 
Ann Intern Med. 141(6):421-431. 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
234 
Faglia E, Clerici G, Clerissi J, Gabrielli L, Losa S, Mantero M, et al. (2006). Early and five-year 
amputation and survival rate of diabetic patients with critical limb ischemia: data of a 
cohort study of 564 patients. Eur J Vasc Endovasc Surg. 32(5):484-90.  
Ferraresi R, Centola M, Ferlini M, Da Ros R, Caravaggi C, Assaloni R, et al. (2009). Long-term 
outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients 
with critical limb ischaemia. Eur J Vasc Endovasc Surg. 37(3):336-42. 
Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV & Prescott RJ. (1991). 
Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral 
arterial disease in the general population. Int J Epidemiol 20(2):384-392 
Fusaro M, Agostoni P & Biondi-Zoccai G. (2008). ‘‘Trans-Collateral’’ Angioplasty for a 
Challenging Chronic Total Occlusion of the Tibial Vessels: A Novel Approach to 
Percutaneous Revascularization in Critical Lower Limb Ischemia. Catheterization and 
Cardiovascular Interventions 71:268-72  
Fusaro M, Dalla Paola L & Biondi-Zoccai G. (2007). Pedal-Plantar LOOP Technique for a 
challenging below-the-knee chronic total occlusion: a novel approach to percutaneous 
revascularization in critical lower limb ischemia. J Invasive Cardiol 19:E34-7. 
Fusaro M, Dalla Paola L & Biondi-Zoccai G. (2006). Retrograde posterior tibial artery access for 
below-the-knee percutaneos revascularization by means of sheathless approach and 
double wire technique. Minerva Cardioangiol. 54:773-7. 
Fusaro M, Dalla Paola L, Brigato C, Marangotto M, Nicolini S, Rripay R, et al. (2007). Plantar to 
dorsalis pedis artery subintimal angioplasty in a patient with critical foot ischemia: a 
novel technique in the armamentarium of the peripheral interventionist. J Cardiovasc 
Med (Hagerstown) 8(11):977-80. 
Fusaro M, Tashani A, Mollicheli N, Medda M, Inglese L & Biondi-Zoccai G. (2007). Retrograde 
pedal artery access for below-the-knee percutaneous revascularisation. J Cardiovasc 
Med (Hagerstown) 8:216-8. 
Gandini R, Pipitone V, Stefanini M, Maresca L, Spinelli A, Colangelo V, et al. (2007). The 
‘‘Safari’’ Technique to Perform Difficult Subintimal Infragenicular Vessels. 
Cardiovasc Intervent Radiol 30:469-73. 
Graziani L, Silvestro A, Monge L, Boffano GM, Kokaly F, Casadidio I, et al. (2008). 
Transluminal angioplasty of peroneal artery branches in diabetics: initial technical 
experience. Cardiovasc Interv Radiol 31:49–55 
Graziani L & Morelli LG. (2011). Combined Retrograde–Antegrade Arterial Recanalization 
Through Collateral Vessels: Redefinition of the Technique for Below-the-Knee 
Arteries. Cardiovasc Intervent Radiol 34:S78–S82 
Hanna GP, Fujise K, Kjellgren O, GP, Feld S, Fife C, Schroth G, et al. (1997). Infrapopliteal 
transcatheter interventions for limb salvage in diabetic patients: importance of 
aggressive interventional approach and role of transcutaneous oximetry. J Am Coll 
Cardiol 30:664-9. 
Häuser H, Bohndorf K, Wack C, Tietze W, Wölfle KD & Loeprecht H. Percutaneous 
transluminal angioplasty (PTA) of isolated crural arterial stenoses in critical arterial 
occlusive disease. Rofo. 164(3):238-43. 
Hiatt WR, Hoag S & Hamman RF. (1995). Effect of diagnostic criteria on the prevalence of 
peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 
91(5):1472-1479. 
Ingle H, Nasim A, Bolia A, Fishwick G, Naylor R, Bell PR, et al. (2002). Subintimal angioplasty 
of isolated infragenicular vessels in lower limb ischemia: long-term results. J 
Endovasc Ther. 9(4):411-6. Erratum in: J Endovasc Ther 9(5):A-6.  
 
Revascularization of Tibial and Foot Arteries: Below the Knee Angioplasty for Limb Salvage 
 
235 
Kullo IJ, Bailey KR, Kardia SL, Mosley TH, Jr., Boerwinkle E &Turner ST. (2003). Ethnic 
differences in peripheral arterial disease in the NHLBI Genetic Epidemiology 
Network of Arteriopathy (GENOA) study. Vasc Med 8(4):237-242. 
Laird JR, Zeller T, Gray BH, Scheinert D, Vranic M, Reiser C, et al. (2006). LACI investigators. 
Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of 
the LACI multicenter trial. J Endovasc Ther. 13:1-11. 
Manzi M, Cester G & Palena LM. (2010). Paclitaxel-coated balloon angioplasty for lower 
extremity revascularization: a new way to fight in-stent restenosis. J Cardiovasc Surg 
51:567-71. 
Manzi M, Fusaro M, Ceccacci T, Erente G, Dalla Paola L & Brocco E. (2009). Clinical results of 
below-the-knee intervention using pedal-plantar loop technique for the 
revascularization of foot arteries. J Cardiovasc Surg 50:331-7. 
McKinsey JF, Goldstein L, Khan HU, Graham A, Rezeyat C, Morrissey NJ, et al. (2008). Novel 
Treatment of Patients With Lower Extremity Ischemia: Use of Percutaneous 
Atherectomy in 579 Lesions. Ann Surg 248:519-28. 
Met R, Van Lienden KP, Koelemay MJ, Bipat S, Legemate DA & Reekers JA. (2008). Subintimal 
angioplasty for peripheral arterial occlusive disease: a systematic review. Cardiovasc 
Intervent Radiol. 31(4):687-97 
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working 
Group et al. (2007). Inter-society consensus for the management of peripheral arterial 
disease (TASC II). J Vasc Surg 45(Suppl.S):S5-S67. 
O'Hare AM, Vittinghoff E, Hsia J & Shlipak MG. (2004). Renal insufficiency and the risk of 
lower extremity peripheral arterial disease: results from the Heart and 
Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol 15(4):1046- 1051. 
Palena LM, Cester G & Manzi M. (2011). Revascularisacion endovascular del pie y de las arterias 
tibiales a traves de caminos alternativos, utilizando la arcada profunda del pie. 
Presented at IX SITE- Symposio Internacional sobre Terapeuticas Endovasculares. 
Barcelona 4-7 May 2011. Published at Tecnicas Endovasculares. 14(1): 3739. 
Patel PJ, Hieb RA & Bhat AP. (2010). Percutaneous revascularization of chronic total 
occlusions. Tech Vasc Interv Radiol. 13(1):23-36. 
Reekers JA, Kromhout JG & Jacobs MJ. (1994). Percutaneous intentional extraluminal 
recanalisation of the femoropopliteal artery. Eur J Vasc Surg. 8(6):723-8. 
Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA & De Luccia N. (2008). Meta-
analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 
47(5):975-81. 
Rosales OR, Mathewkutty S & Gnaim C. (2008). Drug eluting stents for below the knee lesions 
in patients with critical limb ischemia : long-term follow-up. Catheter Cardiovasc 
Interv. 72(1):112-5. 
Saab MH, Smith DC, Aka PK, Browlee RW & Killeen JD. (1992). Percutaneous transluminal 
angioplasty of tibial arteries for limb salvage. Cardiovasc Intervent Radiol. 15:211–6. 
Sarrafian, S. K. (1993). Anatomy of the Foot and Ankle. Philadelphia: Lippincott.. Pp. 294–355. 
Selvin E & Erlinger TP. (2004). Prevalence of and risk factors for peripheral arterial disease in 
the United States: results from the National Health and Nutrition Examination 
Survey, 1999-2000. Circulation 110(6):738-743. 
 Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. (2004). Meta-
analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. 
Ann Intern Med. 141(6):421-431. 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
236 
Senti M, Nogues X, Pedro-Botet J, Rubies-Prat J & Vidal-Barraquer F. (1992). Lipoprotein 
profile in men with peripheral vascular disease. Role of intermediate density 
lipoproteins and apoprotein E phenotypes. Circulation. 85(1):30-36. 
Serino F, Cao Y, Renzi C, Mascellari L, Toscanella F, Raskovic D, et al. (2010). Excimer laser 
ablation in the treatment of total chronic obstructions in critical limb ischaemia in 
diabetic patients. Sustained efficacy of plaque recanalisation in mid-term results. Eur 
J Vasc Endovasc Surg. 39:234-8. 
Sharma S, Kukreja N, Christopoulos C & Gorog DA. (2010). Drug-eluting balloon: new tool in 
the box. Expert Rev Med Devices. 7:381-8. 
Söder HK, Manninen HI, Jaakkola P, Matsi PJ, Räsänen HT, Kaukanen E, et al. (2000). 
Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: 
angiographic and clinical results.  J Vasc Interv Radiol. 11(8):1021-31. 
Spiliopoulos S, Katsanos K, Karanabatidis D, Diamantopoulos A, Kagadis G, Christeas N, et al. 
(2010). Cryoplasty versus conventional balloon angioplasty of the femoropopliteal 
artery in diabetic patients: long-term results from a prospective randomized single-
center controlled trial. Cardiovasc Intervent Radiol. 33:929-38. 
Spinosa DJ, Leung DA, Hathun NL, Cage DL, Angle JF, Hagspiel KD, et al. (2003). 
Simultaneous Antegrade and Retrograde access for subintimal recanalization of 
peripheral arterial occlusion. J Vasc Interv Radiol. 14:1449-54. 
Spinosa DJ, Leung DA, Matsumoto AH, Bissonette EA, Cage D, Harthun NL, et al. (2004). 
Percutaneous intentional extraluminal recanalization in patients with chronic critical 
limb ischemia. Radiology. 232(2):499-507. 
Spinosa DJ, Hathun NL, Bissonette EA, Cage DL, Leung DA,  Angle JF, Hagspiel KD, et 
al.(2005). Subinitmal Arterial flossing with Antegtrade-Retrograde Intervention 
(SAFARI) for Subinitmal Recanalization to Treat Chronic Critical Limb Ischemia. J 
Vasc Interv Radiol. 16:37-44. 
Taylor, G. I. & Minabe, T. (1992). The angiosomes of the mammals and other vertebrates. Plast. 
Reconstr. Surg. 89: 181. 
Taylor, G. I., Corlett, R. J., Caddy, C. M & Zelt, R. G. (1992). An anatomic review of the delay 
phenomenon: II. Clinical applications. Plast. Reconstr. Surg. 89: 408. 
Taylor, G. I. & Pan, W. R. (1998). Angiosomes of the leg: Anatomic study and clinical 
implications. Plast. Reconstr. Surg. 102: 599. 
Tepe G, Zeller T, Heller S, Wiskirchen J, Fischmann A, Coerper S, et al. (2007).  Self-expanding 
nitinol stents for treatment of infragenicular arteries following unsuccessful balloon 
angioplasty. Eur Radiol. 17:2088-95. 
Wack C, Wölfle KD, Loeprecht H, Tietze W & Bohndorf K.(1994). Percutaneous balloon 
dilatation of isolated lesions of the calf arteries in critical ischemia of the leg. Vasa. 
23(1):30-4. 
Waksman R & Pakala R. (2009). Drug-eluting balloon: the comeback kid?. Circulation: 
Cardiovascular Intervention 2:352-8. 
Walsh DB, Gilberstone JJ, Zwolajk RM, Besso S, Edelman GC, Schneider JR, et al. (1991). The 
natural history of superficial femoral artery stenosis. J Vasc Surg. 14:299:304. 
Zeller T, Rastan A, Schwarzwälder U, Frank U, Bürgelin K, Amantea P, et al. (2004). Midterm 
Results after Atherectomy-assisted Angioplasty of Below-Knee Arteries with Use of 
the Silverhawk Device. J Vasc Interv Radiol. 15:1391-7. 
Zeller T, Sixt S, Schwarzwaler U, Schwarz T, Frank U, Burgelin K, et al. (2007). Two-Year 
Results After Directional Atherectomy of Infrapopliteal Arteries With the SilverHawk 
Device. J Endovasc Ther. 14:232-40. 
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
236 
Senti M, Nogues X, Pedro-Botet J, Rubies-Prat J & Vidal-Barraquer F. (1992). Lipoprotein 
profile in men with peripheral vascular disease. Role of intermediate density 
lipoproteins and apoprotein E phenotypes. Circulation. 85(1):30-36. 
Serino F, Cao Y, Renzi C, Mascellari L, Toscanella F, Raskovic D, et al. (2010). Excimer laser 
ablation in the treatment of total chronic obstructions in critical limb ischaemia in 
diabetic patients. Sustained efficacy of plaque recanalisation in mid-term results. Eur 
J Vasc Endovasc Surg. 39:234-8. 
Sharma S, Kukreja N, Christopoulos C & Gorog DA. (2010). Drug-eluting balloon: new tool in 
the box. Expert Rev Med Devices. 7:381-8. 
Söder HK, Manninen HI, Jaakkola P, Matsi PJ, Räsänen HT, Kaukanen E, et al. (2000). 
Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: 
angiographic and clinical results.  J Vasc Interv Radiol. 11(8):1021-31. 
Spiliopoulos S, Katsanos K, Karanabatidis D, Diamantopoulos A, Kagadis G, Christeas N, et al. 
(2010). Cryoplasty versus conventional balloon angioplasty of the femoropopliteal 
artery in diabetic patients: long-term results from a prospective randomized single-
center controlled trial. Cardiovasc Intervent Radiol. 33:929-38. 
Spinosa DJ, Leung DA, Hathun NL, Cage DL, Angle JF, Hagspiel KD, et al. (2003). 
Simultaneous Antegrade and Retrograde access for subintimal recanalization of 
peripheral arterial occlusion. J Vasc Interv Radiol. 14:1449-54. 
Spinosa DJ, Leung DA, Matsumoto AH, Bissonette EA, Cage D, Harthun NL, et al. (2004). 
Percutaneous intentional extraluminal recanalization in patients with chronic critical 
limb ischemia. Radiology. 232(2):499-507. 
Spinosa DJ, Hathun NL, Bissonette EA, Cage DL, Leung DA,  Angle JF, Hagspiel KD, et 
al.(2005). Subinitmal Arterial flossing with Antegtrade-Retrograde Intervention 
(SAFARI) for Subinitmal Recanalization to Treat Chronic Critical Limb Ischemia. J 
Vasc Interv Radiol. 16:37-44. 
Taylor, G. I. & Minabe, T. (1992). The angiosomes of the mammals and other vertebrates. Plast. 
Reconstr. Surg. 89: 181. 
Taylor, G. I., Corlett, R. J., Caddy, C. M & Zelt, R. G. (1992). An anatomic review of the delay 
phenomenon: II. Clinical applications. Plast. Reconstr. Surg. 89: 408. 
Taylor, G. I. & Pan, W. R. (1998). Angiosomes of the leg: Anatomic study and clinical 
implications. Plast. Reconstr. Surg. 102: 599. 
Tepe G, Zeller T, Heller S, Wiskirchen J, Fischmann A, Coerper S, et al. (2007).  Self-expanding 
nitinol stents for treatment of infragenicular arteries following unsuccessful balloon 
angioplasty. Eur Radiol. 17:2088-95. 
Wack C, Wölfle KD, Loeprecht H, Tietze W & Bohndorf K.(1994). Percutaneous balloon 
dilatation of isolated lesions of the calf arteries in critical ischemia of the leg. Vasa. 
23(1):30-4. 
Waksman R & Pakala R. (2009). Drug-eluting balloon: the comeback kid?. Circulation: 
Cardiovascular Intervention 2:352-8. 
Walsh DB, Gilberstone JJ, Zwolajk RM, Besso S, Edelman GC, Schneider JR, et al. (1991). The 
natural history of superficial femoral artery stenosis. J Vasc Surg. 14:299:304. 
Zeller T, Rastan A, Schwarzwälder U, Frank U, Bürgelin K, Amantea P, et al. (2004). Midterm 
Results after Atherectomy-assisted Angioplasty of Below-Knee Arteries with Use of 
the Silverhawk Device. J Vasc Interv Radiol. 15:1391-7. 
Zeller T, Sixt S, Schwarzwaler U, Schwarz T, Frank U, Burgelin K, et al. (2007). Two-Year 
Results After Directional Atherectomy of Infrapopliteal Arteries With the SilverHawk 
Device. J Endovasc Ther. 14:232-40. 
Angioplasty, Various 
Techniques and Challenges in 
Treatment of Congenital and 
Acquired Vascular Stenoses
Edited by Thomas Forbes
Edited by Thomas Forbes
The field of performing transcatheter interventions to treat vascular lesions has 
exploded over the past 20 years. Not only has the technology changed, especially in 
the arena of balloon/stent devices, but the techniques of approaching complex lesions 
has evolved over the past decade. Lesions that no one would have imagined treating 
back in the 1990’s are now being done routinely in the catheterization suite. This book 
provides an update on the current techniques and devices used to treat a wide variety 
of lesions. Though, at first, the outward appearance of the topics appears to be varied, 
they are all related by the common thread of treating vascular lesions. We hope, by 
publishing this book, to accomplish two things: First, to offer insight from experts 
in their field to treat, both medically and procedurally, complex vascular lesions that 
we frequently encounter. Secondly, we hope to promote increased communication 
between areas of medicine that frequently don’t communicate, between adult 
interventional cardiologists, pediatric interventional cardiologists, interventional 
radiologists, and neurosurgeons. Much can be learned from our respective colleagues 
in these areas which can further our own world of interventions.
Photo by HYWARDS / iStock
ISBN 978-953-51-0084-3
A
ngioplasty, Various Techniques and C
hallenges in Treatm
ent of C
ongenital and A
cquired 
Vascular Stenoses
 6827 0
